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Summary 
The exploitation of malarial primary metabolic genes as drug-targets has been 
neglected, partly because early biochemical studies have suggested the absence of a 
functional TCA cycle in Plasmodium falciparum. However, datamining of the malarial 
genome revealed a cohort of DNA sequences that support a potential network of extensive 
glycolytic and TCA pathways. Thus, this study took the challenge of questioning the 
existence of these genes and their physiological roles.  
To start off, a selection of 10 predicted genes encoding primary metabolic enzymes 
were cloned and tested for expression as fusion proteins partnered with glutathione-S-
transferase (GST), maltose binding protein (MBP), or thioredoxin (Trx) tags1. Results 
indicated profound differences in expression levels, peculiar to each target or the fusion 
partner used. Five of the targets could be solubly expressed using GST, resulting in the 
authentication of three enzymes, ie, isocitrate dehydrogenase (ICDH), malate dehydrogenase 
(MDH) and pyruvate kinase 1 (PK1). GST, MBP and Trx were unable to coax the expression 
of the other five selected genes. Comparison of gene sequences coding for these plasmodial 
proteins revealed no clear justification to cite the influence of codon bias, instability index, pI, 
frequency of coiled-coils, or hydrophobicity on their ability to communicate soluble 
expression. The frustration in scarce soluble expression of plasmodial genes is widely 
encountered. Despite the expected hitch, the three soluble and active recombinant malarial 
proteins procured in this study were subjected to biochemical analyses to evaluate their status 
as metabolic enzymes. Further, in order to trace the functions of the non-enzymatic proteins 
linked to primary metabolism, the use of a selection of heat shock proteins, also cloned in this 
study, as baits in yeast-two-hybrid screening led to the identification of an interaction between 
a small heat shock protein (hslv) and a previously identified receptor for activated kinase 
(PfRACK). However, how PfRACK might impact the parasite’s signaling and regulation 
remains to be investigated.  
                                                          
1 The 10 targets were glycerol-3-phosphate dehydrogenase, glycerol kinase (GK), pyruvate kinase 1 (PK1), 
fumarase (FUM), citrate synthase (CS), isocitrate dehydrogenase (ICDH), malate dehydrogenase (MDH), 
glutamate dehydrogenase (GDH), dihydroorotase (DHO), and inosine-5’-monophosphate dehydrogenase. 
. v
To inquire whether the 10 candidate genes were expressed during the 
intraerythrocytic stages, in vitro blood cultures of the parasites were invoked and, via RT-
PCR, all the ORFs were found to be actively transcribed. Unexpectedly, a second pyruvate 
kinase (PK2) which may have a unique function in the apicoplast was identified in these 
experiments. In addition, in search of a link between glycolysis and the TCA pathway, the 
transcription profiles of 15 glycolytic and 11 TCA cycle genes were extracted from a web-
based microarray data. Interestingly, the survey revealed that two enzymes typical of 
mitochondrial activity ie. MDH and fumarase (FUM), appeared to be cytosolically localized, 
suggesting that they may have unusual links to the TCA cycle. Such revelations have raised 
the importance of searching transcription data to correlate the homology-based annotations of 
genome data. 
The functions of eukaryotic proteins are widely defined by their compartments in an 
organism. However, protein localization procedures involving transfection of parasites are 
besotted with technical hurdles. Hence, there is a need for a simple assay to position identified 
cellular targets. A combination of fluorescent markers, organelle-specific probes, phase 
contrast microscopy, and confocal microscopy was used to locate a selection of 
mitochondrial-, nuclear-, and apicoplast-targeting signal peptides from plasmodial proteins in 
CHO-K1 cells2. The respective localizations of these malarial proteins have complied with the 
selected molecular targets, viz. mitochondrial, nuclear and cytoplasmic. Interestingly, MDH 
that is widely known to be resident in eukaryotic mitochondria was found to be cytoplasmic, 
both by computational analysis and by this novel method of gene localization. The absence of 
target sequences ahead of the MDH ORF provided molecular evidence of a protein not 
destined for the mitochondria.  
Taken together, this study has re-opened the search of a plausible network of primary 
metabolic malarial genes, some of which have been defined by biochemical characterization, 
protein-interaction studies, transcription analyses, and finally, by novel in situ localization of 
                                                          
2 These eukaryotic cells served as an in vitro living system for studying the cellular destinations of four 
mitochondrial-targeted TCA-cycle proteins (CS; ICDH; branched chain α-keto-acid dehydrogenase E1α subunit; 
succinate dehydrogenase flavoprotein-subunit), two nuclear-targeted proteins (histone deacetylase; RNA 
polymerase), two apicoplast-targeted proteins (PK2; GDH), and two cytoplasmic resident proteins (MDH; GK).  
. vi
fluorescently-labeled malarial gene targets in eukaryotic CHO-K1 cells, to provide 
endorsement of their proposed functional roles. 
. vii
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CHAPTER 1 INTRODUCTION 
 
1.1 THE GLOBAL MALARIA SITUATION 
 Malaria remains to be a major global problem, causing disease in 300-500 
million people annually (Fidock et al. 2004). The disease kills 1-3 million people 
each year, 1 million of whom are children of less than five years of age 
(translating to one child every 40 seconds) (Kirchgatter and Del Portillo 2005). 
Malaria is currently endemic in over 100 countries, putting 40% of the world’s 
population at risk, particularly children, pregnant women, and non-immune 
travelers. Although most parts of Asia and Americas are at relatively low malaria 
risks, deaths from malaria continue to occur in rural or remote areas where 
treatment is not available or adequate. Hence, malaria is clearly a disease of 
poverty, with 90% of the cases occurring in Africa. The economic impact of 
malaria on welfare and child survival further limits the ability of malarious states 
to contribute to economy. Although there are vaccine initiatives (Table 1-2; 
www.malaria-vaccines.org.uk), the disease is currently controllable through 
vector control or bed nets, as well as drug treatment. However, the problem of 
drug resistance is now so serious that the old affordable first line drugs such as 
chloroquine and sulfadoxine-pyrimethamine are virtually useless in many parts of 
Asia and Africa today (Bathurst and Hentschel 2006). The dwindling 
effectiveness of frontline drugs suggests that new antimalarial drugs are needed 





The basic investigation into the biology of malaria is crucial to the 
development of new drugs and vaccines. Advancement in the understanding of 
the structural and functional properties of plasmodial proteins is central to the 
employment of these proteins as drug-targets in the drug-discovery process. Also, 
educated lead development might come from molecular genetic studies. Hence, 
this study involved the datamining, cloning and functional analyses of plasmodial 
genes encoding metabolic enzymes that might be crucial for the parasite’s 
survival, with the prospect of uncovering functional proteins that may be 
employed as potential targets for anti-malarial drug-screening. Among the four 
Plasmodium species that infect humans (Table 1-3), the most severe malaria is 
caused by P. falciparum which is responsible for almost all the deaths resulting 
from complications. Hence, this study is focused on functional genes from this 
species. The landmark publication of the complete P. falciparum genome 
(Gardner et al. 2002) with draft annotation in late 2002 has made it possible to 
adopt the latest global-genome survey approaches for malaria research. It should 
be emphasized that the exploitation of available global biological information 
relies heavily on the verification of the annotation of plasmodial genes. In this 
study, the validation of potentially important P. falciparum proteins was achieved 
experimentally via recombinant expression and functional characterization. 
Certain aspects of plasmodia metabolism are actively investigated as novel 
targets, including the hemoglobin-processing, shikimate, redox, and primary 
metabolic pathways (reviewed in Chapter 4). This study is focused on the 
functional analysis of primary metabolic enzymes of P. falciparum, resulting in 
the identification of P. falciparum isocitrate dehydrogenase (ICDH), malate 




candidates. Information on the cellular localization and/or protein-protein 
interaction of specific target proteins is invaluable information relevant to the 
validation of a specific target. The functions of proteins are defined in the context 
of compartments that they are organized into, or the proteins they interact with. 
In the latter part of this study, the need for a simple assay for validating the 
cellular localizations of identified drug-targets was highlighted. As a result, 
certain classes of signal peptides (ie. mitochondrial-targeting peptides and 
nuclear localization signals) present on the primary metabolic proteins were 
localized using a novel cellular-targeting assay. The suitability of a yeast-two-
hybrid system for assaying plasmodial protein interaction was also examined in 
this study. 
 
Currently, PlasmoDB (www.plasmoDB.org) is the central malaria 
resource that enables intuitive browsing through the P. falciparum genome and 
its annotated genes. Further integration of genomic information and experimental 
data from transcriptomics, proteomics, “interactomics”, and “secretomics” 
studies are facilitating the generation of a ‘virtual’ P. falciparum parasite (a list 
of useful links to genome databases and several other interesting malaria websites 
is illustrated in Table 3-1). Also, as a result of increased worldwide funding for 
malaria research, an unprecedented number of malaria discovery projects and 
initiatives involving many organizations are now underway (Table 1-1 and 1-2). 
A significant event was the establishment of Medicines for Malaria Venture 
(MMV) in Geneva in 1999. MMV is a not-for-profit organization that brings 
together public, private and philanthropic partners to fund and manage the 




largest malaria research and development portfolio, covering the innovation 
spectrum from basic drug-discovery to advanced clinical development (Bathurst 





Table 1-1.  Examples of current malaria discovery and development 
projects and associated organizations.  
 
Abbreviations: BMS, Bristol-Myers Squibb; CDRI, Central Drug Research 
Institute, India; GSK, GlaxoSmithKline; LSHTM, London School of 
Hygiene and Tropical Medicine; MMV, Medicines for Malaria Venture; 
NIH, National Institutes of Health, USA; STI, Swiss Tropical Institute; TDR, 
UDNP/World Bank/WHO Special Program for Research and Training in 
Tropical Diseases; UCSF, U. California San Francisco; WRAIR, Walter 
Reed Army Institute of Research. 
 
Sources: MMV (website: www.mmv.org) and Fidock et al. 2004. 
 




Fatty acid biosynthesis inhibition MMV, GSK 
Cysteine protease inhibitors MMV, UCSF, GSK 
Dihydrofolate reductase inhibition MMV, BIOTEC Thailand, LSHTM, Monash 
U.  
Protein franesyltransferase inhibitors MMV, BMS, U. Washington, Yale 
New dicationic molecules MMV, U. North Carolina, STI 
8-aminoquinolines  MMV, U. Mississippi, NIH 
4(1H)-pyridones back ups MMV, GSK 
Chalcones National U. Singapore, Lica 
Pharmaceuticals 
Synthetic endoperoxides Johns Hopkins U., U. Laval, CDRI 
  
Development projects  
Pyronaridine artesunate MMV, TDR, Shin Poong  
Chlorproguanil dapsone artesunate MMV, TDR, GSK, LSHTM 
Artemisone  MMV, Bayer, U. Hong Kong 
Azithromycin chloroquine Pfizer 
Short chain chloroquine U. Tulane 
Tafenoquine GSK, WRAIR 







Table 1-2.  Resource of malaria initiatives.  
 
Resource Website Funding 
Medicines for Malaria 
Venture (MMV) 
http://www.mmv.org Rockefeller Foundation, the 
World Bank, the Swiss 
Agency for Development and 
Cooperation, the Wellcome 
Trust 
 
The Malaria Consortium http://www.malariaconsortium.
org/  
WHO, UNICEF, Gates 
Malaria Centre (Ghana), 
Rotary Club 
 
The Wellcome Trust 
 
http://www.wellcome.ac.uk/  An independent charity fund 
Malaria Vaccine Initiative 
(MVI) 
 
http://www.malariavaccine.org/ Bill and Melinda Gates 
Foundation 
 
National Institute of 
Allergy and Infectious 
Diseases (NIAID) 
 
http://www3.niaid.nih.gov/  US government 
Special Program for 
Research and Training in 
Tropical Diseases (TDR) 
 
http://www.who.int/tdr/  UNICEF, World Bank, WHO 
Drugs for Neglected 
Diseases (DNDI)  
 
http://www.dndi.org/  Médecins sans Frontières, 






1.2 PRIMARY METABOLIC ENZYMES AS POTENTIAL 
DRUG-TARGETS  
To date, antimalarial drugs are the only way to treat the disease. Although 
a number of clinical and field trials of various malaria vaccines are ongoing, the 
promise of an effective vaccine against malaria remains unrealized (Waters 
2006). The parasite’s complex interaction with its host, as well as its ability to 
undergo antigenic variation, appears to be chief obstacles to a malaria vaccine. 
However, the widespread resistance to well established drugs has resulted in an 
urgent need to identify and develop alternatives. Identifying novel drug-targets is 
hence a major approach against malaria. Generally, enzymes and receptors are 
found to be good drug targets, with enzymes accounting for 28% of all current 
drug targets (Drews 2000).  
 
The malaria parasite exhibits a rapid growth and multiplication rate 
during many stages of its life-cycle. This necessitates that the parasite acquires 
and metabolize biological molecules efficiently via crucial metabolic pathways 
so as to survive and reproduce. Hence, understanding the parasite's metabolism 
may lead to the development of novel therapeutic strategies which exploit the 
unique yet indispensable metabolic pathways employed by the parasite. The 
dependence of plasmodia upon glycolysis has inspired a fair amount of research 
into inhibitors of this pathway. A key enzyme of this process, P. falciparum 
lactate dehydrogenase (pfLDH), was one of the most advanced examples of 
structure-based drug-design (Mehlin 2005). Comparison of its 3D structure with 
the corresponding human structures revealed that selectivity was possible. 




efficacies, although funding for drug-screening using pfLDH recently ended due 
to the lack of a clinical candidate (www.mmv.org). In contrast to pfLDH, other 
key enzymes of the glycolytic pathway, such as hexokinase, phosphofuctokinase 
and pyruvate kinase, have not yet been examined in detail, although enzyme 
activities for all three enzymes have been detected in asexual-stage plasmodia. 
Among the key glycolytic enzymes, only the gene encoding hexokinase has been 
cloned (Olafsson and Certa 1994). In this study, a gene encoding pyruvate kinase 
in P. falciparum was cloned and characterized. 
 
Authentication of gene functions is a crucial step in validating predicted 
metabolic pathways as well as the exploitation of specific enzymes for 
therapeutic intervention. Although the publication of the entire genome of P. 
falciparum is a major step forward in reaching a more comprehensive 
understanding of Plasmodium metabolism, the information from the malaria 
genome provides, at best, a scrambled image of all the biological functions 
potentially available to the parasite. Hence, the challenge for malaria researchers 
in the post-genomic era is to piece together the genomic jigsaw and obtain a 
meaningful metabolic picture of the malaria parasite.  
 
It is perhaps rather alarming that the biological basis even of major 
antimalarials such as chloroquine and artemisinin are still not fully understood 
(van Dooren et al. 2006). Currently, it is understood that chloroquine targets a 
unique biochemical pathway of P. falciparum in the acidic food vacuole of the 
parasite, where heme released during metabolism of hemoglobin mineralizes to 




and appears to block heme biomineralization by forming lipophilic, cytotoxic 
chloroquine-heme complexes that kill parasites by permeabilizing cell 
membranes (Egan et al. 2002). However, chloroquine frequently fails owing to 
widespread resistance. Chloroquine resistance is linked to a K76T mutation in 
PfCRT, a drug/metabolite transporter located on the food vacuolar membrane 
(Cooper et al. 2002). It is believed that mutated PfCRT acts as a transporter of 
chloroquine, enabling it to leave the food vacuole in which the drug accumulates 
(Sanchez et al. 2007). The emerging resistance to chloroquine is the basis for this 
thesis. 
 
Functional studies involve the cloning of individual genes encoding these 
enzymes, the production of pure and enzymatically active recombinant proteins, 
and the execution of specific biochemical assays. Hence, detailed biochemical 
characterization and physiological studies are components of the drug-target 
validation process aimed at verifying the physiological roles and exploitability of 
selected putative targets. Experimental observations on the cellular localization 
and/or protein-protein interaction of specific target proteins are also relevant to 
the validation of a specific target. These approaches were hence adopted for the 
investigation of the primary metabolic enzymes in this study. However, the 
composition of the malarial genes often presents technical problems during gene 
cloning, and the expression of procured genes must be overcome before active 
recombinant enzymes can be obtained (discussed in Section 3.4). In the next 
chapter, the major aspects of parasite metabolism according to the classes of 





1.3 THE APICOMPLEXANS 
The phylum Apicomplexa includes human parasites of the genera 
Plasmodium, Toxoplasma, Babesia, and Cryptosporidium. An important feature 
of all apicomplexan parasites is the presence of a specialized apical complex, 
which is central to the invasion process. While Toxoplasma and Cryptosporidium 
pass directly between vertebrate hosts (Table 1-3), the life cycles of Plasmodium 
and Babesia involve an arthropod vector that transmits the parasite to a vertebrate 
host during blood-feeding. Babesia is a malaria-like protozoan that also lives and 
reproduces inside red blood cells (RBCs). Infection by this agent is often 
misdiagnosed as drug-resistant malaria. However, unlike malaria, Babesia 
infection (babesiosis) occurs only occasionally in man by accidental intrusion 
into a natural disease cycle of certain animals.  
 
Plasmodium species that infect humans share a similar life cycle, the 
stages of which are depicted in Fig. 1-1. The haploid sporozoites enter the 
bloodstream with the saliva of a feeding mosquito (Anopheles gambiae). After 
invasion of a liver cell, the parasite undergoes a period of growth, followed by 
multiple genome replications and mitotic divisions resulting in the production of 
>20,000 daughter parasites (merozoites) that enters the circulation and invade 
erythrocytes after release from the hepatocyte. After a period of intra-erythrocytic 
development, several mitotic divisions result in the production of 16-32 new 
merozoites per parasite (see also section 2.1). The duration of the erythrocytic 
cycle and the number of merozoites produced are species specific. The asexual 
blood-stage parasites are the cause of pathology. In the blood, a small percentage 




gametocytes that are the precursor cells of the gametes. These cells are activated 
to produce gametes in the midgut when ingested as part of the bloodmeal of the 
anopheline mosquito. Gamete formation is followed by fertilization, resulting in 
the diploid zygote. After one round of meiotic division, the zygote develops into 
a motile ookinete, which penetrates the cells of the midgut and traverses the 
midgut wall to form an oocyst on the basolateral lamina. After growth and 
multiplication, >10,000 sporozoites develop in a single oocyst. When the motile 
sporozoites are released, they migrate through the hemolymph to invade the 
salivary glands, from which they are ready to infect a new victim and continue 
the cycle. In addition to intravascular infection, P. falciparum can also cause 
vascular obstruction due to its ability to enable infected cells to adhere to 
endothelial cell walls, leading to fatal complications (discussed in detail in 
Chapter 2). Goldring (2004) has recently shown that sequestration is a complex 
process that involves parasite ligands interacting with multiple host receptors. 
Hence, P. falciparum causes the most severe morbidity and mortality among the 
4 human malaria species. On the other hand, P. vivax produces persistent, 
“resting” liver forms called hypnozoites which, when “reactivated”, may result in 
relapsing malaria (Cogswell 1992). Hence, infection by this species requires 
treatment that kills dormant protozoan as well as the actively infecting ones. 
Chapter 1 
 
Fig. 1-1. The Plasmodium life-cycle and its associated pathological 
processes.   
  
 Adapted by permission from Macmillan Publishers Ltd: Nature (Miller et 























Table 1-3.  Comparison of diseases caused by Apicomplexans which infect humans.  
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Vector Anopheles mosquito    None None Ticks
Species  P. vivax; P. falciparum; P. ovale; 
P. malariae 
 
Toxoplasma gondii Cryptosporidium parvum Babesia microti 
 
Disease Falciparum malaria is potentially 
fatal as a result of complications 
that include cerebral malaria, 
renal failure, and massive 
hemolysis.  
The clinical course is benign 
and self-limited. Congenitally 
infected children may suffer 
impaired vision and mental 
retardation. AIDS patients 
may have encephalitis. 
 
Causes diarrhea in humans. In 
AIDS patients, the organism 
may cause prolonged, severe 
diarrhea and the organisms 
may invade other organs. 
Mild flu-like symptoms. May 
become severe in persons with a 
weakened immune system. 
Prevalence Endemic in >100 countries in the 
world. 40 % of the world 
population is at malaria risk, 
particularly pregnant women and 
infants. 
 
A common human infection 
throughout the world.   
Worldwide distribution. Mainly affects cattle. Humans 
are infected occasionally. 
Ingestion of oocysts in 
contaminated drinking water 
▼ 
Following ingestion 
sporozoites are released and 
parasitize epithelial cells of the 
gastrointestinal tract, and 
undergo asexual and sexual 
development 
▼ 
Oocysts formed after sexual 
development are excreted by 
the infected host through 
feces 
Cats get infected by eating 
tissue cysts 
▼ 
In the intestine, the parasite 
undergoes sexual cycle 
▼ 
Oocysts shed in the feces 
are ingested by the 
intermediate host (pig, 
sheep, cattle and humans) 
▼ 
Oocysts move to various 
tissues where they encyst 
During a blood meal, an 
infected tick introduces 
sporozoites into animal host 
▼ 
Sporozoites enter erythrocytes 
and undergo asexual 
reproduction 
▼ 
Some parasites differentiate 
into male and female gametes  
▼ 
Once ingested by the tick, 
gametes unite, resulting in 
sporozoites. (Humans enter the 
cycle when bitten by infected 
ticks) 
Sporozoites discharged from the 
salivary glands of the mosquito 
during bite 
▼ 
Sporozoites develop in the liver 
cells which discharge merozoites 
into the bloodstream 
▼ 
Merozoites infect the red blood 
cells, multiply and reinfect other 
erythrocytes 
▼ 
Some merozoites transform into 
gametocytes which initiate sexual 





1.4 OBJECTIVES OF THIS STUDY 
The publication of the P. falciparum genome data has rendered a holistic 
view of metabolic pathways, providing a basis for uncovering novel enzymes for 
therapeutic intervention. Notably, pathway construction, based on a bioinformatic 
interpretation of the genome data, remain theoretical unless the functions of 
predicted genes can be validated and their cellular localizations supported by 
experimental data. Despite the availability of vast bioinformatic databases, there is 
little experimental data about the functions of individual plasmodial genes (Su and 
Wellems, 1998). The objective of this study was to carry out functional analysis on 
genes encoding P. falciparum primary metabolic enzymes and to characterize 
functional recombinant enzymes, so as to assess their potential as drug-targets. At 
the outset, this would entail the production of pure and enzymatically active 
recombinant malaria proteins. Molecular characterization, including structural 
determination of important malaria proteins, relies on the successful in vitro 
production of correctly folded proteins (Hammarström et al. 2002). In this study, a 
data-mining approach would be adopted to survey the current status of the genome 
annotation of glycolytic and TCA cycle enzymes in an attempt to uncover predicted 
genes encoding key enzymes pertinent to recombinant expression and functional 
analysis. Isolation of such solubly expressed and catalytically validated recombinant 
enzymes would facilitate downstream detailed biochemical characterization and 
future potential employment of these enzymes as drug-target for anti-malarial 
compound screening. In addition, it would be important to investigate the status of 




genes expressed during the intra-erythrocytic stages of the parasite’s developmental 
cycle are considered relevant as drug-targets, while genes expressed at other stages 
may be useful for disrupting the life-cycle of the parasite.  
 
Understanding the cellular localizations of metabolic enzymes is part of the 
drug validation process. Hence, the functionalities of resident organelle-targeting 
signals on these enzymes were to be investigated experimentally so as to allow a 
clearer construction of the glycolytic and TCA cycle pathways that exist in P. 
falciparum. The use of green fluorescent protein (GFP) is a valuable approach for 
exploring protein trafficking and localization. However, transfection and creation of 
stable transgenic plasmodial parasites is not a simple process amenable for efficient 
analyses of cellular localization of several targets in parallel. Hence, this study also 
aimed to develop a novel cellular assay capable of providing biological data on the 
cellular localization of the identified targets. Although functional analyses of 
enzymes can be achieved via biochemical assays, the functions of non-enzymatic 
proteins have to be uncovered by indirect methods, such as via uncovering 
information on their protein interactions. In this study, the yeast-two-hybrid 
approach would be examined for its suitability to identify protein interactions in P. 
falciparum. An overview of objectives is depicted in Fig. 1-2. The detailed 








1. Survey the current status of primary metabolic pathway enzymes (glycolysis, 
TCA cycle, and electron transport chain) of P. falciparum to identify steps 
where the gene involved has not been cloned and studied. 
2. Carry out datamining of the P. falciparum genome data to predict putative 
genes that might encode enzymes responsible for the identified steps.  
Target production 
3. Set up a P. falciparum in vitro culture and optimize the conditions for 
isolation of parasite DNA and mRNA.  
4. Clone the genes encoding the identified targets via PCR or RT-PCR for 
recombinant expression of target proteins using an Escherichia coli host and 
a selection of expression vectors; identify and purify solubly expressed 
recombinant plasmodia proteins. 
Target validation 
5. Carry out functional analysis of pure recombinant plasmodial proteins to 
identify active enzymes, and characterize active enzymes kinetically and 
biochemically. 
6. Set up a yeast-two-hybrid system using plasmodial cDNAs for analyzing 
plasmodial protein interactions and investigate the deployability of this 
system for functional analysis of non-enzymatic plasmodial proteins.  
7. Investigate the in vitro expression of selected target genes during the 




and compare resultant observations with existing transcriptomics and 
proteomics data. 
8. Set up a novel cellular method to allow in vitro localization of plasmodial 
genes, and employ the method to uncover the cellular localization of target 
proteins. 
9. Discuss the status of primary metabolic enzymes in P. falciparum based on 
information on their functional authentication, in-vitro expression and 

































3.  DNA amplification, cloning, 
recombinant expression, 
and protein purification 
2.  In-vitro parasite 
culture, DNA/RNA 
extraction 
1.  Datamining and 
identification of 
potential targets 
4.  Biochemical assays, 
protein-protein 
interaction, transcription 
analysis, and cellular 














MOLECULAR AND BIOCHEMICAL 






CHAPTER 2 MOLECULAR AND BIOCHEMICAL 
ASPECTS OF P. FALCIPARUM 
INFECTION 
 
2.1 HOST INVASION 
 Malaria is primarily an intravascular disease caused by the destruction of 
erythrocytes as a result of the parasite’s multiplication during its asexual blood-
stage. The hepatic and gametocyte stages do not contribute to disease (Miller et 
al. 2002a). Among Plasmodium spp. that infect humans, only P. falciparum can 
cause severe malaria, an infection with complications that are potentially fatal. In 
addition to acute anemia brought about by rapid haemolysis, severe falciparum 
malaria is a systemic disorder that damages several tissues and organs, including 
the brain. This is due to the ability of P. falciparum to cause infected red blood 
cells (RBCs) to adhere to the linings of small blood vessels (sequestration), 
causing considerable obstruction of blood circulation to tissues and resulting in 
tissue injury. Sequestration of parasites in the brain leads to cerebral malaria 
(Miller et al. 2002a), a common complication that manifests as coma and 
seizures. Cerebral malaria is the cause of 80% of deaths resulting from malaria. 
In addition, the parasites can also sequester in various organs including the heart, 
kidney and placenta, leading to complications such as kidney failure, 
cardiovascular shock, and premature delivery (Newbold et al. 1999).  
 
 The Plasmodium life cycle begins when mosquitoes inject sporozoites 




liver, passing through several hepatocytes before initiating parasite development. 
The co-receptor on sporozoites that mediates invasion involves, in part, the 
thrombospondin domains on the circumsporozoite protein (CSP) and on 
thrombospondin-related adhesive protein (TRAP) (Miller et al. 2002a; Naitza et 
al. 1998). These domains bind specifically to heparin sulphate proteoglycans 
(HSPGs) on hepatocytes. The CSP covers the entire surface of the sporozoite and 
is considered a vaccine candidate targeted at the parasite’s host-cell recognition 
and invasion processes. Inside the hepatocyte, each sporozoite develops into tens 
of thousands of merozoites which can each invade RBCs on release from the 
liver. The disease begins only once the asexual parasite multiplies in RBCs. P. 
falciparum and P. vivax develop over 48 hours in RBCs, producing around 20 
merozoites per mature parasite. A small proportion of merozoites, upon invasion, 
develops into gametocytes that are essential for transmitting the infection through 
mosquitoes, but cause no clinical symptoms.  
 
To invade a RBC, a merozoite must engage binding receptors on the cell, 
undergo apical orientation (Dvorak et al. 1975) and tight junction formation 
(Aikawa et al. 1978). The parasite induces a vacuole derived from the host cell’s 
plasma membrane and enters the vacuole. Invasion into the erythrocyte by the 
extracellular merozoite is an obligatory and parasite-specific process, an 
Achilles’ heel that can be exploited for development of new treatments (Miller et 
al. 2002a). Merozoite surface protein-1 (MSP-1), the most abundant protein on 
the surface of merozoites (O’Donnell et al. 2000), appear to be involved in early 
recognition and attachment events. MSP-1 (and other MSPs) are thus actively 




be defined (Cowman and Crabb 2006). In contrast to the MSPs, there is clear 
evidence that a number of proteins stored in the apical organelles (micronemes 
and rhoptries) bind to specific receptors on the erythrocyte and are directly 
involved in invasion (Cowman and Crabb 2006). These receptors appear to be 
released from the organelles after contact with the red blood cell. One such 
receptor, AMA-1, may be required to establish the apical interaction and is likely 
to represent a key link between the weak initial contact involving MSPs and 
irreversible tight associations to be formed subsequently (Cowman and Crabb 
2006). Antibodies to AMA1 have been shown to inhibit erythrocyte invasion and 
parasite growth in vitro, indicating that AMA1 is also an attractive vaccine target 
(Kocken et al. 2002). Moreover, as AMA1 is expressed by sporozoites as well as 
merozoites, targeting AMA1 may have the additional advantage of attacking two 
stages of the parasite’s life cycle. However, since the location of AMA1 within 
organelles may protect the parasite from neutralization by limiting their exposure 
to antibodies, the protective effects of antibodies to AMA1 is not entirely 
explainable. 
 
Two other families of Plasmodium apical receptors are involved in 
invasion. The Duffy-binding-like (DBL) family is named after the receptor of P. 
vivax that binds the Duffy blood group protein on the surface of red blood cell. 
Whereas P. vivax possesses a single DBL protein, P. falciparum has several that 
can use receptors other than Duffy. Thus, P. falciparum merozoites will invade 
erythrocytes regardless of whether they are Duffy-positive. Although a second 
family, the Reticulocyte-binding-like (RBL) parasite proteins, has been 




and Crabb 2006). However, P. vivax RBL proteins (PvRBP1 and PvRBP2) bind 
specifically to reticulocytes but not normocytes, suggesting that they are 
responsible for the host-cell preference of this species (Galinski et al. 1992). It is 
possible that each DBL or RBL may mediate specific routes of invasion, 
providing the merozoite with a broad redundancy in invasion pathways. Once 
apical interaction has occurred, the invading merozoite establishes a tight 
junction between the parasite and host membrane. The tight junction moves from 
the apical to the posterior end of the merozoite in a manner that appears to be 
powered by the parasite’s actin-myosin motor (Keeley and Soldati 2004). One of 
the most conspicuous events is the “shedding” of the fuzzy coating covering the 
merozoite surface, a proteolytic event involving SUB2, a serine protease 
(“sheddase”) (Harris et al. 2005). While the TRAP protein interacts with skeletal 
proteins in malaria sporozoites to bring the parasite into the vacuole, the protein 
or proteins that link to the actin-myosin motor have not been specifically 
identified in merozoites. Malaria parasites have intracellular signaling pathways 
mediated by phosphoinositide, cyclic AMP and calcium-dependent mechanisms. 
However, the merozoite surface molecules that recognize the red blood cell 
surface and the signaling pathway that starts the invasion process remains 
unknown.  
 
Although both P. falciparum and P. vivax can cause severe anemia, only 
P. falciparum causes the many complications caused by sequestration. The 
variant antigen family of PfEMP1 is central to host-parasite interaction and 
pathogenesis in P. falciparum. PfEMP1 expressed on the surface of infected red 




receptors through its multiple adhesion domains. PfEMP1 may be responsible for 
(1) sequestration for evading spleen-dependent killing, (2)  antigenic variation, 
(3) binding of uninfected erythrocytes (rosetting), and (4) clumping of infected 
erythrocytes. Upon maturation, the egress of the merozoites involves changes 
that destabilize the infected cell cytoskeleton to disperse the nonmotile 
merozoites (Glushakova et al. 2005). Proteases appear to be involved and 
candidate proteases include members of the serine repeat antigen (SERA) family 
that localize to the parasitophorous vacuole (Hodder et al. 2003; Miller et al. 
2002b). The SERA family is also required in mosquito stages for sporozoite 
egress from oocysts, validating a role in host-cell rupture for plasmodial 
proteases (Aly and Matuschewski 2005). However, there is yet no evidence that 
SERAs exhibits any protease activity. 
 
2.2 GLYCOLYTIC PATHWAYS 
Asexual erythrocytic-stage P. falciparum require glucose for growth, 
which cannot be replaced by ribose, mannose, fructose, or galactose (Geary et al. 
1985). The asexual-stage store no energy reserves in the form of lipids or 
glycogen. As such, blood glucose serves as its direct energy source. P. 
falciparum-infected RBCs use up to 100 times more glucose than uninfected cells 
as a result of parasite-derived glycolytic enzymes (Roth et al. 1982). This rapid 
metabolic rate suggests that plasmodial glycolytic enzymes are essential for the 
survival of the parasite, and that they may have unique biochemical and/or 
structural features, providing support for their exploitation as drug-targets. 
Virtually all of the glucose can be accounted for by the production of lactate and 




regeneration of NAD from NADH produced during glycolysis (Lang-Unnasch 
and Murphy 1998). The dependence of P. falciparum on glycolysis has motivated 
research into inhibitors of this pathway. Lactate dehydrogenase (pfLDH) was the 
first structure determined from P. falciparum (Dunn et al. 1996). Although 
comparison of 3D structures between the P. falciparum and human enzymes 
indicated that selective inhibitors to the parasite enzyme should be possible via a 
structure-based drug design approach (Mehlin 2005), no clinical candidate has 
been found yet (MMV website: www.mmv.org).  
 
Typically, the glycolytic pathway has eleven enzymes to convert glucose 
to lactic acid. Most of the P. falciparum enzymes used for fermentation of 
glucose during asexual erythrocytic growth have now been characterized 
enzymatically and/or genetically (Table 2-1). Crystal structures are now available 
for triosphosphate isomerase, aldolase and phosphoglycerate kinase (Mehlin 
2005). Although most of the glucose utilized by the parasite is converted to 
lactate, some of the glycolytic intermediates may be diverted for synthetic 
purposes. For example, enzymes of the pentose phosphate pathway have been 
identified. This pathway probably provides some of the ribose sugars needed for 
nucleotide metabolism. Similarly, the further metabolism of pyruvate may 
provide intermediates in several biosynthetic pathways. 
 
Hexokinase, phosphofructokinase, and pyruvate kinase are considered to 
be rate-limiting and hence important regulatory enzymes in the glycolytic 
pathway. When cellular levels of ATP generated through glycolysis is high, ATP 




inhibit the vitally important glycolytic pathway. Consistent with their suggested 
importance, elevation of phosphofructokinase levels, and extreme elevations of 
hexokinase and pyruvate kinase levels, were noted in erythrocytes infected with 
P. falciparum parasites (Roth et al. 1988). The current status of these key 
glycolytic enzymes in Plasmodium in comparison to other protozoan parasites is 
shown in Table 2-2. In particular, pyruvate kinase straddle at a major metabolic 
intersection, since its substrate, phosphoenopyruvate (PEP), is both an 
intermediate in glycolysis as well as in synthesis of other metabolites. Moreover, 
studies have indicated that increase in pyruvate kinase levels may lead to the 
sharp decline in the 2,3-diphosphoglycerate content of infected erythrocytes, 
contributing to hypoxia during malaria (Dubey  et al. 2003). Pyruvate kinase has 
been cloned and characterized in Trypanosoma brucei, Toxoplasma gondii, and 
Leishmania mexicana (Maeda et al. 2003; Ernest et al. 1998; Ernest et al. 1994). 
In these organisms, pyruvate kinase is highly regulated by effectors such as 
fructose-2,6-phosphate and glucose-6-phosphate, indicating that this enzyme may 
play important regulatory roles in glycolysis in these parasites. In P. falciparum, 
this enzyme appears to be increased drastically (>11-fold) upon infection (Roth et 
al. 1988). As this enzyme has not been studied in P. falciparum, one objective of 
this study was to clone and characterize pyruvate kinase (designated PK1) from 
P. falciparum. As a result, the functional authentication of this enzyme is 
reported in this study (Chan and Sim 2004a). Like the T. brucei, T. gondii, and L. 
mexicana enzymes, PK1 from P. falciparum was also found to be highly 
regulated (this study). These observations indicate that P. falciparum pyruvate 





Further studies to investigate the usefulness of pyruvate kinase as a drug-
target must take into account presence of alternative copies of enzymes that may 
circumvent the target. In this study, an inspection of the genome data of P. 
falciparum uncovered a putative ORF that may encode another pyruvate kinase 
(designated PK2). Investigations on the expression of both PK1 and PK2 during 
infection, as well as their structural comparison, are important criteria in 
considering pyruvate kinase as a drug-target. Hence, in this study, the active 
transcription of PK1 and PK2 in the intraerythrocytic stages in in vitro cultures 
was investigated. As a result, experimental evidence for the expression of both 
genes during the blood stages of malaria infection was provided (Chan et al. 
2006b). 
 
Malate dehydrogenase is a primary anaplerotic enzyme that converts 
malate to oxaloacetate. This reaction produces two important products: NADH or 
NADPH as reducing equivalents, and oxaloacetate (OAA), a metabolic substrate. 
In eukaryotic cells, there are two MDH isozymes, the cytosolic and the 
mitochondrial forms. The former is involved, together with aspartate 
aminotransferase, in the transfer of reducing equivalents from the cytosol to the 
mitochondrion, whereas the latter is one of the tricarboxylic acid cycle enzymes 
(Gietl 1992). MDHs present in microbodies are thought to be involved in 
distributing substrates, as well as reducing equivalents, among different 
intracellular compartments (Gietl 1992). The existence of different MDHs are 
thought to play an important role in metabolic channeling, thus contributing to 
cellular organization during growth. Malate dehydrogenase (MDH) is 




the reoxidation of reduced NAD for glycolysis in P. falciparum, serving a role 
that is complementary to that of lactate dehydrogenase (Lang-Unnasch and 
Murphy 1998; Fig. 2-1). MDH has also been studied in Trypanosoma brucei 
(Anderson et al. 1998; Vernal et al. 2001) and Giardia lamblia (Roger et al. 
1999). In G. lamblia, a cytosolic MDH is part of a three-enzyme pathway 
coupled to the cofactor pairs NADP/NADPH (Lindmark 1980; Ellis et al. 1993; 
Sanchez et al. 1996). As yet, there is no study on genes encoding MDHs in 
Plasmodium. However, since malarial parasites are thought to be particularly 
sensitive to oxidative stress during infection, it has been suggested that pathways 
of the parasite’s redox reactions, such as those for NADH- or NADPH-
regeneration, are crucial for the organism’s survival and thereby become 
prominent targets for rational drug development. Hence, it is worthwhile to 
investigate the role of specific MDHs in P. falciparum. Both malate and lactate 
dehydrogenases are members of a large family of homologous dehydrogenases 
(Madern 2002). The structural basis of substrate specificity have also been 
identified for both LDH and MDH in porcine enzymes (Chapman et al. 1999). 
Reportedly, MDH has a positively charged residue (Arg at position 81, pfMDH 
numbering) that forms hydrogen bonds with the second carboxyl group of the 
OAA, whereas in LDH, an uncharged residue (generally a Gln) is usually found 
at this position. Interestingly, a P. falciparum LDH (designated pfLDH) cloned 
earlier (Bzik et al. 1993) was subsequently re-designated as being a MDH based 
on phylogenetic and sequence studies (Madern 2002). Intriguingly, inspection of 
its genome sequence data revealed the existence of yet another ORF encoding 
MDH. The cloning of this uncharacterized ORF, and demonstration of its 
biochemical functionality, is herein reported (Chan and Sim 2004b).  
Chapter 2 
 
Fig. 2-1.  Pathways of carbohydrate metabolism in P. falciparum.  
DHAP, dihydroxyacetone-phosphate. Dotted lines represent 
multiple enzymatic steps. ∆ marks genes cloned for the 


















Table 2-1. Status of research of glycolytic enzymes of P. falciparum. 
Enzyme name Gene 






Hexokinase Yes 26% The hexokinase enzyme activity, protein and 
mRNA levels in the erythrocytic-stage P. falciparum 
parasites have been characterized (Olafsson et al. 
1992). The enzyme has been localized to the 
cytosol as well as membrane structures (Olafsson 




Yes 34% The enzyme activity from P. falciparum has been 
characterized (Sherman 1998a). The synthesis of 






Only the enzyme from P. berghei has been studied 
in detail (Buckwitz et al. 1990). The enzyme activity 
has been detected in asexual-stage P. falciparum 
parasites (Roth et al. 1988).  
Aldolase 
 
Yes 55% Antibodies to aldolase were used to localize it in a 
soluble cytoplasmic form and in a membrane-
associated, inactive form (Knapp et al. 1990). 
Evidence suggests that aldolase may associate 
with other glycolytic enzymes by association with 




Yes 45% The gene from P. falciparum has been expressed 
in E. coli, with the resultant protein shown to be 





Yes 64% Recombinant glyceraldehyde-3-phosphate 
dehydrogenase of P. falciparum has been 
expressed in E. coli. The purified recombinant 






60% Recombinant 3-phosphoglycerate kinase of P. 
falciparum has been expressed in E. coli. The 
purified recombinant protein was enzymatically 




No 56% No study so far. This enzyme was not detectable in 







Pal-Bhowmick et al. 2004 cloned, over-expressed 
and purified enolase from P. falciparum in E. coli in 
an active form. Polyclonal antibodies raised against 
P. falciparum enolase was used to localize the P. 
yoelii enolase to the cytosol of parasites from 
infected mice.  
Pyruvate kinase No 44% Although this enzyme has been identified in P. 
falciparum (Roth et al. 1988), there is little 
information on its characteristics.  
Lactate 
dehydrogenase 
Yes 57% Lactate dehydrogenase was one of the first 
plasmodial enzymes to be characterized. It was 
kinetically distinct from the host enzyme (Bzik et al. 
1993).  
                                                 




Table 2-2. Summary of current status of research on genes encoding the 
three key glycolytic enzymes hexokinase, 
phosphofructokinase, and pyruvate kinase in P. falciparum, 
other Plasmodium spp., and other protozoan parasites. 
Accession numbers stated are based on PlasmoDB. 
 
 P. falciparum Other Plasmodium Other parasites 
Hexokinase Present in genome 
(PFF_1155w). Gene 
cloned and functionally 
expressed (Olafsson and 
Certa 1994).  
 
Putative gene identified in 
P. yoelii and P. berghei 
draft genome sequences. 
Cloned and characterized 
in Toxoplasma gondii 
(Saito et al. 2002).  
Phosphofructokinase Present in genome 
(PFI0755c).  
 
Putative gene identified in 
P. chabaudi and P. 
berghei draft genome 
sequences. 
 
Cloned and characterized 
in Leishmania donovani 
and Entamoeba 
histolytica (Lopez et al. 
2002; Saavedra et al. 
2005). 
 










Presence of additional 
putative ORF encoding 
another pyruvate kinase 
(PF10_0363). 
 
Putative PK1 identified  in 
P. yoelii, P. berghei, and 








Putative PK2 identified in 
P. yoelii, P. berghei, and 
P. chabaudi draft genome 
sequences. 
Cloned and characterized 
in Trypanosoma brucei, T. 
gondii, and Leishmania 
mexicana (Maeda et al. 
2003; Ernest et al. 1998; 
Ernest et al. 1994). In 
these organisms, 
pyruvate kinase is highly 
regulated. 
 
Putative PK2 only 






Table 2-3. Status of research of TCA cycle and related enzymes. 































In P. falciparum, only one pyruvate 
dehydrogenase complex was identified. 
It possesses apicoplast targeting 
sequence, and was located in the 
apicoplast (Foth et al. 2005). It 










No One malate dehydrogenase enzyme 
has been identified to be present in 
trophozoites of P. falciparum (Lang-
Unnasch 1992).  
Citrate synthase No Yes 42% Yes There is very little information for this 
enzyme, except that the citrate 
synthase leader sequence was shown 
to direct GFP to the parasite’s 
mitochondria (Tonkin et al. 2004).  
Aconitase Yes 
 
Yes 53% Yes Recombinant P. falciparum aconitase 
expressed in E. coli showed aconitase 
activity (Hodges et al. 2005). The 
enzyme was localized to the parasite’s 







64% Yes Partial purification of an NADP-specific 
isocitrate dehydrogenase from P. 
knowlesi indicated that it is localized in 
the cytosolic fraction (Sahni et al. 
1992). In P. berghei parasite-specific 
isocitrate dehydrogenase was not 
detectable (Howells and Maxwell 1973).
α-ketoglutarate 
dehydrogenase 





Yes No activity of this enzyme was 
detectable. However, dihydrolipoamide 
dehydrogenase (an integral component 
of α-ketoglutarate dehydrogenase) has 
recently been localized to the 










Yes There is no information on this enzyme, 
except that genes encoding this 
enzyme are predicted to be present in 









Yes The P. falciparum genes for the 
catalytic subunits have been cloned and 
their expression in asexual stages 









No There is very little information except 
that the gene was identified in P. 
falciparum genome by prediction 
methods. 
                                                 




Table 2-4. Summary of evidence for and against the operation of the 
TCA cycle in the erythrocytic-stages of P. falciparum. 
 
For  
1. All the TCA cycle enzymes are present in the P. falciparum 
genome (Gardner et al. 2002). 
2. Genes encoding TCA cycle enzymes are transcribed during 
the erythrocytic-stages (Bozdech et al. 2003).  
3. The transcript levels of TCA enzymes are increased during the 
trophozoite stage, including that of the trigger enzyme, citrate 
synthase (Bozdech et al. 2003). 
4. The expression of TCA cycle genes is synchronized with 
mitochondria genes involved in electron transport suggesting 
that electron transport occurs in asexual stage parasites 
(Bozdech et al. 2003).  
5. Mitochondrial respiration has been reported in asexual 
parasites of P. falciparum (Divo et al. 1985). 
 
6. Malate dehydrogenase, succinate dehydrogenase, aconitase 
and isocitrate dehydrogenase have been detected in the 
asexual stages of P. falciparum (Lang-Unnasch  1992, 1995; 




1. The localization of TCA cycle genes is not complete. 
2. Malate dehydrogenase and isocitrate dehydrogenase may be 
cytosolic proteins (Lang-Unnasch  1992, 1995; Sahni et al. 
1992). 
3. The typical connection to glycolysis via pyruvate 
dehydrogenase is not apparent. The expression of pyruvate 
dehydrogenase, which is typically cytosolic in eukaryotic 
systems, has been mapped to the apicoplast of plasmodial 





Fig. 2-2. (a) TCA cycle. Enzymes whose localizations are likely to be 
mitochondrial in P. falciparum are indicated by an asterisk 
(*) (for references see Table 2-3); (b) mitochondrial 
respiratory chain metabolism showing potential electron 
donors. The direction of electron flow is indicated by the 
blue arrows. Sites of known inhibitor actions are in red. ∆ 












2.3 TCA CYCLE AND MITOCHONDRIA 
The conventional function of mitochondria is in the oxidation of 
substrates fed into the tricarboxylic acid cycle. Electrons from this cycle are fed 
into an electron transport chain at the inner mitochondrial membrane so as to 
generate a proton gradient. The latter is in turn harnessed by ATP synthase to 
generate ATP in a process called oxidative phosphorylation. The development of 
cristate mitochondria is generally associated with the presence of an active TCA 
cycle and mitochondrial respiration. Early studies indicated that the mitochondria 
in erythrocytic-stage avian malaria parasites such as Plasmodium lophurae are 
cristate (Aikawa 1966), while those of rodent and most other mammalian malaria 
parasites are acristate (Ladda 1969). The asexual erythrocytic P. falciparum 
parasite has a single acristate mitochondrion (Slomianny and Prensier 1986). 
During gametocyte formation, macrogametocytes begin to show a marked 
increase in cristate mitochondria (Sinden 1982), suggesting that there may be 
metabolic changes in the mitochondrion during the parasite’s life cycle. Hence, 
early studies have led to the notion that erythrocytic-stage avian parasites appear 
to use some respiratory metabolism, but mammalian parasites of this stage, 
including P. falciparum, appear to depend on fermentative metabolism (Scheibel 
1988, Sherman 1979). However, recent studies have detected a functional 
respiratory chain, as well as several TCA cycle and respiratory chain enzymes in 
the asexual stages of P. falciparum. Hence, in contrast to the well-characterized 






Energy generation via the TCA cycle requires the presence of all eight 
enzymes of the TCA cycle (Fig. 2-2a). However, it should be noted that the TCA 
cycle may have biosynthetic roles even if only some of the enzymes are present. 
The current status of plasmodial TCA cycle and related enzymes is summarized 
in Table 2-3. Conventionally, the tricarboxylic acid cycle is fed by acetyl-CoA, a 
2-carbon substrate derived from pyruvate (produced in cytosolic glycolysis) via 
the action of pyruvate dehydrogenase. However, the TCA cycle appears to be 
atypical because efforts to identify activities of three TCA cycle enzymes in 
asexual erythrocytic-stage P. falciparum have led to unusual observations (Table 
2-4). No parasite-specific activity could be detected for α-ketoglutarate 
dehydrogenase (Billker et al. 1998), while the parasite-specific activities of 
malate dehydrogenase (Lang-Unnasch  1992, 1995) and isocitrate dehydrogenase 
(Sahni et al. 1992) appeared to be cytoplasmically localized and may participate 
in other metabolic pathways. Importantly, the inability to feed glycolytic 
products into the TCA cycle was supported by the observation that, although P. 
falciparum contains a pyruvate dehydrogenase, it is localized to the apicoplast 
(Foth et al. 2005).  
 
Typically, eukaryotic cells contain two genetically distinct, cytoplasmic 
and mitochondrial compartmentalized isoenzymes of malate dehydrogenase. 
Only the mitochondrially located isoenzyme functions as part of the TCA cycle. 
The cytosolic malate dehydrogenase is important for gluconeogenesis (Lardy et 
al. 1965) but both forms function together in the malate-aspartate shuttle by 
which the cell controls the distribution of reducing equivalents between the 




from P. falciparum (Lang-Unnasch  1992), it appears that the only malate 
dehydrogenase isoenzyme present in asexual erythrocytic-stage parasites does 
not function in the TCA cycle. An interesting characteristic of the P. falciparum 
malate dehydrogenase purified from trophozoites is its resistance to substrate 
inhibition by oxaloacetate. Since all mitochondrial malate dehydrogenases 
exhibit inhibition by oxaloacetate while cytosolic forms do not (Lang-Unnasch  
1992), it appeared that the malate dehydrogenase from P. falciparum is likely to 
be cytosolic. Further studies are needed to demonstrate that the enzyme is 
actually located in the cytoplasmic compartment of P. falciparum. Furthermore, 
if the P. falciparum trophozoite malate dehydrogenase is indeed a cytosolic 
enzyme, it is unlikely that its function is gluconeogenesis, since during 
intraerythrocytic growth glucose is supplied by the human host. However, one 
possible function might be the regeneration of reducing equivalents in a manner 
analogous to lactate dehydrogenase (section 2.2). 
 
An isocitrate dehydrogenase that is dependent on NADP has been 
identified in P. falciparum infected RBCs (Vander-Jagt et al. 1989). Partial 
purification of an NADP-specific isocitrate dehydrogenase from Plasmodium 
knowlesi indicated that it is localized in the cytosolic fraction (Sahni et al. 1992). 
Assuming that the P. falciparum and P. knowlesi NADP-specific isocitrate 
dehydrogenases are similar, it is unlikely that they function in the TCA cycle. 
Hence, if the NADP-dependent isocitrate dehydrogenase is localized in the 
mitochondria, this would provide evidence for a biosynthetic or energetic role of 
this enzyme in the mitochondria of erythrocytic-stage P. falciparum. Intriguingly, 




Plasmodium berghei infected RBCs, although oocysts could be shown to contain 
parasite-specific isoenzymes of both an NADP- and an NAD-dependent isocitrate 
dehydrogenase (Howells and Maxwell 1973).  
 
Succinate dehydrogenase is a TCA cycle enzyme and is referred to as 
Complex II of the electron transport chain. It contains a flavin adenine 
dinucleotide (FAD) by which electrons are transferred directly to ubiquinone. 
Succinate dehydrogenase activity has been demonstrated in subcellular fractions 
enriched for the mitochondria of asexual erythrocytic-stage P. falciparum or P. 
yoelii (Fry and Beesley 1991). Genes for the flavoprotein and iron-sulphur-
containing subunits of succinate dehydrogenase of P. falciparum have been 
sequenced (accession nos. D86573 and D86574). It has been suggested that in 
asexual erythrocytic-stage P. falciparum, succinate dehydrogenase together with 
an NADH-fumarate reductase might carry out a cyclic interconversion of 
succinate and fumarate to help reoxidize NADH (Fry 1991). As yet, no NADH-
fumarate reductase activity has been identified in Plasmodium, and fumarate does 
not stimulate respiration by P. falciparum or P. yoelii mitochondria (Fry 1991). 
Thus, the role of succinate dehydrogenase in the asexual cycle of these parasites 
remains unclear.  
 
Piecing together current data, recent accumulating evidence suggests the 
physiological significance of the TCA cycle and the electron transport chain 
enzymes in the intraerythrocytic-stages of P. falciparum, even though the roles of 
these enzymes in energy production is not yet fully understood. The TCA cycle 




stages in the absence of a complete TCA cycle. For the complete TCA cycle to 
function, there must be an available source of acetyl-CoA. Intriguingly, in the 
absence of a mitochondrial pyruvate dehydrogenase, this source is unlikely to be 
glycolysis. Nevertheless, it should be noted that acetyl-CoA can be alternatively 
generated through the breakdown of amino acids, via a decarboxylation step 
catalyzed by a branched-chain α-keto acid dehydrogenase. P. falciparum contains 
homologues of all the subunits of this complex ie. E1A (PF13_0070), E1B 
(PFE0225w) and E2 (PFC0170c). The E3 (dihydrolipoamide dehydrogenase) 
subunit appear to be shared with the α-ketoglutarate dehydrogenase (McMillan et 
al., 2005). Determining the source of mitochondrial acetyl-CoA is of a high 
priority in understanding the metabolism of this organelle.  
 
2.4 ELECTRON TRANSPORT 
Despite earlier studies showing acristate mitochondria in P. falciparum, 
there is substantial evidence that asexual erythrocytic-stage P. falciparum have a 
functional electron transport chain. The classical electron transport or respiratory 
chain consists of NADH dehydrogenase (Complex I), succinate dehydrogenase 
(Complex II), ubiquinone, and the cytochromes c, b+c1 (Complex III) and 
cytochrome oxidase (Complex IV). A diagrammatic representation of the 
predicted electron transport pathway in P. falciparum is shown in Fig. 2-2b. 
Extensive searching of the P. falciparum nuclear genome failed to uncover any 
complex I homologues. Consistent with bioinformatics data, purified P. 
falciparum mitochondria do not oxidize NAD-linked substrates, such as α-
ketoglutarate, malate, or pyruvate (Fry 1991). Electrons donated along the 




including complex II, glycerol-3-phosphate dehydrogenase, and dihydroorotate 
dehydrogenase. However, all converge at ubiquinone (coenzyme Q) an 
isoprenoid-containing membrane protein. Thus, the plausibility of electrons 
donated from NADH and NADPH depends on the clarification of the status of 
Complex I and the localization of glycerol-3-phosphate dehydrogenase.  
 
Significantly, a mitochondrial membrane-potential is detectable in 
intraerythrocytic stage P. falciparum parasites (Srivastava et al. 1997). The anti-
malarial compound atovaquone, an inhibitor of complex III, collapses this 
membrane- potential and inhibits parasite respiration, clearly demonstrating that 
mitochondrial functions are essential for parasite survival (Fry and Beesley 
1991). Cytochrome oxidase in P. falciparum has been investigated indirectly by 
assaying the sensitivity of mitochondrial membrane-potential to inactivation by 
cytochrome oxidase inhibitors. As a result, the membrane-potential in P. 
falciparum trophozoites (Divo et al. 1985) but not late-stage gametocytes (Kato 
et al. 1990) was diminished by 1 mM cyanide or 1 mM azide. Strangely, the 
steady-state level of cytochrome-b RNA in late-stage gametocytes is 7-fold 
higher than in asexual erythrocytic P. falciparum as measured using quantitative 
RT-PCR (Petmitr and Krungkrai 1995).  
 
In the alternative respiratory pathway of plants and some fungi, an 
alternative oxidase transfers electrons directly from ubiquinone to oxygen, 
resulting in cyanide-resistant respiratory activity (McIntosh 1994). Milhous et al. 
(1985) observed that 2 mM of cyanide inhibits only about three quarters of the 




oxygen consumption is reportedly sensitive to salicylhydroxamic acid (SHAM) 
and propyl gallate, both well-characterized alternative oxidase inhibitors 
(Murphy et al. 1997). Consistent with evidence for a branched respiratory 
pathway in P. falciparum, SHAM and propyl gallate can potentiate the classical 
respiratory pathway inhibitor, atovaquone. As expected. both SHAM and propyl 
gallate reduced the number of asexual parasites by 70–75%, whereas under the 
same conditions, the number of late-stage gametocytes was reduced by only 25%. 
However, mitochondrial membrane potential in late-stage P. falciparum 
gametocytes is more readily diminished by 1 mM of SHAM or SHAM and 
cyanide than by cyanide alone (Murphy and Unnasch 1994). Since SHAM affects 
mitochondrial membrane potential but not gametocyte survival, the alternative 
respiratory pathway may increase in gametocytes but may be more functionally 
important in the mosquito stages of the parasite’s life-cycle. 
 
2.5 OTHER METABOLIC PATHWAYS 
2.5.1 Fatty acid synthesis 
The type II fatty acid synthase is found in plants and prokaryotes, whereas 
the type I fatty acid synthetase is found in yeast and metazoa. Enzymes 
associated with the type II fatty acid synthesis pathway have been identified in 
Plasmodium and appear to be located in the apicoplast and have apicoplast-
targeting sequences (Lang-Unnasch and Murphy 1998). This pathway appears to 







 2.5.2 Amino acid utilization and redox metabolism  
 The most abundant source of amino acids is from the degradation of 
hemoglobin in the food vacuole (Fig. 2-3a). However, the resultant free heme 
released is toxic due to its ability to lyse membranes. Most of the free heme is 
detoxified by polymerization into hemozoin, the malarial pigment. It is well 
known that chloroquine and other 4-aminoquinolines inhibit pigment formation, 
thereby preventing the detoxification of heme (Pagola et al. 2000; Ursos and 
Roepe 2002). Although the iron bound to hemoglobin is primarily in the ferrous 
state (Fe2+), the release of the heme results in iron being oxidized to the ferric 
state (Fe3+). Electrons liberated by this oxidation of iron promote the formation of 
reactive oxygen intermediates such as superoxide anion radicals and hydrogen 
peroxide, reactive oxygen intermediates that can cause cellular damage (Golenser 
et al. 1991). Superoxide dismutase (SOD) and catalase are cellular enzymes that 
function to prevent oxidative stress by detoxifying the superoxide and hydrogen 
peroxide, respectively. Both of these activities are found in the food vacuole and 
may have been obtained from the host cytoplasm. Hydrogen peroxide can also be 
exported into the parasite cytoplasm where it is detoxified by catalase and 
glutathione peroxidase. Because it is known that Plasmodium is particularly 
susceptible to oxidative challenge, redox enzymes have been suggested to be 
candidates for drug-targeting. Plasmodium spp. use disulphide-reducing systems 
such as glutathione, glutaredoxin, and thioredoxin systems to cope with oxidative 
stress (Atamna and Ginsburg 1997; Kanzok et al. 2000). It is important to note 
that reducing equivalents required for the maintenance of reducing systems 




generating enzymes such as ICDH and MDH, may play important redox roles in 
P. falciaprum. 
 
2.5.3 Nucleotide and nucleic acid synthesis 
The malarial parasite obtains preformed purines via the salvage pathway 
(in which nucleotides are synthesized by phosphoribosylation of preformed 
adenine, guanine, and hypoxanthine), and synthesizes pyrimidines de novo (Fig. 
2-3b). Since the host can obtain both types of bases by either pathway, it may be 
possible to exploit the parasite's limited capability in nucleotide metabolism. The 
primary purine salvaged by the parasite is hypoxanthine which can be obtained 
from the host plasma. Through a series of reactions the hypoxanthine is 
converted into ATP and GTP (or deoxy- ATP and GTP) and incorporated in 
RNA (or DNA).  
 
The parasite cannot utilize preformed pyrimidines and must synthesize 
them from bicarbonate and glutamine (Sherman 1998b). Pyrimidine synthesis 
involves an electron transport in which dihydroorotate dehydrogenase transfers 
electrons to an electron transport chain involving ubiquinone, cytochrome and 
molecular oxygen (Sherman 1998b), a step that is probably located in the 
mitochondria. Pyrimidine synthesis also requires folates as co-factors. 
Dihydrofolate is reduced to tetrahydrofolate by dihydrofolate reductase (DHFR). 
Several anti-malarials, such as pyrimethamine and cycloguanil, preferentially 
inhibit parasite DHFR. The tetrahydrofolate is methylated by serine 
hydroxymethyl transferase and the resulting methylene tetrahydrofolate functions 




dUMP by transferring the methyl group from methylene tetrahydrofolate. During 
this reaction, the methylene tetrahydrofolate is converted back to dihydrofolate, 
which is then recycled. Sulfadoxine inhibit the de novo synthesis of 
dihydrofolate. Fansidar, a combination of sulfadoxine and pyrimethamine, 
inhibits folate metabolism at two distinct places in the pathway (Panisko and 
Keystone 1990).  
Chapter 2 
 
Fig. 2-3.  (a) Hemoglobin degradation and its relation to redox 
pathways. GR, glutathione reductase; GSH, reduced 
glutathione; GSSG, oxidized glutathione. 
 (b) Nucleotide synthesis pathway and its relation to folate 
synthesis. Sites of inhibitor actions are in red. DHOD, 






















2.6 PROTEIN TRAFFICKING 
In eukaryotic cells, specific molecules are compartmentalized in 
organelles so as to carry out defined functions. Hence, determining what proteins 
are imported into an organelle is useful in formulating hypotheses about their 
roles. In addition to the endoplasmic reticulum, Golgi apparatus and 
mitochondria, trafficking in Plasmodium parasites also involves targeting to three 
distinctive apical organelles thought to be central to the invasion process  (Binder 
and Kim K 2004) - the micronemes, rhoptries and dense granules. Besides the 
apical organelles, plasmodial proteins can also be imported into other specialized 
organelles, such as the apicoplast and food vacuole, or exported to the host 
erythrocyte.  
 
In eukaryotes, proteins that are imported into the mitochondrial matrix 
must cross both the outer and inner mitochondrial membranes. As such, N-
terminal mitochondrial-transit peptides (mTPs) are thought to be necessary to 
direct preproteins to the mitochondria via interaction with the import machinery 
present on the mitochondrial membranes. Since the cellular localization of a 
protein is crucial to understanding its physiological function, a part of this study 
involved the functional analysis of mitochondrial-targeting signals present in 
certain TCA cycle proteins using a cellular approach. However, a search in 
current literature revealed that very little is known about the transport machinery 
in Plasmodium. In eukaryotes, the import machinery consists of two import 
complexes, TOM (translocase at outer membrane) and TIM (translocase at inner 
membrane) complex. The two central components of the TOM machinery are the 




protein Tom40 (Hill et al. 1998). The TIM complex comprises the pore-forming 
subunit Tim23, Tim17 (Dekker et al. 1997) and Tim50 (Geissler et al. 2002). The 
import motor on the matrix side, which incorporates the mitochondrial heat shock 
protein 70, drives the completion of protein transport into the matrix. A form of 
Tom22 have been identified in P. falciparum (Macasev et al. 2004). Despite this, 
there are no further studies on TOM and TIM complexes from Plasmodium. 
However, other studies have shown that the protein cargo destined for the 
nucleus is tagged with a nuclear localization signal (NLS) that is recognized by 
specific transport receptors (importins). Importins carry their cargo through 
nuclear pore complexes, which are large structures plugged through the double 
membrane of the nuclear envelope. Mohmmed et al. (2003) identified and cloned 
genes encoding importins from P. falciparum, and suggested that nuclear import 
mechanism in Plasmodium is highly conserved as in other organisms. However, 
no functional studies on plasmodial importins have yet been reported.   
 
Although a bioinformatic approach is possible to point functions to 
certain organelles, both localization and biochemical data are necessary to 
validate the predicted theoretical pathways. Although the use of green fluorescent 
protein (GFP) is a valuable approach for exploring cellular localization of 
proteins, progress in plasmodial protein trafficking has been hampered by the 
lack of an efficient method to transfect parasites. A simple yet reliable method 
for studying subcellular localization of plasmodial proteins is needed to 
substantiate the prediction of the subcellular localization of apicomplexan 
proteins. In this study, a simple method to study sorting of P. falciparum proteins 




transgenic parasites is reported. As a result, it was shown that that sorting signals 















CHAPTER 3 GLOBAL STUDIES ON P. 
FALCIPARUM 
 
3.1 MALARIA RESEARCH IN THE POST-GENOMIC ERA 
 An international effort was launched in 1996 to sequence the 14 
chromosomes of the P. falciparum genome, with the expectation that the genome 
sequence would open new avenues for research. Mainly due to the extreme AT 
bias of the genome, it took almost seven years to complete the 22.8-Mb nuclear 
genome (Gardner et al. 2002). Subsequently, significant amounts of genome data 
became available from P. vivax (Carlton 2003), as well as from the rodent 
malaria parasites P. yoelii, P. berghei and P. chabaudi (Kooij et al. 2006). 
Together with transcriptomics and proteomics data for P. falciparum, P. berghei 
and P. yoelii, it is now possible to engage in the latest global-survey approach for 
malaria research.  
 
In addition, the modification the erythrocyte by malaria parasites, via 
secretion of proteins into the erythrocyte cytosol or membrane, is deemed 
significant in the disease process. Two studies have independently identified a 
conserved bipartite sequence motif present in such secreted proteins (Table 3-1), 
comprising of a canonical N-terminal secretory signal sequence followed by a 
conserved motif termed Plasmodium export element (PEXEL) (Marti et al. 2004) 
or the vacuolar transport signal (VTS) (Hiller et al. 2004). In both studies, 
deletion of Pexel/VTS or point mutation of conserved amino acids within 




parasitophorous vacuole. Predictions using this signal sequence defined a 
‘secretome’ of 300-400 proteins for P. falciparum, some of which are likely to be 
involved in the remodeling of the host erythrocyte. Recently, the first large-scale 
analyses of interactions between proteins during the asexual blood stages of P. 
falciparum have been published using a high-throughput yeast two hybrid assay 
(Table 3-1). However, although clusters of interacting proteins could be 
identified, especially one implicated in host invasion, many of the interactions 
identified involved uncharacterized proteins. Finally, in an effort to understand 
structure-function relationships of plasmodial proteins, the US National Institutes 
of Health (NIH) funded an initiative to attempt a high-throughput elucidation of 
three-dimensional structures of plasmodial proteins (section 3.4).  
 
3.2 GENOME SEQUENCE OF P. FALCIPARUM 
The overall AT composition of the P. falciparum genome is 80.6%, but 
rises to 90% in introns and intergenic regions. Using several gene-finding 
programs and manual curation, approximately 5300 protein-encoding genes were 
identified (Gardner et al. 2002). Introns were predicted in 54% of P. falciparum 
genes, a proportion roughly similar to that in Schizosaccharomyces pombe and 
Dictyostelium discoideum, but much higher than observed in Saccharomyces 
cerevisiae. The mean length of P. falciparum genes was 2.3 kb, substantially 
larger than those in the other organisms, where the average gene lengths range 
from 1.3 to 1.6 kb. The explanation for the increased gene length in P. 
falciparum was not clear, although many large genes (>4kb) appeared to be 
cytosolic. Of the 5,268 predicted proteins, about 60% (3,208 hypothetical 




justify functional assignments (Gardner et al. 2002). Hence, up to 40% of the 
genes might be unique to the malarial parasite. Curiously, only 8% of the P. 
falciparum genes could be assigned functions in metabolism, compared to 17%  
in the yeast Saccharomyces cerevisiae (Kooij et al. 2006). This suggested either 
that P. falciparum genome encodes fewer enzymes as a consequence of its 
parasitic lifestyle, or that the enzymes were more difficult to identify by sequence 
homology in P. falciparum owing to its great evolutionary divergence from other 
organisms. Similarly, the complement of transport molecules appeared to be 
reduced compared with free-living organisms.  
 
The apicoplast is considered to be a relict plastid harbored by malaria 
parasites and other members of the phylum Apicomplexa (McFadden et al. 
1996). It is thought to be homologous to the chloroplasts of plants, but have 
unclear roles. Proteins are targeted into the apicoplast by the use of a bipartite 
targeting signal, consisting of an amino-terminal signal sequence, followed by a 
plastid transit peptide. As the apicoplast encodes only 30 proteins, its proteome is 
supplemented by nuclear-encoded proteins, which are post-translationally 
targeted into the organelle (Gardner et al. 2002). The genome data showed that 
the apicoplast houses the type II fatty-acid biosynthesis machinery as well as 
proteins responsible for isoprenoid biosynthesis. No evidence was found for the 
type I pathway for fatty-acid biosynthesis common to most eukaryotes including 
humans. However, about 60% of the putative apicoplast-targeted proteins were of 
unknown function (Gardner et al. 2002).  
In erythrocytic stages, P. falciparum relies principally on anaerobic 




(Sherman 1998a). As expected, the genes encoding all of the enzymes necessary 
for a functional glycolytic pathway were identified (Gardner et al. 2002). P. 
falciparum appeared to also have all the genes necessary for the TCA cycle. 
However, the pyruvate dehydrogenase complex was predicted to be localized in 
the apicoplast. Also, malate dehydrogenase appears to be cytosolic rather than 
mitochondrial. Thus, the TCA cycle appeared to be unconventional (Gardner et 
al. 2002). A clear cut conventional electron transport chain could not be 
constructed because NADH dehydrogenase complex I could not be identified. 
Hence, ubiquinone reduction has to be carried out by one or more of the 
dehydrogenases targeted to the mitochondria, such as dihydroorotate 
dehydrogenase. Cytochrome b and c complexes could be identified, but unlike 
most eukaryotes the N and C termini of subunit II of cytochrome c were encoded 
on separate genes.  
 
P. falciparum contains three highly variable gene families termed var, rif 
and stevor, which code for erythrocyte membrane protein 1 (PfEMP1), repetitive 
interspersed family (rifin) and sub-telomeric variable open reading frame 
(stevor), respectively. The 3D7 genome contains 59 var, 149 rif and 28 stevor 
genes, as well as a number of pseudogenes and gene truncations. The var genes 
code for proteins which are exported to the surface of infected red blood cells 
where they mediate adherence to host endothelial receptors. These are important 
virulence factors responsible for the sequestration of infected cells in a variety of 
organs, and hence the development of severe disease (Kyes et al. 2001). The 
genome data was consistent with the notion that transcriptional switching 




Although rifins were known to be expressed on the surface of infected RBCs, the 





Table 3-1. Comparison of current status and major findings of global studies on P. falciparum. 
 









Gardner et al. 2002 • Genome size of 22.8 Mb 
• AT content of 80% 
• No. of genes/ predicted proteins 5268 







Borzdech et al. 2003 
 
• Orderly timing of key cellular functions (“transcripts-to-go” model) 
• Related genes share common expression profiles 






Florens et al. 2002 • 2415 parasite proteins identified 
• 46% of proteins detected in 4 stages (sporozoites, merozoites, trophozoites, and 
gametocytes)  
• 6% were common to all 4 stages (housekeeping proteins) 




Winzeler Laboratory/  
Le Roch et al. 2004 
• 80% of the genes present in the genome are expressed during the asexual blood stages 
• 24% expressed exclusively in blood stages 
• 4294 transcripts and 2904 proteins detected 





Marti et al. 2004; Hiller 
et al. 2004 
• Both studies independently identified a conserved sequence motif (RXLX(E/Q)) in secreted 
proteins, termed either the Plasmodium export element (PEXEL) or the vacuolar transport 
signal (VTS) 
• Bioinformatics predicts a ‘secretome’ of 300–400 proteins (~8% of all genes) 
• Functions of secreted proteins include: host erythrocyte remodeling, heat-shock proteins, 





LaCount et al. 2005 • 2846 interactions identified involving 1312 largely uncharacterized proteins using a yeast-
two-hybrid approach 








• 21 structures from P. falciparum resolved (Mehlin 2005) 
• 36 structures from Plasmodium spp. and other apicomplexan parasites (Vedadi et al. 2006) 




3.3 TRANSCRIPTOME AND PROTEOME  
 Although the identification of genes in the genome provided a global 
depiction of the array of gene products potentially available to the parasite, it is the 
expression of the genes and proteins at the various stages of the parasite life cycle 
that may lead to insights on how the parasite carries out various stage-
developments, interacts with its hosts, or responds to drugs. The full transcriptome 
of the asexual intraerythrocytic developmental stages was uncovered by Bozdech et 
al. (2003) in microarray studies using 70-mer oligonucleotides as probes for ORFs 
predicted in the sequenced genome of strain 3D7. The microarray results revealed a 
striking periodicity in the majority of expression profiles, most of which were 
marked by a single maximum and a single minimum. The transcriptome also 
revealed an orderly timing of key cellular functions, whereby groups of functionally 
related genes shared common expression profiles and demonstrated a programmed 
cascade of cellular processes. Hence, it appeared that the transcripts are produced as 
and when they are required (the ‘transcripts to-go’ model) (Bozdech et al. 2003).  
 
Genes induced during the ring and early-trophozoite stages included those 
involved in transcription, translation, and glycolysis. The glycolysis group was 
tightly co-regulated throughout the intraerythrocytic-stages, and contained all of the 
11 known enzymes (Bozdech et al. 2003). Expression continued to increase toward 
maximal expression during the trophozoite stage, when metabolism was at its peak. 
The peak of expression for all TCA factors was detected during the late-trophozoite 
and early-schizont stage. Consistent with the model suggesting a disconnection of 
the TCA cycle from glycolysis, no expression was detected for pyruvate 




synchronized with the expression of a large number of mitochondrial genes, 
including factors of electron transport. Hence, the expression data suggested an 
association of the TCA cycle with mitochondrial development. Interestingly, 
despite the initial expectation that a high percentage of the genome would be 
specialized for each lifecycle stage (mosquito, liver, blood), this was not observed. 
Instead, the mRNA transcripts for 75% of proteins thought to be gamete-, 
gametocyte-, or sporozoite-specific by the mass spectrometry analyses were also 
found to be transcribed in the intraerythrocytic-stages. These findings suggested 
that the majority of the genome is expressed and possibly utilized throughout the 
parasite’s full life-cycle. Furthermore, the lack of continuous chromosomal domains 
with common expression characteristics suggested that the genes may be regulated 
individually. However, the streamlined characteristics of transcriptional control 
observed in this parasite suggested that perhaps only a small number of 
transcription factors could account for the entire cascade.  
 
Florens et al. (2002) reported a comprehensive proteomic view of four 
developmental stages of P. falciparum, ie. sporozoites, merozoites, trophozoites, 
and gametocytes. These proteomes were analyzed by a combination of high-
resolution liquid chromatography and mass spectrometry. As a result of that study, 
2415 parasite proteins were confidently identified to be representing 46% of the 
gene products. Only 152 proteins (6%) were common to all four stages. Those 
common proteins were mostly housekeeping proteins such as ribosomal proteins, 
transcription factors, histones and cytoskeletal proteins. The sporozoite proteome 
appeared markedly different from the other stages, as almost half (49%) of the 




Le Roch et al. (2004) compared mRNA transcript and protein abundance 
levels for seven different stages of the parasite life cycle (six asexual 
intraerythrocytic, merozoite, late gametocyte, and salivary gland sporozoite) using a 
combination of short oligonucleotide array and mass spectometry. Overall, 4294 
transcripts and 2904 proteins were detected at least once out of the seven stages. 
2584 genes were found in both analyses, representing 89% of the identified proteins 
and 60% of the detected transcripts. Proteins were not found for 2167 (50%) 
transcripts detected during the microararray analysis, suggesting that the microarray 
approach provided a greater depth of detection. 38-40% of the missing proteins 
were predicted to be insoluble, illustrating a bias in the analysis of whole-cell 
lysates against the detection of secreted or membrane proteins. Reassuringly, the 
protein content of the different blood stages agrees well with the presence of 
transcripts of the genes encoding these proteins and, therefore, the proteome data 
generally support the ‘transcripts-to-go’ model. An obvious discrepancy observed 
between mRNA and protein abundance was due to a time shift observed between 
the detection of the transcript and its corresponding protein. However, the signals 
required to cause a significant delay between mRNA and protein accumulation is 
still unclear. Noteworthy, both microarray studies observed clear patterns of stage-
specific gene transcription, as well as pinpointed genes encoding surface proteins 
that might serve as vaccine candidates for specific parasite stages.  
  
3.4 STRUCTURE BASED DRUG DISCOVERY 
For a structure-based drug design approach in antimalarial drug-discovery, 
information on the three dimensional configuration of an active site, particularly in 




crystal structures to screen compounds through strictly computational means, called 
“in silico” or “virtual” screening, is highly attractive, in that compounds that were 
completely different classes from those known to be traditional inhibitors can be 
uncovered. The Structural Genomics of Pathogenic Protozoa (SGPP) is an NIH-
funded project which contains among its components, a systematic effort to clone 
and crystallize P. falciparum proteins for structural studies. However, P. falciparum 
is a challenging organism from which to clone and express proteins. Being 
eukaryotic, the frequent presence of introns in the genes requires the use of cDNA 
for cloning purposes. The genome of P. falciparum is 80% AT-rich and exhibits a 
codon bias with heavy emphasis on AT-rich codons, requiring special 
considerations during PCR, such as the use of longer primers and depressed 
annealing temperatures during thermal cycling. Also, the frequent presence of low-
complexity regions may be expected to lead to amplification errors. Thus, like 
many eukaryotic proteins, P. falciparum proteins were often expressed in E. coli as 
insoluble inclusion bodies. There is also accumulating evidence that P. falciparum 
proteins may bind the DNA and RNA which code for them (Mehlin 2005). In turn, 
this regulatory process may hamper attempts to over-express the protein in a 
heterologous host. It is not uncommon for P. falciparum genes to contain cryptic 
start sites for E. coli, leading to the generation of truncated products (Mehlin 2005). 
Finally, P. falciparum proteins can be as much as 50% longer than their yeast 
orthologues, thereby making them more difficult to clone and express (Aravind et 
al. 2003). As reported in that project, soluble expression of only 5% of their first 
368 targets could be obtained. This attrition rate was due mostly to protein either 
being insoluble or unexpressed (Mehlin 2004), even though the vast majority of 




transmembrane regions. Fig. 3-1 shows the status of 90 of the targeted P. 
falciparum proteins. It was observed that large targets were not expressed at all, 
while the small targets, even when expressed, tended not to be soluble. So far, only 
21 high-value target proteins from P. falciparum have been successfully resolved, 
including dihydrofolate reductase, lactate dehydrogenase and triose phosphate 
isomerase.  
 
Methods employed to gain access to refractory proteins include gene 
modification, the use of added tRNAs, and refolding. For example, low expression 
of P. falciparum enoyl-acyl carrier reductase was considerably enhanced by the 
introduction of 4 silent mutations (Perozzo et al. 2002). And, interestingly, the 
expression of active plasmodial cysteine protease orthologues (falcipains and 
berghepains) were successfully achieved after the exclusion of the N-terminal 
portions by cloning just the active domains (Goh et al. 2005; Chan et al. 2005; Goh 
et al. 2003). The RIG plasmid (Baca and Hol 2000), encoding tRNAs for arginine, 
isoleucine, and glycine, and the RIL plasmid (Stratagene), which encodes arginine, 
isoleucine, and leucine tRNAs, were commonly employed to deal with the codon 
bias of P. falciparum genes. However, it was observed in this study that, whilst RIG 
and RIL plasmids were successfully employed to express pfICDH, pfMDH and 
pfPK1, additional copies of tRNAs provided by these plasmids or N-terminal gene 
truncation were not panacean solutions for plasmodial protein expression, 




Fig. 3-1.  The relationship between molecular weight and expression of 


















CHAPTER 4 STATUS AND OUTLOOK OF 
MALARIA DRUG-TARGETS 
 
4.1  THE NEED FOR NEW ANTI-MALARIAL DRUGS 
For several decades, the gold standard for the treatment of malaria was 
mainly chloroquine. This drug is a 4-aminoquinoline that was previously known 
for its efficacy, low toxicity and affordability (less than US $0.20 for a three-day 
treatment course) (White 1996). Chloroquine acts by binding to heme moieties 
produced from proteolytically processed hemoglobin inside infected erythrocytes, 
thereby interfering with heme detoxification (Fig 2-3). Today, chloroquine 
resistance has spread to the vast majority of malaria-endemic areas, rendering 
this drug ineffective (Ridley 2002). Sulphadoxine-pyrimethamine (commonly 
available as Fansidar; marketed by Roche), an antifolate drug, is the only other 
widely used inexpensive antimalarial. However, therapeutic failure as a result of 
resistance has arisen in many areas in Asia, South America and now Africa 
(Plowe 2003). In essence, the two most widely used and affordable antimalarial 
drugs are failing at an accelerating rates in most malaria endemic regions, leading 
to increasing malaria-related morbidity and mortality. Clearly, new drugs are 
desperately needed to combat malaria. 
 
The immediate prospective drugs to replace chloroquine and 
sulphadoxine-pyrimethamine include amodiaquine (a chloroquine-like quinoline) 
and chlorproguanildapsone (LapDap, another antifolate). However, these 




from some cross-resistance with chloroquine and sulphadoxine-pyrimethamine, 
and full-blown resistance to these drugs are predicted to emerge rapidly 
(Winstanley 2001; Lang and Greenwood 2003). This suggests that current drugs 
lack chemical diversity. Clearly, new drugs are needed which are based on novel 
targets that are not encumbered by existing mechanisms of resistance. 
Fortunately, the determination of the genome sequence of P. falciparum offers a 
multitude of potential drug targets. To this end, advances in understanding the 
biology of this parasite and its disease, are needed to offer improved means of 
characterizing potential targets.  
 
4.2 THE STEPS IN DRUG DISCOVERY RESEARCH 
Despite the collective effort of scientists working on malaria worldwide, 
the number of compounds tested against malaria remains very small compared 
with other diseases that attract more attention in the developed world (Olliaro and 
Yuthavong 1999). Not many new compounds with reasonable chances of 
breaking through as antimalarials can be offered at present. To some extent, this 
reflects the current lack of ability to investigate the most critical metabolic 
pathways of the malaria parasite for drug intervention. Among compounds that 
prove active in inhibiting parasite growth in vitro, only a fraction of them is also 
effective in experimental animals. The latter may then fail at any step of the 
subsequent preclinical and clinical development (Fig. 4-1). The major set-back is 
that the human parasite strains differ from animal strains, such that an ideal 
animal model for anti-malarial drug testing has yet to be established. Hence, drug 





(1) Target identification and validation: research meant to demonstrate 
that the target has potential for efficacy and selectivity, both at the 
target level and in vivo in experimental animals. This is often carried 
out using chemical probes and gene knockout experiments 
employing in vitro cell cultures. There are criteria that must be met 
by a putative target to warrant investigation and to receive attention 
for compound testing (summarized in Table 4-1). 
 
(2) Compound generation: various sources of the molecules for 
screening are explored, ranging from synthesis of rationally 
designed chemotypes, to combinatorial libraries, and to natural 
products. 
 
(3) Lead discovery: the screening for suitable bioactive molecules. This 
involves “classical” in vitro screening (using whole parasites in 
culture) and in vivo testing in animals.  
 
(4) Lead optimization: structure-activity relationship investigation 
focusing on a lead compound for further chemical modification, 
done by a combination of medicinal chemistry and combinatorial 
chemistry. 
 
The initial steps of the research and development process are then 
followed by further confirmation of activity and testing for toxicity before they 




to be confirmed in the parasite growth system (Olliaro and Yuthavong 1999), 
there are technical limitations, in that only P. falciparum blood stages can be 
consistently cultured in vitro. Pre-erythrocytic stages, gametocytes, and P. vivax 
blood stages cannot be systematically cultured and tested. Compounds can be 
tested using a nonisotopic method (Makler et al. 1993) in 96-well plates at a 
rather high throughput. Then, selected compounds are tested in the mouse or 
rodent malaria. While these animal models allow us to have an initial idea of the 
product activity and bioavailability, they suffer from obvious limitations, 
including possible Plasmodium species specificity of antimalarial activity. There 
may also be differences in drug absorption or metabolism of a given compound 
in rodents as compared with humans. Nonhuman primates can also be infected 
with P. falciparum (e.g., Aotus monkey), but this model is more commonly 
employed in confirmatory testing because of ethical and cost limitations. Finally, 
the ease of synthesis and favorable “cost-of-goods” (the cost of the active 
principle in the medication and its formulation) are important factors that 
influence the choice of candidate products for development. Even a price of US 
$1 per treatment is probably unacceptable in many regions, considering the 




Table 4-1.  Desirable characteristics of a putative target. 
1. Essential feature of the parasite life cycle differ significantly 
from any analogous process in the host 
2. Lack of alternative pathways that circumvent the target  
3. Selective accessibility of lead compound to the parasite  
4. Accumulation of lead compound within the parasite  
5. Low potential for development of resistance  
6. Involvement in a rate-limiting biochemical process 
7. Ability to readily test effects of inhibitors on the target (to 
validate the target)*  
8. Presence of a straightforward test system for high-
throughput screening 
9. Existence of known specific inhibitors 
 














4.3 IDENTIFYING AND VALIDATING DRUG-TARGETS 
More drug targets are needed because, despite an array of putative targets, 
not all would be validated as effective and safe compounds. Improvements 
toward understanding the biochemistry of malaria parasites has led to the 
identification of many potential targets for new drugs and helped shed light on 
the modes of action of known drugs. Targets can be selected from enzymes or 
pathways that are (i) present in both parasite and human; or (ii) present in the 
malaria parasite but absent from human. The parasite may use metabolic 
pathways similar to those of the host, but it may have adapted its own enzymes to 
have different kinetic properties or structures. Hence, there may be differences 
between the parasite and host enzymes, including sensitivity to inhibitors. Hence, 
targets that are shared between the parasite and human host offer opportunities 
for chemotherapy if structural differences can be exploited. For example, 
inhibitors of dihydrofolate reductase, ie. pyrimethamine and proguanil, are 
important antimalarial drugs because they select for the parasite enzyme (Fidock 
et al. 2004). It is important to recognize that one advantage of targets that are also 
present in the host is that, in certain cases, the host target has already been 
considered as a therapeutic target for other disease indications. As a result, the 
cost of drug discovery can be reduced if antimalarials can be justified from 
established therapeutic drugs used for treatment of other diseases in man. As 
examples, antimalarial drug discovery efforts directed against parasite cysteine 
proteases and protein farnesyl transferases are benefiting from industry projects 
directed against inhibitors of the human cysteine protease cathepsin K and 
farnesyl transferases, currently used as treatments for osteoporosis and cancer, 




Alternatively, targets can be selected from enzymes or pathways that are 
present in the malaria parasite but absent from humans. Here, the added difficulty 
of identifying such a target is offset by the high degree of selectivity that should 
be provided by inhibitors of the parasite target. One example is the use of 
prokaryotic protein synthesis inhibitors, including tetracyclines and clindamycin, 
which were found to have antimalarial activity. These compounds presumably act 
selectively against malaria parasites because of their action against the 
prokaryote-like plasmodial organelle apicoplast, which seem to have bacterial or 
plastid origins. In addition, type II fatty acid and isoprenoid biosynthetic 
pathways are targets for existing antibacterial compounds, providing initial leads 
for antimalarial drug discovery (Missinou et al. 2002; Surolia and Surolia 2001). 
Understanding the nature of previously unidentified targets which can be 
inhibited by  existing antimalarial drugs can also be a basis for new drug 
discovery. One example relates to chloroquine, which acts by interfering with the 
production of the malarial pigment hemozoin, allowing intraparasitic build-up of 
toxic free heme (Pagola et al. 2000). This has defined inhibition of hemozoin 
formation as an attractive target for new antimalarial drugs. 
 
As a result of the availability of the P. falciparum genome sequence, 
investigators now have access to a sophisticated database which facilitates 
genome searches and analysis. These genome sequences can dramatically 
accelerate the early steps of drug discovery by enabling the rapid identification of 
putative plasmodial targets that are homologous to target proteins from other 
systems. Additional means of validating drug targets are made possible by new 




pathways of interest, particularly if functionally related genes share common 
transcriptional profiles (Bozdech et al. 2003), while proteomic studies should 
help investigators to identify the mechanisms of action of known drugs, thereby 
suggesting novel chemotherapeutic approaches. For example, transcriptional 
analysis of the P. falciparum folate pathway in response to treatment with folate 
inhibitors revealed that serine hydroxymethyltransferase might have a regulatory 
role in the folate pathway and, consequently, could provide a potent point of 
inhibition for the development of novel antifolate drugs (van Vugt et al. 2000).  
 
Methodologies have been developed to transfect P. falciparum with 
plasmids expressing either selectable markers, and to thereby knock out genes of 
interest (Crabb et al. 1997; van Dijk et al. 1996; Wu et al. 1996) or to localize 
gene products (Foth et al. 2005; McMillan et al. 2005). One example is the 
analysis of the P. falciparum serine repeat antigen (SERA) gene family, which 
encodes proteins with homology to cysteine proteases (Miller et al. 2002b). This 
gene family comprises nine members, eight of which are clustered on 
chromosome 2. Gene knockout studies indicated that four of the SERA genes 
could be disrupted and only the expressed SERAs in the centre of the cluster, 
SERA4, SERA5 and SERA6, appeared to be essential for parasite growth (Miller 
et al. 2002b). Although inability to obtain a gene knockout does not confirm that 
the gene of interest is essential, this information is an important part of target 
validation, when considered together with some understanding of its biological 
function (Cowman and Crabb 2003). RNAi was used to decrease the expression 
of Falcipain 1 and Falcipain 2 which resulted in the death of the parasites, 




2002). While these initial results in P. falciparum are encouraging, the usefulness 
of this technology needs to be confirmed with other genes. Importantly, although 
transfection of P. falciparum is possible, it is still not widely available in many 
laboratories (Cowman and Crabb 2003). Hence, further development of the 
genetic tools for the parasite is crucial for increasing the number of approaches 




Fig. 4-1. Drug discovery process leading to the pre-clinical and 
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4.4 METABOLIC PATHWAYS AS DRUG TARGETS 
Although each pathway has a number of enzymatic steps, only one or 
more enzymes are considered to be rate-limiting, “pace-maker” enzymes. For 
example, although the Embden-Meyerhof glycolytic pathway has eleven 
enzymes to convert glucose to lactic acid, only three of these enzymes are 
considered to be rate-limiting (ie. hexokinase, phosphofructokinase, and pyruvate 
kinase). Rate-limiting enzymes are usually good targets for drug design. 
Moreover, in a multienzyme pathway, inhibition of two enzymes by two different 
drugs can have more inhibitory effect on the metabolic pathway than the use of 
either drug alone (Mansour 2002). However, although the biochemical 
information about target enzymes have a role in determining their physiological 
roles, the regulation of these enzymes within the activity of other enzymes in the 
metabolic pathway cannot be predicted. Moreover, some enzymes may be 
influenced by signaling systems such as protein kinases or membrane transport of 
metabolites for the pathway. Nevertheless, detailed information regarding the 
biochemistry of the enzyme, particularly the active site, can be obtained by 
cloning the enzyme. Hence, the expression of the cloned enzyme in appropriate 
bacterial or eukaryotic hosts is essential for providing ample amounts of pure 
bioactive material for further studies and for screening inhibitors. New targets for 
antimalarial chemotherapy have been broadly classified into three categories (see 
Table 4-2 and Fig. 4-2): 
(1) Those responsible for processes occurring in the Plasmodium 




(2) Enzymes involved in antioxidant defense mechanisms that take 
place in the cytoplasm as well as the digestive vacuole of the 
parasite.  
(3)  Enzymes involved in primary metabolism. This section includes 
nucleic acid metabolism, phospholipid metabolism, glycolysis, and 
tubulin assembly. 
(4) Apicoplast targets.  
 
4.5 TARGETS IN THE DIGESTIVE VACUOLE 
The digestive vacuole presents several potential targets (Olliaro and 
Goldberg 1995). Quinine and the 4-aminoquinoline antimalarials, which are 
thought to act via binding to heme (Chou et al. 1980; Jearnpipatkul et al. 1980), 
have enjoyed a long span of effective use. It appears that the parasite seems to 
have difficulties in finding alternative processes for heme detoxification. The 
consequence of this binding of drug to heme molecule may be inhibition of heme 
polymerization and consequent toxicity to vacuolar membrane by unpolymerized 
heme (Orjih et al. 1994; Egan et al. 1996). A putative protein drug target for such 
drugs is as yet unknown. Nevertheless, resistance has emerged via drug 
accumulation or extrusion mechanisms at the digestive vacuole (Slater 1993).  
 
There is sufficient evidence to support the validity of the vacuolar 
proteases as chemotherapeutic targets: inhibitors of these enzymes have been 
shown to block hemoglobin degradation and kill the parasites in culture 
(Rosenthal et al. 1991). To date, virtually all the hemoglobin-degrading 




(Gluzman et al. 1994; Dame et al. 1994) and two cysteine proteases (analogous to 
cathepsin L) (Rosenthal et al. 1988; Rosenthal and Nelson 1992). The first 
aspartic protease (plasmepsin I) makes a single cleavage in the hemoglobin hinge 
region, unraveling the molecule for further proteolysis. A second aspartic 
protease (plasmepsin II) has preferential activity on denatured globin. The 
cysteine proteases (Falcipains 2A and 2B) conceivably act downstream, as it does 
not recognize native hemoglobin, but cleaves the globin apoprotein readily. The 
genes for the vacuolar proteases have been cloned and the recombinant proteins 
actively expressed in soluble forms (Goh et al. 2003; Goh et al. 2005). Cathepsin 
D and L are intracellular human enzymes with “housekeeping” functions and 
could be affected by plasmepsin or Falcipain inhibitors. The human enzymes are 
available for in vitro screening to assess compound specificity. The degree of 
homology with respect to the human counterparts is low enough to allow the 
design of specific inhibitors of the parasite enzymes. Importantly, site-specific 
mutagenesis studies involving amino acids at strategic positions in Falcipains in 
comparison with the human counterpart suggested that specificity of protease 
inhibitors toward parasite, but not host, enzymes can be achieved (Goh and Sim 
2005; Goh and Sim 2004).  
 
4.6 TARGETS IN PRIMARY METABOLIC PATHWAYS  
The intra-erythrocytic malarial parasite depends primarily on glycolysis 
for its energy generation (Sherman 1979), producing lactate as the end-product of 
the pathway. Lactate dehydrogenase (LDH) has no substrate inhibition by 
pyruvate, allowing fast energy production as required by the rapidly growing 




for inhibition versus human LDH. Specific inhibition may be possible, as the 
plasmodial enzyme differs from its human counterpart by the presence of a 5 
amino acid insertion at the pyruvate binding site. The malarial enzyme also has a 
large cleft in the active site that can accommodate bulky inhibitors such as 
gossypol derivatives (Sessions et al. 1997). Accordingly, selective inhibitors of P. 
falciparum lactate dehydrogenase have been identified (Deck et al. 1998) and 
some compounds have demonstrated in vitro antimalarial activity 
(Razakantoanina et al. 2000). However, there are no confirmed lead compounds 
at present. Mitochondrial functions, such as electron transport and protein 
synthesis, appear to be essential for survival and constitute potential targets for 
certain antimalarials. Atovaquone appears to act by inhibiting mitochondrial 
electron transport and by depolarizing malarial mitochondria (Srivastava et al. 
1997).  
 
Enzymes of the purine and pyrimidine biosynthetic pathways are also 
potential new drug targets. Malaria parasites cannot synthesize purines and have 
to rely on salvaging its host’s purines for nucleic acid synthesis. The principal 
source of purines in P. falciparum appears to be hypoxanthine, and 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) has been considered 
as a potential drug target (Keough et al. 1999). In contrast to the case with 
purines, malaria parasites cannot salvage pyrimidines and are thus self-reliant on 
pyrimidine synthesis. Hence, differences between pyrimidine synthetic enzymes 
of parasites and humans, such as dihydrofolate reductase (DHFR), are actively 




Fig. 4-2. Schematic representation of new and existing therapeutic targets in P. falciparum depicted according to 












































Enzyme Current status References 
Hemoglobin 
metabolism 
Plasmepsin 1, 2, 4 Genes cloned and expressed. Crystal structure of P. falciparum 
Plasmepsin 2 and 4 are solved. Available for screening. 
Banerjee et al. 2002, 
Prade et al. 2005 
 
 Falcipains 1, 2A, 2B, 3 Cloned and expressed initially insoluble. Goh et al. achieved high 
level soluble and functional  expression of all the 4 Falcipains.  
Goh et al. 2005,  
Goh et al. 2003 
 
Oxidant defense Glutathione reductase 
 
Crystal structure available. Assay available for screening. 
 
Sarma et al. 2003 
 Superoxide dismutase 
 
No enzyme available for screening yet. - 
Glycolysis Lactate dehydrogenase Genes cloned and expressed. Crystal structure solved. High 
throughput screening was carried out, but no suitable drug 









Enzyme has been expressed solubly and actively in E. coli.  
 
Baldwin et al. 2002 




Gene cloned and expressed solubly. Recombinant enzyme 
requires an incubation step for activation.  
 
Raman et al. 2005 




The gene encoding this bifunctional enzyme has been cloned and 
expressed. There is a long history of DHFR inhibitors (anti-folates) 
used clinically as antimalarials but not TS. However, anti-folates 
were subject to resistance very soon after their introduction. TS 
inhibitors are still an active area of antimalarial research. 
 







Crystal structures available, including those of inhibitor bound 
enzymes. The gene encoding this enzyme has been cloned and 
actively expressed. This project has been taken up by Medicines 
for Malaria Venture (MMV). 














CHAPTER 5 MATERIAL  AND 
METHODS 
 
5.1 ORGANISMS AND VECTORS 
 The bacteria strains and plasmids used in this study are described in Table 
5-1. 
 
5.2 CULTURE CONDITIONS 
E. coli was cultured in Luria-Bertani (LB) medium at 37°C on a rotary 
shaker set at 250 rpm. Where necessary, ampicillin or kanamycin was used at a 
final concentration of 50 µg/ml.  Stocks of  E. coli  strains were  stored  in  20%  
glycerol at -80°C. Yeasts were cultured in YPD or SD medium supplemented 
with the appropriate drop-out (DO) supplement (Clontech). Mammalian cells 
were cultured in DMEM (Gibco) supplemented with 10% fetal calf serum and 
incubated at 37°C in a CO2 incubator. 
 
The parasites were cultured in vitro using treated human red blood cells 
and  RPMI 1640 medium containing 10% human serum according to the candle-
jar technique of Trager and Jensen (1976). Before use, the erythrocytes were 
washed 3 times in RPMI 1640 to remove anticoagulants and leukocytes, and 
diluted to 5% hematocrit with RPMI 1640 containing 10% human serum. 
Infected RBCs were added to an appropriate parasitemia (about 1%). The culture 
was placed in a candle jar. A condition of low oxygen was obtained by burning 




everyday. To check the parasitemia, Giemsa (Sigma) staining of a thin smear was 
carried out. Parasites were subcultured before the parasitemia reaches 15%. 
 
5.3 MEDIA, BUFFERS AND SOLUTIONS 
 Media, buffers and solutions used in this study are in Appendix 1. Unless 
otherwise stated, all buffers and media were sterilized by autoclaving for 15 
minutes at 121°C. Thermolabile components were filter-sterilized using Millipore 
filters (0.2 µm). 
 
5.4 DNA AMPLIFICATION AND RT-PCR 
Genomic DNA was extracted from cell cultures exhibiting about 10% 
parasitemia using the QIAamp DNA Blood Mini Kit (Qiagen) according to 
manufacturer’s instructions. The primers used were designed based on the 5’ and 
3’ approximately 20-bp DNA sequences of the selected ORFs (Table 5-2). The 
forward and reverse primers for transcription analysis of PK1, PK2, FUM and 
GK by amplification of partial cDNA are shown in Table 5-5. The DNA 
amplification cycle is as follows: 94°C for 1 min; 94°C for 0.5 min, 45°C for 2 
min, 68°C for 3 min for 35 cycles; and finally extension at 68°C for 10 min. Total 
P. falciparum RNA was extracted from mixed-stage cultures exhibiting 7-10% 
parasitemia using Rneasy Mini kit (Qiagen) according to manufacturer’s 
instructions. The mRNA used in RT-PCR was purified from total RNA using the 
Oligotex Mini kit (Qiagen). RT-PCR was performed using Sensiscript two-step 
RT-PCR (Qiagen) and a RT step at 37°C for 1 hour, followed by a PCR step 




Table 5-1 Organisms and vectors used in this study. 
 
 Relevant characteristics Source/Reference 
Bacterial strains 











Host for cloning of PCR products 
 
Expression host. Carries T7 RNA polymerase 
gene placed under the control of lacUV5 
promoter 
 
Carries RIL plasmid which encodes E. coli  































































Kanamycin resistance marker, cloning vector  
 
Ampicillin resistance marker, N-terminal GST 
tag, tac promoter, PreScission protease site for 
cleavage of GST tag, MCS 
 
Ampicillin resistance marker, N-terminal MBP 
tag, MCS 
 
Ampicillin resistance marker, N-terminal Trx tag, 
MCS 
 
Chloramphenicol resistance marker. Encodes E. 
coli tRNAs for arg, ile, and gly 
 
Directional TOPO Entry cloning vector, 
kanamycin resistance marker 
 
Destination vector for expression of C-terminal 
GFP fusion proteins in mammalian cells 
 
Yeast bait vector, GAL4-DNA-BD, MCS, TRP1 
selection marker, T7 promoter, kanamycin 
resistance marker, yeast-E.coli shuttle vector, c-
myc tag 
 
Yeast prey vector, GAL4-AD, LEU2 selection 
marker, T7 promoter, ampicillin resistance 































1 A gift from Dr. Wong Siew Heng, National University of Singapore 




Table 5-2.  Primer pairs used for the PCR amplification of genes employed in bacterial expression and functional analysis. The 
restriction enzyme sites are underlined. The accession numbers shown are based on PlasmoDB numbering. 
 




5’ GGATCCATTAAAAAAGTTGCTATT 3’ 
      BamHI 
5’ GTCGACTTATATTGTATCTTTTAG 3’ 
        SalI 
GK /PF13_0269 
 
5’ GGATCCAATGTCATATTAAGTATA 3’ 
      BamHI 
5’ GTCGACTTATAACTGTATTAATGT 3’ 
        SalI 
PK1 / MAL6P1.160 5’ GGATCCAGTTCATTTAAGTACAAA 3’ 
      BamHI 
5’ GTCGACTTATTCAATTTGTACAAC 3’ 
        SalI 
FUM / PFI1340w 
 
5’ GGATCCATAAAGTTTAAAGAAGCT 3’ 
      BamHI 
5’ GAATTCTTATGATGGTAACCATTT 
      EcoRI 
CS /PF10_0218 
 
 5’ GGATCCGAAGGAATAAGATACCTA 3’ 
      BamHI 
 5’ GTCGACTTATTCATATTCTTCAAT 3’ 
        SalI 
ICDH / PF13_0242 
 
5’ GGATCCTCGAAGAGATGTATTCAA 3’ 
      BamHI 
5’ GAATTCTTATGTTGAATGTTCTTG 
      EcoRI 
MDH / MAL6P1.242 
 
5’ GGATCCACTAAAATTGCCTTAATA 3’ 
      BamHI 
5’ CTCGAGTTATTTAATTAAGTCGAA 
         XhoI 
GDH /PF14_0286 
 
5’ GGATCCATTTTGTATTCATGTGTT 3’ 
      BamHI 
 5’ GTCGACTTATAAACCTCCTTGCTC 3’ 
         SalI 
DHO / PF14_0697 5’ GGATCCAAAAATTACTTTTATATT 3’ 
      BamHI 
5’ GAATTCTTAAAACTTACTTACATA 
      EcoRI 
IMPDH /PFI1020c 
 
5’ GGATCCGCTAGCGGATGGAAAGCA 3’ 
      BamHI 
 5’ GTCGACTTATGTAGTAAACTTTTT 3’ 
         SalI 
  
 
                                                 
1 PGDH, glycerol-3-phosphate dehydrogenase; GK, glycerol kinase; PK1, pyruvate kinase 1; FUM, fumarase; CS, citrate synthase; ICDH, isocitrate 





Table 5-3.  Primer pairs used for the PCR amplification of DNA fragments employed for mammalian expression of GFP fusion 
proteins. The CACC required for Gateway directional cloning and the Kozak motifs are underlined and italicized, 
respectively. The accession numbers shown are based on PlasmoDB numbering. 
 




5’ CACCATGGAAGGAATAAGATAC 3’ 5’ AAAATTAAAATATCGCTT 3’ 
ICDH /PF13_0242 
 
5’ CACCATGGGAAAGCATATACGA 3’ 5’ GATTAATTTTTCTTTTAT 3’ 
BCKDH /PF13_0070 
 
5’ CACCATGGGAAGAAATATTGTTCAGAAATAC 3’ 
 
5’ AGGCATTTTTATAACTTCATT 3’ 
SDH /PF10_0334 
 
5’ CACCATGGGAATTAGGAATAATAAAAAATAC 3’ 
 
5’ TGCTACCTTGTATTTATTTTT 3’ 
HDAC /PF14_0690 
 
5’ CACCATGGGAAAAAAATGCAAAAAATGT 3’ 5’ CTTTTTACATTTTTTACA 3’ 
RPOL /PF14_0207 
 
5’ CACCATGGGATATATTAGAAAAAAAAAA 3’ 5’ TTTTCCTTTTTTCTTCTT 3’ 
PK2 /PF10_0363 
 
5’ CACCATGGGAAATTTAATTCATATTTGT 3’ 5’ TTCAACAAAAGTATTATTATC 3’ 
GDH /PF14_0286 
 
5’ CACCATGGGAATTTTGTATTCATGTGTT 3’ 
 
5’ TCCACCCATTGGAAGTGT 3’ 
MDH /PFF0895w 
 
5’ CACCATGGGAACTAAAATTGCCTTA 3’ 5’ ACCAAGAATGTTTCTATT 3’ 
GK /PF13_0269 5’ CACCATGGGAAATGTCATATTAAGTATA 3’ 
 
5’ TTCATTCATTAAATTATA 3’ 
 
                                                 
2 BCKDH, branched chain α-keto-acid dehydrogenase E1α subunit; SDH, succinate dehydrogenase flavoprotein-subunit; HDAC, histone deacetylase; 




Table 5-4.  Primer pairs used for the PCR amplification of genes employed as baits for the yeast-two-hybrid study. The 
restriction enzyme sites are underlined. The accession numbers shown are based on PlasmoDB numbering. 
 
Gene /PlasmoDB ID Forward primer Reverse primer 
 
Heat shock protein hslv, 
putative/ PFL1465c 
5’ GGATCCGTAAGTGGTATTGTTTGATC 3’ 
      BamHI 
5’ GTCGACTTACAATGTTTCACAAAT 3’ 
        SalI 
Heat shock 40 kDa protein, 
putative/ PFB0595w 
5’ GGATCCGTGGGAAGGATTATTATTCA 3’ 
      BamHI 
5’ GTCGACTTAGAATGTATTTGCCAA 3’ 
        SalI 
HSP60/ PF10_0153 
 
5’ GGATCCGTATATCAACATTACGAGGG 3’ 
      BamHI 
5’ GTCGACTTAATACATTCCCCCCAT 3’ 
        SalI 
heat shock 70 kDa protein / 
PF08_0054 
5’ GGATCCGTGCTAGTGCAAAAGGTTCA 3’ 
      BamHI 
5’ GTCGACTTAATCAACTTCTTCAAC 3’ 




Table 5-5.  Primer pairs employed for transcription analysis of FUM, GK, PK1 and PK2 by amplification of partial cDNA 
fragments. 
 
DNA fragment  Forward primer Reverse primer 
 
300bp FUM from 5’ terminus 
 
5’ GGATCCATAAAGTTTAAAGAAGCT 3’ 
 
5’ ACCATGTTCATCTAAAAAAT 3’ 
300bp GK from 5’ terminus 
 
5’ GGATCCAATGTCATATTAAGTATA 3’ 
 
5’ AGCATTGTATAAAGGTTTTC 3’ 
540bp PK1 from 5’ terminus  
 
5’ AGATCTATGAGTTCATTTAAGTACAAA 3’ 5’ CCTAGGAATAACAGCTGAATTTAATAC 3’ 
540bp PK2 from 5’ terminus 
 





5.5 VECTOR CONSTRUCTION FOR HETEROLOGOUS 
EXPRESSION IN E. COLI 
The amplified gene products were purified from agarose gel using the 
MinElute Gel Purification kit (Qiagen). The purified target DNA was cloned into 
pCR-BluntII-TOPO (Invitrogen) using a DNA topoisomerase I-directed ligation 
method, carried out  according to manufacturer’s instructions. DNA inserts in 
positive recombinant clones obtained were sequenced using the ABI PRISM 
BigDye terminator cycle sequencing kit (Applied Biosystems) and loaded onto 
an ABI PRISM 377 DNA sequencer for sequence determination. Finally, the 
target genes were excised from the cloning vector by appropriate double-
digestion and ligated into pGEX-6P1 (Pharmacia Biotech), pMAL-c (New 
England Biolabs), or pthiohisA (Invitrogen) for expression according to the 
restriction digestion and ligation procedures as described in section 5.8. The 
recombinant constructs were transformed into E. coli BL21 (DE3) or BL21 
CodonPlus (DE3)-RIL (both from Stratagene) using the procedure described in 
section 5.7. Where noted, the RIG plasmid (a gift from Professor Wim G. J. Hol, 
University of Washington) was co-transformed with recombinant constructs.  
 
5.6 VECTOR CONSTRUCTION FOR MAMMALIAN CELL  
TRANSFECTION USING GATEWAY TECHNOLOGY 
DNA fragments encoding 60 N-terminal amino acid residues of P. 
falciparum citrate synthase (CS), isocitrate dehydrogenase (ICDH), malate 
dehydrogenase (MDH), and glycerol kinase (GK) were amplified from plasmids 




2004b). The other DNA fragments encoding 60 N-terminal amino acid residues 
of the E1α subunit of the branched chain α-keto-acid dehydrogenase (BCKDH) 
and the flavoprotein-subunit of succinate dehydrogenase (SDH) were amplified 
from genomic DNA extracted from in vitro cultures of P. falciparum. The DNA 
fragments encoding the internal NLSs of histone deacetylase (HDAC) and RNA 
polymerase (RPOL) were also amplified from the P. falciparum genomic DNA. 
In addition, DNA fragments encoding 187 N-terminal amino acid residues of 
pyruvate kinase 2 (PK2) and glutamate dehydrogenase (GDH) were similarly 
amplified from P. falciparum genomic DNA. The primer pairs for each of the 
above 10 PCR amplification sets are indicated in Table 5-3. The CACC signature 
sequence required for Gateway directional cloning (Invitrogen), and the Kozak 
motifs were incorporated into the designed primers as recommended in the 
manufacturer’s instruction. PCR was carried out using pfu DNA polymerase 
(Stratagene), and was performed according to the conditions stated above  
(section 5.4). The reactions were held at 4°C after thermal cycling. Thereafter, the 
amplified DNA products were directionally cloned into the Entry vector pENTR 
(Invitrogen), and recombined into the Destination vector pcDNATM-DEST47 
(Invitrogen) using the Gateway rapid recombination technology according to the 
manufacturer’s protocol. A collection of the clones obtained was fully sequenced 
to verify in-frame insertion of the DNA sequences upstream of the C-terminal-
GFP ORF of pcDNATM-DEST47. DNA sequencing was carried out using the 
ABI PRISM BigDye terminator cycle sequencing kit (Applied Biosystems) and 






5.7 ELECTRO-TRANSFORMATION OF E. COLI 
 A single colony of an E. coli plate culture was inoculated into 10 ml of 
LB and incubated overnight at 37°C with shaking at 250 rpm. 5 ml of overnight 
culture was inoculated into 500 ml of LB medium and incubated with shaking 
(250 rpm) at 37°C until the OD of the culture at 600 nm reached 0.6 to 0.8. The 
culture was chilled on ice for 15 mins and then centrifuged at 6000 rpm for 3 
mins at 4°C. The cell pellet was resuspended in 500 ml of ice cold water. The 
supernatant was discarded after spinning at 6000 rpm for 3 mins at 4°C. The 
resultant cells were resuspended in ice cold 10% glycerol and 200 µl of the cells 
were aliquoted separately into sterile microfuge tubes. These tubes were quickly 
frozen by immersion into cold (-70°C) ethanol. Competent cells were stored at -
80°C (Sambrook et al. 1989). 
 
 For tansformation, cells were thawed gently and then immediately placed 
on ice. 40 µl of the cells were mixed gently with 1-2 µl of DNA. The mixture 
was transferred to a cold 0.2 cm electroporation cuvette. The cuvette was placed 
in the chamber slide of the Gene Pulser apparatus (Bio-Rad) set at 25 µF, 200 Ω, 
2.5 kV. The cells were pulsed once. Immediately, 1 ml of LB medium was added 
to the cuvette followed by pipetting to resuspend the cells. The suspension was 
transferred to a fresh tube and incubated at 37°C for 1 hr with shaking at 250 rpm. 
100 µl aliquots were plated onto each plate containing the appropriate antibiotic 






5.8 RESTRICTION DIGESTION AND LIGATION OF DNA 
 DNA was digested with commercially available restriction enzymes 
under the optimal conditions specified by the manufacturers. The volume of 
DNA was adjusted with sterile deionized water to 8.5 µl before 1 µl of 10X 
buffer and 0.5 µl of the appropriate restriction enzyme were added. The reaction 
was carried out at the recommended temperature for 60 mins and the extent of 
digestion was analyzed by agarose gel electrophoresis. Ligation of DNA was 
accomplished with T4 DNA ligase (Invitrogen). Vector and insert DNA were 
mixed at a ratio of 1:2 and the volume was adjusted to 15 µl. 4 µl of 10X T4 
ligase buffer and 1 µl of T4 ligase (1 unit) were added to the DNA sample. 
Ligation was carried out at 16°C for 16 hours. 
 
5.9 AGAROSE GEL ELECTROPHORESIS 
 DNA fragments were resolved by electrophoresis on horizontal agarose 
gels. For each preparation, 100 ml of molten agarose gel, containing 0.8 to 1.0% 
of agarose in TAE buffer and 0.5 µg/ml ethidium bromide, was poured into a gel 
casting tray after it cooled to about 55°C. Electrophoresis was carried out in 
agarose gels submerged in TAE buffer. Electrophoresis was performed at 3 V/cm 
field strength until the bromophenol blue dye in the original samples had moved 
a distance of about 3/4 the length of the gel. The DNA could be viewed and 







5.10 DNA SEQUENCING 
 DNA sequencing was carried out using the BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems) according to manufacturer’s 
instructions. Thermal cycling was carried out using the GeneAmp PCR System 
9700 (Applied Biosystems). After completion of thermal cycling, DNA in the 
reaction was precipitated using 2 µl of 3M NaAc (pH 4.6) and 50 µl of ethanol. 
The precipitate was pelleted by centrifugation at 12 000 rpm for 20 mins. After 
careful aspiration of the ethanol with a micropipetter, the pellet was rinsed by 
adding 250 µl of 70% ethanol. The ethanol was aspirated and the pellet was dried 
in a 55°C oven for about 5 mins. The dried DNA pellet which contained the 
extension products to be resolved was submitted for sequence determination. 
Reaction products were resolved and analyzed using the ABI 377 Sequencer 
(Applied Biosystems). 
 
5.11 GROWTH AND INDUCTION OF E. COLI CELLS 
 E. coli BL21(DE3) cultures containing expression vectors were grown in 
LB medium containing the appropriate antibiotics. The E. coli cells then were 
introduced to give an initial OD at 600 nm of 0.1 in 50 ml of fresh LB medium 
containing antibiotics. This was incubated at 37°C with agitation at 250 rpm until 
the OD at 600 nm reached 0.6-1.0, at which time IPTG was added to final a 
concentration of 1mM to induce the expression of the recombinant protein. The 
cultures were then incubated for 15 hours with shaking at 25°C to allow for 





5.12 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS OF 
 TOTAL PROTEINS 
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
using the SE 250 Mighty Small II system (Hoefer). The glass plates used for 
preparing the gels were cleaned with 70% ethanol and assembled according to 
the manufacturer’s instructions. A 10% polyacrylamide resolving gel was 
prepared by adding the solutions listed in Table 5-6. A solution without TEMED, 
APS and SDS was prepared and degassed for 15 mins using a vacuum pump. 
SDS was added followed by TEMED and APS. Without delay, the mixture was 
swirled and poured into the gap between the plates. To get a leveled loading 
surface, the acrylamide was overlaid with 70% alcohol and the gel was left to 
polymerize at room temperature. This takes about 30 mins. After the gel has 
polymerized, the alcohol layer was discarded and the gel  rinsed with deionized 
water to remove the alcohol. In a similar way, 15 ml of stacking gel was prepared 
(Table 5-6). The gel was pipetted onto the polymerized resolving gel. A teflon 
comb was immediately inserted and the gel was left to polymerize at room 
temperature. After polymerization, the comb was removed, the wells rinsed with 
deionized water and the gel was mounted onto the electrophoresis apparatus. 
Electrophoresis buffer was added to the reservoirs. 
 
 Protein samples and standard markers (Biorad) were suspended in loading 
buffer and heated in a boiling water bath for 3 mins. The ratio of protein sample: 
loading buffer was 3:1. 20-50 µg of protein samples were loaded into each well. 




the gel. At the end of electrophoresis, the plates were pried open and the gel was 
stained with staining solution for 1 hour, after which it was destained by soaking 
in destaining solution until all background had been satisfactorily removed. 
 
5.13 PREPARATION OF CELL-FREE EXTRACTS 
 Bacterial cells were harvested by centrifugation at 10 000 rpm for 5 to 10 
mins. The supernatant was discarded and cells were resuspended in 10 ml of 
TDE buffer, afterwhich the cells were again pelleted by centrifugation. Three 
washings were done, afterwhich the cells were suspended in 1-2 ml of TDE. E. 
coli cells were lysed by sonicating in 6 short bursts of 10 sec with a rest period of 
20 sec in-between the bursts. The sample was then centrifuged at 10 000 rpm for 
10 mins and the supernatant, which constituted the soluble protein fraction of the 





Table 5-6. Solutions for SDS-PAGE. 





Acrylamide solution (30% mix, Biorad) 
 
1.5 M Tris HCl (pH 8.8) 
 
1.0 M Tris HCl (pH 6.8) 
 




10% ammonium persulfate (APS) 
 







































5.14 PROTEIN PURIFICATION AND ENZYME ASSAYS 
Cells for expression analysis were harvested after overnight induction of 
expression at 25°C with 1mM IPTG. Total protein was obtained by sonication 
using a Soniprep (Sanyo) sonicator set at an amplitude of 18 µ. Recombinant 
GST-fusion protein was purified by column glutathione elution method using the 
GST Purification Module (Amersham) according to manufacturer’s instructions. 
Lysates expressing the pMAL vectors were purified by affinity chromatography 
using amylose resin (New England Biolabs) followed by elution using 10 mM 
maltose. The protein concentration of crude and purified enzyme preparations 
were determined using Biorad Protein Assay Reagent according to 
manufacturer’s instructions. 
 
ICDH Assay: The assay of NADP-dependent ICDH activity was based on 
established method of monitoring of NADP reduction to NADPH (ε340 = 6.22 
mM–1.cm–1) (Sahni et al. 1992). The standard assay solution (1 ml) contained 50 
mM Tris buffer (pH7), 0.1 mM NADP, 4 mM DL-isocitrate, and 2 mM MnSO4, 
unless noted otherwise. One unit of enzyme activity is defined as the amount of 
enzyme reducing 1 nmol of NADP per minute at 25oC. All the drugs and reagents 
used for the inhibition study were of analytical grade.  
 
MDH Assay: The assay of NADH-dependent MDH activity was based on 
established method of monitoring of NADH oxidation to NAD (ε340 = 6.22 mM–
1.cm–1) (Lang-Unnasch 1992). The standard assay solution (1 ml) contained 50 




enzyme activity is defined as the amount of enzyme oxidizing 1 µmol of NADH 
per minute at 25oC.  
 
Pyruvate kinase Assay: The enzyme assay for pyruvate kinase was based 
on the formation of NAD in the presence of lactate dehydrogenase in an indirect 
assay (Malcovati and Valentini 1982). The standard enzyme assay was adapted 
for kinetic measurement using a monochromator-based spectrophomometric 
plate-reader (Safire, Tecan Instruments). 200µl of the standard assay mixture 
contained 10mM HEPES buffer pH 7.5, 10mM MgCl2 (Merck), 50mM KCl 
(Merck), 0.5mM NADH, 1mM PEP, and 1mM ADP and 22U lactate 
dehydrogenase. Each assay was carried out with a final concentration of 1.5ng of 
enzyme per ml of assay mixture. Kinetic parameters for PEP under saturating 
conditions for ADP (3mM) were carried out using PEP concentrations ranging 
from 0.1 to 2mM.  Those for ADP were carried out using ADP concentrations 
ranging from 0.1 to 2mM ADP in the presence of 7mM PEP (saturation). The 
reaction was started by the addition of pure enzyme and monitored at a 
wavelength of 340nm at room temperature (26°C) for up to 4 mins. Enzyme 
activity was calculated by measurement of slope (A340/min) under lineal time 
conditions. One unit (U) of pyruvate kinase activity is defined as the amount of 
enzyme required to produce 1 µmol of pyruvate from PEP in one min. Analytical 
gel filtration was carried out using a Superdex 200 HR 10/30 column run on the 
AKTA Purifier liquid chromatography system (Amersham Biosciences).  
 
DHO Assay: The assay of DHO was performed by measuring the rate of 




contained pure recombinant enzyme and 1 pmol of dihydroorotate (Sigma) in 50 
mM Tris phosphate buffer (pH 8.0) in a total volume of 1 ml. The reaction was 
initiated by the addition of enzyme. The linear decrease in absorbance at 230 nm 
due to substrate consumption was followed.  
 
FUM Assay: The assay of FUM was carried out according to Hill and 
Bradshaw (1969). The reaction mixture contained pure recombinant enzyme and 
10 mM of L-malate (Sigma) in 50 mM of phosphate/NaOH Buffer (pH8.0) in a 
final volume of 1 ml. The  malate was added  last. The assay was carried out in 
quartz cuvettes and read at 250 nm. An increase in absorbance was recorded.  
 
5.15 MAMMALIAN TRANSFECTION AND CONFOCAL 
MICROSCOPY 
CHO-K1 cells were cultured in DMEM (Gibco) supplemented with 10% 
fetal calf serum (Gibco) and without antibiotics. The constructed plasmids were 
transfected into CHO-K1 cells in 6-well plate formats at confluencies of 90-95% 
using Lipofectamine2000 (Invitrogen) as per manufacturer’s instructions. 
Transfected cells were cultured in OptiMEM (Gibco) without serum and without 
antibiotics for 48 hours, after which they were observed using a BX60 
fluorescence microscope (Olympus) or FluorView FV1000 confocal laser 
scanning microscope (Olympus). Mitochondria staining of live cells was done 
using the Mitotracker Red (Molecular Probes, USA) at a concentration of 500 
nM (red emission with green excitation) as per manufacturer’s instructions. 




Hoechst 33342 (Invitrogen) as the cell-permeant nucleic acid stain. The green 
emission of GFP was visualised with blue excitation (490-505 nm for BX60 or 
488 nm for FV1000).  
 
5.16 YEAST TWO-HYBRID SCREENING 
 The yeast two-hybrid approach (BD Matchmaker Two-Hybrid system) 
was used to identify novel plasmodial protein interactions and confirm the 
suspected interactions. In this assay, a bait gene was expressed as a fusion to the 
GAL4 DNA-binding domain (DNA-BD), while a plasmodial cDNA library was 
expressed as a fusion to the GAL4 activation domain (AD). Interaction between 
the bait and library fusion proteins in the yeast host AH109 causes the DNA-BD 
and AD being brought into proximity, resulting in the activation of transcription 
of the reporter genes: ADE2, HIS3, and MEL1. The ADE2 and HIS3 provides 
nutritional selection, while MEL1 codes for α-galactosidase, a secreted enzyme 
that can be detected by the use of X-α-Gal (BD) in the selection plate. If MEL1 is 
active, the colony will turn blue in the presence of X-α-Gal. To screen for two-
hybrid interactions, the first step was to construct a DNA-BD fusion vector (from 
pGBKT7), followed by mRNA isolation, cDNA synthesis, and AD fusion library 
construction. In the latter step, the fusion of the double-stranded cDNA with the 
GAL4 AD plasmid (pGADT7) occurred in vivo via homologous recombination. 
Finally, the cDNA library and the BD Matchmaker vectors were co-transformed 






 The gene fragments were generated by RT-PCR from P. falciparum 
mRNA using designed 5’ and 3’ primers that contain restriction sites BamHI and 
SalI respectively (Table 5-4). The obtained amplified fragments were then cloned 
into pENTR by TOPO cloning, and subsequently subcloned into pGBKT7 via 
conventional ligation. Bait vectors were initially tested for transcriptional 
activation by transformation into the yeast host AH109. The bait protein is 
inactive if the transformant colonies are white and do not grow on SD/–his/–trp 
or SD/–ade/–trp. To test the bait for toxicity, the growth rate (as indicated by 
OD600) in liquid culture of AH109 cells transformed with the empty pGBKT7 
vector were compared with cells transformed with the bait plasmid. The baits 
were considered not toxic provided that  the bait strain did not grow noticeably 
slower. Messenger RNA transcripts were copied into ds cDNA using BD 
SMART technology employing MMLV (Moloney Murine Leukemia Virus) 
reverse transcriptase. Yeast-two-hybrid screening was carried out by the co-
transformation approach, during which the yeast strain AH109 was co-
transformed with ds cDNA, SmaI linearized pGADT7, and bait vector. The co-
transformation consisted of 20 µl of  ds cDNA, 6 µl pGADT7 (0.5 µg/µl), and 5 
µg bait plasmid DNA and was carried out according to the manufacturer’s 
protocol. The transformed cells were incubated at 30°C until colonies appear. 
 
To identify the positive inserts, the plasmids were isolated from yeast,  
transformed into E. coli TOP10 cells, and selected on LB/ampicillin plates. 
Plasmids were isolated from individual colonies and identified by DNA 
sequencing. The identified protein-protein interactions in yeast were re-tested by 




identified prey plasmids. The appropriate negative controls were included, which 
consisted of yeast cells transformed with prey plasmid and an empty pGBKT7 
bait vector, and cells transformed with empty pGADT7 prey vector and bait.  
 
5.17 TRANSFORMATION OF YEAST CELLS 
The small-scale LiAc procedure was used for transformation of yeast 
cells. 1 ml of YPD was inoculated with several colonies. The suspension was 
vortexed vigorously to disperse any clumps. This suspension was transferred into 
a flask containing 50 ml of YPD. The culture was incubated at 30°C for 16-18 hr 
with shaking at 250 rpm to stationary phase (OD600>1.5). 30 ml of the overnight 
culture was transferred to a flask containing 300 ml of YPD. The culture was 
incubated at 30°C for 3 hr with shaking (230 rpm). At this point, the OD600 
should be 0.4-0.6. The cells were placed in 50 ml tubes and centrifuged at 1,000 
x g for 5 min at room temperature. After discarding the supernatant, the cell 
pellet was thoroughly resuspended in sterile distilled water. The cells were then 
centrifuged at 1,000 x g for 5 min at room temperature, after which they were 
resuspended in 1.5 ml of freshly prepared, sterile 1X TE/1X LiAc. 0.1 mg of 
plasmid DNA and 0.1 mg of herring testes carrier DNA were added to a fresh 
1.5-ml tube and mixed. For cotransformation (using two different plasmids), 0.1 
mg of each plasmid was used. 0.1 ml of yeast competent cells were added to each 
tube, followed by 0.6 ml of sterile PEG/LiAc solution. After  incubating at 30°C 
for 30 min with shaking at 200 rpm, 70 µl of DMSO was added. The cell 
suspension was then subjected to heat shock for 15 min in a 42°C water bath. 




room temperature. The cells were resuspended in 0.5 ml of sterile 1X TE buffer 
and plated on each SD agar plate to select for the desired transformants.  
 
5.18 COMPUTATIONAL ANALYSES AND ACCESSION 
NUMBERS 
Multiple alignment analyses were carried out using ClustalW (Thompson 
et al. 1994) and viewed with Boxshade (Bioinformatics Group, The Swiss 
Institute for Experimental Cancer Research). Phylogenetic trees were visualized 
using the Treeview program (University of Glasgow). Biophysical parameters 
were calculated using the Compute pI/Mw, ProtParam, Paircoil, and SAPS 
programs available at the Expasy website (www.expasy.org.ch). Codon 
frequencies were calculated using the freewares General Codon Usage Analysis 
v1.0 distributed by James McInerney of University of Ireland, Maynooth, and 
Rare Codon Calculator (RaCC) written by Cameron Mura (University Of 
California, USA). The accession numbers for the targets were based on 
assignments from PlasmoDB. 3D modeling was done using the Swiss-Model 
program (http://swissmodel.expasy.org//SWISS-MODEL.html). Models were 
visualized using DeepView version 3.7 distributed by Glaxo Welcome 
Experimental Research (Geneva; www.expasy.org/spdbv). 
 
Cellular localizations were predicted using the PlasMit (Bender et al. 
2003), PATS (Zuegge et al. 2001), and PlasmoAP (Foth et al. 2003) available at 
the PlasmoDB website (www.plasmodb.org). Sequences for multiple alignment 




Retrieval System (website: http://tw.expasy.org/sprot/), using the search string, 
“mitochondrion”, in the Feature Key field. Nuclear-targeting signals were 
predicted using PredictNLS (website: http://cubic.bioc.columbia.edu/predictNLS/) 
(Cokol et al. 2000). Metabolic pathway predictions were carried out using the 
MR4-ATCC website: http://malaria.atcc.org/metabolic_pathways/index.html 













IDENTIFICATION OF POTENTIAL 





CHAPTER 6 IDENTIFICATION OF POTENTIAL 




Obtaining functional malaria enzymes are primary prerequisites for 
biomedical applications including drug-screening and therapeutic vaccine 
production. To achieve, a priori, whole proteome expression, a reliable approach 
must be identified to express malaria proteins from diverse families. However, 
there is as yet no systematic study to identify optimum expression conditions for 
expressing malaria metabolic enzymes, apart from the isolation of proteins ad 
hoc. In particular, functional enzymes which can be assayed in straightforward 
test systems are suitable for high-throughput screening and are more attractive 
potential drug-target candidates. As a result, 10 candidate predicted genes were 
identified and then cloned into plasmid vectors for heterologous protein 
expression in an E. coli host. The status of recombinant expression of these target 
genes is reported in this chapter. Understanding the cellular localizations of 
metabolic enzymes are part of the drug validation process. Hence, the 
functionalities of resident organelle-targeting signals on these enzymes were 
investigated experimentally so as to allow a clearer construction of the glycolytic 







6.2 TARGET SELECTION 
A systematic survey of 13 and 12 glycolysis- and TCA cycle-related 
predicted ORFs was carried out, with particular attention paid to predicted genes 
that have not been functionally validated (Tables 6-1 and 6-2). This resulted in a 
selection of 10 potentially interesting ORFs suitable for expression analysis 
(Table 6-3). These targets were sampled from a diverse range of metabolic 
reactions, predicted cellular localizations (Table 6-4), and molecular weights (34 
to 78 kDa). In addition, these targets were selected to fulfill the criteria of being 
(i) absent, or significantly different, from their corresponding enzymes in the 
human host (28-64% identities in amino acid sequences; Table 6-4); (ii) probably 
expressed in the intraerythrocytic-stage as based on existing microarray data in 
PlasmoDB; and (iii) not overly complex and difficult to express (enzyme 
complexes made up of subunits from several ORFs, such as pyruvate 
dehydrogenase and α-ketoglutarate dehydrogenase, were not selected for 
functional analysis). Fumarase (FUM), malate dehydrogenase (MDH), and 
inosine-5’-monophosphate dehydrogenase (IMPD), have less than 15%, 25% and 
20% to their corresponding human counterparts, and can be considered to be 
absent in humans. In particular, MDH may be involved in a unique pathway that 
serves to re-oxidise NAD during glycolysis (Fig. 2-1), making it a good drug 
target. Isocitrate dehydrogenase (ICDH) has rather high homology (64%) to its 
human counterpart but may take part in parasite-specific functions. Pyruvate 
kinase 1 (PK1), citrate synthase (CS) and dihydroorotase (DHO) exhibited 42-
49% homologies to their human counterparts. PK1 is thought to play crucial 
metabolic roles in parasitic organisms, and has been indicated as a potential 




(Maeda et al. 2003; Ernest et al. 1998; Ernest et al. 1994). The rest of the targets 
(PGDH, GK, and GDH) exhibit rather low (29-40%) homologies to their 
respective human counterparts.  
 
Although the selected targets exhibited as low as ≤15% homology to the 
human counterparts, they exhibited 39-67% identities in their amino acid 
sequences to annotated sequences in organisms other than Plasmodium spp. 
(Table 6-4). This showed that the annotations in PlasmoDB were consistent with 
predictions made by BlastP searches of the Genbank database using these 
sequences, supporting the PlasmoDB annotations. Interestingly, it was also noted 
that for the selected enzymes, the expected cellular localizations of some 
enzymes based on their conventional roles were not necessarily consistent with 
their assigned cellular localizations using prediction softwares that identify 
organelle targeting signals such as PATS, PlasmoAP, and PlasMit. PATS and 
PlasmoAP identify apicoplast-targeting signals while PlasMit identifies 
mitochondrial-targeting signals (Table 6-4). This observation suggests that 
although P. falciparum may possess metabolic enzymes similar to those of the 
host, it may have adapted its own enzymes to have different physiological 
functions. Hence, experimental investigation of the localizations of these selected 
enzymes were pursued subsequently (Chapter 9). Strictly speaking, GDH, DHO, 
and IMPD are not TCA cycle enzymes. However, GDH and DHO have been 
predicted to be involved in the transfer of electrons to the electron transport chain 
in P. falciparum (Sherman 1998a; see also Fig 6-1), while IMPDH may have an 
effect on the electron transport chain via influencing the levels of fumarate (Fig. 




Table 6-1. Genome data on glycolysis and related genes in P. falciparum. 
 




Gene from P. falciparum 
cloned and expressed in 
E.coli? 
References 
1     Hexokinase
 
PFF1155w 55.2 Gene cloned. Recombinant
protein expressed in E.coli was 
inactive.  
Olafsson and Certa 
1994 
2 Glucose phosphate isomerase 
 
PF14_0341 67.3 Functionally expressed in E. coli. Kaslow and Hill 1990 
3  Phosphofructokinase
 





PF14_0425 59.5 Functionally expressed in E. coli. Dobeli et al. 1990 
 5 Triose phosphate isomerase 
 
PF14_0378 27.9 Functionally expressed in E. coli. Ranie et al. 1993 
6  Glyceraldehyde-3-phosphate
dehydrogenase  
PF14_0598 36.6 Functionally expressed in E. coli. Daubenberger et al. 
2000 
7  Phosphoglycerate kinase
 
PFI1105w 45.4 Functionally expressed in E. coli. Pal et al. 2004  
8  Phosphoglycerate mutase
 
PF11_0208 28.7 No. (This enzyme activity was 




PF10_0155 48.6 Functionally expressed in E. coli. Pal-Bhowmick et al. 
2004 
10 Pyruvate kinase 1 
 
MAL6P1.160 
(new ID PFF1300w) 
55.6 No. Selected for this study. - 
11  Lactate dehydrogenase
 
PF13_0141 30.0 Functionally expressed in E. coli. Bzik et al. 1993 
12    Glycerol-3-phosphate
dehydrogenase  
PFC0275w 74.6 No. Selected for this study.  
13    Glycerol kinase
 




 Table 6-2. Genome data on TCA cycle and related genes in P. falciparum. 
 




Gene from P. falciparum cloned 
and expressed in E.coli? 
References 






PF14_0441 (E1β)  
PF10_0407 (E2)  





Recombinant catalytic domain of E2 
subunit shown to be enzymatically 
active. 
Foth et al. 2005 




(new ID PFF0895w) 
34.0 No. Selected for this study. - 
3    Citrate synthase
 
PF10_0218 65.0 No. Selected for this study. - 
4  Aconitase
 
PF13_0229 103.3 Functionally expressed in E. coli. Hodges et al. 
2005 
5    Isocitrate dehydrogenase
 











No. (Very large complex). - 
7 Succinyl CoA synthetase 
 
 
PF11_0097 (α subunit) 
PF14_0295 (β subunit) 
47.5 (α subunit) 
52.1 (β subunit) 
No.  -







Genes cloned but no functional 
studies reported. 
Takeo et al. 2000 
9    Fumarase
 
PFI1340w 78.3 No. Selected for this study. - 
10    Glutamate dehydrogenase
 
PF14_0286 57.3 No. Selected for this study. - 
11 
 
Dihydroorotase   PF14_0697 41.7 No. Selected for this study. - 
12    Inosine-5’-monophosphate
dehydrogenase  




Table 6-3. Summary status of predicted genes selected for analysis in this study (I): Predicted functions and 
nomenclature. 
 





Abbrev Introns Gene length 
(kb) 
Homologs 
1     Glycerol-3-phosphate
dehydrogenase  
 
PFC0275w Glycolysis PGDH No 1.962 2 other copies  
2    Glycerol kinase
 
 
PF13_0269 Glycolysis GK No 1.506 No other copies 




(new ID PFF1300w) 




PFI1340w TCA cycle FUM No 2.046 No other copies 
5     Citrate synthase
 
 
PF10_0218 TCA cycle CS No 1.692 1 other copy  





ICDH No 1.407 No other copies 




(new ID PFF0895w) 
TCA cycle MDH No 0.942 No other copies 






No 1.533 2 other copies





 DHO No 1.077 No other copies 









Table 6-4. Summary status of predicted genes selected for analysis in this study (II): Predicted localizations. A, apicoplast; C, 
cytosol; M, mitochondria. huLDH, human lactate dehydrogenase; huMDH, human malate dehydrogenase. 
 
No. Gene name Identity to human homolog 
(accession numbers in brackets) 
Identity to most homologous 











1     Glycerol-3-
phosphate 
dehydrogenase  
36% (NP_000399) 47% to Caenorhabditis 
elegans PGDH (P90795) 
C Absent Absent C
2      Glycerol kinase
 
 
40% (NP_976325) 42% to Leifsonia xyli GK 
(YP_061540) 
C Absent Absent C
3 Pyruvate kinase 1 
 
44% (NP_872270) 67% to Toxoplasma gondii 
PK (BAB47171) 
C    Absent Absent C
4      Fumarase
 
 
No significant homology (<15% to 
NP_000134) 
58% to Cytophaga 
hutchinsonii FUM class I 
(ZP_00311105) 
M Absent Absent C
5      Citrate synthase
 
 
42% (NP_004068) 43% to Drosophila 
pseudoobscura CS 
(EAL32663) 
M Absent Present M
6     Isocitrate
dehydrogenase 
 
64% (NP_002159) 65% to Toxoplasma gondii 
ICDH (AAV33246) 
C2 Absent Present M
7      Malate
dehydrogenase 
 
28% (NP_002291; huLDH).  
No significant homology (<25%) to 
huMDH (NP_005909; AAC16436) 
47% to Toxoplasma gondii 
MDH (AAT67462) 
M Absent Absent C
8      Glutamate
dehydrogenase 
 
29% (NP_036216) 60% to Chlorella sorokiniana 
plastid GDH (P28998) 
C Present Absent A
9     Inosine-5’-
monophosphate 
dehydrogenase  
No significant homology (<20% to 
P27708) 
50% to Danio rerio IMPD 
(CAI21140) 
C Absent Absent C
10     Dihydroorotase 
 
 
49% (NP_899066) 39% to Toxoplasma gondii 
DHO (AAM46078) 
C Absent Absent C





























































6.3 CLONING OF SELECTED TARGETS INTO EXPRESSION 
VECTORS  
All the targets except PK1 and GDH were non-intronic. These non-intronic 
genes were hence cloned by PCR from P. falciparum genomic DNA (Fig. 6-2). As 
the genes encoding PK1 and GDH contained introns, these ORFs were cloned via 
RT-PCR of P. falciparum mRNA (Fig. 8-1). The PCR or RT-PCR success rate was 
100% for which an amplified fragment of correct size could be obtained. Despite the 
extreme AT contents of Plasmodium genes, products of the wrong size, or failure to 
acquire product, during the amplification step were not encountered, although such 
observations were sometimes reported in other similar experiments using the human 
genome, for example Hammarström et al. (2002). The amplified genes were 
successfully cloned into TOPO vectors, and subsequently subcloned into pGEX-6P1 
for heterologous expression in E. coli (Fig. 6-2). The identities, as well as in-frame 
insertion of the ORF into the expression vectors, were confirmed by DNA sequencing 











Fig. 6-2. PCR amplification and cloning of selected drug targets in pGEX-6p1. 
The expected size of the pGEX-6P1 vector is 4.9kb.The expected 































 M      1      2      3      4      5      6      7       
(a)
(a) PCR amplification of DHO, ICDH, FUM, and MDH 
from P. falciparum genomic DNA.  Lanes: M, DNA 
marker; 1, DHO; 2, ICDH; 3, FUM; 4, MDH; 5 to 8, 
corresponding  negative (non-template) controls. The 
















564(b) PCR amplification of PGDH, GK, IMPDH, and CS 
from P. falciparum genomic DNA.  Lanes: M, DNA 
marker; 1, PGDH; 2, GK; 3, IMPD; 4, CS; 5 to 8, 






(c) Restriction digest analysis of positive 
pGEX-6P1 expression clones for DHO 
(Lanes: 1, p1A-12; 2, p1A-13; 3, p1A-
14; 4, p1A-21) and ICDH (Lanes: 5, 
p2A-21; 6, p2A-24). The gene insert 
from each plasmid is indicated by an 
arrow. Lane M, DNA marker. 
 
(d) Restriction digest analysis of positive 
pGEX-6P1 expression clones for FUM 
(Lanes: 1, p3A-13; 2, p3A-24) and MDH 
(Lanes: 3, p4B-11). The gene insert 
from each plasmid is indicated by an 





(e) Restriction digest analysis of positive 
pGEX-6P1 expression clone for PGDH 
(Lane: M, DNA marker; 1, p38-12). The 


























(f) Restriction digest analysis of positive 
pGEX-6P1 expression clone for PGDH 
(Lane: M, DNA marker; 1, p38-21). The 
gene insert is indicated by an arrow.  
 
(g) Restriction digest analysis of positive 
pGEX-6P1 expression clone for GK 
(Lanes: M, DNA marker; 1, p39-14). 





Fig. 6-2. (Cont’d) 
 



































(h) Restriction digest analysis of positive pGEX-6P1 
expression clones for IMPD (Lanes: M, DNA marker; 1, 
p41-11; 2, p41-14) and CS (Lanes: 3, p42-12; 6, p42-


















202M      1      2       
expression clones for GDH (Lanes: M, DNA marker; 1, 
p92-21-1; 2, p92-21-2; 3, p92-21-3). The gene insert 














(j) Restriction digest analysis of positive pGEX-6P1 
expression clones for PK1 (Lanes: M, DNA marker; 1, 















6.4 RECOMBINANT EXPRESSION OF SELECTED TARGETS AS 
FUSION PARTNERS 
In order to express the selected targets as recombinant GST-fusion proteins, 
the amplified DNA encoding the 10 targets in pCR-BluntII-TOPO vectors were 
subcloned into pGEX-6P1 to create the corresponding expression clones. After 
transformation of expression plasmids into BL21 CodonPlus (DE3)-RIL (Stratagene, 
USA) cells, the resultant expression clones were analyzed for successful expression 
by visualization of recombinant GST-fusion proteins after affinity purification in 
SDS-PAGE gels (Fig. 6-3). As a result, there were profound differences in expression 
levels and solubilities peculiar to each target or the fusion partner used. Using GST as 
the fusion partner, 5 out of 10 (50%) of the gene constructs were expressible (Table 
6-5). Disulphide bonds in proteins function to stabilize their structures in native 
conformations. The thioredoxin fusion-tag, known to enhance the formation of 
disulfide bonds in the cytoplasmic proteins of E. coli (Molloy et al. 1998), was 
investigated for its ability to forge such linkages in 7 of the 10 gene constructs, viz 
GK, CS, ICDH, MDH, GDH, IMPDH, DHO. These ORFs were PCR amplified from 
recombinant pCR-BluntII-TOPO plasmids carrying the genes using primers carrying 
appropriate restriction sites for sub-cloning into pthiohisA. However, despite its 
efficacy in encouraging soluble expression for eukaryotic proteins as compared to 
GST and MBP (Hammarström et al. 2002), the thioredoxin affinity tag was not found 
to be useful in partnering malarial gene expression in this study. Apparently, none of 
the 7 selected ORFs could be expressed as Trx-fusion proteins. This suggests that 




successful expression of malaria proteins. Although it has been reported that FP1, 
FP2A and FP3, which were insoluble when expressed using GST, could be solubly 
expressed as MBP-tagged proteins (Goh et al. 2003), the efficiency of MBP could not 
be demonstrated for ICDH. Subcloning of this gene into pMAL-c2x did not result in 
any expression of MBP-fusion ICDH proteins. Hence, the efficacy of MBP may not 
apply invariably across the set of targets in this study. One possible hindrance could 
be due to the additional baggage of MBP at 52 kDa, making efficient expression of 
the resultant 100 kDa protein rather difficult. Hence, although Trx and MBP have 
been reported to be more useful than GST for recombinant expression of human 
genes elsewhere (Dyson et al. 2004), GST was observed to be the most suitable N-
terminal protein fusion for expressing the plasmodial targets investigated in this 
study. 
 
The ability to express plasmodial proteins originally localized in mitochondria 
or food vacuole (Goh et al. 2003) suggests that the location of the target protein is not 
an important factor governing whether a protein can be expressed in a heterologous E. 
coli host (Table 6-6). Subsequently, biochemical investigation of the solubly 
expressed recombinant proteins validated the enzyme activities of 3 out of 5 of the 
expressed targets (Chapter 7). However, no very clear trend emerged when the 
biophysical parameters of the actively-expressed and non-expressible targets were 
inspected. There was no apparent correlation between expression and the protein’s 
instability index, pI, aliphatic index, % α-helices, or % of coiled-coils (Table 6-6). 




composition of 2.5%, 0.66 low complexity regions, and Mw of 73.74. Targets that 
cannot be expressed have, on average, a Gravy score of -0.28, cysteine composition 
of 1.96%, 1.2 low complexity regions, and Mw of 87.95. Hence, high Gravy scores 
and cysteine compositions, but low molecular weights and occurrences of complexity 
regions, appeared to be associated with success in expression. The decreasing 
efficiencies of expressing products with increasing molecular weights are likely to be 
due to increasing protein complexity, perhaps requiring specialized eukaryotic 
chaperones for folding or stabilizing binding bonds in the proteins. Interestingly, 
Braun et al. (2002), as well as Dyson et al. (2004), also observed a similar 
relationship between lower molecular weights and expression success with their sets 
of 32 and 30 human proteins respectively. There seemed to be a correlation between 
positive Gravy scores and success of soluble expression (Table 6-6), as two out of 
three of the functionally expressed genes have positive scores, while all problematic 
genes have negative Gravy scores. Interestingly, the truncation of the N-terminal 
prodomain of FP2A, which resulted in a shift from failed to successful expression 
(Goh et al. 2003), was also correlated with an increase in the Gravy score.  
 
In order to assess the effect of N-terminal truncation on expression, primers 
were designed to clone the GDH gene without its N-terminal 60 amino acids. 
However, truncation of GDH failed to bring about expression. Hence, N-terminal 
truncation may not be invariably applicable to obtaining soluble expression for all 
malaria target genes (Dyson et al. 2004). A common strategy to optimize 




(18oC) after the IPTG induction step. However, expression of all ten target genes at 
18oC did not result in any difference in status of these genes as compared to 
expression at 25oC. Furthermore, SDS-PAGE analyses of insoluble fractions obtained 
at both expression temperatures confirmed the absence of insoluble recombinant 
proteins. Similarly, extension of induction time from 15 to 30 hrs indicated that lack 
of expression for 5 of the targets was not due to inadequate induction time. 
 
Since about 9% of the expressed malarial genes consist of rare AT-rich 
codons, the importance of RIG and RIL plasmids, proposed to supplement the E. coli 
host with tRNAs encoding rare codons, were assessed by quantifying expressions of 
MDH and ICDH with or without RIG or RIL. The tRNAs for Arg (AGA) and Ile 
(AUA) could be provided by both RIG and RIL, while those for Leu (CUA) or Gly 
(GGA) were provided by RIL or RIG respectively. Results showed that ICDH and 
MDH recombinant proteins could be expressed regardless of whether RIG or RIL 
were included (Fig. 6-4), suggesting that codon bias is not a mandatory consideration 




Table 6-5. Expression data for all the targets as N-terminal GST-fusion 
proteins. 
 


















PFC0275w 100.67 Not expressible - 




PF13_0269 82.635 Not expressible - 














PFI1340w 104.387 Soluble 
expression 
22.3 + 6.7 









PF13_0242 79.576 Soluble 
expression 

























PF14_0697 67.700 Soluble 
expression 





Table 6-6. Comparison of biophysical parameters of solubly expressed active proteins to those which were not 




























Cytoplasm         0.033 38.29
(stable) 
7.5 2.9 103.82 1 36.79 33.46 81.643
MDH 
PFF0895w 
Cytoplasm         0.114 26.7
(stable) 
 7.03 2.2 107.48 1 39.62 29.07 60.023
ICDH 
PF13_0242 
Mitochondrion -0.417        38.84
(stable) 
 8.76 2.4 85.85 0 40.38 31.62 79.576
 




Cytoplasm          -0.378 47.25
(unstable) 
6.98 2.0 91.48 0 43.85 33.24 67.700
FUM 
PFI1340w 
Cytoplasm         -0.459 36.48 
(stable) 
9.09 1.5 88.06 1 36.27 31.13 104.387
 




Cytoplasm          -0.427 27.03
(stable) 
8.69 1.7 90.49 3 41.50 37.67 100.67
CS 
PF10_0218 
Mitochondrion -0.267        39.49
(stable) 
 9.3 2.3 95.56 0 49.38 31.08 91.023
GDH 
PF14_0286 




9.02 2.0 84.84 1 43.14 29.80 83.325
GK 
PF13_0269 
Cytoplasm         -0.208 33.34
(stable) 
 5.92 2.4 91.82 1 41.52 30.14 82.635
IMPD  
PFI1020c 
Cytoplasm         -0.192 30.66
(stable) 





Fig. 6-3. SDS-PAGE analysis of expressed recombinant proteins after affinity 
purification from soluble E. coli fractions. Bands representing the 

















































































Fig. 6-4. Assessment of the impact of codon bias in expression of malaria 
proteins by investigating the effect of RIG or RIL plasmids in 



























































































FUNCTIONAL EXPRESSION OF 
RECOMBINANT PROTEINS FROM  





CHAPTER 7 FUNCTIONAL EXPRESSION OF 




Recombinant expression experiments based on predictions of novel 
targets using PlasmoDB have led to the soluble heterologous expression of ORFs 
encoding ICDH, MDH, PK1, DHO and FUM. The biochemical activities of 
ICDH, MDH, and PK1 were demonstrated. The activities of DHO and FUM, 
however, could not be detected despite multiple experimentations employing 
varying assay conditions. The functional authentication and biochemical 
characterization of ICDH, MDH and PK1 are herein described. 
 
7.2 RELEVANCE OF ICDH AS A POTENTIAL DRUG-
TARGET 
Although ICDH has been suggested to be useful for diagnosis and clinical 
investigation of certain infectious agents (Nguyen and Hirai 1999; Florio et al. 
2002), there is no information on ICDH from P. falciparum. The NADP-
dependent isocitrate dehydrogenase (EC 1.1.1.42) (ICDH) is a redox enzyme 
which catalyses the oxidative decarboxylation of isocitrate, leading to the 
formation of 2-oxoglutarate, CO2 and NADPH. 2-Oxoglutarate can be further 
oxidized within the cycle or reductively aminated to glutamate. ICDH thus 




metabolism, as well as a precursor for biosynthesis. Since the reaction catalyzed 
by ICDH represents an important branch point between catabolic and anabolic 
processes in the cell, ICDH can be considered as an anaplerotic enzyme. During 
infection, the malaria parasite Plasmodium falciparum multiplies and 
differentiates within the erythrocytes. At this stage, the protozoan is particularly 
sensitive to oxidative stress (Kanzok et al. 2000). Hence, it has been suggested 
that pathways of the parasite’s redox metabolism, especially those for NADH- or 
NADPH-regeneration, are prominent targets for rational drug development. The 
licensed antimalarial drug primaquine, for example, appears to act partly via 
direct oxidation of NADPH (Smith et al. 1987). In this study, pfICDH was shown 
to be enzymatically active when expressed in E. coli BL21. The kinetics and 
coenzyme specificity of purified pfICDH, as well as the effects of certain 
chemicals on pfICDH enzyme activity, were also investigated.  
 
7.3 SEQUENCE ANALYSIS OF P. FALCIPARUM ICDH 
The full-length ORF encoding P. falciparum ICDH was obtained by PCR 
amplification from P. falciparum Tan strain genomic DNA followed by cloning 
of the gene product into pCR-BluntII-TOPO. Further sub-cloning was carried out 
to obtain recombinant constructs harboring the pfICDH gene in expression 
vectors pGEX-6P1 (designated p2A-21 and p2A-24; Fig. 6-2c). DNA sequencing 
of recombinant plasmids was employed to confirm the identities of the cloned 
inserts and in-frame insertion of the intact gene into the expression vectors.  
 
Comparison of the pfICDH DNA sequence obtained with the predicted 




pfICDH gene cloned was identical to the corresponding PlasmoDB entry. The 
pfICDH ORF encodes 468 amino acids with a computed molecular mass of 53.5 
kDa, consistent with those of known homodimeric NADP-dependent ICDHs (40-
57 kDa) (Chen and Gadal 1990). In terms of aa sequence, pfICDH was most 
similar to a predicted ORF for NADP-dependent ICDH in P. yoelii (84% 
identity). The closest mammalian counterpart was bovine NADP-dependent 
ICDH (65%). In addition, pfICDH shares 64% identity with human NADP-
dependent ICDH. Multiple-alignment of diverse genes coding for eukaryotic 
NADP-dependent ICDH revealed high primary sequence homology (45-97%). In 
addition, 9 out of 12 of the aa residues known to be involved in catalysis or 
substrate binding in E. coli ICDH (Hurley et al. 1989) were conserved among the 
ICDH sequences aligned (Fig. 7-1). Of the non-conserved residues, I320 (based 
on the E. coli ICDH numbering as indicated in Fig. 7-1) present conservative 
change. The similarity in the primary structures of known ICDH sequences 
suggests that the enzymes may have a similar reaction mechanism or structure. 
The 3D-structures for the porcine as well as four bacterial ICDHs are available.  
The aa sequence of pfICDH shared sufficient similarity in the central domain 
with the porcine ICDH to enable homology-based 3D-modeling of pfICDH using 
the latter 3D-structure as a template (Fig. 7-2). However, the unique C-terminal 
could not be modeled since this segment is absent in the porcine ICDH crystal 
structure. It is uncertain whether differences at the N- and C- termini would 
influence its eventual folding. 
 
A phylogenetic tree (Fig. 7-3) generated by aligning the ICDHs showed 




I (NAD- or NADP-dependent ICDH from Archaea and Bacteria), subfamily II 
(NADP-dependent ICDH from Eukarya), and subfamily III (NAD-dependent 
ICDH from Eukarya and Bacteria). Subfamilies I and II comprise of 
homodimeric ICDHs while subfamily III comprises NAD-dependent complex 
multimeric mitochondrial isocitrate dehydrogenases and one bacterial 
homodimeric NADP-ICDH. Although all three subfamilies are monophyletic, 
subfamily I is the only clearly defined cluster. Interestingly, pfICDH seemed to 
be a rather deeply rooted member of subfamily II. It should be noted that a 
bootstrap value of 862 indicates some degree of uncertainty in the grouping of 
pfICDH in this subfamily. The interfamilial homology between subfamily II and 
the other two subfamilies do not exceed 17%. Phylogenetic analysis revealed that 
pfICDH is not grouped distinctively with mammalian or bacterial ICDHs, 
suggesting significant dissimilarities between pfICDH and the mammalian or 
bacterial homologs. In addition, there are clear sequence differences between 
pfICDH and mammalian or bacterial ICDHs at the N- and C-termini, particularly 
a C-terminal extension of 26 aa not present in the human, bovine or E. coli 
homologs (Fig. 7-1). 
 
7.4 BIOCHEMICAL CHARACTERIZATION OF P. 
FALCIPARUM ICDH 
To confirm the enzymatic function of the cloned pfICDH gene, the ORF 
was heterologously expressed as a GST fusion-protein. In addition, the GST 
fusion-protein was purified by affinity chromatography followed by glutathione 
elution (Fig. 6-3). E. coli cell-free extracts expressing pfICDH exhibited 




corresponding expression vectors without pfICDH gene insert (Fig. 7-4a). 
Importantly, purified GST-tagged pfICDH exhibited high levels of ICDH 
activity, which represented significant concentration of the recombinant protein 
from the cell-free extract. In contrast, no ICDH activity was detected in fractions 
purified from extracts expressing pGEX-6P1 without pfICDH gene insert, 
confirming that the purified pfICDH was enzymatically active (Fig. 7-4b). The 
specific activity of recombinant pfICDH was determined to be 3270 U/mg. The 
GST-pfICDH fusion protein exhibited an apparent molecular mass of ca. 78 kDa, 
larger than the computed molecular weight of pfICDH due to the presence of the 
GST-tag (26 kDa). Based on protein assay, the yield of pure product that could 
be obtained from each induced culture of 50ml was 75.2 + 6.7 µg in a final 
purified fraction of 300 µl (mean of four separate experiments). Hence, pfICDH 
could be solubly expressed in E. coli BL21 DE3, with its enzymatic function 
intact, as a GST-fusion protein. In addition, comparison between enzymatic 
activities in extracts expressing pfICDH with and without RIG or RIL plasmid 
indicated that co-transformation with these plasmids did not seem to elevate the 
yield of recombinant proteins significantly (Fig. 7-4a).  
 
The properties of purified pfICDH are summarized in Table 7-1. The 
enzyme exhibited a specific requirement for NADP; substitution of NAD for 
NADP in the enzyme assay led to total loss of enzyme activity. Inclusion of 5 
mM EDTA in the enzymatic assay eliminated enzymatic activity, suggesting 
dependence on cations as cofactors. Like many eukaryotic ICDHs, ATP 
significantly inhibited pfICDH activity. This observation suggests that in vivo 




may be regulated in terms of flux of primary metabolites in the cell. Interestingly, 
pfICDH shares certain features with its counterpart from the simian malaria 
parasite P. knowlesi, in that it was markedly inhibited by chloroquine, as well as 
by cupric and argentic ions (Sahni et al. 1992). Kinetic analysis showed that the 
Km for isocitrate and NADP were 0.24 mM and 0.17 mM respectively. These 
parameters were comparable to those of the native enzyme (0.15 mM for 
isocitrate and 0.08 mM for NADP) determined earlier (Vander-Jagt et al. 1989). 
Oxalomalate, a well-known inhibitor of human NADP-dependent isocitrate 
dehydrogenase (Yang and Park 2003), also competitively inhibits pfICDH. In the 
presence of 2mM oxalomalate, the Km for isocitrate increased to 0.57 mM (Fig. 
7-4c). Hence, biochemical characterization of the recombinant pfICDH 
confirmed certain eukaryotic properties of the enzyme, as well as certain 





 Fig. 7-1. Multiple alignment of pfICDH aa sequences with bovine, 
human and E. coli ICDH sequences. Conserved residues 
are shaded. Boxed residues and residues marked by an 
arrow are those that contact substrate and coenzyme, 
respectively, in the E. coli enzyme. Only 3 out of total of 29 
sequences used for multiple alignment are shown. Their 
accession numbers are: bovine, Q04467; human, O75874; 
and E. coli, P08200. 
 
bovine          1 MAGYLRVVRSLCRASGSGSAWAPRALTAPNLQEQPRRHYADKRIKVAKPVVEMDGD-EMT 
human           1 ---------------------------------------MSKKISGGS-VVEMQGD-EMT 
pfICDH          1 -----------MGKHIRILKNQYLQFMSKRCIQSKAAFNICGKINVENPIVELDGD-EMT 
E. coli         1 ------------------------------MESKVVVPAQGKKITLQNGKLNVPENPIIP 
consensus       1                               .        . ..*............ ... 
 
bovine         60 RIIWQFIKEKLILPHVDVQLKYFDLGLPNRDQTNDQVTIDSALATQKYSVAVKCATITPD 
human          20 RIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPD 
pfICDH         49 RIIWKDIKEKLILPYVNLKIKYFDLSIENRDKTNDQVTIEAAEEIKKTSVGIKCATITPD 
E. coli        31 YIEGDGIGVDVTPAMLKVVDAAVEKAYKGERKISWMEIYTGEKSTQVYGQDVWLPAETLD 
consensus      61 .*... *........... .........................  ...........*.* 
 
bovine        120 EARVEEFKLKK--------MWKSPNGTIRNILGGTVFREPIICKN-IPRLVPG-WTKPIT 
human          80 EKRVEEFKLKQ--------MWKSPNGTIRNILGGTVFREAIICKN-IPRLVSG-WVKPII 
pfICDH        109 AARVKEFNLKE--------MWKSPNGTIRNILDGTVFRTPILIKN-IPKLVPN-WKKPIV 
E. coli        91 LIREYRVAIKGPLTTPVGGGIRSLNVALRQELDLYICLRPVRYYQGTPSPVKHPELTDMV 
consensus     121 ..*......*         ...*.*...*..* ............ .*..*.. ...... 
 
bovine        170 IGRHAHGDQYKATDFVVDRAGTFKVVFTPKDGSGPKEWEVYNFPAGG-VGMGMYNTDESI 
human         130 IGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSI 
pfICDH        159 IGRHAYADQYKQKSLKIEKSGKFEIVFTPDDNSQVLRETVFHFKSPG-VCLGMYNTEESI 
E. coli       151 IFRENSEDIYAGIEWKADSADAEKVIKFLREEMG---VKKIRFPEHCGIGIKPCS-EEGT 
consensus     181 *.*....*.*..... ....... .........  . . ...*................. 
 
bovine        229 SGFAHSCFQYAIQKKWP-LYMSTKNTILKAYDGRFKDIFQAIFEKHYKTEFDKHKIWYEH 
human         190 EDFAHSSFQMALSKGWP-LYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEH 
pfICDH        218 RNFALSCFQYALDLKMP-VYMSTKSTILKIYDGLFKDIFDEIYEKQFKKSFEQHNLWYEH 
E. coli       207 KRLVRAAIEYAIANDRDSVTLVHKGNIMKFTEGAFKDWGYQLAREEFGGELIDGGPWLKV 
consensus     241 . ........*. .... .....*..*.* ..*.***............... ...*... 
 
bovine        288 R-------------LIDDMVAQVLKSSGGF-VWACKNYDGDVQSDILAQGFGSLGLMTSV 
human         249 R-------------LIDDMVAQAMKSEGGF-IWACKNYDGDVQSDSVAQGYGSLGMMTSV 
pfICDH        277 K-------------LIDDMVAQVLKSEGGF-LWACKNYDGDIQSDAVAQGYGSLGLMSSV 
E. coli       267 KNPNTGKEIVIKDVIADAFLQQILLRPAEYDVIACMNLNGDYISDALAAQVGGIGIAPGA 
consensus     301 .             ..*....*........ ..**.*..**..**..*...*..*..... 
 
bovine        334 LVCPDGKTIEAEAAHGTVTRHYREHQKGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIR 
human         295 LVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAF 
pfICDH        323 LLCPDGVTCVSEAAHGTVTRHYRAYQKGEKTSTNPIASIFAWTKGLEHRAKLDKNDNLKQ 
E. coli       327 NIG--DECALFEATHGTAPKYAGQDK------VNPGSIILSAEMMLRHMG-------WTE 
consensus     361 ...........**.***...... ....  ...**...*......*.*..... . ..   
 
bovine        394 FAQTLEKVCVETVESGAMTKDLAGCIHGLSNVKLNEHFLNTSDFLDTIKSNLDRALGQQ- 
human         355 FANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSD-YLNTFEFMDKLGENLKIKLAQAK 
pfICDH        383 FCYALEKACIETVEDGLMSKDLAGCIKGIKNVTEKD-YIFTQDLINAINEKLKLKILQNQ 
E. coli       372 AADLIVKGMEGAINAKTVTYDFERLMDGAK-------LLKCSEFGDAIIENM-------- 
consensus     421 ................ ...*......*....   . ........... ..........  
 
bovine            --------------------------- 
human         414 L-------------------------- 
pfICDH        442 SKNDPQATSYKLKNDNWNFYAPQEHST 
E. coli           --------------------------- 





Fig. 7-2.  Homology model of pfICDH (yellow) superimposed on the 
porcine ICDH crystal structure (blue) used as the template for 
threading. The PDB code for the porcine enzyme used in this 




































Fig. 7-3. Phylogenetic tree of ICDHs from prokaryotic and eukaryotic 
organisms. M mitochondrial; C cytoplasmic; B β-subunit; G 
γ-subunit; 1 subunit 1; 2 subunit 2. Bootstrap values 
indicated at the nodes were generated from 1000 replicates. 
 
The accession numbers of other sequences used in this study are as 
follows: alfalfa, S28423; Anabaena sp., A55591; Aeropyrum pernix, 
A72658; Bacillus subtilis, P39126; bovine (NADP-dependent, subfamily 
II), Q04467; bovine (NAD-dependent, subfamily III), P41563; E. coli, 
P08200; human (NAD-dependent, subfamily III), S55282; human 
(NADP-dependent, cytoplasmic, subfamily II), O75874; human (NADP-
dependent, mitochondrial, subfamily II), P48735; monkey (γ-subunit), 
P41564; monkey (α-subunit), X82632; rat (NAD-dependent, subfamily 
III), P41565; mouse (NADP-dependent, mitochondrial, subfamily II), 
P54071; Plasmodium yoelii, EAA17070 ;rat (NADP-dependent, 
subfamily II), P41562; Salmonella typhimurium, AAL20167; 
Sphingomonas yanoikuyae, P50125; soybean, Q06197; Streptococcus 
salivarius, L14780; Synechocystis sp., P80046; Thermus thermophilus, 
P33197; tobacco, P50218; Vibrio sp., B49341; Saccharomyces 
cerevisiae (subunit 1, NAD-dependent, subfamily III), P28834; 
Saccharomyces cerevisiae (subunit 2, NAD-dependent, subfamily III), 
P28241; Saccharomyces cerevisiae (NADP-dependent, mitochondrial, 
subfamily II); P21954; Saccharomyces cerevisiae (NADP-dependent, 












































































Fig. 7-4.  Enzymatic activity and purification of pfICDH expressed in E. 
coli BL21.  
(a) ICDH enzyme activities of cell-free extracts from 
recombinant clones harboring pfICDH gene and controls 
harboring vectors without inserts.  
(b) ICDH enzyme activities of affinity purified pfICDH and 
purified fractions from non-insert negative controls.  
(c) Kinetic analysis of recombinant pfICDH in the presence or 














































































































% ICDH enzyme activity b
Standard condition 
 
Substitution of NADP with NAD 
 
5 mM EDTA 
 








0.1 mM CuSO4.5H2O (Cu2+ ion)a
 







42.4 + 6.0 
 
75.5 + 4.2 
 
100.1 + 6.6 
 
104.7 + 4.4 
 
32.1 + 2.1 
 
80.0 + 5.1 
 
a The enzyme was incubated with the drug or reagent for 15 min at 37 oC 
prior to assay. 
b The % activity value is the mean of at least two separate observations 






7.5 RELEVANCE OF MDH AS A POTENTIAL DRUG 
TARGET 
MDHs are thought to play important roles in metabolic channeling, thus 
contributing to cellular organization during growth. Two classes of MDH have 
been described, ie MDHs coupled to NADH or NADPH, and LDH-like MDHs 
which function like MDH but are structurally closer to LDH. Indeed MDHs have 
been purified, characterized, and sequenced from a wide variety of organisms 
representative of the Bacterial, Archaeal, and Eukaryal domains of life (Goward 
and Nicholls 1994). For example, an unconventional NADPH-dependent malate 
dehydrogenase resembling lactate dehydrogenase (LDH) in primary structure 
was identified in Archaea (Madern 2002). In protists, MDH has been studied in 
Trypanosoma brucei (Anderson et al. 1998; Vernal et al. 2001) and Giardia 
lamblia (Roger et al. 1999). In G. lamblia, a cytosolic MDH is part of a three-
enzyme pathway coupled to the cofactor pairs NADP/NADPH (Lindmark 1980; 
Ellis et al. 1993; Sanchez et al. 1996). As yet, there is no study on genes 
encoding MDHs in Plasmodium. Hence, it is worthwhile to investigate the role of 
specific MDHs in P. falciparum. Intriguingly, inspection of its genome sequence 
data revealed the existence of an ORF encoding pfMDH. The cloning of this 
uncharacterized ORF, and demonstration of its biochemical functionality, is 
herein reported. Biocomputational and phylogenetic studies ascertained its 








7.6 SEQUENCE ANALYSIS OF P. FALCIPARUM MDH 
The pfMDH ORF encodes 313 aa with a computed molecular mass of 
34.0 kDa, consistent with those of known MDHs (30-40 kDa). In terms of aa 
sequence, pfMDH was most similar to an ORF encoding a putative MDH in P. 
yoelii (62% identity), followed by Caulobacter crescentus MDH (43%). The 
closest mammalian and human homologues were pig LDH and human LDH 
(both 28%) (Genbank accession numbers Q9TSX5 and NP_002291, 
respectively). Phylogenetic analysis of diverse genes belonging to the 
MDH/LDH superfamily led to the observation of three main groups within the 
superfamily, comprising LDHs, MDHs, and [LDH-like] MDHs, the latter of 
which are MDHs resembling LDHs (Fig. 7-5). Within the MDH group, the 
bacterial, cytosolic, mitochondrial, chloroplastic and glycosomal sequences were 
clearly defined. The pfMDH cloned in this study was clearly clustered with the 
[LDH-like] MDH group, together with P. yoelii MDH. Madern (2002) re-
assigned pfLDH and that of Toxoplasma gondii as [LDH-like] MDHs based on 
their phylogenetic positions as well as the identities of their conserved residues. 
As expected, these LDHs clustered with [LDH-like] MDHs. Interestingly, the 
pfMDH cloned in this study shares only 37% identity in amino acid sequence 
with pfLDH but are structurally quite similar (Fig. 7-8a), an observation similar 
to the comparison of isopenicillin N synthase and deacetoxycephalosporin N 
synthase (Sim et al. 2003). As expected, the multiple-alignment showed that the 
active site residue (His 174), as well as those for substrate (Arg 81, Arg 87 and 
Arg 150) and coenzyme binding (Gly 8, Ile 12 and Ser 227) in the MDH family 
(Chapman et al. 1999), are also conserved in pfMDH. Furthermore, pfMDH 




categorizing it as a [LDH-like] MDH (Fig. 7-6). Specifically, the Arg at position 
81 is replaced by a Gln in LDH. Also, pfMDH possesses a Pro residue at 232 that 
is conserved in all [LDH-like] MDHs (Madern 2002). LDHs have instead an Ile 
at 232. Interestingly, a five-residue insertion adjacent to the active site residue 
Arg 87, peculiar only to P. falciparum, T. gondii and Cryptosporidium parvum 
LDHs within the entire superfamily, was also absent in pfMDH. The Asp at 
residue 32, observable in all the NADH-dependent enzymes, was conserved in 
pfMDH. In Methanobacterium thermoautotrophicum and Methanocaldococcus 
jannaschii, replacement of this residue is thought to lead to the use of NADPH as 
cofactor (Madern 2002). In this study, phylogenetic and sequence analyses 
clearly defined the pfMDH cloned as belonging to the group of NADH-
dependent [LDH-like] MDH. Furthermore, it is clear that malarial MDHs are not 
grouped distinctively with mammalian homologs, reflecting significant sequence 
dissimilarities between the malarial and mammalian homologs. The availability 
of crystal structures for pfLDH (ExPDB code 1ldg_) and Chlorobium 
vibrioforme [LDH-like] MDH (ExPDB code 1gv1C), has made it possible to 
generate the 3D structure of pfMDH by homology modeling (Fig. 7-8). 
Interestingly, the superimposition of the obtained model for pfMDH over the 
porcine cytosolic MDH (PDB code 5MDH) revealed significant conformational 
differences in the active site loop (A) and other solvent exposed regions (B, C) 
(Fig. 7-8). Therefore, together with primary structure comparisons, these 
observations suggest a large scope for the use of some of the domains of malarial 
MDHs as potential drug targets. Finally, the use of bioinformatics softwares to 
detect organellar localization signals did not identify any mitochondrial or 




7.7 BIOCHEMICAL CHARACTERIZATION OF P. 
FALCIPARUM MDH 
To demonstrate the enzymatic function of the cloned pfMDH gene, the 
ORF was heterologously expressed as a GST fusion-protein. The recombinant 
protein was then purified by affinity chromatography followed by glutathione 
elution. As expected, the GST-pfMDH fusion protein exhibited an apparent 
molecular mass of ca. 60 kDa, larger than the computed molecular weight of 
pfMDH due to the presence of the 26 kDa GST-tag (Fig 6-3). Purified GST-
tagged pfMDH exhibited high levels of MDH activity (Fig. 7-7). No MDH 
activity was detected in fractions purified from extracts expressing pGEX-6P1 
without the pfMDH gene insert, confirming that the purified pfMDH was 
enzymatically active. E. coli extracts expressing recombinant pfMDH exhibited 
significant MDH activity after purification, in contrast to those obtained from the 
corresponding expression vectors without the gene insert, the latter representing 
basal or endogenous levels of E. coli host enzymes. It was also observed that 
active pfMDH could be competently expressed without the support of the RIG 
plasmid, suggesting that co-transformation with RIG plasmid is not a prerequisite 
for the heterologous expression of pfMDH. A screen for possible regulators of 
pfMDH using a wide range of known metabolites did not uncover any molecule 
that could affect the activity significantly (Fig. 7-7b). Recombinant pfMDH 
exhibits a specific activity of 50.0 U/mg, and Km of 0.25 mM and 0.20 mM with 
respect to NADH and oxaloacetate respectively. The specific activity observed 
was comparable to that for the native enzyme (80 U/mg) determined earlier 




Fig. 7-5. Phylogenetic tree of MDHs and LDHs from prokaryotic and 

























































































































Table 7-2. Accession numbers and list of sequences used to compute 
the phylogenetic tree for MDHs and LDHs.  
Assignment Enzyme Organism Accession Number 
hvul LDH A H. vulgare P22988 
xlae LDH A X. laevis P42120 
fhet LDH B F. heteroclitus P20373 
hvul LDH B H. vulgare P22989 
xlae LDH B X. laevis P42119 
fhet LDH C F. heteroclitus Q06176 
apla LDH H A. platyrhychos P13743 
ggal LDH H G. gallus P00337 
hsap LDH H H. sapiens P07195 
sscr LDH H S. scrofa P00336 
hsap LDH M H. sapiens P00338 
sscr LDH M S. scrofa P00339 
apla LDH M A. platyrhychos P13491 
bpsy LDH  B. psychrosaccharolyticus P20619 
bsub LDH  B. subtilis E69649 
lcas LDH  L. casei P00343 
zmay LDH  Z. mays P29038 
smut LDH  S. mutans P26283 
pfLDH LDH  P. falciparum Q27743 
tgon LDH  T. gondii AAC47443 
cpar LDH  C. parvum AAG17668 
ssol LDH  S. solfatarius SSO2585 
tvag LDH  T. vaginalis AAC72735 
mthe MDH  M. thermoautotrophicum AAK42709 
pfMDH (this study) MDH P. falciparum NP_703844 
sscr MDH S. scrofa Q9TSX5 
pyoe MDH P. yoelii EAA22943 
bbra MDH B. braunii AAB38970 
bhal MDH B. halodurans BAB06877 
bsub MDH B. subtilis I40383 
taci MDH T. acidophilum CAC12081 
ctep MDH C. tepidum P80039 
caur MDH C. aurantiacus CAA61436 
sysp MDH Synechocyctis sp. S75735 
rpro MDH R. prowaekii CAA14835 
ccre MDH C. crecentus AAK25617 
aper MDH A. pernix E72655 
aaeo MDH A. aeolicus O67655 
mjan MDH M. jannanschii Q60176 
aful MDH A. fulgidus O08349 
hmar MDH H. marismortui Q07841 
cjej MDH C. jejuni CAB75168 
hsap MDH H. sapiens P40925 
sscr MDH S. scrofa A32472 
mmus MDH M. musculus P14152 
fbid MDH F. bidentis P46489 
psat MDH P. sativum CAA52614 
zmay MDH Z. mays P15719 
tvag MDH T. vaginalis AAC46986 
glam MDH G. lamblia AAD44473 
tfla MDH T. flavus P10584 
mcry MDH M. crystallinum CAA65384 
mlep MDH M. leprae CAC31472 
gmax MDH G. max AAC37464 
clan MDH C. lanatus P17783 
egun MDH E. gunnii CAA55383 
mmus MDH M. musculus NP_032643 
sscr MDH S. scrofa AAA31071 
scer MDH S. cerevisiae NP_012838 
ecol MDH E. coli P06994 
hinf MDH H. influenzae P44427 
ppro MDH P. profondum P37226 
tcru MDH T. cruzi AAC05706 
tbru MDH T. brucei AAC27101 
phsp MDH Phytomonas sp. AAG01146 
lmaj MDH L. major CAB55506 
tcru HacDH (hydroxyacid 
dehyrogenase) 














































Fig. 7-6. Multiple alignment of pfMDH aa sequences with pfLDH, P. 
yoelii MDH, T. gondii LDH, E. coli MDH, and human 
cytosolic MDH sequences. Conserved residues (as 
discussed in the text) are shaded. The active site is marked 
by an asterisk (*). Sites for substrate and coenzyme binding 
are marked by crosses (+) and arrows (▲) respectively. The 




                                                     8   12 
                                                    |   | 
pfMDH           -----------------------------MTKIALIGSGQIGAIVGELCLLENLG-----
pyoe            MCVYAKFFFSLFSFSFFLFSFYFLFIFLKMTKISLIGSGQIGAIVGQLCLSENIG-----
pfLDH           ---------------------MAP-----KAKIVLVGSGMIGGVMATLIVQKNLG-----
tgon            ---------------------MAPALVQRRKKVAMIGSGMIGGTMGYLCALRELA-----
ecol            -----------------------------MKVAVLGAAGGIGQALALLLKTQLPSGS---
hsap            -------------------------MSEPIRVLVTGAAGQIAYSLLYSIGNGSVFGKDQP
                                                    ▲   ▲     
                      32                                                81 
                      |                                                 | 
pfMDH           -DLILYDVVPGIPQGKALDLKHFSTILGVNRNILGTNQIED-IKDADIIVITAGVQRKEG
pyoe            -DIVLYDVANGVPQGKSLDLKHFSTIIGVNRKIIGTNNIED-IKDSDVIVITAGVQRKEG
pfLDH           -DVVLFDIVKNMPHGKALDTSHTNVMAYSNCKVSGSNTYDD-LAGADVVIVTAGFTKAPG
tgon            -DVVLYDVVKGMPEGKALDLSHVTSVVDTNVSVRAEYSYEAALTGADCVIVTAGLTKVPG
ecol            -ELSLYDIAPVTP-GVAVDLSHIPTAVKIKG-FSGEDATPA-LEGADVVLISAGVARKPG
hsap            IILVLLDITPMMGVLDGVLMELQDCALPLLKDVIATDKEDVAFKDLDVAILVGSMPRREG
                                                                        + 
                       87 
                       | 
pfMDH           -----MTREDLIGVNGKIMKSVAESVKLHCSKAFVICVS-NPLDIMVNVFHKFSNLP---
pyoe            -----MSREDLIGINGKIIKSVAESVKQYAPNAFVICVT-NPLDVMVNVFHKYSNLP---
pfLDH           KSDKEWNRDDLLPLNNKIMIEIGGHIKKNCPNAFIIVVT-NPVDVMVQLLHQHSGVP---
tgonL           KPDSEWSRNDLLPFNSKIIREIGQNIKKYCPKTFIIVVT-NPLDCMVKVMCEASGVP---
ecolM           -----MDRSDLFNVNAGIVKNLVQQVAKTCPKACIGIIT-NPVNTTVAIAAEVLKKAGVY
hsapMc          -----MERKDLLKANVKIFKSQGAALDKYAKKSVKVIVVGNPANTNCLTASKSAPSIP--
                       + 
                               150                      174  
                               |                        | 
pfMDH           -HEKICGMAGILDTSRYCSLIADKLKVSAEDVN-AVILGGHGDLMVPLQRYTSVNGVPLS
pyoe            -YEKICGMAGILDTSRFRYLLGEKLNVSPENIN-AIILGGXGDLMMPLPRYCSISGIPLL
pfLDH           -KNKIIGLGGVLDTSRLKYYISQKLNVCPRDVN-AHIVGAHGNKMVLLKRYITVGGIPLQ
tgon            -TNMICGMACMLDSGRFRRYVADALSVSPRDVQ-ATVIGTHGDCMVPLVRYITVNGYPIQ
ecol            DKNKLFGVT-TLDIIRSNTFVAELKGKQPGEVE-VPVIGGHS----------GVTILPLL
hsap            --KENFSCLTRLDHNRAKAQIALKLGVTANDVKNVIIWGNHSSTQYPDVNHAKVKLQGKE
                               +                        *   
                                                      227  232 
                                                      |    | 
pfMDH           EFVKKNMISQNEIQ-EIIQKTRNMGAEIIKLA----KASAAFAPAAAITKMIKSYLY---
pyoe            DYIKNHDMSEKDIX-DIIEKTRNMGGEIIKLA----KSSAIFAPAASILKMIKSYLQ---
pfLDH           EFINNKLISDAELE-AIFDRTVNTALEIVNLH-----ASPYVAPAAAIIEMAESYLK---
tgon            KFIKDGVVTEKQLE-EIAEHTKVSGGEIVRFLG---QGSAYYAPAASAVAMATSFLN---
ecol            SQVPGVSFTEQEVA-DLTKRIQNAGTEVVEAKAGGGSATLSMGQAAARFGLSLVRAL---
hsap            VGVYEALKDDSWLKGEFVTTVQQRGAAVIKAR----KLSSAMSAAKAICDHVRDIWFGTP
                                                      ▲ 
 
 
pfMDH           NENNLFTCAVYLNGHYNCSNLFVGSTAKINNKG-AHPVEF-PLTKEEQDLYTESIASVQS
pyoe            DQNQLFT-------------------SIINKTG-AHPIEF-ILTXEEQASYQKSIXBXRE
pfLDH           DLKKVLICSTLLEGQYGHSDIFGGTPVVLGANGVEQVIEL-QLNSEEKAKFDEAIAETKR
tgon            DEKRVIPCSVYCNGEYGLKDMFIGLPAVIGGAGIERVIEL-ELNEEEKKQFQKSVDDVMA
ecol            QGEQGVVECAYVEGD-GQYARFFSQPLLLGKNGVEERKSIGTLSAFEQNALEGMLDTLKK




pfMDH           NTQKAFDLIK-- 
pyoe            NTQKALNAVN-- 
pfLDH           M--KALA----- 
tgon            LN-KAVAALQA- 
ecol            DIALGEEFVNK- 






Fig. 7-7. (a) MDH enzyme activities of recombinant clones 
harboring pfMDH gene and controls harboring vectors 
without inserts. 
 (b)   Effect of a range of metabolites on pfMDH activity. All 
the metabolites were used at a final concentration of 






























































































































Fig. 7-8. (a) Homology model of pfMDH (yellow) superimposed on pfLDH template used in threading (blue). (b) Model of pfMDH 
(yellow) superimposed on porcine cytosolic MDH showing conformational differences in the active site loop (A, position 
Arg 81 to Arg 87) as well as other exposed regions (B and C). The B and C domains are approximately Gln 244 to Thr 
251, and Val 187 to Phe 195 respectively.   
 
(a)                                                           (b) 







7.8 RELEVANCE OF P. FALCIPARUM PK1 AS A 
POTENTIAL DRUG-TARGET 
Hexokinase, phosphofructokinase, and pyruvate kinase are important 
regulatory enzymes in the glycolytic pathway. In many protozoan parasites 
(Trypanosoma brucei, Toxoplasma gondii, and Leishmania mexicana), pyruvate 
kinase is highly regulated (Maeda et al. 2003; Ernest et al. 1998; Ernest et al. 
1994), suggesting that this enzyme may play important regulatory roles in 
glycolysis in these parasites. In P. falciparum, pyruvate kinase activity is 
detectable in the parasite’s intraerythrocytic stages (Roth et al. 1988). 
Importantly, the enzyme appears to be increased drastically (>11-fold) upon 
infection (Roth et al. 1988). Furthermore, recent studies have indicated that 
pyruvate kinase of parasite origin may play a role in decreasing the levels of 2,3-
diphosphoglycerate in red blood cells, thereby contributing to hypoxia during 
malaria (Dubey et al. 2003). These observations indicate that P. falciparum 
pyruvate kinase may play a central role in malarial infection and deserves further 
detailed study. 
 
Pyruvate kinase (EC 2.7.1.40) catalyzes the irreversible substrate level 
phosphorylation of ADP at the expense of phosphoenolpyruvate (PEP), yielding 
pyruvate and ATP. Almost all pyruvate kinases are homotetrameric enzymes. 
Among protozoans, the pyruvate kinases from T. brucei, T. gondii, L. mexicana, 
and Entamoeba histolytica have been characterized in detail. Although pyruvate 
kinases of most species are activated by fructose-1,6-bisphosphate (F16BP), the 
T. gondii enzyme is insensitive to F16BP but markedly activated by glucose-6-




kinases are quite similar, both being activated predominantly by F26BP. E. 
histolytica pyruvate kinase is activated by F16BP but inhibited by citrate, malate, 
phosphate, and α-ketoglutarate (Saavedra et al. 2005). Although pyruvate kinase 
activity has been identified in P. falciparum (Roth et al. 1988; Roth et al. 1982) 
and P. berghei (Buckwitz et al. 1990) infected red cells, little is known about 
their characteristics. Experimentation started with obtaining the cDNA of a 
predicted pyruvate kinase gene in the P. falciparum genome and determining 
whether the predicted gene encodes a functional pyruvate kinase enzyme. The 
functional validation of a cDNA encoding P. falciparum pyruvate kinase (PK1) 
and the detailed kinetic properties of the enzyme are herein reported. 
 
7.9 SEQUENCE ANALYSIS OF P. FALCIPARUM PK1 
As the putative P. falciparum pyruvate kinase gene deposited in the P. 
falciparum genome resource (PlasmoDB) was predicted to contain two introns, 
the cDNA encoding PK1 was cloned by RT-PCR using mRNA purified from an 
in-vitro culture (Chapter 6; Fig. 6-2j). Full DNA-sequencing of the cDNA 
demonstrated a 1536 bp ORF encoding PK1, and confirmed the absence of 
introns in the cloned cDNA. The obtained PK1 ORF is identical in DNA 
sequence to that of strain 3D7 deposited in the PlasmoDB (accession no. 
MAL6P1.160). BLAST analysis of the PK1 DNA sequence against P. 
falciparum genome sequence indicated that the pyruvate kinase gene exists as a 
single copy in P. falciparum. The ORF encodes a protein with a computed 
molecular mass of 55.6 kDa and an isoelectric point of 7.5, similar to those from 
other parasites such as L. mexicana (molecular mass of 54.3 kDa and isoelectric 




In terms of amino acid sequence, PK1 exhibits the highest identity to 
pyruvate kinase of Plasmodium yoelii (88%) followed by that of T. gondii (67%). 
Interestingly, PK1 is almost as distant from human pyruvate kinases (44%) as 
from plant pyruvate kinases (46-47%). There are 4 domains in pyruvate kinase: N 
(a variable N-terminus), A, B, and C (Ridgen et al. 1999). The active site is 
located in the A and B domains, whereas the C domain, and a cleft between the A 
and C domains, appear to contain the binding sites for effectors. Multiple-
alignment of amino acid sequences of protozoan pyruvate kinases with those of 
rabbit and human enzymes (Fig. 7-9) revealed that known binding sites for ADP, 
PEP, and cation, located in N, A and B domains, were well conserved (76-
100%); whereas sites for effector binding, located in domain C, were not 
conserved. In this dataset, the A domain was significantly more well conserved 
(43%) than the B and C domains (17% and 9% respectively). This observation is 
in agreement with that on pyruvate kinases from a wide variety of organisms 
(Allert et al. 1991). Phylogenetic analysis showed a wide divergence between 
PK1 and the isozymes in human (Fig. 7-10). This data, together with the 
observation of a low sequence identity between these genes, support the use of 
this enzyme as a drug-target. In addition, some deletions in an effector binding 
site in the C domain which are unique to pyruvate kinases from P. falciparum, P. 
yoelii, T. gondii, and Eimeria tenella, were observed (Fig. 7-9). This site could be 
a target for selective inhibitors to be designed or for new  drugs that act against 






7.10 KINETIC CHARACTERISTICS OF OVEREXPRESSED 
PK1 
PK1 was expressed at high levels in E. coli as a GST-tagged protein (Fig. 
6-3). SDS-PAGE analysis of pfPK1 purified by affinity chromatography from 
lysates of E. coli expressing the recombinant protein showed that the molecular 
weight of the expressed protein was approximately 80 kDa (Fig. 6-3), in good 
agreement with the expected molecular weight for PK1 incorporated with a 26 
kDa GST moiety. The purified PK1 was enzymatically active, indicating that the 
ORF encoded an authentic pyruvate kinase. As expected, no absorbance change 
was detectable from negative controls comprising of GST expressed from non-
insert vector. Control assays in which one or the other co-substrate was omitted 
confirmed that there were no contaminating NADH consuming activities in the 
enzyme preparations. No net absorbance change was detected in these negative 
controls (<0.00 A340nm/min). In order to determine the oligomerization state of 
PK1, the purified enzyme was subjected to analytical gel-filtration. The 
recombinant PK1 eluted from the column with an apparent molecular weight of 
approximately 316 kDa, as estimated using standard proteins of known molecular 
weights (Fig. 7-11). This data suggests that PK1 exists as a homotetramer. As 
expected, SDS-PAGE analysis of the eluted fractions containing PK1 recovered a 
single polypeptide with the expected molecular weight for PK1. The eluted 
fractions corresponding to the tetrameric form of PK1 were enzymatically active 
(Fig. 7-11). Hence, like almost all pyruvate kinases from other organisms 
including those from T. gondii and T. brucei, active pfPK1 exists as a 
homotetramer. However, it should be noted that while it is shown that GST-




to the employment of a GST-tagged recombinant protein in the gel filtration 
experiments. The specific activity of PK1 was 126 + 4 U/mg protein at room 
temperature (26oC) under optimal substrate concentrations in the presence of 
magnesium as the divalent cation. In terms of yield, 0.45 to 0.6 mg of 
recombinant PK1 could be reproducibly obtained from each fermentation batch 
comprising of 100 ml of E. coli culture. In separate experiments, enzymatic 
analysis of recombinant PK1 after proteolytic removal of the GST affinity-tag 
indicated that untagged pfPK1 is also enzymatically active with comparable 
specific activity. Hence, the presence of the GST-tag did not seem to influence 
the enzymatic activity or the quaternary configuration of the enzyme. However, 
because the recovery of pure untagged proteins after proteolytic cleavage was 
typically low, pure GST-tagged pfPK1 enzyme was used for further biochemical 
analyses.  
 
The kinetic behavior of pfPK1 for PEP and ADP were investigated (Fig. 
7-12) and the obtained parameters summarized in Table 7-3. Among protist 
pyruvate kinases, L. mexicana exhibited sigmoidal kinetics for both substrates 
(Ernest et al. 1994), while for T. gondii kinetic behavior was sigmoidal for PEP 
but hyperbolic for ADP (Maeda et al. 2003). In terms of kinetics, pfPK1 
resembled E. histolytica pyruvate kinase in that it exhibited hyperbolic kinetics 
with respect to both substrates under saturating conditions (Saavedra et al. 2005). 
Although F16BP was an activator for many pyruvate kinases including those of 
E. histolytica, T. gondii pyruvate kinase was not sensitive to F16BP but instead is 
activated by G6P. In the case of T. gondii pyruvate kinase, the presence of G6P 




(Maeda et al. 2003). Interestingly, pfPK1 did not respond significantly to either 
F16BP (1mM) or G6P (1mM) over a wide range of PEP and ADP 
concentrations, under both saturating as well as non-saturating conditions (Fig. 7-
12a,c; Table 7-3). Pyridoxal-5’-phosphate (PLP) is a known inhibitor of rabbit 
muscle pyruvate kinase (George and Deal 1970). In an earlier study on rabbit 
muscle pyruvate kinase, treatment by PLP inactivated the enzyme by 90%. In 
order to assess the sensitivity of PK1 to inactivation by PLP, enzyme inactivation 
study was carried out together with rabbit muscle pyruvate kinase for 
comparison. For these experiments, the test enzymes were incubated with PLP at 
the indicated concentrations (Fig. 7-12f) for 15 mins before their employment in 
the enzyme assays. It was observed that pfPK1 was also sensitive to PLP. 
However, as compared to rabbit muscle pyruvate kinase, which could be 
inactivated up to 75% in this study, pfPK1 was less disposed to inactivation, 
being inactivated up to 22% maximally.  
 
As there are almost no known inhibitor known for pfPK1, the effect of a 
wide array of metabolites were screened for their effect on pfPK1 activity (Fig. 
7-13). Interestingly, among the compounds tested, 2mM citrate was found to 
inhibit pfPK1 markedly (>97%) in a standard enzyme assay. The inhibition 
appeared to be specific to citrate, and does not apply to all carboxylic acids, 
because the other carboxylic acids (α-ketoglutaric acid and isocitric acid) tested 
at identical concentrations did not show inhibitory effects. In addition, the 
enzyme was 64% inhibited by 2mM ATP. Aspartate, the end-product of the PEP 
carboxykinase-aspartate aminotransferase pathway (which competes with pfPK1 




inhibitors (ATP and citrate) was subsequently carried out to ascertain the nature 
of inhibition with respect to each co-substrate under saturating conditions (Fig. 7-
12; Table 7-3). When present at a concentration of 1mM, citrate appears to be a 
competitive inhibitor of PEP. Interestingly, results revealed a transition from 
hyperbolic to sigmoidal kinetics for PEP in the presence of 1.5mM and 2mM 
citrate, with Hill coefficients of 1.9 and 2.4 respectively (Fig. 7-12e). Significant 
competitive inhibitory behavior was observed for 2mM and 2.5mM ATP with 




































Fig. 7-9. (Next page). Amino-acid sequence alignment of P. 
falciparum PK1 with pyruvate kinases from other species. 
Accession numbers are: pfPK1, P. falciparum (this study; 
MAL6P1.160); Pyoelii, P. yoelii (EAA16536); Tgondii, T. 
gondii (BAB47171); Etenella, E. tenella (AF043910); 
Tbrucei, T. brucei (X17618); Lmexicana, L. mexicana 
(X74944); rabbit,  rabbit muscle pyruvate kinase 
(15987970); humanM1, human muscle isozyme 1 (S64635); 
humanM2, human muscle isozyme 2 (O18919). The 3D-
domains (N/A/B/C) are indicated by vertical lines. A box 
indicates pyruvate kinase signature sequences. Open 
circles indicate ADP binding sites. The binding sites of the 
sugar, 1-phosphate, and 6-phosphate moieties of F16BP 
are indicated by closed circles, open squares, and closed 
squares, respectively. Asterisks and triangles indicate the 































































                                                       N-domain | A-domain 
pfPK1     ------------------MSSFKYKNSAAGASMQSAANITLRQILEP-NNVNLRSKKTHIVCTLGPACKSVETLVKLIDAGMDICRFNFS
Pyoelii   ------------------MNPFKFKNATAGASLQSAANITLRQILEP-NNVNLRSKKTHIVCTLGPACKSVETLVQMIDAGMDICRFNFS
Tgondii   MASKQPQTLSAGAVESGRVARLVSASSVMTQQLGKSTNIRMSQILEPRSEEDWTAHRTRIVCTMGPACWNVDTLVKMIDAGMNVCRLNFS
Etenella  MANPTHSQVVAAPDSSGRLLRLVSASSVMMQLLGKSTNIRMSQILEHHEDEDFSAHRTKIVCTMGPSCWDVDKMVQLIDAGMNVCRLNFS
Lmexicana --------------------------------MSQLAHNLTLSIFDP----VANYRAARIICTIGPSTQSVEALKGLIQSGMSVARMNFS
Tbrucei   --------------------------------MSQLEHNIGLSIFEP----VAKHRANRIVCTIGPSTQSVEALKNLMKSGMSVARMNFS
rabbit    ----------SKSHSEAGSAFIQTQQLHAAMADTFLEHMCRLDIDSA----PITARNTGIICTIGPASRSVETLKEMIKSGMNVARMNFS
humanM1   ---------MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSP----PITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFS
humanM2   ---------MSKSHSEAGSAFIQTQQLHAAMADTFLEHMCRLDIDSA----PITARNTGIICTIGPASRSVETLKEMIKSGMNVARMNFS
                                                                                               ○ ○ 
          1........10........20........30........40........50........60........70........80....*....
                                         A-domain | B-domain 
pfPK1     HGSHEDHKEMFNNVLKAQELRPNCL-----LGMLLDTKGPEIRTGFLK---NKEVHLKEGSKLKLVTD--YEFLGDETCIACSYKKLPQS
Pyoelii   HGTHDDHKQMFENVLKAQAQRPNCT-----LGMLLDTKGPEIRTGLLK---NKEAHLKEGSKLKLVTD--YSYLGDETCIACSYTKLPQS
Tgondii   HGDHETHARTVQNIQEAMKQRPEAR-----LAILLDTKGPEIRTGFLKD--HKPITLQQGATLKIVTD--YNLIGDETTIACSYGALPQS
Etenella  HGDHEAHGRVVKNLQEALKQRPGKR-----VALLLDTKGPEIRTGMLEG--DKPIELHAGDMLKIVTD--YSFVGNKSCIACSYEKLPSS
Lmexicana HGSHEYHQTTINNVRQAAAELGVN------IAIALDTKGPEIRTGQFVG---GDAVMERGATCYVTTDPAFADKGTKDKFYIDYQNLSKV
Tbrucei   HGSHEYHQTTINNVRAAAAELGLH------IGIALDTKGPEIRTGLFKD---GEVSFAPGDIVCVTTDPAYEKVGTKEKFYIDYPQLTNA
rabbit    HGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKV
humanM1   HGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKV
humanM2   HGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKV
          ○                                         ○ 
          91.......100.......110.......120.......130*......140.......150.......160.......170........
                                                    B-domain | A-domain| 
pfPK1     VKPGNIILIADGSVSCKVLETHED-HVITEVLNSAVIGERKNMNLPNVKVDLPIISEKDKNDILNFAIPMGCNFIAASFIQSADDVRLIR
Pyoelii   VKPGSIILIADGSVSCRVLETHDD-HVITEVLNNATIGEKKNMNLPNVKVDLPIISEKDKDDILNFAIPMGCNFIAASFIQSAEDVRLIR
Tgondii   VKPGNTILIADGSLSVKVVEVGSD-YVITQAQNTATIGERKNMNLPNVKVQLPVIGEKDKHDILNFGIPMGCNFIAASFVQSADDVRYIR
Etenella  VKPGNTILIADGSLSVEVVECGKD-YVMTRVMNPAIIGNKKNMNLPGVKVDLPVIGEKDKNDILNFGIPMGCNFIAASFVQSADDVRYIR
Lmexicana VRPGNYIYIDDGILILQVQSHEDEQTLECTVTNSHTISDRRGVNLPGCDVDLPAVSAKDRVD-LQFGVEQGVDMIFASFIRSAEQVGDVR
Tbrucei   VRPGGSIYVDDGVMTLRVVSKEDDRTLKCHVNNHHRLTDRRGINLPGCEVDLPAVSEKDRKD-LEFGVAQGVDMIFASFIRTAEQVREVR
rabbit    VDVGSKVYVDDGLISLQVKQKGPD-FLVTEVENGGFLGSKKGVNLPGAAVDLPAVSEKDIQD-LKFGVEQDVDMVFASFIRKAADVHEVR
humanM1   VEVGSKIYVDDGLISLQVKQKGAD-FLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQD-LKFGVEQDVDMVFASFIRKASDVHEVR
humanM2   VDVGSKVYVDDGLISLQVKQKGPD-FLVTEVENGGFLGSKKGVNLPGAAVDLPAVSEKDIQD-LKFGVEQDVDMVFASFIRKAADVHEVR
                                                  ○ 
          181......190.......200.......210.......220.......230.......240.......250.......260........
 
pfPK1     NLLGPRGRHIKIIPKIENIEGIIHFDKILAESDGIMIARGDLGMEISPEKVFLAQKLMISKCNLQGKPIITATQMLESMTKNPRPTRAEV
Pyoelii   NLLGPRGRHIKIIPKIENIEGIINFDKILAEADGIMIARGDLGMEISAEKVFLAQKLMISKCNLQGKPIITATQMLESMTKNPRPTRAEV
Tgondii   GLLGPRGRHIRIIPKIENVEGLVNFDEILAEADGIMIARGDLGMEIPPEKVFLAQKMMIAKCNVVGKPVITATQMLESMIKNPRPTRAEA
Etenella  SILGTKGRNIKIIPKIENVEGLLNFDEILQEADGIMIARGDLGMEIPPEKVFLAQKMMISKCNVAGKPVITATQMLESMTKNPRPTRAEA
Lmexicana KALGPKGRDIMIICKIENHQGVQNIDSIIEESDGIMVARGDLGVEIPAEKVVVAQKILISKCNVAGKPVICATQMLESMTYNPRPTRAEV
Tbrucei   AALGEKGKDILIISKIENHQGVQNIDSIIEASNGIMVARGDLGVEIPAEKVCVAQMCIISKCNVVGKPVICATQMLESMTSNPRPTRAEV
rabbit    KILGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMIIGRCNRAGKPVICATQMLESMIKKPRPTRAEG
humanM1   KVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPPPTRAEG
humanM2   KILGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMIIGRCNRAGKPVICATQMLESMIKKPRPTRAEG
                       *******                  ▲▲▲▲▲                            **** 
          271......280....▲..290.......300.......310.......320.......330.......340.......350........
                                            A-domain | C-domain 
pfPK1     TDVANAVLDGTDCVMLSGETAGGKFPVEAVTIMSKICLEAEACIDYKLLYQSLVNAIETPISVQEAVARSAVETAESIQASLIIALTETG
Pyoelii   TDVANAVLDGTDCVMLSGETAGGKFPVEAVTIMSKICLEAEACIDYKLLYQSLVNAIQTPISVQEAVARSAVETAESIEASVIITLTETG
Tgondii   ADVANAVLDGTDCVMLSGETANGEFPVITVETMARICYEAETCVDYPALYRAMCLAVPPPISTQEAVARAAVETAECVNAAIILALTETG
Etenella  ADVANAVLDGTDCVMLSGETANGSFPVQAVTVMSRVCFEAEGCIDYQQVFRATCQATMTPIDTQEAVARAAVETAQSINASLILALTETG
Lmexicana SDVANAVFNGADCVMLSGETAKGKYPNEVVQYMARICLEAQSALNEYVFFNSIKKLQHIPMSADEAVCSSAVNSVYETKAKAMVVLSNTG
Tbrucei   SDVANAVLNGADCVMLSGETAKGKYPNEVVQYMARICVEAQSATHDTVMFNSIKNLQKIPMCPEEAVCSSAVASAFEVQAKAMLVLSNTG
rabbit    SDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELARASSHSTDLMEAMAMGSVEASYKCLAAALIVLTESG
humanM1   SDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELVRASSHSTDLMEAMAMGSVEASYKCLAAALIVLTESG
humanM2   SDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEAAAVGAVEASFKCCSGAIIVLTKSG
                                                                                                ■ ■ 
          361......370.......380.......390.......400.......410.......420.......430.......440........
 
pfPK1     YTARLIAKYKPSCTILALSASDSTVKCLNVHRGVTCIKVGSF------QGTDIVIRNAIEIAKQRNMAKVGDSVIAIHGIKEEVSGGTNL
Pyoelii   YTARLIAKYKPSCTILALSASDSTVRCLNVHRGVTCIKVGSF------QGTDNVLRNAIEIAKERNIVKPGDSAICIHGIKEEVSGSTNL
Tgondii   QTARLIAKYRPMQPILALSASESTIKHLQVIRGVTTMQVPSF------QGTDHVIRNAIVVAKERELVTEGESIVAVHGMKEEVAGSSNL
Etenella  RTARLIAKYRPMQPILALSASEETIKQLQVIRGVTTFLVPTF------QGTDQLIRNALSAAKELQLVSEGDSIVAVHGIKEEVAGWSNL
Lmexicana RSARLVAKYRPNCPIVCVTTRLQTCRQLNITQGVESVFF-DADKLGHDEGKEHRVAAGVEFAKSKGYVQTGDYCVVIHADHK-VKGYANQ
Tbrucei   RSARLISKYRPNCPIICVTTRLQTCRQLNVTRSVVSVFY-DAAKSGEDKDKEKRVKLGLDFAKKEKYASTGDVVVVVHADHS-VKGYPNQ
rabbit    RSAHQVARYRPRAPIIAVTRNHQTARQAHLYRGIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRP-GSGFTNT
humanM1   RSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRP-GSGFTNT
humanM2   RSAHQVARYRPRAPIIAVTRNHQTARQAHLYRGIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRP-GSGFTNT
          ■                                            ●   □   □                       ●        ● 
          451......460.......470.......480.......490.......500.......510.......520.......530........
 
pfPK1     MKVVQIE 
Pyoelii   MKVIQVE 
Tgondii   LKVLTVE 
Etenella  LKVLVVE 
Lmexicana TRILLVE 
Tbrucei   TRLIYLP 
rabbit    MRVVPVP 
humanM1   MRVVPVP 
humanM2   MRVVPVP 








Fig. 7-10. Phylogenetic (Neighbor-joining) tree constructed using 
pyruvate kinase amino acid sequences. The Genbank 
accession numbers, in addition to those indicated in Fig. 7-
9, are as follows: soybean (AAM94349), rice (CAE05765), 
tobacco (CAA82628), zebrafish (NP_955365), 
Caenorhabditis elegans (CAA93424), Anopheles gambiae 
(EAA10555), frog (AAH44007), rat (NP_445749), 
































































Fig. 7-11. Determination of oligomerization state of PK1 by gel-
filtration. Enzyme activity of eluted fractions ( ) 
corresponded to elution of PK1 as a tetramer. Inset: 
Calibration curve. The column is calibrated using protein 
standards: (a) aldolase, (b) catalase, (c) ferritin and (d) 
thyroglobulin. Elution fractions indicated were analyzed by 
SDS-PAGE electrophoresis and the results confirmed the 
presence of PK1 in the enzymatically active fraction. M, 

























a b pfPK1 

















































Fig. 7-12. Kinetic properties of PK1. (a) Hanes plot using varying 
concentrations of PEP in the absence of effectors (closed 
lozenges ), or in the presence of 1mM glucose-6-phosphate 
(open squares ), or 1mM fructose-1,6-bisphosphate (open 
circles {); (b) Hanes plot using varying concentrations of PEP in 
the absence of effectors (closed lozenges ), or 2.5mM ATP 
(crosses ±), 2mM ATP (open lozenges ), or 1mM citrate (open 
triangles U); (c) Hanes plot using varying concentrations of ADP 
in the absence of effectors (closed lozenges ), or in the 
presence of 1mM glucose-6-phosphate (open squares ), 1mM 
fructose-1,6-bisphosphate (open circles {); (d) Hanes plot using 
varying concentrations of ADP in the absence of effectors (closed 
lozenges ), or in the presence of 3mM citrate (asterisks ½), 
2.5mM citrate (open triangles U), or 3mM ATP (open squares ); 
(e) Hill plot of log(v/V-v) vs log[PEP] in the presence of citrate 
(1.5mM or 2mM); (f) effect of enzyme inactivation by various 
concentrations of pyridoxal 5’ phosphate. Closed circles (●) 
indicate control experiments to confirm that pyridoxal phosphate 
has no effect on lactate dehydrogenase employed in the coupled 
enzyme assay for pyruvate kinase. Experiments using pfPK1 and 
rabbit muscle pyruvate kinase are indicated by open circles ({) 























































































y = 2.4x - 1.0138
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Fig. 7-13. Effect of various effector compounds on pfPK1 activity. All 
compounds were tested at a final concentration of 2mM in 
the assay system. Relative activities were expressed in % 






































































Table 7-3. Enzyme kinetic parameters of pfPK1. Kinetic analysis of 
PEP and ADP (saturating conditions) were carried out using 
co-substrate concentrations of 3mM ADP and 7mM PEP 
respectively. Kinetic analysis of PEP and ADP (non-
saturating conditions) were carried out in the presence of 
1mM ADP and PEP respectively.  
 





 no effector 
  
 + F16P (1mM) 
  
 + G6P (1mM) 
  
 + citrate (1mM) 
 + citrate (1.5mM) 
 + citrate (2mM) 
  
 + ATP (2mM) 
 + ATP (2.5mM) 




0.190 + 0.028 (100%) 
 
0.214 + 0.004 (112%) 
 
0.143 + 0.030 (75%) 
 




0.497 + 0.074 (261%) 




276 + 28 (100%) 
 
291 + 26 (105%) 
 
326 + 15 (118%) 
 




246 + 17 (89%) 


















 no effector 
  
 + F16P (1mM) 
  
 + G6P (1mM) 
  
 + citrate (2.5mM) 
 + citrate (3mM) 
 + citrate (3.5mM) 
  
 + ATP (3mM) 
  
 
0.126 + 0.043 (100%) 
 
0.163 + 0.027 (129%) 
 
0.204 + 0.085 (161%) 
 
0.149 + 0.060 (118%) 
0.154 + 0.002 (122%) 
0.143 + 0.057 (113%)  
 
0.151 + 0.060 (119%) 
  
 
258 + 15 (100%) 
 
300 + 3 (116%) 
 
375 + 93 (145%) 
 
154 + 18 (60%) 
136 + 2 (52%) 
38 + 8 (14%) 
 





 no effector 
  
 + F16BP (1mM) 
  
 + G6P (1mM) 
 
 
0.337 + 0.031 (100%) 
 
0.307 + 0.070 (91%)  
 




96.8  + 9.4 (100%) 
 
86.8 + 4.7 (90%) 
 




 No effector 
 
 



















TRANSCRIPTION ANALYSES OF 





CHAPTER 8 TRANSCRIPTION ANALYSES OF 
TARGETS AND PROTEIN 
INTERACTION 
 
8.1 TRANSCRIPTION ANALYSIS  
After the target genes were identified, the next step was to investigate the 
status of transcription of these genes in in vitro cultures of P. falciparum. This is 
because genes expressed during the intra-erythrocytic stages of the parasite’s 
developmental cycle are relevant as drug-targets, while genes expressed at other 
stages may be useful for disrupting the life-cycle of the parasite. The current 
proteomics (mass spectrometry) data (Table 8-1) only indicated the presence of 5 
of the targets active in the asexual blood stage, even though currently available 
transcriptome data (Le Roch et al. 2004; Bozdech et al. 2003) indicated that all 
the 10 targets are transcribed in the blood stage. Incongruence between 
microarray data and transcription analysis of specific Plasmodium genes have 
recently been observed (Sijwali and Rosenthal 2004; Tripathi et al. 2004). Hence, 
RT-PCR was carried out to investigate the expression of the 10 targets in the 
intraerythrocytic-stage. The identities of the obtained bands in the RT-PCR were 
further confirmed by DNA sequencing. Attempts to amplify the full length 
cDNA using RT-PCR resulted in the isolation of cDNA encoding all selected 
ORFs except FUM and GK (Fig 8-1a, b, c). For the non-intronic genes, negative 
controls in which reverse transcriptase was not added, did not result in any band, 
indicating that the amplified products obtained were not due to contamination by 




GK, RT-PCR using primers re-designed (Table 5-5) to amplify the N-terminal 
300bp of these ORFs resulted in positive bands of expected sizes after analysis 
using agarose-gel electrophoresis (Fig. 8-1d). As expected, negative controls 
without reverse transcriptase did not give any amplified products, confirming the 
authenticity of the obtained partial cDNA for FUM and GK. The correct 
identities of the 300bp fragments were further ascertained by full DNA 
sequencing of these fragments. Hence, all the predicted ORFs selected in this 
study were found to be actively transcribed in the intraerythrocytic-stage and are 
indeed authentic coding regions. This observation was in good agreement to 
existing microarray data but did not correlate well with existing mass-
spectrometry data, suggesting a difference in sensitivity of detection between 
transcription and proteomic approaches.  
 
The transcriptome of P. falciparum has revealed a programmed timing of 
key cellular functions during the parasite’s development, with functionally 
related genes sharing common expression profiles (Bozdech et al. 2003). 
However, specific metabolic pathways should be examined for departures from 
this trend so as to visualize parasite-specific peculiarities. Datamining of the 
transcriptome data was carried out to uncover information about the glycolytic 
and TCA pathways. The transcription profiles of 15 glycolytic and 11 TCA cycle 
genes were extracted from the intraerythrocytic-stage microarray data (DeRisi), 
and microarray data of human and mosquito-stages (Winzeler) (Fig. 8-2). Among 
the glycolytic genes, there were two annotations each for phosphofructokinase 
(PFI0755c and PF11_0294), triose phosphate isomerase (PF14_0378 and 




pyruvate kinase (PFF1300w and PF10_0363). Only one gene from each pair 
showed transcription profiles typical of glycolytic genes and appeared to be the 
functional component of the glycolytic pathway. In the case of 
phosphofructokinase and triose phosphate isomerase, the latter copies were not 
detected in the intraerythrocytic-stages, suggesting that these genes may be 
nonfunctional or redundant homologues (Fig. 8-2a). Likewise, overlays of 
transcription profiles showed that only one copy of triose phosphate isomerase 
(PF14_0378), phosphoglycerate mutase (PF11_0208), and pyruvate kinase 
(PFF1300w) showed profiles typical of glycolysis genes (Fig. 8-2c).  
Transcriptions of all the TCA cycle components were detected, although malate 
dehydrogenase (PFF0895w) and fumarase (PFI1340w) appeared to be localized 
in the cytosol. Nevertheless, they possessed microarray profiles typical of TCA 
cycle components, suggesting that they may have functional links to the TCA 
cycle (Fig. 8-2b). In conclusion, these observations suggest that datamining the 
transcriptome data for glycolysis and TCA cycle components may extend 






Fig 8-1.  RT-PCR analysis of predicted ORFs selected for functional analysis. Arrows 
indicate major bands with sizes that correspond to each target investigated. 
(a) RT-PCR analysis of ORFs which are non-intronic. Lanes: 1, DHO; 3, 
ICDH; 5, FUM; 7, MDH; 9, PGDH; 11, GK; 13, GDH; 15, CS; 17, DNA 
marker; negative controls for the respective ORFs (no reverse 
transcriptase added) were loaded in the even lanes;  
(b) RT-PCR analysis of PK1 (intronic). Lanes: 1, PK1; 2, DNA marker;  
(c) RT-PCR analysis of GDH (intronic). Lanes: 1, GDH; 2, DNA marker;  
(d) RT-PCR of 300bp cDNA of FUM and GK. Lanes: 1, FUM; 2, GK; 3, DNA 
marker; 4 and 5, negative controls (no reverse transcriptase added) for 
the respective FUM and GK reactions. DNA sequencing was carried out 
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Table 8-1. Comparison of RT results with microarray and proteomics.  
S, sporozoites; R, rings; T, trophozoites; M, merozoites; G, 



















PFC0275w + + 9  9  9 S,T,M,G 




PF13_0269 + + 9  9 9 9 No data 














PFI1340w + + 9 9 9 9 9 G 


































PF14_0697 + + 9 9 9 9 9 T,G 




Fig. 8-2. Transcription profiles of (a) glycolysis and (b) TCA enzymes extracted from microarray data. Relative 
transcription levels are indicted on the Y-axes. The x-axes for DeRisi data represent time over a period of 
48hrs. Overlays of transcription profiles are shown in (c). 
Stages: ER, early rings; LR, late rings; ET, early trophozoites; LT, late trophozoites; ES, early schizonts; LS, 
late schizonts; M, merozoites; S, sporozoites; G, gametocytes 
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(a) Glycolytic enzymes (b) TCA cycle enzymes
DeRisi                           Winzeler DeRisi                           Winzeler DeRisi                           Winzeler DeRisi                           Winzeler 
Chapter 8 
 
Fig. 8-2 (Cont’d). Transcription profiles of glycolysis and TCA enzymes. 
 

































































8.2 AUTHENTICATION OF ANOTHER COPY OF PYRUVATE 
KINASE (PK2) 
Further studies to investigate the usefulness of pyruvate kinase as a drug-
target must take into account presence of alternative copies of enzymes that may 
circumvent the target. An inspection of the genome data of P. falciparum showed 
that there might be a putative ORF that may encode another pyruvate kinase 
(designated PK2). Investigations on the expression of both PK1 and PK2 during 
infection, as well as their structural comparison, are important criteria in the 
employment of pyruvate kinase as a drug-target. Hence, in this study, we set out 
to investigate the active transcription of PK1 and PK2 in the intraerythrocytic 
stages in in vitro cultures. Ideally, enzymes identified as drug targets should 
differ significantly from any analogous process in the host. Hence, structural 
analysis was carried out to identify structural differences between the P. 
falciparum pyruvate kinases and the corresponding enzyme from its human host. 
The diversity of both genes among Plasmodium and the human host were 
investigated via phylogenetic analysis. 
 
There is existing mass spectrometry-based evidence for the expression of 
PK1 in the intraerythrocytic stages (PlasmoDB). There is comparatively less 
supporting evidence for the expression of PK2, with only one peptide fragment 
detected by mass spectrometry in the trophozoite stage (PlasmoDB). Microarray 
data indicated that both PK1 and PK2 were transcribed, although PK1 appear to 
possess higher transcription levels (Fig. 8-3). To investigate the expression of 
PK1 and PK2, primers specific for PK1 or PK2 were constructed to amplify a 




extracted from P. falciparum in vitro cultures. Results indicated that both PK1 
and PK2 were indeed actively transcribed (Fig. 8-4). As expected, no bands were 
observed from negative controls in which reverse transcriptase were omitted, 
indicating that positive bands were indeed amplified from cDNA and not due to 
genomic DNA contamination. The positive bands corresponding to amplified 
PK1 and PK2 cDNA were then purified; their identities were confirmed by DNA 
sequencing. Hence, RT-PCR results were consistent with microarray and mass 
spectrometry data, indicating that both PK1 and PK2 were indeed expressed 
during the intraerythrocytic stages. 
 
8.3 STRUCTURAL COMPARISON BETWEEN PK1 AND PK2 
The 1536bp cDNA of P. falciparum PK1 encodes a protein of 511aa, 
with a computed molecular mass of 55.6 kDa. The gene for PK2 is 2.1kb and 
encodes a protein of 745aa with a computed molecular mass of 86.6 kDa. Hence, 
PK2 appears to be a larger protein compared to PK1. In addition, there is an 
approximately 130aa N-terminal extension that was predicted to be an apicoplast 
targeting signal by software for apicoplast targeting signals, PATS (Zuegge et al. 
2001) and PlasmoAP (Foth et al. 2003) (Fig. 8-5). PK1 does not appear to carry 
any targeting sequence and was therefore predicted to be cytosolic.  
 
In terms of amino acid sequence diversity, PK1 was closest to P. yoelii 
pyruvate kinase (90.8% identity). Contrastingly, the identity between PK1 and 
PK2 is only 20.0%. In addition, although the conserved domain for pyruvate 
kinase (pfam id: cd00288) is detected in both PK1 and PK2, the latter appeared to 




signature (Fig. 8-5). Multiple-alignment of PK1 and PK2 with known pyruvate 
kinases showed that the binding sites for ADP, PEP, and divalent cation were 
well conserved in the human pyruvate kinases, PK1, and PK2, despite the low 
identities between PK2 and PK1 (20.0% identity), or between PK2 and the 
human pyruvate kinases (19.7% identities) (Fig. 8-6). Moreover, the secondary 
structural identity between PK1 and PK2 was approximately 70%.  
 
Finally, molecular investigations to elucidate the binding sites for 
effectors may be relevant to design of molecules that would inhibit the parasite’s 
enzymes. A comparison of amino acid residues at these binding sites revealed 
some significant differences, as listed in Table 8-2. These differences may 
account for the distinction in response to effectors by PK1, PK2, and human 
pyruvate kinases. In pyruvate kinases, the lysine at position 418 (PK1 
numbering) is thought to be involved in binding the 6-phosphate moiety of 
fructose-1,6-bisphosphate. Consistent with non-allosteric enzymes, PK1 was not 
activated by fructose-1,6-bisphosphate (Chan and Sim 2004a) and has a 
glutamate at residue 418. In contrast, asparagines were observed at position 418 
in pyruvate kinases activated by fructose-2,6-bisphosphate, such as L. mexicana 
pyruvate kinase. Intriguingly, PK2 has an asparagine at this position, suggesting 
that it may respond to fructose-2,6-bisphosphate. The physiological significance 
of this observation deserves further experimental investigation. In addition, some 
deletions near the effector binding sites in the C domain which are unique to 
pyruvate kinases from P. falciparum, P. yoelii, T. gondii, and Eimeria tenella, 
were observed (Fig. 8-6). This site could also be a target for selective inhibitors 




8.4 PK2 APPEARS TO BE CONFINED TO 
APICOMPLEXANS 
Pyruvate kinase is found in all living organisms. In vertebrates, there are 
four tissue-specific isozymes: L (liver), R (red cells), M1 (muscle, heart and 
brain), and M2 (early fetal tissue). In plants, pyruvate kinase exists as 
cytoplasmic and plastid isozymes. Interestingly, while most bacteria and lower 
eukaryotes have one form, P. falciparum appears to have two non-identical 
isozymes, PK1 and PK2. Phylogenetic analysis showed a wide divergence 
between PK1, PK2 and the human isozymes (Fig. 8-7). This data, together with 
the observation of a low sequence identity between these genes, support the use 
of this enzyme as a drug-target. Interestingly, Genbank search revealed that the 
“PK2” type of enzyme appears to be confined to Apicomplexans. In addition, 
two of the “PK2”-type of pyruvate kinase from the Apicomplexans Plasmodium 
berghei and Theileria parva also appeared to carry apicoplast targeting signals, 
suggesting that this type of pyruvate kinase may be involved in apicoplast 
specific functions. Based on metabolic pathway predictions using the MR4-
ATCC website: http://malaria.atcc.org/metabolic_ pathways/index.html 
(compiled and maintained by Hagai Ginsburg), it is possible that PK1 might be 
involved in glycolytic processes and pyruvate metabolism while PK2 may be 
involved in lipid metabolism (Fig. 8-8). Transcription data appear to support this 
possibility, in that the transcription profile of PK2 seems to resemble those of 
apicoplast lipid synthesis genes (Fig. 8-3).  
 
In summary, this study provided experimental evidence for the expression 




Biocomputational characterization of both PK1 AND PK2 provided specific sites 
that may be employed in drug design. The uniqueness of PK2 among pyruvate 
kinases was demonstrated, an important information supporting the use of PK2 as 
a drug-target. Soluble expression, and functional validation of PK2 would then 




Table 8-2. Significant primary structural differences between PK1, PK2, 
and human pyruvate kinases at their effector binding sites. 
 
 
Binding site Human PK1 PK2 
6-phosphate     
419 ser thr glu 
421 arg tyr asn 
 
sugar 
   
461 trp ser absent 
 
1-phosphate 
   










Fig. 8-3. Comparison of transcription profiles of PK1 and PK2 based 
on existing transcriptomics data. The profile of PK2 appears 
to follow those of apicoplast lipid synthesis genes. In 
contrast, PK1 levels appear to be consistently high 
throughout the erythrocytic-stage. Abbreviations: PyDH, 
























































Fig. 8-4. RT-PCR amplification of cDNA encoding PK1 and PK2. The 
positive bands representing PK1 and PK2 cDNA are 
indicated by an arrow. Lane 1, amplification of PK2; lane 2, 
amplification of PK1; lane 3, DNA molecular weight marker; 
lane 4 and 5, negative controls for PK1 and PK2 cDNA 














Fig. 8-5. n of the conserved domains of PK1 and PK2. 
PK2 might possess a N-terminal apicoplast targeting 
sequence and appears to contain a large unknown domain. 





































































Amino-acid sequence alignment of P. falciparum PK1 and 
PK2 with pyruvate kinases from other species. Accession
); 
Pyoelii, P. yoelii (EAA16536); Tgondii, T. gondii 
(BAB47171); Etenella, E. tenella (AF043910); Lmexicana, 
L. mexicana (X74944); rabbit,  rabbit muscle pyruvate 
kinase (15987970); humanM1, human muscle isozyme 1 
(S64635); humanM2, human muscle isozyme 2 (O18919). 
PK2, P. falciparum (this study; PF10_0363); Pberghei2, P. 
berghei (XP_680419); Pyoelii2, P. yoelii (XP_724095); 
Tparva2, Theileria parva (EAN32420). The 3D-domains 
(N/A/B/C) are indicated by vertical lines. The pyruvate 
kin nderlin  indicate ADP 
bin nding sites of the sugar, 1-phosphate, 
and 6-phosphate moieties of F16BP are indicated by closed 
circles, open squares, and closed squares, respectively. 
Asterisks and triangles indicate the PEP and divalent-cation 
binding-sites, respectively. 
ed. Open circlesase signature is u




                                                                                               
pfPK1             -------------------------------------------------------------MSSFKYKNSAAGAS--------------- 14 
Pyoelii           -------------------------------------------------------------MNPFKFKNATAGAS--------------- 
Tgondii           -------------------------------------------------------------MASKQPQTLSAGAVESGRVARLVSASSVM 
Etenella          -------------------------------------------------------------MANPTHSQVVAAPDSSGRLLRLVSASSVM 
Lmexicana         ------------------------------------------------------------------------------------------ 
humanM1           -------------------------------------------------------------MSKPHSEAGTAFIQT---------QQLHA 
humanM2           -------------------------------------------------------------MSKSHSEAGSAFIQT---------QQLHA 
Pberghei2         ----------------MRLSSFYLIAELITCFVYGLK-NNSHLNNLDLHHTGDGLLFLNNAYINKTLENKRNRITAKMASGKKRNAIYSQ 
Pyoelii2          ------------------------------------------------------------------------------------------ 
pfPK2             ----------------MNLIHICLFIIVIKCYVNCIKKNNKHIAYDKFYKQGSNTIVGSGNGSGDLLFLNNININKNVERKKNILAHSEI 
Tparva2           MILFITTTLLMFKRYHFSIITNSILLSIIFYNVRFTNGVNNYTSLGKYAYLPRSSMQPEKKYSEENTSYKVRNIKRNIYDVKAPFDKEHA 
consensus                                                                                              .           
                                 N-domain | A-domain 
pfPK1             ---MQSAANITLRQILEP-NNVNLRSKKTHIVCTLGPACKSVETLVKLIDAGMDICRFNFSHGSHEDHKEMFNNVLKAQELRPNCL---- 96 
Pyoelii           ---LQSAANITLRQILEP-NNVNLRSKKTHIVCTLGPACKSVETLVQMIDAGMDICRFNFSHGTHDDHKQMFENVLKAQAQRPNCT---- 
Tgondii           TQQLGKSTNIRMSQILEPRSEEDWTAHRTRIVCTMGPACWNVDTLVKMIDAGMNVCRLNFSHGDHETHARTVQNIQEAMKQRPEAR---- 
Etenella          MQLLGKSTNIRMSQILEHHEDEDFSAHRTKIVCTMGPSCWDVDKMVQLIDAGMNVCRLNFSHGDHEAHGRVVKNLQEALKQRPGKR---- 
Lmexicana         ---MSQLAHNLTLSIFDP----VANYRAARIICTIGPSTQSVEALKGLIQSGMSVARMNFSHGSHEYHQTTINNVRQAAAELGVN----- 
humanM1           AMADTFLEHMCRLDIDSP----PITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILY- 
humanM2           AMADTFLEHMCRLDIDSA----PITARNTGIICTIGPASRSVETLKEMIKSGMNVARMNFSHGTHEYHAETIKNVRTATESFASDPILY- 
Pberghei2         NNFED---LQITNISNTNTKTNKISFTKCKQIATVGPSTEMFENLEKLYLSGIDVFRLNFSHGPKSIKKYIINAIRILEKKYN------- 
Pyoelii2          ----------------------------------------MFENLEKLYLSGIDVFRLNFSHGPKSIKKYIINAIRILEKKYN------- 
pfPK2             GTVRN---IDDINLLNHN-KKNEISFTKCKQIATIGPASENFEQLEKLYLNGIDVFRLNFSHGLKSIKKYIINSIRILEKKYD------- 
Tparva2           IEYFSSCLKATCKTFEPREIPEGEILTLTKQVATLGPATNNAESIKSLFDAGVDVFRLNFSHDSRLSKHLVSKTIRQLEINEPPKNYPFN 
consensus                  .    .        .. . ........... .....  .. .*. . ○.○**○.... .  ...... .             
                                                                          * 
                          A-domain | B-domain 
pfPK1             -------LGMLLDTKGPEIRTGFLK-----------NKEVHLKEGSKLKLVTD--YEFLGDETCIACSYKKLPQSVKPGNIILIADGSVS 166 
Pyoelii           -------LGMLLDTKGPEIRTGLLK-----------NKEAHLKEGSKLKLVTD--YSYLGDETCIACSYTKLPQSVKPGSIILIADGSVS 
Tgondii           -------LAILLDTKGPEIRTGFLKD----------HKPITLQQGATLKIVTD--YNLIGDETTIACSYGALPQSVKPGNTILIADGSLS 
Etenella          -------VALLLDTKGPEIRTGMLEG----------DKPIELHAGDMLKIVTD--YSFVGNKSCIACSYEKLPSSVKPGNTILIADGSLS 
Lmexicana         -------IAIALDTKGPEIRTGQFVG-----------GDAVMERGATCYVTTDPAFADKGTKDKFYIDYQNLSKVVRPGNYIYIDDGILI 
humanM1           -----RPVAVALDTKGPEIRTGLIKG--------SGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLIS 
humanM2           -----RPVAVALDTKGPEIRTGLIKG--------SGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVDVGSKVYVDDGLIS 
Pberghei2         -----TSIGILGDIQGPKIRIGEFEKNEQNQ---IDDEKNTFVELKEGDTFSFDLSNNLGNKNRVFLNYPDLLKNIKPGQIILLDDGNLK 
Pyoelii2          -----TSIGILGDIQGPKIRIGEFEKNEQNQ---IDDEKNTFVELKEGDTFSFDLSNKLGNKNRVFLNYPDLLKNVKPGQIILLDDGNLK 
pfPK2             -----TTIGILGDIQGPKIRIGEFEKNQIN-----ENDNNTFVELKEGDLFSFDLMNSLGNQNRVQLNYPELIKNAKAGQIILLDDGNLK 
Tparva2           GDHVVEHKSILGDIQGPKLRIGKFMPNLDVPGVLPGSKGCEFVELKAGDLFTFDAYDVLGSKSRVQLDFPEILKELKVGDKILLDDGNLS 
consensus                .....*..**..○.* ..             .. .  .  ... ..  .  ..    ... .  . . ...*. ....** .. 
                                     * 
                                         B-domain | A-domain                                      
pfPK1             CKVLET--HED-----HVITEVLNSAVIGERKNMNLPNVKVDLPIISEKDKNDILNFAIPMGCNFIAASFIQSADDVRLIRNLLGPRGR- 248 
Pyoelii           CRVLET--HDD-----HVITEVLNNATIGEKKNMNLPNVKVDLPIISEKDKDDILNFAIPMGCNFIAASFIQSAEDVRLIRNLLGPRGR- 
Tgondii           VKVVEV--GSD-----YVITQAQNTATIGERKNMNLPNVKVQLPVIGEKDKHDILNFGIPMGCNFIAASFVQSADDVRYIRGLLGPRGR- 
Etenella          VEVVEC--GKD-----YVMTRVMNPAIIGNKKNMNLPGVKVDLPVIGEKDKNDILNFGIPMGCNFIAASFVQSADDVRYIRSILGTKGR- 
Lmexicana         LQVQSH--EDEQ----TLECTVTNSHTISDRRGVNLPGCDVDLPAVSAKDRVD-LQFGVEQGVDMIFASFIRSAEQVGDVRKALGPKGR- 
humanM1           LQVKQK--GAD-----FLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQD-LKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGK- 
humanM2           LQVKQK--GPD-----FLVTEVENGGFLGSKKGVNLPGAAVDLPAVSEKDIQD-LKFGVEQDVDMVFASFIRKAADVHEVRKILGEKGK- 
Pberghei2         MKVEGIAYSSD--QDISVKATVLTGGKLYSKKGFCIPNMIMPIEVLSEKDIKD-ILFCINEGVDYLGYSFVQTEYDLIFLKNIINDYYES 
Pyoelii2          MKVEGIAYNSD--QDISVKATVLTGGKLYSKKGFCIPNMIMPIEVLNEKDIKD-ILFCINEGVDYLGYSFVQTEYDLIFLKNIINDYYES 
pfPK2             MKILENNYDTSNIQNSYIKVQVLTGGKLYSKKGFCIPNMIMPIDVLSEKDIKD-ILFCINEEVDFLGYSFVQTEYDLIFLRNIINDYYES 
Tparva2           MTVVKTNPEEP-----SVTAEVKNDYKLSSRKGFSVPKVVLPIEFLDEKDVKD-AIFCLGIGVDFLGVSFVQNKSDILYLINILNDFYTS 
consensus         ....      .      ... . . . ....○....* . ........**. * . *..  .......**.... ..  .. .......  
 
pfPK1             ------------------------------------------------------------------------------------------ 
Pyoelii           ------------------------------------------------------------------------------------------ 
Tgondii           ------------------------------------------------------------------------------------------ 
Etenella          ------------------------------------------------------------------------------------------ 
Lmexicana         ------------------------------------------------------------------------------------------ 
humanM1           ------------------------------------------------------------------------------------------ 
humanM2           ------------------------------------------------------------------------------------------ 
Pberghei2         DFYKNIK-KNRIVYDVNELQYKDYDDTTDFYIKEINDYYNNYYLKKYHTYKQIYNVYKNNNLDVGDMDQEMNDR--DTHFEDANEVSGNS 
Pyoelii2          DFYKNIK-KNRIVYDVNELQYKDYDDNTDFYIKEINDYYNNYYLKNYHTYKQIYNVYKNNNLDVGDMDQEMNDR--GTHFEDANVVSANS 
pfPK2             DFYNNIKRKDRINFDQNNLQMKTFDDENDFYIKEVNDYYNNYYLKNVQKYKQIYDVYKNQDLYINDNIQNHYNKNIVTNIGDDKNIIDEQ 
Tparva2           DYYKQLK----ERLNNLDVEVFDANREDTIVENILNRYYNDSYLPKKDIFKSVVPKE--------------------------------- 
  
pfPK1             ----------------------------HIKIIPKIENIEGIIHFDKILAESDGIMIARGDLGMEISPEKVFLAQKLMISKCNLQG-KPI 309 
Pyoelii           ----------------------------HIKIIPKIENIEGIINFDKILAEADGIMIARGDLGMEISAEKVFLAQKLMISKCNLQG-KPI 
Tgondii           ----------------------------HIRIIPKIENVEGLVNFDEILAEADGIMIARGDLGMEIPPEKVFLAQKMMIAKCNVVG-KPV 
Etenella          ----------------------------NIKIIPKIENVEGLLNFDEILQEADGIMIARGDLGMEIPPEKVFLAQKMMISKCNVAG-KPV 
Lmexicana         ----------------------------DIMIICKIENHQGVQNIDSIIEESDGIMVARGDLGVEIPAEKVVVAQKILISKCNVAG-KPV 
humanM1           ----------------------------NIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAG-KPV 
humanM2           ----------------------------NIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMIIGRCNRAG-KPV 
Pberghei2    SSFSKKLDNEIYKYT----LNKDVNKIFIISKIEKPSAVKNIDNIIKISDGIMIARGDLGIETNLSNLPILQKKIINLCKTKYNKIV      GES
Pyoelii2     GESSSFNKNLDNEISKYT----LNKDVNKIFIISKIEKPSAVKNIDNIIKLSDGIMIARGDLGIETNLSNLPILQKKIINLCKTKYNKIV      
pfPK2        HIHNNNNNNIDNIMKNYSNLYNINKDHNKIAIISKIEKPSAIKNIENIIKLSDGIMIARGDLGIETNLSNLPILQKKLINLCRIKYNKPV      
Tparva2      -------------------------NLSG     VGIIPKIEKQAALDDIHEILKVSDGLMVARGDLGIETDLANLPIVQKRLIQLCRVVYRKPC 
consensus                                      ..**********.  ..*.*.******.*▲▲▲▲▲...*...* .*.. . *.. 
                                                      ▲ 
                                                                         A-domain | C-domain      
pfPK1              388 ITATQMLESMTKNPRPTRAEVTDVANAVLDGTDCVMLSGETAGGKFPVEAVTIMSKICLEAEACIDYKLLYQSLVNAIE-----------
Pyoelii           NP  ITATQMLESMTK RPTRAEVTDVANAVLDGTDCVMLSGETAGGKFPVEAVTIMSKICLEAEACIDYKLLYQSLVNAIQ-----------
Tgondii           ITATQMLESMIKNPRPTRAEAADVANAVLDGTDCVMLSGETANGEFPVITVETMARICYEAETCVDYPALYRAMCLAVP----------- 
Etenella          ITATQMLESMTKNPRPTRAEAADVANAVLDGTDCVMLSGETANGSFPVQAVTVMSRVCFEAEGCIDYQQVFRATCQATM----------- 
Lmexicana         ICATQMLESMTYNPRPTRAEVSDVANAVFNGADCVMLSGETAKGKYPNEVVQYMARICLEAQSALNEYVFFNSIKKLQH----------- 
humanM1           ICATQMLESMIKKPPPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELVRASS----------- 
humanM2           ICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAP----------- 
Pberghei2         IVATQMLESMRFIPSPTRAEVTDVATAIYDGADCVMLSAETATGKYPILSSSTQNSIIQNVEKDYYFYEYTQKKVENVN--SNSISFVNT 
Pyoelii2          IVATQMLESMRFIPSPTRAEVTDVATALYDGADCVMLSAETATGKYPILSSSTQNSIIQNVEKDYYFYEYTQKKAENIN--SNNISFVNT 
pfPK2             IVATQMMESMRFLPSPTRAEVTDVATALYDGSDCVMLSAETATGQYPILTVSTQNKIIKDVENDYYYYEYTQRKNDKLKMLDHKNNCCHE 
Tparva2           IVATQMLETMRSSPTPTRAEVSDVSNAVFDGADAVMLSAESATGHYPKASVNVQRRVLFTTEMDPYFPTMQIIKEMLIDENLISSIKSQR 
consensus          * ****.*.* . *.*****..**..*...*.*..***.*.* * .*.. . .. ..  ...  ...  ... .   .            
                                                                       418 
pfPK1             452  -------------------------TPISVQEAVARSAVETAESIQASLIIALTE-TGYTARLIAKYKPSCTILALSASDSTVKCLNVHR
Pyoelii            -------------------------TPISVQEAVARSAVETAESIEASVIITLTE-TGYTARLIAKYKPSCTILALSASDSTVRCLNVHR
Tgondii            -------------------------PPISTQEAVARAAVETAECVNAAIILALTE-TGQTARLIAKYRPMQPILALSASESTIKHLQVIR
Etenella          -------------------------TPIDTQEAVARAAVETAQSINASLILALTE-TGRTARLIAKYRPMQPILALSASEETIKQLQVIR 
Lmexicana         -------------------------IPMSADEAVCSSAVNSVYETKAKAMVVLSN-TGRSARLVAKYRPNCPIVCVTTRLQTCRQLNITQ 
humanM1           -------------------------HSTDLMEAMAMGSVEASYKCLAAALIVLTE-SGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYR 
humanM2           -------------------------ITSDPTEAAAVGAVEASFKCCSGAIIVLTK-SGRSAHQVARYRPRAPIIAVTRNHQTARQAHLYR 
Pberghei2         HNHLKQLGNISDISSEQ---QKKASSDTSHFDKLIYSIRDISNNINLKSIILFSN-DFNKILKLSNLKTKAPIVVVTDNKHLSRKLQLAW 
Pyoelii2          HNHLKQLGNISDTSNEQ---KKKTSSDTSHFDKLIYSIRDISNNINLKSIVLFSN-DFNKILKLSNLKTKAPIVVVTDNKHLSRKLQLAW 
pfPK2             NKDIQQINKYNHEYIQNNKYEQDIQNNISYFDKLIFSIRDISNNINLKSIILFSN-EFNKIQKLSNLRTKAPIIVITENKYLARKLQLTW 
Tparva2           PHLYKKMDNLLNIDIHH---YNEYLKSKSHLKKCLDDVAEIFAYNDVDVIGIHSDDGLEFLQWISSQRYMIPIVLVTSNPTLSRHSQLTW 
consensus        
                 
                            ..  .... ....    ...  ....■ .■.■..  ......  .*.... .  . . ... . 
                                                                  
pfPK1             GVT------CIKVGSFQGTDIVIRNAIEIAKQRNMAKVGDSVIAIHGIKEEVSGGTNLMKVVQIE-- 511 
Pyoelii           GVT------CIKVGSFQGTDNVLRNAIEIAKERNIVKPGDSAICIHGIKEEVSGSTNLMKVIQVE-- 
Tgondii           GVT------TMQVPSFQGTDHVIRNAIVVAKERELVTEGESIVAVHGMKEEVAGSSNLLKVLTVE-- 
Etenella          GVT------TFLVPTFQGTDQLIRNALSAAKELQLVSEGDSIVAVHGIKEEVAGWSNLLKVLVVE-- 
Lmexicana         GVESVFF-DADKLGHDEGKEHRVAAGVEFAKSKGYVQTGDYCVVIHADHK-VKGYANQTRILLVE-- 
humanM1           GIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRP-GSGFTNTMRVVPVP-- 
humanM2           GIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRP-GSGFTNTMRVVPVP-- 
Pberghei2         GIYPYYS--TIETGTNKDFISLINYGCQISKQEGFVNSPDEYSLVTFTENIKNSANLIYLCQPCLEN 
Pyoelii2         EYSLVTFTENIKNSANLIYLCQPCLEN  GIYPYYS--TIETGTNKDFISLINYGCQISKQEGFVTSPD
pfPK2            EYSLVTFSKNIN-SANLLYLCQPCLTN  GIYPHLS--KKQNLFNHDLFSLINYGCDVSKKEGFVNSPD
Tparva2           GVKSHFM--PKG----ADPMEFFKY-----VVKEYPMPVKDAVYLEIKDNKIQSRQVLKLE------ 
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Fig. 8-8. Possible involvement of PK1 and PK2 in predicted lipid and glycolytic metabolic pathways of P. falcip
were predicted based on the present knowledge of parasite biochemistry and on pathways known to occur in other 
arum. The maps 












































8.4 EVALUATION OF YEAST-TWO-HYBRID FOR 
SCREENING PLASMODIAL PROTEIN INTERACTION 
 An important aspect towards understanding the physiological roles of a 
drug target, in addition to its cellular localization, is the identification of other 
cellular proteins with which it can interact. Protein interactions play important 
roles in diverse processes, such signal transduction, the regulation of apoptosis 
(Sato et al. 1994), and the control of gene expression through the selective 
association of transcription factors (Feaver et al. 1993). A number of approaches 
for studying protein association are in use, including co-immunoprecipitation of 
purified proteins, and assay by two-hybrid systems, such as the yeast-two-hybrid 
system (Fields and Song 1989). The yeast-two-hybrid approach was examined in 
this study. A first protein (bait) is fused to a GAL4 DNA-binding domain (BD) 
and a second protein (prey) is fused to a transcriptional activation domain (AD). 
Coexpression of the two chimeric proteins in yeast cells results in transcriptional 
activation of reporters only if the chimeric proteins associate. The yeast-two-
hybrid approach can detect novel proteins that interact with a given bait by the 
employment of an appropriate cDNA library (Fig. 8-9) in place of a specific prey 
protein.  
 
 Although LaCount et al. (2005) identified more than 2800 plasmodial 
protein interactions using a high-throughput yeast-two-hybrid approach, most of 
these interactions included uncharacterized or hypothetical proteins, so that the 
physiological significance of the identified interactions remain elusive. Some 




screening (not reported in this study). A search of the interactome database using 
this drug target revealed that the interactions identified in this laboratory 
extended the yeast-two-hybrid data in the interactome study. This suggests that 
differences between independent protocols employed during the screening 
process, such as bait design, may lead to variations in results. Hence, one of the 
aim of this project is to further investigate the suitability of the yeast-two-hybrid 
approach for characterizing specific plasmodial proteins. A search of the 
interactome data (LaCount et al. 2005) failed to identify any significant 
interaction for the selected 10 drug-targets employed for functional analysis in 
this study, indicating that these proteins were not likely to be involved in protein 
interactions, or that their interactions may have precluded detection in a 
heterologous system. Hence, another set of proteins were employed as baits in 
this study. A set of putative heat shock proteins possibly related to primary 
metabolism was chosen because these types of proteins were most likely to 
function in protein interactions. The baits chosen were: heat shock protein hslv 
(PFL1465c) (Fig. 8-9), heat shock 40 kDa protein (PFB0595w), hsp60 
(PF10_0153), and heat shock 70 kDa protein (PF08_0054). These genes were 
amplified by RT-PCR using specific primers (Table 5-4) and cloned into 
pGBKT7 for use as baits in yeast-two-hybrid screening. The identities of the 
resultant recombinant plasmids were then confirmed by DNA sequencing.  
 
 Yeast clones transformed with each of the 4 bait vectors satisfied the 
required tests for transcriptional-activation (no growth on –his/–trp or –ade/–trp) 
and toxicity (healthy growth of cells transformed with the bait plasmid compared 




designated R5) yielded colonies on quaternary drop-out selection medium 
(QDO) after co-transformation with P. falciparum cDNA and linearized 
pGADT7. After ruling out false positives via re-transformation of bait vector 
(pGBKT7-R5) with rescued pGADT7 carrying putative positive inserts, one 
confirmed prey, designated Q4 was obtained (Table 8-3). As expected for a 
verified positive prey, co-transformants of Q4 with R5 were able to grow on 
QDO (Fig. 8-10 b and h), and were X-α-gal positive (Fig. 8-10 f and j). Co-
transformants of Q4 with empty bait (pGBKT7), or transformants of Q4 alone, 
were not able to grow on QDO (Fig. 8-10 a, c, h, i). Similarly, co-transformants 
of R5 with empty prey vector (pGADT7), or transformants of R5 alone, were 
unable to grow on QDO (Fig. 8-10 d and e). This indicated that neither the bait 
R5, nor the prey Q4, alone was capable of auto-activation of marker genes 
(HIS3, ADE2, MEL1), and only in the presence of both R5 and Q4 will these 
reporters be turned on. Hence, R5 and Q4 represented a validated pair of 
interacting proteins.  
 
 DNA sequence analysis of Q4 identified that this insert encoded the C-
terminal 167 amino acid residues of a receptor for activated C kinase (RACK) 
protein previously cloned by Madeira et al. 2003 (Fig. 8-11). As expected, this 
partial gene was inserted in-frame to the GAL4 AD and the HA epitope 
expressed from pGADT7. The PfRACK protein has conserved cores of repeating 
units that fit to the conserved pattern [GH–X23–41–WD] described for WD-40 
repeats (Neer et al. 1994; Fig. 8-11). The domains that are important for binding 
to protein kinase C are almost totally conserved in PfRACK (Madeira et al. 




either stably or reversibly. The WD40 domain is known to cover a wide variety 
of functions including a role as an adaptor module in signal transduction, pre-
mRNA processing and cytoskeleton assembly. Despite the identification of 
PfRACK in malaria parasites, its interaction with other signaling proteins has not 
yet been elucidated. Although the biological role of pfRACK has not yet been 
elucidated, observations from this study suggest an involvement of heat shock 




Fig. 8-9 (a) Agarose gel electrophoresis of resultant ds cDNA library 
synthesized from P. falciparum mRNA showing moderate 
strong smear from approximately 0.25 kb to 5 kb (lane 2); 
(b) RT-PCR and cloning of bait (hslv). Lanes: 3, RT-PCR 
product (presence of non-specific band); 5, positive insert 
cloned in pGBKT7 (7.3 kb); 1 and 4, DNA markers.  
 
 

































Table 8-3 Summary of yeast-two-hybrid confirmation results for bait 
R5 and prey Q4. 
 
Growth on  




R5 + Q4 
(Bait + prey) 
+ +   + 
R5 + pGADT7 
(Bait + empty prey vector) 
- +   - 
pGBKT7 + Q4 
(Empty bait vector + prey) 
- +   - 
R5 
(Bait alone) 
- - - + - 
Q4 
(Prey alone) 






Fig. 8-11 The partial receptor for activated C kinase (RACK) cDNA 
insert in prey Q4 (highlighted) in relation to the full cDNA. 
The WD40 domain is underlined. 
 
 
  1 mmdnikeaei slrgvleggh sdwvtsvstp tdpklktivs asrdkklivw nintdddsge 
                       <--------------------------------------------- 
 
 61 igtarksltg hsqaindvsi ssdglfalsg swdrsvrlwd lslgetirsf ightsdvfsv 
    ----------------------------------------------------------------- 
 
121 sfspdnrqiv sasrdktikl wntlaqckyt itdqqhtdwi tyvrfspspn qaiivscgwd 
    ----------------------------------------------------------------- 
 
181 klvkvwnlkn cdlnknlegh tgvlntvtis pdgslcasgg kdgvaklwdv kegkhlysle 
    -----------------------------------------------------------------  
 
241 tgstinslcf spcdywlcaa tdrfiriwnl eskliiseiy pvkqskigvp wctsltwsan 
    ----------------------------------------------------------------- 
 
301 gqllycgstd gniyvyevkk hsv 
    ----------------->   
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Fig. 8-10. Yeast-two-hybrid results for bait (R5) and prey (Q4). (a) to (f) Spread plates of yeast transformations using 
pGBKT7-R5, pGADT7-Q4, empty bait vector (pGBKT7), and empty prey vector (pGADT7). For simplicity these 
plasmids were labeled as R5, Q4, pGBK, and pGAD respectively. (h) to (k) Streak plates of colonies obtained 
































































EVALUATION OF PLASMODIAL PROTEIN 
LOCALIZATION USING A RELEVANT 
LIVE-CELL SYSTEM AND PROTEIN-





CHAPTER 9 EVALUATION OF PLASMODIAL 
PROTEIN LOCALIZATION USING A 
RELEVANT LIVE-CELL SYSTEM AND 
PROTEIN-INTERACTION SCREENING 
 
9.1 RELEVANCE OF PROTEIN LOCALIZATION IN DRUG-
TARGET VALIDATION 
The increasing resistance of malaria parasites to available drugs 
emphasizes the need to understand the biology of the malaria parasite from 
different facets, including protein trafficking. To this end, although the 
availability of the complete nuclear genome of P. falciparum has been most 
useful for cloning relevant genes for functional analyses, it lacks reliable 
indication of the cellular organization of potentially five thousand gene products 
(Gardner et al. 2002). Although genome databanks (eg. PlasmoDB) and 
biocomputing tools (eg. PlasMit, PlasmoAP, PATS) are useful in providing a 
global albeit predictive view of the myriad of genes, only 40% are annotated, 
with few cases of endorsed subcellular localizations of the corresponding 
proteins in animal models. For example, although several genes encoding 
enzymes of the central respiratory pathway TCA cycle have been cloned, and the 
expressed proteins reported to be functional (this study; Chan and Sim 2004a, 
2004b, 2003), it remains to be seen whether these enzymes are destined to be in 
the mitochondria. Mitochondrial transit peptides (mTPs) have been proposed to 




(Bender et al. 2003; Neupert and Brunner 2002). While genes that are expected to 
be mitochondrial-targeted have upstream transit peptides, there are other genes of 
the TCA cycle, for example malate dehydrogenase and fumarase, which appeared 
not to possess such signal sequences. Also, although the cellular distribution of 
pfICDH is central to deducing its involvement in a TCA cycle role, the 
functionality of its resident mTP has not been experimentally demonstrated thus 
far. Similarly, genes encoding nuclear proteins have been cloned and 
characterized (Mohmmed et al. 2003), but their intracellular localization has not 
been demonstrated.  
 
There are limited but interesting features of plasmodial signal peptides. 
Molecular studies of mTPs have indicated that most mTPs are situated at the N-
termini with few exceptions (Emanuelsson et al. 2001). Bender et al. (2003) 
analyzed the amino acid codon usage in plasmodia mTPs and observed that there 
were significant differences between their mTPs and those from other eukaryotic 
organisms. Similarly, proteins with nuclear localization signals (NLSs) are 
reportedly transported to the nucleus. These NLSs were characterized by tandem 
stretches (4-8 residues) containing lysine and arginine residues and can be 
located anywhere within a protein, not necessarily at the N-terminus 
(Emanuelsson et al. 2001). The apicoplast-targeting signals were found to be 
bipartite sequences containing a canonical signal sequence in their first 20 
residues, followed by a specialized, Plasmodium-specific transit signal of 





Although existing computational softwares are available for predicting 
the cellular locations of many proteins (Bender et al. 2003; Zuegge et al. 2001; 
Nielsen et al. 1997), the extension of the use of such computational predictive 
tools for localizing plasmodial proteins can only be cursory until more supporting 
experimental evidence is available. The use of green fluorescent protein (GFP) is 
a valuable approach for exploring protein trafficking and localization in the 
human pathogen, P. falciparum (Tonkin et al. 2004). However, transfection of 
Plasmodium parasites is not a simple process of creating stable transgenic 
parasites (Kim and Weiss 2004). Indeed, the elusive lifestyles of plasmodia are 
such that although stable transformation of Plasmodium yoelii and Plasmodium 
berghei is achievable, the in vitro cultivation of these rodent malaria species is 
still not possible. In Cryptosporidium, another apicomplexan parasite for which 
transfection is currently not possible, transgene transfection and localization 
studies have been carried out using yeast (Lagier et al. 2003) and Toxoplasma 
(O’Connor et al. 2003) as surrogate hosts. Since a reasonable test of organellar 
targeting function is whether the questioned target motif sequence is sufficient to 
direct a protein to its appropriate organelle in a heterologous host, this study 
attempted to examine whether trafficking complexes in the cytosol of 
mammalian cells were able to also recognize the parasite’s transit signals. Thus, 
we have adopted the eukaryotic CHO-K1 cell line to synergistically provide 
interim yet valuable proof of biological principle.  
 
In this study, a combination of fluorescent markers, organelle-specific 
probes, phase contrast microscopy, and confocal microscopy was used to locate a 




cells. These eukaryotic cells serve as an in vitro living system for studying the 
cellular destinations of four mitochondrial-targeted TCA-cycle proteins (citrate 
synthase, CS; isocitrate dehydrogenase, ICDH; branched chain α-keto-acid 
dehydrogenase E1α subunit, BCKDH; succinate dehydrogenase flavoprotein-
subunit, SDH), two nuclear-targeted proteins (histone deacetylase, HDAC; RNA 
polymerase, RPOL), two apicoplast-targeted proteins (pyruvate kinase 2, PK2; 
glutamate dehydrogenase, GDH), and two cytoplasmic resident proteins (malate 
dehydrogenase, MDH; glycerol kinase, GK). The respective localizations of 
these malarial proteins have complied with the selected molecular targets, viz. 
mitochondrial, nuclear and cytoplasmic. Interestingly, MDH that is widely 
known to be resident in eukaryotic mitochondria, was not mitochondrial in P. 
falciparum, due to the absence of target sequences. Since the localization of 
plasmodial proteins is central to the authentication of their physiological roles, 
this experimental system will serve as a useful a priori approach. 
 
9.2 COMPUTATIONAL ANALYSES OF PLASMODIAL 
MITOCHONDRIA TRANSIT PEPTIDES IN 
COMPARISON WITH EUKARYOTIC SEQUENCES 
 
To investigate the conservedness of Plasmodium mTPs among mTPs 
from other eukaryotes, the N-terminal sequences of the selected six plasmodial 
ORFs (CS, ICDH, BCKDH, SDH, MDH, GK) were subjected to computation by 
the existing localization prediction programs for eukaryotes (TargetP, iPSORT, 
WoLF-PSORT, MitoProt) and compared to analysis by PlasMit, a prediction 




and PlasMit provided consistent predictions for the six proteins studied. 
Although MitoProt was able to predict the localization of these six selected 
plasmodial proteins correctly, predictions using a large dataset of known genes 
suggested that this program lacks selectivity (Bender et al. 2003). The differential 
predictions by the other three programs (TargetP, iPSORT, WoLF PSORT), and 
the known differences in the biochemical components of malaria mTPs from 
other eukaryotic mTPs cast doubts on the reliability of the available softwares for 
predicting plasmodial mTPs. 
 
It is known that in mTPs, the amino acid residues Arg, Ala, and Ser are 
over-represented while negatively-charged amino acid residues (Asp and Glu) are 
rare (Emanuelsson et al. 2000). When the amino acid compositions of the N-
terminal regions of plasmodial mitochondrial (CS, ICDH, BCKDH, SDH) and 
cytosolic (MDH, GK) gene sequences were compared, it was apparent that 
mitochondrial ones harbor 16-23% of Arg, Ala and Ser amino acid residues while 
cytosolic ones have less (10-13%). Similarly, mitochondrial ones harbor 0-3% of 
Asp and Glu amino acid residues while cytosolic ones have 10-13%. This could 
well be explained by a relatively positively-charged function for mitochondrial-
targeting. A multiple alignment study was carried out using representative mTPs 
in comparison with N-terminal 30 amino acid residues of P. falciparum CS, 
ICDH, BCKDH, and SDH to investigate whether it was possible to group closely 
related genetic sequences to collective clades. The resultant multiple alignment 
and phylogenetic tree (Fig. 9-1) obtained indicated that the plasmodial mTPs 
were not clustered in a group, consistent with the observation that these mTPs do 




9.3 TARGETING GFP FUSION PROTEINS TO THE 
MITOCHONDRIAL NETWORK OF CHO-K1 USING ICDH, CS, 
BCKDH, AND SDH N-TERMINAL SIGNALS 
 Although computational analyses are useful, they are superficial without 
experimental support. To provide further evidence for the predicted locations of 
plasmodial proteins, we have allowed GFP fusion proteins to dynamically locate 
themselves in a surrogate eukaryotic host. As indicated, plasmid vectors were 
constructed to test for the ability of the N-terminal signal peptides of CS, ICDH, 
BCKDH, and SDH to deliver GFP to the mitochondrial network of CHO-K1 
cells. The N-terminal residues of the predicted cytosolic proteins, MDH and GK, 
do not carry targeting signals, but were also employed as controls to illustrate a 
cytoplasmic fluorescence scenario. Although most known eukaryotic mTPs are 
about 20 amino acid residues in length, an extensive search of data has suggested 
that the mTPs of P. falciparum vary greatly in length (from 23 to 169 amino 
acids). Hence, the vectors in this study were constructed to express GFP fused to 
the N-terminal 60 amino acid residues of CS, ICDH, BCKDH, SDH, MDH and 
GK (designated as CS-GFP, ICDH-GFP, BCKDH-GFP, SDH-GFP, MDH-GFP, 
and GK-GFP respectively). Fluorescence microscopic analysis of transfected 
cells indicated that CS, ICDH, BCKDH and SDH mTPs can correctly target GFP 
to the mitochondria, as indicated by the branched and tubular intracellular 
fluorescence pattern typical for mitochondrial staining (Mukame and Kimchi 
2004; Karbowski et al. 2000) (Fig. 9-2a-d). As expected, the GFP fusions tagged 
with the N-terminal residues of cytoplasmic MDH and GK showed dispersed 




The PredictNLS program predicted two NLSs each in HDAC (residues 
674-692 and 1619-1659) and RPOL (residues 27-33 and 27-69). Residues 1619-
1659 of HDAC and 27-69 of RPOL were predicted with the highest accuracy (ie. 
with a score of 0% non-nuclear proteins in the database possessing the signature). 
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 The mitochondrial localization of CS-GFP, ICDH-GFP, BCKDH-GFP 
and SDH-GFP were subsequently confirmed in co-localization studies employing 
Mitotracker Red (Molecular Probes, USA), a mitochondrial-specific probe. 
Furthermore, confocal microscopy images (Fig. 9-3) clearly indicated co-
localization of CS-GFP, ICDH-GFP, BCKDH-GFP and SDH-GFP with 
Mitotracker Red, confirming the mitochondrial localization of GFP tagged with 
CS, ICDH, BCKDH, and SDH mTPs. In contrast, there was clearly no co-
localization between MDH-GFP or GK-GFP with the Mitotracker Red, thus 
confirming the cytoplasmic localization of MDH-GFP and GK-GFP. Finally, 
vectors expressing CS-GFP, ICDH-GFP, BCKDH-GFP, and SDH-GFP were co-
transfected with another vector, pDsRed2-Mito (Clontech, USA) which expresses 
a mitochondrial-targeted red fluorescent marker protein. Consistent with earlier  
observations, CS-GFP, ICDH-GFP, BCKDH-GFP, and SDH-GFP clearly co-
localized with the red fluorescent organelles exhibited by the mitochondrial 
marker protein expressed from pDsRed2-Mito (Fig. 9-4), again confirming the 
mitochondrial localization of CS-GFP, ICDH-GFP, BCKDH-GFP and SDH-
GFP. 
 
9.4 LOCALIZATION OF THE NUCLEAR LOCALIZATION SIGNALS 
(NLSS) FROM HDAC AND RPOL, AND THE APICOPLAST-
TARGETING SIGNALS FROM PK2 AND GDH 
Chapter 9 
 
As such, these sequences were selected for experimental analysis for nuclear 
trafficking functions. PATS predicted both PK2 and GDH to encode apicoplast-
targeting signals with high scores of 0.89 and 0.85 (values close to 1 are 
apicoplast-targeted). Similarly, PlasmoAP predicted both PK2 and GDH to be 
apicoplast-targeted with the highest score (5 out of 5 score). As expected, 
PredictNLS, PATS, or PlasmoAP predictions using cytosolic proteins such as 
MDH and GK were not predicted to carry any reliable NLSs or apicoplast-
targeting signals.  
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Transfection experiments using GFP-tagged NLSs from HDAC and 
RPOL (HDAC-GFP and RPOL-GFP respectively) showed the expected nuclear 
localization for the GFP fusion proteins (Fig. 9-2 e-f). Co-localization studies 
using the cell-permeant DNA dye Hoechst 33342 confirmed co-localization of 
HDAC-GFP and RPOL-GFP with the cell nuclei (Fig. 9-5 a-b). As a negative 
control, cytosolic-staining exhibited by GK-GFP did not co-localize with the 
nuclear-staining pattern produced by Hoechst 33342 (Fig. 9-5 c). Finally, GFP 
tagged with apicoplast-targeting signals from PK2 and GDH (PK2-GFP and 
GDH-GFP) showed uniform fluorescence consistent with cytosolic disposition 
(Fig 9-2 g-h). Hence, these experiments indicated that plasmodial NLSs from 
HDAC and RPOL were functionally conserved in these live cells. Likewise, 
repeated experiments showed that the apicoplast-targeting signals were not 
obviously functional in the CHO-K1 cells, as expected.  
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Table 9-1. Comparison of mitochondrial localization prediction programs in the prognosis of cellular localizations of a 
selection of P. falciparum proteins. 
Plasmodium  specific
TargetP iPSORT WoLF PSORT MitoProt PlasMit
Neural network based
Decides based on two 
elements: an amino acid 
index rule, and an 
alphabet 
indexing+pattern rule. 
To be judged "yes", the 
input amino acid 
sequence must satisfy 
both of the rules. 
Makes predictions 
based on both known 
sorting signal motifs 
and some correlative 
sequence features 






Not stated First 30 residues Not stated Minimum of 12 residues First 24 residues
Emanuelsson et al. 
(2000) Bannai et al. (2002)
Nakai and Kanehisa 
(1991) 
Claros and Vincens 













90% 70% No information 76-94% 84-90%
ICDH mitochondrion (low confidence) mitochondrion extracellular mitochondrion mitochondrion
CS cytoplasmic non-mitochondrion extracellular mitochondrion mitochondrion













Fig. 9-1. Phylogenetic tree for mTPs from protozoan, animal, plant and fungal 
sequences. The sequences were downloaded from SwissProt using the 
search term “mitochondrion” in the Feature Key field. The accession 
numbers for the protozoan mTPs are indicated in the tree. The N terminal 
30 amino acid residues from each sequence were used for the analysis. 


































































































































Fig. 9-2. Fluorescence microscope images of CHO-K1 cells transfected with 
vectors expressing (a) CS-GFP, (b) ICDH-GFP, (c) BCKDH-GFP, (d) 
SDH-GFP, (e) HDAC-GFP, (f) RPOL-GFP, (g) PK2-GFP, (h) GDH-GFP, 

















































ig. 9-3. Confocal laser scanning images of CHO-K1 cells transfected with vectors 
expressing (a) CS-GFP, (b) ICDH-GFP, (c) BCKDH-GFP, (d) SDH-GFP, 
(e) MDH-GFP, and (f) GK-GFP, and subjected to in situ staining using 
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Fig. 9-4. Fluorescence microscope images of CHO-K1 cells co-transfected with 
pDsRed2-Mito and vectors expressing (a) CS-GFP, (b) ICDH-GFP, (c) 
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Fluorescence microscope images of CHO-K1 cells transfected with vectors expres
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Fig. 9-5. 
HDAC-GFP 33 MergedHoechst 342 Phase contrast
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CHAPTER 10 DISCUSSION 
 
10.1 HETEROLOGOUS EXPRESSION OF MALARIAL ORFS 
Obtaining soluble active recombinant proteins is a key prerequisite for 
functional studies of malaria enzymes and their biological roles in the parasite. In 
turn, understanding the biophysical factors that govern the successful expression 
of malaria proteins in E. coli is important for obtaining copious amounts of 
malarial proteins for functional analysis and biochemical studies. Recombinant 
expression of ten gene targets, viz glycerol-3-phosphate dehydrogenase, glycerol 
kinase, pyruvate kinase 1, fumarase, citrate synthase, isocitrate dehydrogenase, 
malate dehydrogenase, glutamate dehydrogenase, dihydroorotase, and inosine-5’-
monophosphate dehydrogenase, was investigated in this study. The proteins 
encoded were of different molecular sizes and differed in their predicted 
localizations. (Integral membrane and secreted proteins were excluded because 
they require separate optimization and purification methods.) So far, there has 
been no systematic study describing factors which influence the expression of 
malaria metabolic enzymes. Indeed, it is rather evident that successful expression 
of active eukaryotic genes is hard to achieve. For example, when 2078 randomly 
selected Caenorhabditis elegans full length genes were cloned and expressed in 
E. coli, only 11 % yielded soluble protein (Finley et al. 2004). And, for 32 cloned 
human proteins with size limitations ranging from 17 to 158 kDa, Braun et al. 
(2002) found that 81% were expressed solubly as GST fusions. Based on reports 
so far (Mehlin et al. 2006), it appeared that malaria proteins were as difficult to 
be expressed in E. coli as  C. elegans proteins. In this study, the bottleneck for 




amplification as shown by the successful amplification of all corresponding 
ORFs by PCR or RT-PCR. Instead, soluble active expression appeared to be 
more influenced by the fusion partner employed for recombinant protein 
production, ie. protein affinity purification tags can profoundly influence the 
solubility and expression levels of malaria proteins expressed in E. coli. It was 
also observed that the codon bias of Plasmodium vs Escherichia, as well as 
biophysical parameters such as instability index, pI, aliphatic index, as well as 
frequencies of coiled-coils and α-helices, did not influence the heterologous 
expression in a predictable manner. The results obtained also showed that the 
protein yield appeared to be dependent on the size of the recombinant protein to 
be expressed. Similarly, in a study on 30 full-length mammalian proteins by 
Dyson et al. (2004), protein features such as molecular weight and low 
complexity regions, but not pI or sub-cellular location, were correlated with 
soluble protein expression. However, while they found no relationship between 
successful expression and Gravy scores, it was observed in this study that 
expression of soluble and active plasmodial proteins tended to be correlated with 
more positive Gravy scores. Dyson et al. (2004) found Trx and MBP to be the 
best N-terminal fusion partner for mammalian proteins, while in this study GST 
seemed to be most effective for plasmodial proteins. Hence, it is clear from these 
observations that each malarial gene and its expressed protein is differently 
affected by their molecular construction and biophysical properties. Further, the 






Importantly, although a protein’s solubility has been shown to be a good 
indicator of correct folding (Himanen et al. 2001; Molloy et al. 1998), solubly 
expressed malaria proteins that failed to be enzymatically active have also been 
observed. In similar studies on eukaryotic proteins, functional experiments were 
either not done or only carried out on a small sample of soluble proteins. For 
example, in a study of expression of 32 human cDNAs in E. coli, the activities of 
only 2 soluble proteins were biochemically validated (Braun et al. 2002). Our 
study demonstrated that soluble proteins were not necessarily active (refering to 
DHO and FUM) and stresses on the importance of functional verification of 
solubly expressed proteins (ICDH, MDH and PK1). The availability of purified 
proteins in their catalytically active forms should facilitate further biochemical 
and structural analysis of these target genes. 
 
It has been recognized that malaria proteins are among the most difficult 
proteins to express heterologously (Flick et al. 2004). As the Plasmodium 
falciparum genome exhibits extreme AT-bias, it has been thought that efficient 
expression of heterologous proteins in E. coli may be impaired by the rarity of 
certain tRNAs that are abundant in the malaria parasite. When limited levels of 
tRNAs are exhausted, the lack of tRNAs will result in a drop-off of the ribosomal 
unit from the mRNA template. As a result, premature translation termination has 
been cited as a common reason for expression failure (Flick et al. 2004). 
Production of insoluble inclusion bodies in bacterial cells has also been observed. 
Although methods have been developed to obtain correctly folded proteins from 
inclusion bodies, the process of refolding cannot be invariably applied to all 




correctly folded eukaryotic proteins in E. coli, including truncation of long multi-
domain proteins into separate domains, and co-expression with stabilizing 
chaperones (Dyson et al. 2004). Given the extreme codon bias of malaria genes, 
one strategy was to over-express rare tRNAs via co-expression with the RIL 
(Stratagene, USA) or RIG plasmids (Baca and Hol 2000). In this study, however, 
these plasmids were found to be not critical for successful expression. Currently, 
one of the most successful common strategies to enhance the expression of 
soluble proteins is forging fusion with solubility enhancing tags, such as maltose 
binding protein, thioredoxin and GST. In this study, successful fusion protein 
expression of malaria proteins was demonstrated for GST, but not for Trx or 
MBP.  
 
So far, different host organisms have been employed for the production of 
malaria proteins, including Escherichia coli, baculovirus, yeast, and even 
transgenic mice (Flick et al. 2004). Among these, the E. coli expression system is 
the most attractive and most frequently used, because of the availability of 
advanced genetic tools, rapid growth and attainable high-level protein production 
(Baneyx 1999). However, successful production of correctly folded functional 
recombinant products is not always assured, particularly for the expression of 
eukaryotic proteins. So far, the cloning and recombinant expression of  malaria 
metabolic enzymes have not been well studied. Protein misfolding into inactive 
aggregates has been attributed to the lack of molecular chaperones, specialized 
post-translational modifications, or ability to be targeted to sub-cellular 
compartments in E. coli (Dyson et al. 2004). Obtaining soluble expression of 




baculovirus, have also been daunting. The codon sequences of malarial antigens 
needed to be optimized for expression in P. pastoris, while only a few proteins 
have been successfully produced using a baculoviral system because many 
plasmodia proteins turned out to be toxic to the insect cells (Flick et al. 2004). 
Hence, functional recombinant plasmodial proteins are still mostly obtained 
using E. coli (Table 10-1). 
 
10.2 ISOCITRATE DEHYDROGENASE (pfICDH) 
Once in the red blood cell, primary metabolic pathways enable the 
parasite to derive the energy and reducing equivalents required for proliferation. 
Some primary metabolic enzymes of P. falciparum have been cloned, but these 
were mainly confined to those involved in the glycolytic pathway. In this study, 
the cloning and heterologous expression of functional pfICDH is reported. The 
DNA sequence encoding pfICDH was originally deposited as draft sequence 
from the P. falciparum genome project. The ORF encoding pfICDH was 
identified by several automated prediction programs (eg. GlimmerM, Genefinder 
etc) as well as by predictions from the sequencing center. In addition, the 
translated aa sequence contained the pfam domain PF00180 which represents 
conserved motifs for ICDHs. However, it should be noted that assignment of 
gene function by a sequence similarity alone is not always accurate. Hence, the 
function of the cloned pfICDH gene was confirmed by ICDH activity in 
expression studies. This is an important prerequisite in endorsing the 
functionality of genes predicted from genome data bases.  The pfICDH ORF was 
found to be located in chromosome 13 (nt 1746298-1747704). However, 




from each end of the ICDH ORF, did not uncover any segment with homology to 
related primary metabolic genes found in other organisms. It is possible that 
genome sequence might fail to identify related genes, given that 60% of predicted 
ORFs in the P. falciparum genome did not have sufficient similarity to known 
proteins to justify functional assignments (Gardner et al. 2002).  
 
Redox enzymes have been suggested to be candidates for drug targeting 
because it is thought that the malaria parasite has a requirement for reduced 
environment during infection in red blood cells (Kanzok et al. 2000).  
Plasmodium spp. use glutathione and thioredoxin systems to cope with oxidative 
stress (Atamna and Ginsburg 1997; Kanzok et al. 2000). Both of these systems 
are known to require reducing equivalents such as NADPH to function. 
Interestingly, G6PD-deficient individuals, who produce less NADPH than 
normal individuals, have been thought to be somewhat protected against malaria 
(Brueckner et al. 2001). The distribution of populations with high frequencies of 
G6PD deficiency (G6PD-) alleles also coincides with the general distribution of 
malaria, and studies have demonstrated that the most common G6PD- alleles 
confer a degree of resistance to malaria. It is therefore assumed that G6PD- 
alleles have risen in frequency due to natural selection by malaria. The 
observation that pfICDH requires NADP exclusively supports the proposal that it 
may play a redox role in NADPH replenishment during infection.  Hence, it is 
possible that pfICDH may be useful as a target for drug therapy aimed at the 
parasite’s redox pathways. Further, Dzierszinski et al. 1999 showed that some 
metabolic enzymes of malarial parasites exhibit distinct primary structural 
differences from their human homologs and are possibly of plant origin. In this 
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study, phylogenetic studies revealed clear differences between pfICDH and its 
mammalian homologs. These observations suggest a plausible scope for the use 
of some of the domains of malarial metabolic enzymes as potential drug targets. 
The ICDH enzyme from the simian malaria parasite P. knowlesi has been 
purified and characterized (Sahni et al. 1992). The enzyme is manganese or 
magnesium ion dependent, has a molecular mass of about 48.5 kDa, and is 
cytosolic. Cupric and argentic ions have a marked inhibitory effect on its activity. 
Importantly, the enzyme is significantly inhibited by chloroquine and 
oxytetracycline in vitro, but to a lesser degree by tetracycline. However, the gene 
encoding ICDH from P. knowlesi has yet to be identified and cloned to facilitate 
further investigation. The availability of active recombinant pfICDH allows the 
characterization of this enzyme in terms of its sensitivities to antimalarials such 
as chloroquine and primaquine. The inhibitory effect of chloroquine on both 
pfICDH and P. knowlesi ICDH suggests that chloroquine may be exercising its 
antimalarial effect by diminishing the NADPH pool available to the parasite. As 
such, it would be important to investigate the in vivo expression of pfICDH and 
the possible role of pfICDH in the pathogenecity of the parasite.  
 
 
The existence of different MDHs are thought to play an important role in 
metabolic channeling, thus contributing to cellular organization during growth. In 
this study, the cloning and functional expression of a gene encoding a NADH-
dependent [LDH-like] pfMDH was reported. The prediction of cytosolic 
localization of pfMDH was consistent with earlier biochemical studies which 




Unnasch 1992). The DNA sequence encoding pfMDH was originally deposited 
as draft sequence from the P. falciparum genome project. The ORF encoding 
pfMDH was identified by several automated prediction programs (eg. 
GlimmerM, Genefinder etc) as well as by predictions from the sequencing center. 
In addition, the translated aa sequence contained the pfam domains PF00056 and 
PF20866, representing conserved motifs for the NAD-binding and alpha/beta C-
terminal domains of lactate/malate dehydrogenases respectively. However, that 
assignment of gene function by sequence similarity alone is not accurate. Hence, 
it is impertinent to validate or reassess the biochemical functionality of predicted 
targets (ORFs) prior to inhibitor studies on the corresponding enzymes. In this 
study, the function of the cloned pfMDH gene was confirmed by detection of 
MDH activity in expression studies. However, the possibility that pfMDH may 
encode other dehydrogenase activities, such as LDH activity, or the employment 
of NADPH as a cofactor, is not ruled out.  
 
Phylogenetic studies revealed substantial sequence differences between 
pfMDH and mammalian MDHs, suggesting that pfMDH may have unique 
properties, which could be exploited for the design of therapeutic agents that act 
by specifically inhibiting parasite enzymes. Indeed, studies with 
phosphofructokinase of T. gondii have shown that it is possible to use inhibitors 
targeted specifically to the enzymes involved in carbohydrate or energy 
metabolism of the parasite as potential drugs for the treatment of toxoplasmosis 
(Peng et al. 1995). Since pfLDH was later revealed to be a MDH based on 
detailed phylogenetic and sequence studies, the gene encoding pfMDH reported 




Proteomic studies in P. falciparum suggested that MDH enzyme activity was 
associated with the sporoziotic and gametocytic stages (Florens et al. 2002). 
However, P. falciparum LDH mRNA was only detectable at erythrocytic stages. 
As yet there is no comparative study on the expression or kinetics of MDH 
isozymes in P. falciparum; it is thus possible that these isoforms may be 
kinetically distinct and/or regulated by distinct pathways. In G. lamblia, cytosolic 
MDH, together with phosphoenolpyruvate carboxykinase and the malic enzyme, 
serve to convert phosphoenolpyruvate into pyruvate (Lindmark 1980), suggesting 
that the three-enzyme pathway may function to transfer reducing equivalents 
from NADH to NADPH (Lindmark 1980; Ellis et al. 1993; Sanchez et al. 1996). 
Although the physiological role of pfMDH has not yet been resolved, the cloning 
and functional validation of pfMDH may allow the differences in enzymatic 
properties between the two MDH isoforms in P. falciparum to be investigated.  
 
10.4 PYRUVATE KINASE 1 (pfPK1) 
Because of the crucial role of pyruvate kinase in the metabolism of 
parasitic organisms, it has been indicated as a potential drug target against 
Trypanosomes and Leishmania (Ernest et al. 1998; Ernest et al. 1994). The 
recombinant T. brucei pyruvate kinase is currently being crystallized as a step 
towards its use in designing selective inhibitors for development of anti-
trypanomosamal drugs (Ernest et al. 1998). Although the response of parasitic 
pyruvate kinase to phosphorylated sugars appears to be unusual in many parasitic 
organisms, relatively little is known about the pyruvate kinase from Plasmodium. 
Interestingly, it has been reported that in a mouse model, pyruvate kinase 




importance of this pathway for the parasite’s survival (Coburn 2004), and that 
pyruvate kinase may be considered as a potential target for the design of new 
drugs against malaria. Recent studies have indicated that an increase in pyruvate 
kinase level, in the absence of a compensating increase in diphosphoglycerate 
mutase level, may lead to the sharp decline in the 2,3-diphosphoglycerate content 
of infected erythrocytes, contributing to hypoxia during malaria (Dubey  et al. 
2003). This compound, 2,3-diphosphoglycerate, is an important metabolite in the 
glycolytic pathway of erythrocytes and is formed from 1,3- diphosphoglycerate 
by diphosphoglycerate mutase. The presence of 2,3-diphosphoglycerate is known 
to affect the oxygen binding capacity of hemoglobin (Dubey et al. 2003). 
Observations indicating the potential importance of pyruvate kinase in malaria 
(Dubey et al. 2003; Coburn 2004) prompted us to uncover the gene encoding for 
pfPK1 and to produce active recombinant pfPK1 for detailed characterization and 
comparison with its counterparts in other parasites, namely T. brucei, L. 
mexicana and T. gondii. RT-PCR using mRNA extracted from P. falciparum 
infected cells indicated that pfPK1 was expressed during the intraerythrocytic-
stage. DNA sequencing of the cloned pfPK1 cDNA validated the positions of 
introns predicted in PlasmoDB. A BLAST search against the complete P. 
falciparum genome sequence data (PlasmoDB) using pfPK1 amino acid sequence 
did not uncover any other ORF with significant similarity to pyruvate kinases. 
Hence, pyruvate kinase gene cloned in this study appears to exist as a single copy 






The affinity of pfPK1 for ADP and PEP appeared to be higher than the 
corresponding enzymes from mammalian enzymes (Km for ADP is 0.35mM for 
cow and pig pyruvate kinases; Km for PEP is 0.57mM for rat pyruvate kinases; 
website: www.brenda.com). The affinity for PEP was also higher than that of 
pyruvate kinase from T. gondii (Km of 1mM). Similar to pyruvate kinases from 
T. gondii, rabbit muscle pyruvate kinase and human M1 isozyme, pfPK1 was not 
activated by F16BP, the common activator of most pyruvate kinases (Maeda et 
al. 2003). In pyruvate kinases, the lysine at position 418 is thought to be involved 
in binding the 6-phosphate moiety of F16BP (Fig. 10-1). However, similar to 
non-allosteric enzymes, pfPK1 has a glutamate at residue 418. In contrast, lysines 
are observed at position 418 in pyruvate kinases activated by F16BP, such as the 
human muscle isozyme 2. Hence, the observed properties of pfPK1 agreed with 
published amino acid sequence data. However, unlike T. gondii pyruvate kinase, 
pfPK1 was not significantly activated by G6P. Hence, activation by G6P may not 
be a universal property related to parasitism as proposed earlier (Maeda et al. 
2003). Interestingly, pfPK1 differs from T. gondii at three positions (K37, H40 
and I473) identified by Ernest et al. (1998) to be important in effector binding. 
These differences may account for the distinction in response to G6P between 
pfPK1 and T. gondii pyruvate kinase. The observation of sensitivity of pfPK1 to 
citrate, PLP and ATP was interesting because no inhibitors have been described 
for pfPK1 so far. ATP, citrate, α-ketoglutarate and a number of organic acids 
were known to inhibit E. histolytica pyruvate kinase (Saavedra et al. 2004). 
However, it is interesting to note that while the E. histolyica enzyme is inhibited 
by 21mM citrate and 6mM ATP (Saavedra et al. 2004), pfPK1 appeared to be 




pyruvate kinase by citrate was not accompanied by a transition from hyperbolic 
to sigmoidal kinetics observed in pfPK1. The binding sites for citrate are as yet 
unknown but have been suggested to be separate from those for phosphorylated 
sugars. Nevertheless, the observation of distinct mechanisms of inhibition by 
citrate and ATP suggests independent binding sites for these inhibitors. Also, the 
physiological significance of inactivation by PLP has yet to be determined 
because the status of PLP in P. falciparum is unknown. Nevertheless, the 
difference in the susceptibility to PLP between pfPK1 and rabbit muscle pyruvate 
kinase may reflect structural differences in accessibility of binding sites to PLP.  
 
The results in this study showed that P. falciparum genome encodes a 
biologically active pyruvate kinase that is expressed during the intraerythrocytic 
stage. The inhibition of pfPK1 by citrate, PLP, and ATP, as well as its 
uniqueness in its insusceptibility to F16BP and G6P, were characterized in detail. 
These observations suggest that pfPK1 appears to be kinetically unique among 
protozoan pyruvate kinases and that pfPK1 is regulated by effectors that may be 
correlated with energy flow or metabolite levels in the cell. Molecular 
investigations to elucidate the binding sites for the uncovered inhibitors may be 
relevant to the design of molecules that would inhibit the parasite’s enzyme. 
Currently, the availability of active soluble recombinant pfPK1 can easily 






Fig. 10-1. Alignment of the binding site of the 6-phosphate moiety of 
F16BP within the C-domain. The essential amino acids for 
the binding of the 6-phosphate moiety within the binding site 
are indicated by arrows. The box indicates the residues at 












                           ▼ ▼ ▼ 
pfPK1           410 ASLIIALTETGYTARLIAKYK 430 
P.yoelii        410 ASVIITLTETGYTARLIAKYK 430 
T.gondii        440 AAIILALTETGQTARLIAKYR 459 ┐ 
rabbit          425 AAALIVLTESGRSAHQVARYR 444 | non-allosteric   
humanM1         425 AAALIVLTESGRSAHQVARYR 444 ┘ 
T.brucei        394 AKAMLVLSNTGRSARLISKYR 413 ┐ activated by F26BP 
L.mexicana      394 AKAMVVLSNTGRSARLVAKYR 413 ┘ 
humanM2         425 SGAIIVLTKSGRSAHQVARYR 444 ] activated by F16BP 
  
10.5 LOCALIZATION AND PROTEIN INTERACTION  
 The identification of the subcellular locations and interactions of proteins 
is fundamental to the understanding of biosynthetic pathways because the 
functions of proteins are defined in the context of compartments that they are 
organized into, and the proteins they interact with. Hence, one aim of the target-
validation aspect of this study was to explore the use of a live eukaryotic cellular 
assay to localize organellar transit signals of plasmodial genes. A comparison of 
the efficiencies of generic softwares for predicting eukaryotic mTPs with that of 
a Plasmodium-specific software suggested that with the broad sequence 
divergence of plasmodial mTPs, their signal peptide recognition should be 
augmented by experimental investigations.  
 
 A search of current literature revealed that biochemical studies on 
malarial TCA cycle enzymes could not provide convincing information 
concerning their subcellular characteristics. For example, studies on an isocitrate 





to the supposition that this enzyme is localized in the cytoplasm (Sahni et al. 
1992), whereas paradoxically, parasite-specific isocitrate dehydrogenase was not 
detectable in P. berghei (Howells et al. 1973). Similarly, there is very little 
information on the subcellular localization of plasmodial malate dehydrogenase 
and succinate dehydrogenase, except the conjecture that malate dehydrogenase 
appeared to be cytoplasmic based on its biochemical properties (Lang-Unnasch 
1992). In this study, the plasmodial TCA cycle proteins CS, ICDH, BCKDH and 
SDH were predicted to be mitochondrial and this was supported by visualization 
of the mitochondrial-targeting functions of their N-terminal signal peptides in 
CHO-K1 cells. CS has been previously localized to the mitochondrion via in 
vitro transfection of P. falciparum (Tonkin et al. 2004), validating the cellular 
system in this study. The PlasMit software predicted MDH and a fumarase to be 
cytosolic, suggesting the loss of these enzymes from the conventional 
mitochondria. This study corroborated the above prediction by providing 
experimental evidence for the absence of mitochondrial-targeting of MDH. 
Hence, observations from this study raised the interesting possibility that the 
TCA cycle in the Plasmodium mitochondria is unusual with some enzymic 
components of the cycle operating in the cytoplasm.  
 
The study of the plasmodial mTPs, NLSs and apicoplast-targeting signals 
supported the premise that authentic mTPs and NLSs could be directly 
recognized by its locations in the eukaryotic live cells. Hence, this approach will 
allow the substantiation of computer predictions of localizations without the need 
for generating expensive specific antibodies or transgenic parasites. This method 




culture and transfection are available, such as Eimeria and Cryptosporidium 
(Kim and Weiss 2004). Indirect evidence supports the notion that the apicoplast-
targeting signals cannot be recognized or localized in CHO-K1 cells. This 
observation is interesting, since the first part of the bipartite apicoplast-targeting 
signal appeared to be a canonical signal sequence that was able to direct GFP to 
the secretory pathway in P. falciparum (Waller et al. 2000). It is increasingly 
recognized that organisms may possess several distinct modes of targeting which 
may be denoted by specific signal sequences (Zheng and Gierasch 1996). Hence, 
it is possible that there may be differences in the targeting pathways between P. 
falciparum and mammalian cells, and it is perhaps not suprising that the 
apicoplast-targeting signal did not result in targeted proteins. Hence, the 
experimental system described in this study might be useful for comparing the 
sorting machinery of apicomplexans with that of mammalian cells.  
 
Since efficient targeting to appropriate subcellular compartments is one of 
the criteria for the production of correctly folded recombinant proteins in 
surrogate hosts, the use of the native plasmodial signal peptides may allow the 
expression of functionally active heterologous proteins in eukaryotic systems. In 
this study, the correct targeting of the P. falciparum mTPs and NLSs to the 
mitochondria and nuclei, respectively, in CHO-K1 cells suggests that their 
corresponding mitochondrial and nuclear proteins are likely to fold and 
translocate correctly for potentially useful mammalian cell studies. Hence, these 
results showed that the localizations of plasmodial mitochondrial and nuclear 




experimental system will serve as a useful a priori approach to authenticate the 
pathophysiological roles of novel plasmodial proteins.  
  
Recently, efforts were initiated to apply the two-hybrid assay for P. 
falciparum proteins on a high throughput basis (LaCount et al. 2005). Although 
this has led to the identification of about 2000 interactions, it should be noted that 
a high prevalence of spurious data was generated, as was typical of high 
throughput approaches. Experimental validation of data obtained in yeast-two-
hybrid screening studies require focused experiments on a variety of biological 
processes. It is known that the difficulties in working with this organism 
currently preclude the types of experimental validation that are available in 
model organisms, such as co-immnuoprecipitation (LaCount et al. 2005). Indeed, 
preliminary experiments in bacterial expression of pfRACK as a HA-tagged 
protein in co-immunoprecipitation experiments suggested that this prey may not 
be expressible in E. coli (not shown). Hence, future validation experiments 
should be aimed at either (i) independent confirmation of the interaction by a 
mammalian-two-hybrid approach, or (ii) optimization of expression of HA-
tagged pfRACK in E. coli. The identification of RACK in the yeast-two-hybrid 
study is interesting because a role for RACK in the control of cellular division 
and antigen-presentation mechanism in parasites has been proposed (Madeira et 
al. 2003). The present finding suggests an involvement of the small heat-shock 
protein hslv in the RACK signalling pathway during the malaria parasites’ 
asexual life cycle. In view of the importance of RACK, further studies to 
elucidate its intracellular mechanisms in Plasmodium are warranted. The 




interaction, and localization analyses of plasmodial primary metabolic genes are 
summarized in Fig. 10-2. 
 
10.6 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
10.6.1 Exploiting primary metabolic enzymes as potential 
drug-targets 
 The identification of novel drug-targets for drug-discovery relies on 
advancement in the understanding of the functional properties of plasmodial 
proteins. With the exception of lactate dehydrogenase (Mehlin 2005), primary 
metabolic enzymes have so far not been actively pursued as drug-targets, 
possibly based on the presumption that such enzymes may share too much 
similarity to host enzymes such that derivation of parasite-specific inhibitors 
might prove to be difficult. Indeed, even for lactate dehydrogenase, for which 3D 
structural studies supported the possibility of specific inhibitors, selectivity for 
the parasite enzyme is still an issue (Mehlin 2005). This early setback was also 
partly due to reported suggestions of the absence of an active TCA cycle during 
the intraerythrocytic-stage of the parasite’s life-cycle. However, a u-turn is likely, 
based on more recent data from microarray, molecular, and biochemical studies 
which have revealed a modified TCA cycle that appears to be unrelated to ATP 
generation. 
 
Selectivity of a drug depends on inhibitors which can fit in the relevant 
grooves of an enzyme destined for inactivation. This, therefore demands the 
target enzyme to be innately expressed. In short, the selectivity problem is 




heterologously. The Structural Genomics of Pathogenic Protozoa (SGPP) 
(Mehlin 2004), a systematic effort to clone and crystallize P. falciparum proteins, 
has reported soluble expression of only about 5% for their first 368 targets, an 
attrition rate due mostly to unsuccessful expression of large targets, or insoluble 
expression of small ones. Another technical difficulty is the cellular localization 
of potential targets. Although the use of green fluorescent protein (GFP) is a 
valuable approach for exploring protein trafficking and localization in P. 
falciparum (Tonkin et al. 2004), transfection of Plasmodium parasites is not 
straightforward nor widely available to all laboratories. In this study, the 
recombinant expression patterns for a selection of primary metabolic genes 
identified for targeting are documented (Chapter 6). The usefulness of cellular 
techniques in validating the localization of plasmodial genes by circumventing 
the difficulties associated with the in vitro manipulation of P. falciparum was 
also demonstrated (Chapter 9).  
 
10.6.2 Heterologous expression of primary metabolic genes 
In an initiative to complete the functional status for the entire set of genes 
encoding the glycolysis and TCA cycle, the recombinant expression of 10 
targeted P. falciparum genes was tested in E. coli. These targets were selected on 
the basis that they have not yet been functionally validated, but are considered to 
be important for the parasite’s survival. To ascertain their suitability as drug-
targets, the intraerythrocytic-stage active transcription of these genes were 
confirmed via RT-PCR using mRNA extracted from in vitro cultures of P. 
falciparum. As a result, profound differences in expression levels and solubilities 




the fusion partner, 30% of the gene constructs were expressible solubly with 
verifiable biochemical activities. In comparison, in a large-scale expression study 
on 1000 P. falciparum proteins as His-tagged proteins (Mehlin et al. 2006), a 
much lower rate of soluble expression (6.3%) was observed, suggesting the 
usefulness of the GST fusion-partner in enhancing soluble expression. The only 
published study of a large number of P. falciparum proteins expressed using 
fusion-tags reported 5 soluble proteins from 95 single-exon constructs fused to 
MBP (maltose binding protein) or GST (5.2%) (Aguiar et al. 2006). Compared 
with other genomes, a recent attempt in the expression of 32 cloned human 
proteins ranging from 17 to 158 kDa as GST fusions yielded a soluble expression 
rate of 81% (Braun et al. 2002), while an effort to clone and express 135 small 
proteins from Oryza sativa (rice) obtained a 53% solubility rate with the use of 
fusion proteins (Tsunoda et al. 2005). The general trends appear to be that (i) 
affinity tags play a significant role in enhancing soluble expression, and that (ii) 
plasmodial genes are more difficult to express than most other eukaryotes. It 
should also be noted that comparisons across datasets or genomes may not be 
straightforward due to the use of different expression vectors, expression 
conditions, or criteria for successful expression.  
 
Observations from this study suggested that codon bias was not a 
mandatory consideration for expressing malaria proteins. Interestingly, after 
testing 1000 plasmodial targets, statistical comparison of the AT content of 
expressed and inexpressible genes led Mehlin et al. (2006) to conclude that there 
would be little benefit in using codon-optimized E. coli strains. In the same 




targets tested, and none of the 3 expressed proteins were soluble as His-tagged 
fusions presented in an E. coli host. Clearly, gene structure may not be the only 
factor contributing to expressibility. Similar to most large-scale expression 
studies of Plasmodium genes, no clear trend emerged when the biophysical 
parameters of the actively-expressed and non-expressible targets were inspected. 
To sum up, no single approach has yet been shown to be most effective. Future 
efforts to achieve soluble expression of specific P. falciparum proteins should 
include some or all of the current approaches: full gene synthesis, removal of 
signal peptide or prodomain, molecular weight reduction, induction at low 
temperatures, and employment of a battery of solubility enhancing tags.  
 
10.6.3 The prospects of surrogates and orthologues 
Orthologues have proven to be valuable in the structural genomics of E. 
coli and Thermotoga maritima for boosting the success rates for soluble 
expression beyond those achievable with either genome alone. The availability of 
substantial genomic information from other Apicomplexan genomes, including 
P. yoelii, P. vivax, C. parvum and T. gondii offered an opportunity to overcome 
the difficulties associated with the soluble expression of P. falciparum proteins 
by exploiting the accessibility of soluble recombinant orthologous proteins. The 
SGPP endeavor has demonstrated that over 3000 orthologous genes from P. 
yoelii and P. berghei, and another 1800 orthologues from Cryptosporidium 
parvum, could be effectively exploited to overcome the lack of information on P. 
falciparum proteins that are not available as soluble proteins, by making cross-
reference to data from diverse orthologous parasites. This has led the group to 




been fewer purified proteins, crystals and structures; there would be no proteins, 
crystals or structures for more than half of the targets. 
 
In this study, it has been demonstrated that, to circumvent technical 
difficulties in transfection with P. falciparum, it is possible to use mammalian 
host cells as surrogates for cellular studies. In Cryptosporidium, another 
Apicomplexan parasite for which transfection is currently not possible, transgene 
transfection and localization studies have been carried out using yeast (Lagier et 
al. 2003) and Toxoplasma (O’Connor et al. 2003) as surrogate hosts. In this 
study, in order to test the usefulness of a cellular system for plasmodial 
localization, GFP tagged to P. falciparum mitochondrial and nuclear targeting 
signals were expressed in CHO-K1 cells. After using a combination of 
fluorescent markers, organelle-specific probes, phase contrast microscopy, and 
confocal microscopy to locate a selection of 10 signal peptides, it was found that 
the respective localizations of these malarial proteins have complied with the 
selected molecular targets, viz. mitochondrial, nuclear and cytoplasmic. Hence, 
the use of cellular surrogates is promising and could be further explored to 
include the use of surrogate libraries in two-hybrid screening. In this respect, 
although the interactome data is available, the use of a P. falciparum cDNA 
expression library is still subjected to problems associated with low expressibility 
of P. falciparum proteins. Hence, screening surrogate (yeast or human) libraries 
with high expression rates may uncover information that has eluded detection 
because of an inexpressible interacting partner. Another possibility may be the 




cell-cycle proteins, in view of the immense logistical difficulty of carrying out 
flow-cytometry for a locally classified BSL3 organism.  
 
10.6.4 The current status of glycolytic and TCA 
cycle genes 
The observations obtained from studies on the function, transcription, 
protein interaction, and localization analyses of plasmodial primary metabolic 
genes are summarized in Fig. 10-2 and Table 10-1. All the expected enzymes for 
a conventional glycolytic and TCA cycle are present in the P. falciparum genome 
(Gardner et al. 2002). All of the steps have been shown to be transcriptionally 
active, with most of the corresponding enzyme activities detectable in vitro. 
Despite problems associated with hexokinase (Olafsson and Certa 1994), 
succinate dehydrogenase (Takeo et al. 2000), CS and FUM (this study), active 
recombinant expression of many of the enzymes in E. coli has been achieved. It 
is quite established that the parasite is highly dependent on the glycolytic 
pathway for its energy supply. Hexokinase, phosphofructokinase, and pyruvate 
kinase are considered to be rate-limiting and hence important regulatory enzymes 
to be targeted. Consistent with the suggested importance of pyruvate kinase, 
extreme elevations in its levels was noted in erythrocytes infected with P. 
falciparum parasites (Roth et al. 1988). In this study, the functional 
authentication of pfPK1 was reported. Like the T. brucei, T. gondii, and L. 
mexicana enzymes, PK1 from P. falciparum was also found to be highly 
regulated. P. falciparum appears to possess a putative ORF that may encode 
another pyruvate kinase (PK2). The experimental evidence for the expression of 





The expression of TCA cycle genes is synchronized with mitochondria 
genes involved in electron transport (Bozdech et al. 2003). Furthermore, 
mitochondrial respiration has been reported in asexual parasites of P. falciparum 
(Divo et al. 1985). Hence, diverse evidence suggested that the TCA cycle and the 
electron transport systems indeed occurs in asexual stage parasites, validating 
these pathways as potential drug targets. Despite earlier predictions that malate 
dehydrogenase and isocitrate dehydrogenase may be cytosolic proteins, cellular 
assays (this study) have ascertained the mitochondrial localization of isocitrate 
dehydrogenase. It is hence possible that malate dehydrogenase may play a role in 
the reoxidation of reduced NAD for glycolysis, serving a role that is 
complementary to that of lactate dehydrogenase (Lang-Unnasch and Murphy 
1998). Although the role of succinate dehydrogenase in the asexual cycle of these 
parasites remains unclear, this enzyme has been localized to the mitochondria 
(this study). Also, the localization of isocitrate dehydrogenase in the 
mitochondria (this study) provided evidence for a biosynthetic or energetic role 
of this enzyme in the mitochondria of erythrocytic-stage P. falciparum. Together, 
cellular assays and in vitro localization studies have provided information on the 
localization of most of the steps in the TCA cycle. Although the typical 
connection to glycolysis via pyruvate dehydrogenase is not apparent (Foth et al. 
2005), branched chain ketoacid dehydrogenase, a similar enzyme with the 
potential to provide acetyl-coA, was localized to the mitochondria in this study. 
In summary, recent data are progressively validating the mitochondrial 
localization of many TCA enzymes, supporting that some part of the TCA cycle 




PfLDH exemplifies an actively pursued malaria drug-target. Modified 
gossypol compounds with reduced cytotoxity have been shown to exhibit anti-
malarial activities (Razakantoanina et al. 2000). It is thought that a five-residue 
insertion in the substrate-specificity loop of pfLDH forms the basis for the 
selectivity for the parasite’s enzyme (Bzik et al. 1993). However, to date no 
structure has been reported for the inhibitory complex formed between gossypol 
and pfLDH. Subsequent to our identification of the genes encoding pfMDH, 
Tripathi et al. (2004) found that treatment of P. falciparum trophozoites with the 
LDH inhibitor, gossypol led to increased mRNA and protein levels of both 
pfMDH and pfLDH. This suggests that these enzymes may have complementary 
roles in NAD recycling, a hypothesis relevant to targeting MDH. Similarly, 
Wrenger and Muller (2003) observed that pfICDH transcript levels respond to 
oxidative stress in in vitro cultures, suggesting that pfICDH play critical redox 
functions. Future research into glycolysis and TCA cycle enzymes, including 
molecular explorations using GFP and in vitro gene knockout studies, would 
clarify the essentiality of these exciting pathways and uncover unique aspects that 




Table 10-1. Current status for P. falciparum primary metabolic enzymes. 




Localization Most likely role 
Glycolysis 
1 Hexokinase 9 Olafsson et al. 1992 9 Olafsson et al. 1992 9 Cytosol Olafsson and Certa 1994 Energy production 
2 Glucose phosphate isomerase 9 Sherman 1998a 9 Kaslow and Hill 1990    Energy production 
3 Phosphofructokinase 9 Roth et al. 1988      Energy production 
4 Aldolase 9 Roth et al. 1988 9 Dobeli et al. 1990 9 Cytosol Knapp et al. 1990 Energy production 
5 Triose phosphate isomerase 9 Roth et al. 1988 9 Ranie et al. 1993    Energy production 
6 Glyceraldehyde-3-P dehyd. 9 Roth et al. 1988 9 Daubenberger et al. 2000    Energy production 
7 Phosphoglycerate kinase 9 Roth et al. 1988 9 Pal et al. 2004    Energy production 
8 Phosphoglycerate mutase 8 Not detectable1        Unclear
9 Enolase 9 Roth et al. 1988 9 Pal-Bhowmick et al. 2004 9 Cytosol Pal-Bhowmick et al. 2004 Energy production 
10 Pyruvate kinase 9 Roth et al. 1988 9 This study    Energy production 
11 Lactate dehydrogenase 9 Roth et al. 1988 9 Bzik et al. 1993    NAD regeneration 
12 Glycerol kinase   8 Inexpressible (this study)  9 Cytosol This study Unclear 
TCA cycle and electron transport 
1 Pyruvate dehydrogenase   9 Foth et al. 2005 9 Apicoplast Foth et al. 2005 Fatty acid biosynthesis 
2 Malate dehydrogenase 9 Lang-Unnasch 1992 9 This study 9 Cytosol This study NAD regeneration 
3 Citrate synthase   8 Inexpressible (this study)  9 Mitochondria This study TCA cycle 
4 Aconitase 9 Hodges et al. 2005 9 Hodges et al. 2005 9 Mitochondria Hodges et al. 2005 TCA cycle 
5 Isocitrate dehydrogenase 9 Fry and Beesley 1991 9 This study 9 Mitochondria This study TCA cycle 
6 α-ketoglutarate dehydrogenase 8 Not detectable2    9 Mitochondria McMillan et al. 2005 Unclear 
7 Succinyl CoA synthetase        Unclear 
8 Succinate dehydrogenase 9 VanderJagt et al. 1989   9 Mitochondria This study TCA/electron transport 
9 Fumarase   8 Inactive (this study)     Unclear 
10 Branched chain ketoacid dehyd     9 Mitochondria This study TCA cycle 
                                                 
1 Roth et al. 1988 
2 Billker et al. 1998 
Chapter 10 
 





























































































APPENDIX I MEDIA, BUFFERS AND 
SOLUTIONS 
 
A. CULTURE MEDIA 
RPMI 1640 
        For 1L: 
RPMI 1640 powder (Gibco)      10.43 g 
HEPES (Gibco)       6 g 
NaHCO3       2 g 
Distilled water was added to 1 L and the medium was sterilized by autoclaving. 
Before use, the medium was supplemented by 0.5 ml of gentamicin (from 50 mg/ml 




        For 1L: 
Difco peptone       20 g 
Yeast extract       10 g 
Glucose       20 g 
Agar (for plates only)      20 g 
Distilled water was added to 1 L and the pH was adjusted to 6.5. The medium was 
then autoclaved at 121°C for 15 min.  
 
SD 
        For 1L:
Yeast nitrogen base without amino acids (Difco)   6.7 g 
Glucose       20 g 
Agar (for plates only)      20 g 
Distilled water was added to 1 L and the pH was adjusted to 5.8 if necessary. The 
specified amount of dropout (DO) supplement (Clontech) was added, afterwhich the 
medium was autoclaved. For X-α-GAL plates, 200ul of X-α-GAL (Clontech) 
(20mg/ml stock solution dissolved in N,Ndimethylformamide) was spread onto SD 
agar plates.    
 
Luria-Bertani (LB) broth 
        for 1 L:
Bacto-tryptone (Oxoid)     10 g 
Yeast extract (Oxoid)      5 g 
NaCl (Merck)       10 g 
Ingredients were dissolved in 950 ml of deionized water. The pH was adjusted to 7.0 
with 5M NaOH. Deionized water was added to bring the volume up to 1 L. 
 
LB agar and antibiotic plates 
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Agar technical 3 (Oxoid) was added at 1.8% (w/v) to LB broth before sterilization. 
Upon cooling to 55oC, 20 ml of molten agar were poured into each 90 mm diameter 
petri-dish and allowed to set. LB agar was prepared as above but antibiotic (50 µg/ml 
of kanamycin or 100 µg/ml of ampicillin) was added after cooling to 55oC before 




PEG/LiAc solution (polyethylene glycol/lithium acetate) 
        For 10 ml: 
PEG 4000        8 ml of 50% PEG 
TE buffer        1 ml of 10X TE 
LiAc         1 ml of 10X LiAc 
The solution was prepared fresh just prior to use.  
 
1XTE/1XLiAc solution         
                                                                    For 10 ml: 
TE buffer        1 ml of 10X TE 
LiAc         1 ml of 10X LiAc 
The volume was made up to 10 ml. The solution was prepared fresh just prior to use.  
 
TE Buffer 
Tris base (Sigma)      24.2 g 
EDTA        7.2 g 
The pH was adjusted to 8.0 and the volume made up to 1 L. The final concentration 
was 10 mM Tris, 1 mM EDTA. 
 
TDE Buffer 
Tris HCl       0.05 M 
Dithiotreitol       0.1 mM 
EDTA        0.01 mM 
 
TAE Buffer 
Tris acetate        40 mM 
EDTA        1 mM 
 
 
C. MISCELLANEOUS SOLUTIONS 
20% Glycerol 
20 g of glycerol was dissolved in 100 ml of water and autoclaved. 
 
3M NaAc (Sodium Acetate) 
This was prepared by dissolving 24.6 g of sodium acetate in 80 ml of water and 
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adjusted to the required pH (5.2 or 4.6) with glacial acetic acid and the final volume 
adjusted to 100 ml. 
 
1.5 mM Tris-HCl, pH 8.8 
54.45 g of Tris base was dissolved in 150 ml of deionized water. pH was adjusted to 
8.8 with 1 N HCl and the volume made up to 300 ml with water. 
 
1.0 mM Tris-HCl, pH 8.8 
12 g of Tris base was dissolved in 60 ml of deionized water. pH was adjusted to 6.8 
with 1 N HCl and the volume made up to 100 ml with water. 
 
4 X SDS-PAGE Sample Buffer 
Distilled water       4 ml 
Tris-HCl (1 M, pH 6.8)     0.5 ml 
Glycerol        0.8 ml 
10 % SDS (BRL)      1.6 ml 
β-mercaptoethanol      0.4 ml 
Bromophenol Blue      0.1 µg 
 
5 X Electrode Running Buffer 
Tris base       45 g 
Glycine       216 g 
SDS        15 g 
Deionized water      to a final volume of 3 L 
 
Staining Solution 
Coomassie Brilliant Blue (BRL)    0.1 % (w/v) 
Methanol        40% (v/v) 
Glacial acetic acid       10 % (v/v) 
 
Destaining Solution 
Methanol        30% (v/v) 
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Abstract
Understanding the functional genomics and proteomics of plasmodia underpins the development of new approaches to antimalarial che-
motherapy. Although genome databanks (e.g. PlasmoDB) and biocomputing tools (e.g. PlasMit, PlasmoAP, PATS) are useful in providing a
global albeit predictive view of the myriad of about 5000 genes, only 40% are annotated, with few cases of endorsed subcellular localizations of
the corresponding proteins in animal models. Progress in plasmodial protein trafficking has been hampered by the lack of a simple yet reliable
method for studying subcellular localization of plasmodial proteins. In this study, we have used a combination of fluorescent markers, organelle-
specific probes, phase contrast microscopy, and confocal microscopy to locate a selection of signal peptides from 10 plasmodial proteins in CHO-
K1 cells. These eukaryotic cells serve as an in vitro living system for studying the cellular destinations of four mitochondrial-targeted TCA cycle
proteins (citrate synthase, CS; isocitrate dehydrogenase, ICDH; branched chain α-keto-acid dehydrogenase E1α subunit, BCKDH; succinate
dehydrogenase flavoprotein-subunit, SDH), two nuclear-targeted proteins (histone deacetylase, HDAC; RNA polymerase, RPOL), two
apicoplast-targeted proteins (pyruvate kinase 2, PK2; glutamate dehydrogenase, GDH), and two cytoplasmic resident proteins (malate dehydro-
genase, MDH; glycerol kinase, GK). The respective localizations of these malarial proteins have complied with the selected molecular targets,
viz. mitochondrial, nuclear and cytoplasmic. Interestingly, MDH that is widely known to be resident in eukaryotic mitochondria was found to be
cytoplasmic, probably due to the absence of molecular target sequences. Since the localization of plasmodial proteins is central to the authentica-
tion of their pathophysiological roles, this experimental system will serve as a useful a priori approach.
© 2006 Elsevier Masson SAS. All rights reserved.
Keywords: Malaria; Plasmodium falciparum; Green fluorescent protein; Localization; Heterologous expression
1. Introduction
The malaria-causing parasite Plasmodium falciparum is a
major health threat in many regions of the world. The increas-
ing resistance of malaria parasites to available drugs empha-
sizes the need to understand the biology of the malaria parasite
from different facets, including protein trafficking. To this end,
the availability of the complete nuclear genome of
P. falciparum has been most useful for cloning relevant genes
for functional analyses, but lacks reliable indication of the cel-
lular organization of potentially 5000 gene products [1]. For
example, although several genes encoding enzymes of the cen-
tral respiratory pathway TCA cycle have previously been
cloned, and the expressed proteins reported to be functional
[2–5], it remains to be seen whether these enzymes are destined
to be in the mitochondria. Mitochondrial transit peptides
(mTPs) have been proposed to be necessary to facilitate protein
translocation to the mitochondrial matrix [6,7]. While genes
that are expected to be mitochondrial-targeted have upstream
transit peptides, there are other genes of the TCA cycle, for
example malate dehydrogenase and fumarase, which appeared
not to possess such signal sequences. Similarly, genes encod-
www.elsevier.com/locate/biochi
Biochimie 88 (2006) 1367–1375
Abbreviations: BCKDH, branched chain α-keto-acid dehydrogenase E1α
subunit; CS, citrate synthase; GDH, glutamate dehydrogenase; GFP, green
fluorescent protein; GK, glycerol kinase; HDAC, histone deacetylase; ICDH,
isocitrate dehydrogenase; MDH, malate dehydrogenase; mTP, mitochondrial
transit peptide; NLS, nuclear localization signal; PK2, pyruvate kinase 2;
RPOL, RNA polymerase; SDH, succinate dehydrogenase flavoprotein-
subunit..
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ing nuclear proteins have been cloned and characterized [8],
but their intracellular localization has not been demonstrated.
There are limited but interesting features of plasmodial sig-
nal peptides. Molecular studies of mTPs have indicated that
most mTPs are situated at the N-termini with few exceptions
[9]. Bender et al. [6] analyzed the amino acid codon usage in
plasmodia mTPs and observed that there were significant dif-
ferences between their mTPs and those from other eukaryotic
organisms. Similarly, proteins with nuclear localization signals
(NLSs) are reportedly transported to the nucleus. These NLSs
were characterized by tandem stretches (four to eight residues)
containing lysine and arginine residues and can be located any-
where within a protein, not necessarily at the N-terminus [10].
The apicoplast-targeting signals were found to be bipartite
sequences containing a canonical signal sequence in their first
20 residues, followed by a specialized, Plasmodium-specific
transit signal of approximately 80 residues [11].
Although existing computational softwares are available for
predicting the cellular locations of many proteins [6,12,13], the
extension of the use of such computational predictive tools for
localizing plasmodial proteins can only be cursory until more
supporting experimental evidence is available. The use of
green fluorescent protein (GFP) is a valuable approach for
exploring protein trafficking and localization in the human
pathogen, P. falciparum [14]. However, transfection of Plas-
modium parasites is not a simple process of creating stable
transgenic parasites [15]. Indeed, the elusive lifestyles of plas-
modia are such that although stable transformation of Plasmo-
dium yoelii and Plasmodium berghei is achievable, the in vitro
cultivation of these rodent malaria species is still not possible.
In Cryptosporidium, another apicomplexan parasite for which
transfection is currently not possible, transgene transfection
and localization studies have been carried out using yeast
[16] and Toxoplasma [17] as surrogate hosts. Since a reason-
able test of organellar targeting function is whether the ques-
tioned target motif sequence is sufficient to direct a protein to
its appropriate organelle in a heterologous host, this study
attempted to examine whether trafficking complexes in the
cytosol of mammalian cells were able to also recognize the
parasite’s transit signals. Thus, we have adopted the eukaryotic
CHO-K1 cell line to synergistically provide interim yet valu-
able proof of biological principle.
In this study, we have located 10 predicted plasmodial pro-
teins to intracellular targets by using the predicted transit sig-
nals from each gene tagged to GFP and CHO-K1 cells as living
surrogate hosts. The 10 selected P. falciparum proteins com-
prised of four mitochondrial TCA cycle proteins, and two
each of nuclear, apicoplast, and cytosolic proteins. As a result,
it was established that the selected mTPs and NLSs were able
to direct the respective GFP fusion proteins to the appropriate
compartments in the eukaryotic cellular system. Not unexpect-
edly, the plasmodial apicoplast transit signals could not be
organelle-targeted because the resident host has no apicoplasts.
2. Materials and methods
2.1. Parasite cultivation for genomic DNA extraction
P. falciparum Tan strain from the National University Hos-
pital, Singapore was used in this study. The strain was cultured
in vitro using a mixture of treated human red blood cells and
serum according to the method of Trager and Jensen [18].
Genomic DNA was extracted from cell cultures exhibiting
about 10% parasitemia using the QIAamp DNA blood mini
kit (Qiagen) according to the manufacturer’s instructions.
2.2. Vector construction for eukaryotic host cell transfection
DNA fragments encoding 60 N-terminal amino acid residues
of P. falciparum citrate synthase (CS), isocitrate dehydrogenase
(ICDH), malate dehydrogenase (MDH), and glycerol kinase
(GK) were amplified from plasmids carrying cloned and veri-
fied copies of these genes [3,4]. The other DNA fragments
encoding 60 N-terminal amino acid residues of the E1α subunit
of the branched chain α-keto-acid dehydrogenase (BCKDH)
and the flavoprotein-subunit of succinate dehydrogenase
(SDH) were amplified from genomic DNA extracted from in
vitro cultures of P. falciparum. The DNA fragments encoding
the internal NLSs of histone deacetylase (HDAC) and RNA
polymerase (RPOL) were also amplified from the
P. falciparum genomic DNA. In addition, DNA fragments
Table 1
Primer pairs used for the PCR amplification of DNA encoding the amino acid sequences of the genes employed in this study. The CACC required for Gateway
directional cloning and the Kozak motifs are underlined and italicized, respectively. The accession numbers shown are based on PlasmoDB numbering
Gene/PlasmoDB ID Forward primer Reverse primer
CS/PF10_0218 5′ CACCATGGAAGGAATAAGATAC 3′ 5′ AAAATTAAAATATCGCTT 3′
ICDH/PF13_0242 5′ CACCATGGGAAAGCATATACGA 3′ 5′ GATTAATTTTTCTTTTAT 3′
BCKDH/PF13_0070 5′ CACCATGGGAAGAAATATTGTTCAGAAATAC 3′ 5′ GATTAATTTTTCTTTTAT 3′
SDH/PF10_0334 5′ CACCATGGGAATTAGGAATAATAAAAAATAC 3′ 5′ TGCTACCTTGTATTTATTTTT 3′
HDAC/PF14_0690 5′ CACCATGGGAAAAAAATGCAAAAAATGT 3′ 5′ CTTTTTACATTTTTTACA 3′
RPOL/PF14_0207 5′ CACCATGGGATATATTAGAAAAAAAAAA 3′ 5′ TTTTCCTTTTTTCTTCTT 3′
PK2/PF10_0363 5′ CACCATGGGAAATTTAATTCATATTTGT 3′ 5′ TTCAACAAAAGTATTATTATC 3′
GDH/PF14_0286 5′ CACCATGGGAATTTTGTATTCATGTGTT 3′ 5′ TCCACCCATTGGAAGTGT 3′
MDH/PFF0895w 5′ CACCATGGGAACTAAAATTGCCTTA 3′ 5′ ACCAAGAATGTTTCTATT 3′
GK/PF13_0269 5′ CACCATGGGAAATGTCATATTAAGTATA 3′ 5′ TTCATTCATTAAATTATA 3′
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encoding 187 N-terminal amino acid residues of pyruvate
kinase 2 (PK2) and glutamate dehydrogenase (GDH) were simi-
larly amplified from P. falciparum genomic DNA. The primer
pairs for each of the above 10 PCR amplification sets, and the
accession numbers for the genes investigated are indicated in
Table 1. The CACC signature sequence required for Gateway
directional cloning (Invitrogen, USA), and the Kozak motifs
were incorporated into the designed primers as recommended
in the manufacturer’s instruction. PCR was carried out using
pfu DNA polymerase (Stratagene, USA), and was performed
according to the following conditions: 94 °C for 1 min; 94 °C
for 0.5 min, 45 °C for 2 min, 68 °C for 3 min for 35 cycles;
68 °C for 10 min. The reactions were held at 4 °C after thermal
cycling. Thereafter, the amplified DNA products were direc-
tionally cloned into the Entry vector D-TOPO (Invitrogen,
USA), and recombined into the Destination vector pcDNA™-
DEST47 (Invitrogen, USA) using the Gateway rapid recombi-
nation technology according to the manufacturer’s protocol. A
collection of the clones obtained was fully sequenced to verify
in-frame insertion of the DNA sequences upstream of the C-
terminal-GFP ORF of pcDNA™-DEST47. DNA sequencing
was carried out using the ABI PRISM BigDye terminator
cycle sequencing kit (Applied Biosystems) and loaded onto an
ABI PRISM 377 DNA sequencer for sequence determination.
2.3. Microscopic evaluation of transfected cells
CHO-K1 cells were cultured in DMEM (Gibco, USA) sup-
plemented with 10% fetal calf serum (Gibco, USA) and with-
out antibiotics. The constructed plasmids were transfected into
CHO-K1 cells in 6-well plate formats at confluencies of 90–
95% using Lipofectamine2000 (Invitrogen, USA) as per man-
ufacturer’s instructions. Transfected cells were cultured in
OptiMEM (Gibco, USA) without serum and without antibiotics
for 48 hours, after which they were observed using a BX60
fluorescence microscope (Olympus, Japan) or FluorView
FV1000 confocal laser scanning microscope (Olympus,
Japan). Mitochondria staining of live cells was done using the
Mitotracker Red (Molecular Probes, USA) at a concentration
of 500 nM as per manufacturer’s instructions. Nuclear staining
was carried out using Hoechst 33342 (Invitrogen, USA) as the
cell-permeant nucleic acid stain.
2.4. Biocomputational analyses to predict subcellular
localization
Sequences for multiple alignment of plant, animal and fun-
gal mTPs were downloaded from SwissProt Sequence Retrie-
val System (website: http://tw.expasy.org/sprot/), using the
search string, “mitochondrion”, in the Feature Key field. Multi-
ple alignment analyses were carried out using ClustalW [19]. A
comparison of consulted mitochondrial localization predictions
in this study are listed in Table 2. Nuclear-targeting signals
were predicted using PredictNLS (website: http://cubic.bioc.
columbia.edu/predictNLS/) [20]. Apicoplast-targeting signals
were predicted using PATS [12] and PlasmoAP [11], both
available from the P. falciparum genome resource PlasmoDB
(website: http://www.plasmodb.org).
3. Results
3.1. Computational analyses of plasmodial mitochondria
transit peptides in comparison with eukaryotic sequences
To investigate the conservedness of Plasmodium mTPs
among mTPs from other eukaryotes, the N-terminal sequences
of the selected six plasmodial ORFs (CS, ICDH, BCKDH,
SDH, MDH, GK) were subjected to computation by the exist-
ing localization prediction programs for eukaryotes (TargetP,
iPSORT, WoLF-PSORT, MitoProt) and compared to analysis
by PlasMit, a prediction program specific for predicting
P. falciparum genes (Table 2). Only MitoProt and PlasMit pro-
vided consistent predictions for the six proteins studied.
Although MitoProt was able to predict the localization of
these six selected plasmodial proteins correctly, predictions
using a large dataset of known genes suggested that this pro-
gram lacks selectivity [6]. The differential predictions by the
other three programs (TargetP, iPSORT, WoLF PSORT), and
the known differences in the biochemical components of
malaria mTPs from other eukaryotic mTPs cast doubts on the
reliability of the available softwares for predicting plasmodial
mTPs.
It is known that in mTPs, the amino acid residues Arg, Ala,
and Ser are over-represented while negatively-charged amino
acid residues (Asp and Glu) are rare [21]. When the amino
acid compositions of the N-terminal regions of plasmodial
mitochondrial (CS, ICDH, BCKDH, SDH) and cytosolic
(MDH, GK) gene sequences were compared, it was apparent
that mitochondrial ones harbor 16–23% of Arg, Ala and Ser
amino acid residues while cytosolic ones have less (10–13%).
Similarly, mitochondrial ones harbor 0–3% of Asp and Glu
amino acid residues while cytosolic ones have 10–13%. This
could well be explained by a relatively positively-charged
function for mitochondrial-targeting. A multiple alignment
study was carried out using representative mTPs in comparison
Table 2
Comparison of mitochondrial localization prediction programs in the prognosis of cellular localizations of a selection of P. falciparum proteins
Prediction of locality for proteins in this study
Program used TargetP iPSORT WoLF PSORT MitoProt PlasMit
CS Cytoplasmic Non-mitochondrial Extracellular Mitochondrial Mitochondrial
ICDH Mitochondrial (low confidence) Mitochondrial Extracellular Mitochondrial Mitochondrial
BCKDH Mitochondrial Non-mitochondrial Cytoplasmic Mitochondrial Mitochondrial
SDH Mitochondrial Mitochondrial Mitochondrial Mitochondrial Mitochondrial
MDH Secretory pathway Non-mitochondrial Cytoplasmic Non-mitochondrial Non-mitochondrial
GK Cytoplasmic Non-mitochondrial Cytoplasmic Non-mitochondrial Non-mitochondrial
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with N-terminal 30 amino acid residues of P. falciparum CS,
ICDH, BCKDH, and SDH to investigate whether it was possi-
ble to group closely related genetic sequences to collective
clusters. The resultant multiple alignment and phylogenetic
tree obtained (not shown) indicated that the plasmodial mTPs
were not clustered in a group, consistent with the observation
that these mTPs do not possess a consensus sequence [21].
3.2. Targeting GFP fusion proteins to the mitochondrial
network of CHO-K1 using ICDH, CS, BCKDH, and SDH
N-terminal signals
Although computational analyses are useful, they are super-
ficial without experimental support. To provide further evi-
dence for the predicted locations of plasmodial proteins, we
have allowed GFP fusion proteins to dynamically locate them-
selves in a surrogate eukaryotic host. As indicated, plasmid
vectors were constructed to test for the ability of the N-
terminal signal peptides of CS, ICDH, BCKDH, and SDH to
deliver GFP to the mitochondrial network of CHO-K1 cells.
The N-terminal residues of the predicted cytosolic proteins,
MDH and GK, do not carry targeting signals, but were also
employed as controls to illustrate a cytoplasmic fluorescence
scenario. Although most known eukaryotic mTPs are about
20 amino acid residues in length, an extensive search of data
[6] has suggested that the mTPs of P. falciparum vary greatly
in length (from 23 to 169 amino acids). Hence, the vectors in
this study were constructed to express GFP fused to the N-
terminal 60 amino acid residues of CS, ICDH, BCKDH,
SDH, MDH and GK (designated as CS-GFP, ICDH-GFP,
BCKDH-GFP, SDH-GFP, MDH-GFP, and GK-GFP, respec-
tively). Fluorescence microscopic analysis of transfected cells
indicated that CS, ICDH, BCKDH and SDH mTPs can cor-
rectly target GFP to the mitochondria, as indicated by the
branched and tubular intracellular fluorescence pattern typical
for mitochondrial staining [22,23] (Fig. 1a–d). As expected, the
GFP fusions tagged with the N-terminal residues of cytoplas-
mic MDH and GK showed dispersed fluorescence consistent
with cytoplasmic localization (Fig. 1i–j).
The mitochondrial localization of CS-GFP, ICDH-GFP,
BCKDH-GFP and SDH-GFP were subsequently confirmed in
co-localization studies employing Mitotracker Red (Molecular
Probes, USA), a mitochondrial-specific probe. Furthermore,
confocal microscopy images (Fig. 2) clearly indicated co-
localization of CS-GFP, ICDH-GFP, BCKDH-GFP and SDH-
GFP with Mitotracker Red, confirming the mitochondrial loca-
lization of GFP tagged with CS, ICDH, BCKDH, and SDH
mTPs. In contrast, there was clearly no co-localization between
MDH-GFP or GK-GFP with the Mitotracker Red, thus con-
firming the cytoplasmic localization of MDH-GFP and GK-
GFP. Finally, vectors expressing CS-GFP, ICDH-GFP,
BCKDH-GFP, and SDH-GFP were co-transfected with another
vector, pDsRed2-Mito (Clontech, USA) which expresses a
mitochondrial-targeted red fluorescent marker protein. Consis-
tent with earlier observations, CS-GFP, ICDH-GFP, BCKDH-
GFP, and SDH-GFP clearly co-localized with the red fluores-
cent organelles exhibited by the mitochondrial marker protein
expressed from pDsRed2-Mito (Fig. 3), again confirming the
mitochondrial localization of CS-GFP, ICDH-GFP, BCKDH-
GFP and SDH-GFP.
3.3. Localization of the NLSs from HDAC and RPOL,
and the apicoplast-targeting signals from PK2 and GDH
The PredictNLS program predicted two NLSs each in
HDAC (residues 674–692 and 1619–1659) and RPOL (resi-
dues 27–33 and 27–69). Residues 1619–1659 of HDAC and
27–69 of RPOL were predicted with the highest accuracy
(i.e. with a score of 0% non-nuclear proteins in the database
possessing the signature). As such, these sequences were
selected for experimental analysis for nuclear trafficking func-
tions. PATS predicted both PK2 and GDH to encode
apicoplast-targeting signals with high scores of 0.89 and 0.85
(values close to 1 are apicoplast-targeted). Similarly, Plas-
moAP predicted both PK2 and GDH to be apicoplast-targeted
with the highest score (5 out of 5 score). As expected, Pre-
dictNLS, PATS, or PlasmoAP predictions using cytosolic pro-
teins such as MDH and GK were not predicted to carry any
reliable NLSs or apicoplast-targeting signals.
Transfection experiments using GFP-tagged NLSs from
HDAC and RPOL (HDAC-GFP and RPOL-GFP, respectively)
showed the expected nuclear localization for the GFP fusion
proteins (Fig. 1e–f). Co-localization studies using the cell-
permeant DNA dye Hoechst 33342 confirmed co-localization
of HDAC-GFP and RPOL-GFP with the cell nuclei (Fig. 4a,
b). As a negative control, cytosolic-staining exhibited by GK-
GFP did not co-localize with the nuclear-staining pattern pro-
duced by Hoechst 33342 (Fig. 4c). Finally, GFP tagged with
apicoplast-targeting signals from PK2 and GDH (PK2-GFP
and GDH-GFP) showed uniform fluorescence consistent with
cytosolic disposition (Fig. 1g–h). Hence, these experiments
indicated that plasmodial NLSs from HDAC and RPOL were
functionally conserved in these live cells. Likewise, repeated
experiments showed that the apicoplast-targeting signals were
not obviously functional in the CHO-K1 cells, as expected.
4. Discussion
The identification of the subcellular locations of proteins is
fundamental to the understanding of biosynthetic pathways
because the functions of proteins are defined in the context of
compartments that they are organized into. The primary aim of
this study was to explore the use of a live eukaryotic cellular
assay to localize organellar transit signals of plasmodial genes.
A comparison of the efficiencies of generic softwares for pre-
dicting eukaryotic mTPs with that of a Plasmodium-specific
software suggested that with the broad sequence divergence
of plasmodial mTPs, their signal peptide recognition should
be augmented by experimental investigations.
A search of current literature revealed that biochemical stu-
dies on malarial TCA cycle enzymes could not provide convin-
cing information concerning their subcellular characteristics.
For example, studies on an isocitrate dehydrogenase from the
simian malarial parasite Plasmodium knowlesi have led to the
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supposition that this enzyme is localized in the cytoplasm [24],
whereas paradoxically, parasite-specific isocitrate dehydrogen-
ase was not detectable in P. berghei [25]. Similarly, there is
very little information on the subcellular localization of plas-
modial malate dehydrogenase and succinate dehydrogenase,
except the conjecture that malate dehydrogenase appeared to
be cytoplasmic based on its biochemical properties [26]. In
this study, the plasmodial TCA cycle proteins CS, ICDH,
BCKDH and SDH were predicted to be mitochondrial and
this was supported by visualization of the mitochondrial-
targeting functions of their N-terminal signal peptides in
CHO-K1 cells. The PlasMit software predicted MDH and a
fumarase to be cytosolic, suggesting the loss of these enzymes
from the conventional mitochondria. This study corroborated
Fig. 1. Fluorescence microscope images of CHO-K1 cells transfected with vectors expressing (a) CS-GFP, (b) ICDH-GFP, (c) BCKDH-GFP, (d) SDH-GFP, (e)
HDAC-GFP, (f) RPOL-GFP, (g) PK2-GFP, (h) GDH-GFP, (i) MDH-GFP, (j) GK-GF.
Scale bar represents 20 μm.
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Fig. 2. Confocal laser scanning images of CHO-K1 cells transfected with vectors expressing (a) CS-GFP, (b) ICDH-GFP, (c) BCKDH-GFP, (d) SDH-GFP, (e)
MDH-GFP, and (f) GK-GFP, and subjected to in situ staining using Mitotracker Red. Scale bar represents 20 μm.









l   
co
py
the above prediction by providing experimental evidence for
the cytoplasmic localization of MDH. Hence, observations
from this study raised the interesting possibility that the TCA
cycle in the Plasmodium mitochondria is unusual with some
enzymic components of the cycle operating in the cytoplasm.
The study of the plasmodial mTPs, NLSs and apicoplast-
targeting signals supported the premise that authentic mTPs
and NLSs could be directly recognized by its locations in the
eukaryotic live cells. Hence, this approach will substantiate
computer predictions of localizations without the need for gen-
erating expensive specific antibodies or transgenic parasites.
This method might also be very useful for parasites for which
no reliable methods for in vitro culture and transfection are
available, such as Eimeria. Indirect evidence supports the
notion that the apicoplast-targeting signals cannot be recog-
nized or localized in CHO-K1 cells. This observation is inter-
esting, since the first part of the bipartite apicoplast-targeting
signal appeared to be a canonical signal sequence that was able
to direct GFP to the secretory pathway in P. falciparum [27]. It
is increasingly recognized that organisms may possess several
distinct modes of targeting which may be denoted by specific
signal sequences [28]. Hence, it is possible that there may be
Fig. 3. Fluorescence microscope images of CHO-K1 cells co-transfected with pDsRed2-Mito and vectors expressing (a) CS-GFP, (b) ICDH-GFP, (c) BCKDH-GFP,
(d) SDH-GFP. Scale bar represents 20 μm.
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differences in the targeting pathways between P. falciparum
and mammalian cells, and that the experimental system
described in this study might be useful for comparing the sort-
ing machinery of apicomplexans with that of mammalian cells.
Since efficient targeting to appropriate subcellular compart-
ments is one of the criteria for the production of correctly
folded recombinant proteins in surrogate hosts, the use of the
native plasmodial signal peptides may allow the expression of
functionally active heterologous proteins in eukaryotic sys-
tems. In this study, the correct targeting of the P. falciparum
mTPs and NLSs to the mitochondria and nuclei, respectively,
in CHO-K1 cells suggests that their corresponding mitochon-
drial and nuclear proteins are likely to fold and translocate cor-
rectly for potentially useful mammalian cell studies.
5. Conclusion
These results showed that the localizations of plasmodial
mitochondrial, nuclear, and cytosolic proteins could be evalu-
ated in an in vitro live-cell assay system. This experimental
system will serve as a useful a priori approach to authenticate
the pathophysiological roles of novel plasmodial proteins.
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Background: Global travellers are increasingly at risk of contracting malaria. The
increasing occurrence of drug-resistance in many endemic areas emphasizes the need
for novel drug targets for antimalarial-screening. In this study, the use of pyruvate kinase
as a drug-target is evaluated. The functional validation of a gene encoding pyruvate kinase
(designated PK1) has previously been reported. However, alternative copies of this enzyme
encoded by Plasmodium falciparum could also circumvent the role of PK1. A survey of
genome data revealed a putative ORF seemingly coding for another pyruvate kinase
(designated PK2).
Methods: The expression of PK1 and PK2 in in vitro cultures were investigated by RT-PCR.
Biocomputational analysis was carried out to identify structural differences between the P.
falciparum pyruvate kinases and the corresponding enzymes from its human host.
Results: Both PK1 and PK2 were indeed actively transcribed during the intraerythrocytic
stages, suggesting the involvement of both enzymes during infection. A comparison of
amino acid residues at the effector binding sites of PK1 and PK2, to those of the human
pyruvate kinases revealed some significant differences that could serve as targets for
selective inhibitors to be designed against parasitic pyruvate kinases.
Conclusion: Experimental evidence for the expression of both PK1 and PK2 during the
blood stages of malaria infection was provided. Interestingly, phylogenetic analysis
revealed that the ‘‘PK2’’ type of enzyme appears to be confined to Apicomplexans, an
important observation with respect to the assessment of PK2 as a drug-target.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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sg (T.S. Sim).Introduction
Malaria is a life-threatening tropical disease that causes
1.5–2.7 million deaths annually.1 Malaria exists in over 100




























Figure 1 Comparison of transcription profiles of PK1 and PK2
based on existing transcriptomic data.20 The profile of PK2
appears to follow those of apicoplast lipid synthesis genes. In
contrast, PK1 levels appear to be consistently high throughout
the erythrocytic-stage. Abbreviations: PyDH, pyruvate dehy-
drogenase; ACP, acyl carrier protein; syn, synthase.
M. Chan et al.126international travellers every year.2 Each year, up to 30 000
international travellers may have fallen ill with malaria
while visiting countries where the disease is endemic.2
International travellers are at high malaria risk because they
are non-immune and often exposed to late or wrong malaria
diagnosis when returning to their home country. The
problem is aggravated by increasing drug-resistance in many
areas in Asia, South America and now Africa.3 As a result,
antimalarial drugs are failing at an accelerating rate in most
malaria endemic regions, with consequent increases in
malaria-related morbidity and mortality.4 Cross-resistance
between current drugs has been observed, indicating that
they lack chemical diversity.5 Clearly, new drugs based on
novel targets, not encumbered by existing mechanisms of
resistance, are desperately needed.
The glycolytic pathway is a vital pathway that may be a
novel target. Typically, it has 11 enzymes to convert glucose
to lactic acid, three of which are considered to be rate-
limiting: hexokinase, phosphofructokinase, and pyruvate
kinase. When cellular levels of ATP generated through
glycolysis are high, ATP may inhibit these enzymes. Rate-
limiting enzymes are good enzyme targets to inhibit the
vitally important glycolytic pathway. The current status of
these key glycolytic enzymes in Plasmodium and other
protozoan parasites is shown in Table 1. In particular,
pyruvate kinase has been cloned and characterized in
Trypanosoma brucei, Toxoplasma gondii, and Leishmania
mexicana.6–8 In these organisms, pyruvate kinase is highly
regulated by effectors such as fructose-2,6-phosphate and
glucose-6-phosphate, indicating that this enzyme may play
important regulatory roles in glycolysis in these parasites. As
a result, our laboratory has previously cloned and char-
acterized pyruvate kinase (PK1) from Plasmodium falcipar-
um. This enzyme appears to be increased drastically (411-
fold) upon infection.9 Also, recent studies have indicated
that pyruvate kinase of parasite origin may contribute to
osmotic fragility of host cells and hypoxia during malaria.10Table 1 Summary of current status of research on genes
phosphofructokinase, and pyruvate kinase in P. falciparum, othe
P. falciparum Ot




























Accession numbers stated are based on PlasmoDB.These observations indicate that P. falciparum pyruvate
kinase may play a central role in malarial infection.
Further studies to investigate the usefulness of pyruvate
kinase as a drug-target must take into account presence of
alternative copies of enzymes that may circumvent theencoding the three key glycolytic enzymes hexokinase,
r Plasmodium spp., and other protozoan parasites.
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Antimalarial drug-screening 127target. An inspection of the genome data of P. falciparum
showed that there might be a putative ORF that may encode
another pyruvate kinase (designated PK2). Investigations on
the expression of both PK1 and PK2 during infection, as well
as their structural comparison, are important criteria in the
employment of pyruvate kinase as a drug-target. Hence, in
this study, we set out to investigate the active transcription
of PK1 and PK2 in the intraerythrocytic stages in in vitro
cultures. The diversity of both genes between Plasmodium
and the human host were investigated via phylogenetic
analysis. Ideally, enzymes identified as drug targets should
differ significantly from any analogous process in the host.
Hence, structural analysis was carried out to identify
structural differences between the P. falciparum pyruvate
kinases and the corresponding enzyme from its human host.
Materials and methods
Cultivation conditions and RT-PCR
The source of P. falciparum Tan strain was from the National
University Hospital (Singapore). The parasites were cultured










Figure 2 RT-PCR amplification of cDNA encoding PK1 and PK2.
The positive bands representing PK1 and PK2 cDNA are indicated
by an arrow. Lane 1, amplification of PK2; lane 2, amplification
of PK1; lane 3, DNA molecular weight marker; lanes 4 and 5,
negative controls for PK1 and PK2 cDNA amplification (no
reverse transcriptase).
Figure 3 Comparison of the conserved domains of PK1 and PK2. PK
appears to contain a large unknown domain.according to the method of Trager and Jensen.11 Total P.
falciparum RNA was extracted from a population of
parasites exhibiting mixed-stages (ring, trophozoite and
schizont forms) using Rneasy Mini kit (Qiagen) according to
manufacturer’s instructions. The mRNA used in RT-PCR was
purified from total parasite RNA using the Oligotex Mini kit
(Qiagen), which employs an oligo-dT matrix principle of
purification. RT-PCR was performed using Sensiscript two-
step RT-PCR (Qiagen) and a RT step at 37 1C for 1 h, followed
by a PCR step using pfu polymerase (Stratagene) and
standard thermal cycling conditions. The forward and
reverse primers for RT-PCR contain the sequences 50
AGATCTATGAGTTCATTTAAGTACAAA 30 and 50 CCTAGGAATAA-
CAGCTGAATTTAATAC 30 (for PK1), and 50 AGATCTATGAATT-
TAATTCATATTTGT 30 and 50 CCTAGGTTCAACAAAAGTA-
TTATTATC 30 (for PK2), respectively.DNA purification and automated DNA sequencing
The amplified gene products were excised from agarose gels
and purified using MinElute gel extraction kit (Qiagen)
according to manufacturer’s instructions. The purified gene
products were then subjected to agarose gel electrophoresis
using 0.8% agarose gels. Amplified DNA fragments were
sequenced using the ABI PRISM BigDye terminator cycle
sequencing kit (Applied Biosystems) and loaded onto an ABI
PRISM 377 DNA sequencer for sequence determination.Biocomputational analysis and phylogenetic
constructions
Multiple sequence alignment and phylogenetic tree con-
struction were performed using the Clustal X program12 and
viewed with Boxshade (Bioinformatics Group, ISREC). Trees
were visualized using the Treeview program (University of
Glasgow). Molecular mass calculation was performed using
the Compute Mw Tool of the Expasy website (www.expa-
sy.org.ch). Apicoplast targeting signals were predicted using
the PATS13 and PlasmoAP14 available at the Plasmodium
Genome Resource PlasmoDB (www.plasmodb.org). Meta-
bolic pathway predictions were carried out using the MR4-
ATCC website: http://malaria.atcc.org/metabolic_path-
ways/index.html (complied and maintained by Hagai Gins-
burg).2 might possess a N-terminal apicoplast targeting sequence and
ARTICLE IN PRESS
Figure 4 Amino-acid sequence alignment of P. falciparum PK1 and PK2 with pyruvate kinases from other species. Accession numbers
are: PK1, P. falciparum (this study; MAL6P1.160); Pyoelii, P. yoelii (EAA16536); Tgondii, Toxoplasma gondii (BAB47171); Etenella, E.
tenella (AF043910); Lmexicana, L. mexicana (X74944); rabbit, rabbit muscle pyruvate kinase (15987970); humanM1, human muscle
isozyme 1 (S64635); humanM2, human muscle isozyme 2 (O18919). PK2, P. falciparum (this study; PF10_0363); Pberghei2, P. berghei
(XP_680419); Pyoelii2, P. yoelii (XP_724095). The 3D-domains (N/A/B/C) are indicated by vertical lines. The pyruvate kinase
signature is underlined. Open circles indicate ADP binding sites. The binding sites of the sugar, 1-phosphate, and 6-phosphate
moieties of F16BP are indicated by closed circles, open squares, and closed squares, respectively. Asterisks and triangles indicate the
PEP and divalent-cation binding-sites, respectively.
M. Chan et al.128
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Antimalarial drug-screening 129Results and discussion
Both PK1 and PK2 are actively transcribed in the
intraerythrocytic stages
There is existing mass spectrometry-based evidence for the
expression of PK1 in the intraerythrocytic stages (Plasmo-
dium Genome Resource PlasmoDB; website: www.plasmod-
b.org). There is comparatively less supporting evidence for
the expression of PK2, with only one peptide fragment
detected by mass spectrometry in the trophozoite stage
(PlasmoDB). Microarray data indicated that both PK1 and
PK2 are transcribed, although PK1 appears to possess higher
transcription levels (Fig. 1). To investigate the expression of
PK1 and PK2, primers specific for PK1 or PK2 were
constructed to amplify a 540bp cDNA fragment encoding
PK1 or PK2 by RT-PCR using purified mRNA extracted from P.
falciparum in vitro cultures. Results indicated that both PK1
and PK2 were indeed actively transcribed (Fig. 2). As
expected, no bands were observed from negative controls
in which reverse transcriptase were omitted, indicating that
positive bands were indeed amplified from cDNA and not dueFigure 5 Phylogenetic analysis of PK1 and PK2. PK2 exh
Table 2 Significant primary structural differences
between PK1, PK2, and human pyruvate kinases at their
effector binding sites.
Binding site Human PK1 PK2
6-Phosphate
419 ser thr glu
421 arg tyr asn
Sugar
461 trp ser Absent
1-Phosphate
469 val ile ileto genomic DNA contamination. The positive bands corre-
sponding to amplified PK1 and PK2 cDNA were then purified;
their identities were confirmed by DNA sequencing. Hence,
RT-PCR results were consistent with microarray and mass
spectrometry data, indicating that both PK1 and PK2 were
indeed expressed during the intraerythrocytic stages.Structural comparison between PK1 and PK2
The 1536 bp cDNA of P. falciparum PK1 encodes a protein of
511aa, with a computed molecular mass of 55.6 kDa. The
gene for PK2 is 2.1 kb and encodes a protein of 745aa with a
computed molecular mass of 86.6 kDa. Hence, PK2 appears
to be a larger protein compared to PK1. In addition, there is
an approximately 130aa N-terminal extension that is
predicted to be an apicoplast targeting signal by soft-
ware for apicoplast targeting signals, PATS13 and PlasmoAP14
(Fig. 3). PK1 does not appear to carry any targeting
sequence and is therefore predicted to be cytosolic.
In terms of amino acid sequence diversity, PK1 is closest
to P. yoelii pyruvate kinase (90.8% identity). Contrastingly,
the identity between PK1 and PK2 is only 20.0%. In addition,
although the conserved domain for pyruvate kinase (pfam
id: cd00288) is detected in both PK1 and PK2, the latter
appears to contain a large unknown domain inserted within
the pyruvate kinase conserved signature (Fig. 3). Multiple-
alignment of PK1 and PK2 with known pyruvate kinases
showed that the binding sites for ADP, PEP, and divalent
cation were well conserved in the human pyruvate kinases,
PK1, and PK2, despite the low identities between PK2 and
PK1 (20.0% identity), or between PK2 and the human
pyruvate kinases (19.7% identities) (Fig. 4). Moreover, the
secondary structural identity between PK1 and PK2 is
approximately 70%.
Finally, molecular investigations to elucidate the binding
sites for effectors may be relevant to design of molecules
that would inhibit the parasite’s enzymes. A comparison of
amino acid residues at these binding sites reveal someibits low homologies to most other pyruvate kinases.
ARTICLE IN PRESS
Figure 6 Possible involvement of PK1 and PK2 in predicted lipid and glycolytic metabolic pathways of P. falciparum. The maps were
predicted based on the present knowledge of parasite biochemistry and on pathways known to occur in other unicellular eukaryotes.
Not all reactions illustrated have been conclusively shown to operate in Plasmodium spp.
M. Chan et al.130significant differences, as listed in Table 2. These differ-
ences may account for the distinction in response to
effectors by PK1, PK2, and human pyruvate kinases. In
pyruvate kinases, the lysine at position 418 (PK1 numbering)
is thought to be involved in binding the 6-phosphate moiety
of fructose-1,6-bisphosphate. Consistent with non-allosteric
enzymes, PK1 is not activated by fructose-1,6-bispho-
sphate15 and has a glutamate at residue 418. In contrast,
asparagines are observed at position 418 in pyruvate kinases
activated by fructose-2,6-bisphosphate, such as L. mexicana
pyruvate kinase. Intriguingly, PK2 has an asparagine at this
position, suggesting that it may respond to fructose-2,6-
bisphosphate. The physiological significance of this observa-
tion deserves further experimental investigation. In addi-
tion, some deletions in an effector binding site in the C
domain which are unique to pyruvate kinases from P.
falciparum, P. yoelii, Toxoplasma gondii, and Eimeria
tenella, were observed (Fig. 4). This site could also be a
target for selective inhibitors to be designed or for new
drugs that act against parasitic pyruvate kinases.PK2 appears to be confined to Apicomplexans;
there may be independent roles for pyruvate kinase
in cytoplasm and apicoplast
Pyruvate kinase is found in all living organisms. In
vertebrates, there are four tissue-specific isozymes: L
(liver), R (red cells), M1 (muscle, heart and brain), and M2
(early foetal tissue). In plants, pyruvate kinase exists as
cytoplasmic and plastid isozymes. Interestingly, while most
bacteria and lower eukaryotes have one form, P. falciparum
appears to have two non-identical isozymes, PK1 and PK2.
Phylogenetic analysis showed a wide divergence between
PK1, PK2 and the human isozymes (Fig. 5). This data,
together with the observation of a low sequence identity
between these genes, support the use of this enzyme as adrug-target. Interestingly, Genbank search revealed that the
‘‘PK2’’ type of enzyme appears to be confined to Apicom-
plexans. In addition, two of the ‘‘PK2’’-type of pyruvate
kinase from the Apicomplexans P. berghei and Theileria
parva also appeared to carry apicoplast targeting signals,
suggesting that this type of pyruvate kinase may be involved
in apicoplast-specific functions. Based on metabolic path-
way predictions using the MR4-ATCC website: http://
malaria.atcc.org/metabolic_pathways/index.html (com-
plied and maintained by Hagai Ginsburg), it is possible that
PK1 might be involved in glycolytic processes and pyruvate
metabolism while PK2 may be involved in lipid metabolism
(Fig. 6). Transcription data appear to support this possibility,
in that the transcription profile of PK2 seems to resemble
those of apicoplast lipid synthesis genes (Fig. 1).
In conclusion, this study provided experimental evidence
for the expression of both PK1 and PK2 during the blood
stages of the malaria infection cycle. Biocomputational
characterization of both PK1 and PK2 provided specific sites
that may be employed in drug design. The uniqueness of PK2
among pyruvate kinases was demonstrated, an important
information supporting the use of PK2 as a drug-target. The
soluble expression and functional validation of PK1 has been
previously reported15. Soluble expression, and functional
validation of PK2 would then facilitate the use of both PK1
and PK2 in drug-screening.
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BBRCFunctional analysis, overexpression, and kinetic characterization
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Received 29 October 2004Abstract
The important role of pyruvate kinase during malarial infection has prompted the cloning of a cDNA encoding Plasmodium fal-
ciparum pyruvate kinase (pfPyrK), using mRNA from intraerythrocytic-stage malaria parasites. The full-length cDNA encodes a
protein with a computed molecular weight of 55.6 kDa and an isoelectric point of 7.5. The puriﬁed recombinant pfPyrK is enzy-
matically active and exists as a homotetramer in its active form. The enzyme exhibits hyperbolic kinetics with respect to phospho-
enolpyruvate and ADP, with Km of 0.19 and 0.12 mM, respectively. pfPyrK is not aﬀected by fructose-1,6-bisphosphate, a general
activating factor of pyruvate kinase for most species. Glucose-6-phosphate, an activator of the Toxoplasma gondii enzyme, does not
aﬀect pfPyrK activity. Similar to rabbit pyruvate kinase, pfPyrK is susceptible to inactivation by 1 mM pyridoxal-5 0-phosphate, but
to a lesser extent. A screen for inhibitors to pfPyrK revealed that it is markedly inhibited by ATP and citrate. Detailed kinetic anal-
ysis revealed a transition from hyperbolic to sigmoidal kinetics for PEP in the presence of citrate, as well as competitive inhibitory
behavior for ATP with respect to PEP. Citrate exhibits non-competitive inhibition with respect to ADP with a Ki of 0.8 mM. In
conclusion, P. falciparum expresses an active pyruvate kinase during the intraerythrocytic-stage of its developmental cycle that
may play important metabolic roles during infection.
 2004 Elsevier Inc. All rights reserved.
Keywords: Malaria; Plasmodium falciparum; Glycolysis; Citrate; Pyruvate kinase; cDNA cloningGlycolysis has been recognized as a promising target
for new drugs against Plasmodium falciparum, because
the intraerythrocytic life-cycle of the parasite is highly
dependent on glucose for energy [1]. During infection,
the parasite utilizes as much as 100 times more glucose
than uninfected erythrocytes [2], resulting in the forma-
tion of mainly lactate [3]. The levels of several glycolytic
enzymes in infected cells are drastically elevated [2], as a
result of increase in enzymes which are of parasitic ori-
gin [2]. Initial characterization of some glycolytic en-
zymes of P. falciparum have suggested that they may
diﬀer biochemically and structurally from their host0006-291X/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2004.11.018
q Abbreviations: pfPyrK, Plasmodium falciparum pyruvate kinase;
PEP, phosphoenolpyruvate; PLP, pyridoxal-5 0-phosphate.
* Corresponding author. Fax: +65 6776 6872.
E-mail address: micsimts@nus.edu.sg (T.-S. Sim).counterparts [3]. For example, P. falciparum lactate
dehydrogenase has been characterized in detail [4], and
selective inhibitors against the enzyme have demon-
strated in vitro antimalarial activities [5]. A functional
P. falciparum malate dehydrogenase possessing a poten-
tial site for speciﬁc inhibitor design has also been re-
ported [6]. Hexokinase, phosphofructokinase, and
pyruvate kinase are important regulatory enzymes in
the glycolytic pathway. In many protozoan parasites
(Trypanosoma brucei, Toxoplasma gondii, and Leish-
mania mexicana), pyruvate kinase is highly regulated
[7–9], suggesting that this enzyme may play important
regulatory roles in glycolysis in these parasites. In P. fal-
ciparum, pyruvate kinase activity is detectable in the
parasites intraerythrocytic-stages [2]. Importantly, the
enzyme appears to be increased drastically (>11-fold)
upon infection [2]. Furthermore, recent studies have
M. Chan, T.-S. Sim / Biochemical and Biophysical Research Communications 326 (2004) 188–196 189indicated that pyruvate kinase of parasite origin may
play a role in decreasing the levels of 2,3-diphosphogly-
cerate in red blood cells [10], thereby contributing to os-
motic fragility of host cells and hypoxia during malaria
[10]. These observations indicate that P. falciparum
pyruvate kinase may play a central role in malarial
infection and deserves further detailed study.
Pyruvate kinase (EC 2.7.1.40) catalyzes the irrevers-
ible substrate level phosphorylation of ADP at the ex-
pense of phosphoenolpyruvate (PEP), yielding pyruvate
and ATP. Almost all pyruvate kinases are homotetra-
meric enzymes. Among protozoans, the pyruvate kinases
from T. brucei, T. gondii, L. mexicana, and Entamoeba
histolytica have been characterized in detail [7–9,11].
Although pyruvate kinases of most species are activated
by fructose-1,6-bisphosphate (F16BP), the T. gondii en-
zyme is insensitive to F16BP but markedly activated by
glucose-6-phosphate (G6P) instead. The kinetics of L.
mexicana and T. brucei pyruvate kinases are quite simi-
lar, both being activated predominantly by F26BP. E.
histolytica pyruvate kinase is activated by F16BP but
inhibited by citrate, malate, phosphate, and a-ketoglu-
tarate. Although pyruvate kinase activity has been iden-
tiﬁed in P. falciparum [2,12] and Plasmodium berghei [13]
infected red cells, little is known about their characteris-
tics. We hence started our experiments by obtaining the
cDNA of a predicted pyruvate kinase gene in the P. fal-
ciparum genome and determining whether the predicted
gene encodes a functional pyruvate kinase enzyme. In
this paper, the molecular cloning of a cDNA encoding
P. falciparum pyruvate kinase (pfPyrK), overexpression
of the active recombinant enzyme in Escherichia coli,
and the detailed kinetic properties of the enzyme are
reported.Materials and methods
Cultivation conditions, RT-PCR, and cDNA cloning. The source of
P. falciparum Tan strain was from the National University Hospital
(Singapore). The parasites were cultured in vitro using treated human
red blood cells and serum according to the method of Trager and
Jensen [14]. Total P. falciparum RNA was extracted from a population
of parasites exhibiting mixed-stages (ring, trophozoite, and schizont
forms) using Rneasy Mini kit (Qiagen) according to manufacturers
instructions. The mRNA used in RT-PCR was puriﬁed from total
parasite RNA using the Oligotex Mini kit (Qiagen) which employs an
oligo(dT) matrix principle of puriﬁcation. RT-PCR was performed
using Sensiscript two-step RT-PCR (Qiagen) and a RT step at 37 C
for 1 h, followed by a PCR step using pfu polymerase (Strategene) and
standard thermal cycling conditions. The forward and reverse primers
for PCR contain the sequences 5 0aaggatccagttcatttaagtacaaac3 0 and
5 0ttgtcgacttattcaatttgtacaa3 0, respectively. The EcoRI and SalI
restriction sites incorporated are underlined. The ampliﬁed gene
products were subjected to agarose gel electrophoresis using 0.8%
agarose gels.
Cloning and heterologous expression. The target DNA was cloned
into pCR-BluntII-TOPO (Invitrogen) according to manufacturers
instructions. DNA inserts in positive recombinant clones obtained
were sequenced using the ABI PRISM BigDye terminator cyclesequencing kit (Applied Biosystems) and loaded onto an ABI PRISM
377 DNA sequencer for sequence determination. Finally, the target
genes were excised from the cloning vector by appropriate double-
digestion and subcloned into pGEX-6P1 for expression as a glutathi-
one-S-transferase (GST)-tagged fusion protein. Cells for expression
analysis were harvested after overnight induction of expression at
25 C with 1 mM IPTG. Total protein was obtained by sonication
using a Soniprep (Sanyo) sonicator set at an amplitude of 18 lm.
Recombinant GST-fusion protein was puriﬁed by column glutathione
elution method using the GST Puriﬁcation Module (Amersham)
according to manufacturers instructions. SDS–PAGE was performed
using a Hoefer Mighty Small (Amersham) electrophoresis system.
Biochemical and kinetic assays. The enzyme assay for pyruvate ki-
nase was based on the formation of NAD in the presence of lactate
dehydrogenase in an indirect assay [15]. The standard enzyme assay
was adapted for kinetic measurement using a monochromator-based
spectrophotometric plate-reader (Saﬁre, Tecan Instruments, Austria).
Two hundred microliters of the standard assay mixture contained
10 mM Hepes buﬀer, pH 7.5, 10 mM MgCl2 (Merck), 50 mM KCl
(Merck), 0.5 mM NADH, 1 mM PEP, and 1 mM ADP and 22 U
lactate dehydrogenase. Each assay was carried out with a ﬁnal con-
centration of 1.5 ng of enzyme/ml of assay mixture. Kinetic parameters
for PEP under saturating conditions for ADP (3 mM) were carried out
using PEP concentrations ranging from 0.1 to 2 mM. Those for ADP
were carried out using ADP concentrations ranging from 0.1 to 2 mM
ADP in the presence of 7 mM PEP (saturation). The reaction was
started by the addition of pure enzyme and monitored at a wavelength
of 340 nm at room temperature (26 C) for up to 4 min. Enzyme
activity was calculated by measurement of slope (A340/min) under
lineal time conditions. One unit (U) of pyruvate kinase activity is de-
ﬁned as the amount of enzyme required to produce 1 lmol of pyruvate
from PEP in 1 min. Protein was quantiﬁed using Bradford assay re-
agent (Bio-Rad) according to manufacturers instructions. Analytical
gel ﬁltration was carried out using a Superdex 200 HR 10/30 column
run on the AKTA Puriﬁer liquid chromatography system (Amersham
Biosciences).Results
cDNA cloning and sequence analysis of P. falciparum
pyruvate kinase
As the putative P. falciparum pyruvate kinase gene
deposited in the P. falciparum genome resource (Plas-
moDB) [16] was predicted to contain two introns, the
cDNA encoding pfPyrK was cloned by RT-PCR using
mRNA puriﬁed from an in vitro culture (Fig. 1). Full
DNA sequencing of the cDNA demonstrated a
1536 bp ORF encoding pfPyrK and conﬁrmed the ab-
sence of introns in the cloned cDNA. The obtained
pfPyrK ORF is identical in DNA sequence to that of
strain 3D7 deposited in the PlasmoDB (Accession No.
MAL6P1.160). BLAST analysis of the pfPyrK DNA se-
quence against P. falciparum genome sequence indicated
that the pyruvate kinase gene exists as a single copy in
P. falciparum. The ORF encodes a protein with a com-
puted molecular mass of 55.6 kDa and an isoelectric
point of 7.5, similar to those from other parasites such
as L. mexicana (molecular mass of 54.3 kDa and isoelec-
tric point of 6.5), and T. gondii (molecular mass of
57.5 kDa).
Fig. 1. RT-PCR ampliﬁcation of cDNA encoding pfPyrK (A) and
SDS-PAGE analysis of puriﬁed recombinant pfPyrK (B). The positive
bands representing pfPyrK cDNA and protein are indicated by
arrows.
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highest identity to pyruvate kinase of Plasmodium yoelii
(88%) followed by that of T. gondii (64%). Interestingly,
pfPyrK is almost as distant from human pyruvate ki-
nases (42%) as from plant pyruvate kinases (46–47%).
There are four domains in pyruvate kinase: N (a vari-
able N-terminus), A, B, and C [17]. The active site is lo-
cated in the A and B domains, whereas the C domain,
and a cleft between the A and C domains, appear to
contain the binding sites for eﬀectors [17]. Multiple-
alignment of amino acid sequences of protozoan pyru-
vate kinases with those of rabbit and human enzymes
(Fig. 2) revealed that known binding sites for ADP,
PEP, and cation, located in N, A, and B domains, are
well conserved (76–100%); whereas sites for eﬀector
binding, located in domain C, are not conserved. In this
dataset, the A domain is signiﬁcantly more well con-
served (43%) than the B and C domains (17% and 9%,
respectively). This observation is in agreement with that
on pyruvate kinases from a wide variety of organisms
[18]. Phylogenetic analysis showed a wide divergence be-
tween pfPyrK and the isozymes in human (Fig. 3).
These data, together with the observation of a low se-
quence identity between these genes, support the use
of this enzyme as a drug target. In addition, some dele-
tions in an eﬀector binding site in the C domain which
are unique to pyruvate kinases from P. falciparum, P.
yoelii, T. gondii, and Eimeria tenella were observed
(Fig. 2). This site could be a target for selective inhibi-
tors to be designed or for new drugs that act against par-
asitic pyruvate kinases.
Kinetic characteristics of overexpressed pfPyrK
pfPyrK is expressed at high levels in E. coli as a GST-
tagged protein. SDS–PAGE analysis of pfPyrK puriﬁed
by aﬃnity chromatography from lysates of E. coli
expressing the recombinant protein showed that the
molecular weight of the expressed protein is approxi-
mately 80 kDa (Fig. 1), in good agreement with theexpected molecular weight for pfPyrK incorporated
with a 26 kDa GST moiety. The puriﬁed pfPyrK is
enzymatically active, indicating that the ORF encodes
an authentic pyruvate kinase. As expected, no absor-
bance change was detectable from negative controls
comprising of GST expressed from non-insert vector.
Control assays in which one or the other co-substrate
was omitted conﬁrmed that there are no contaminating
NADH consuming activities in the enzyme prepara-
tions. No net absorbance change was detected in these
negative controls (<0.00 A340 nm/min). In order to
determine the oligomerization state of pfPyrK, the puri-
ﬁed enzyme was subjected to analytical gel ﬁltration.
The recombinant pfPyrK eluted from the column with
an apparent molecular weight of approximately
316 kDa, as estimated using standard proteins of known
molecular weights (Fig. 4). These data suggest that re-
combinant pfPyrK exists as a homotetramer. As ex-
pected, SDS–PAGE analysis of the eluted fractions
containing pfPyrK recovered a single polypeptide with
the expected molecular weight for pfPyrK. The eluted
fractions corresponding to the tetrameric form of
pfPyrK are enzymatically active (Fig. 4). Hence, like al-
most all pyruvate kinases from other organisms includ-
ing those from T. gondii and T. brucei, active pfPyrK
exists as a homotetramer. The speciﬁc activity of pfPyrK
was 126 ± 4 U/mg protein at room temperature (26 C)
under optimal substrate concentrations in the presence
of magnesium as the divalent cation. In terms of yield,
0.45–0.6 mg of recombinant pfPyrK could be reproduc-
ibly obtained from each fermentation batch comprising
of 50 ml of E. coli culture. In separate experiments, enzy-
matic analysis of recombinant pfPyrK after proteolytic
removal of the GST aﬃnity-tag indicated that untagged
pfPyrK is also enzymatically active with comparable
speciﬁc activity (not shown). Hence, the presence of
the GST-tag does not seem to inﬂuence the enzymatic
activity or the quaternary conﬁguration of the enzyme.
However, because the recovery of pure untagged pro-
teins after proteolytic cleavage was typically low, pure
GST-tagged pfPyrK enzyme was used for further bio-
chemical analyses.
The kinetic behaviors of pfPyrK for PEP and ADP
were investigated (Fig. 5) and the obtained parameters
are summarized in Table 1. Among protist pyruvate ki-
nases, L. mexicana exhibits sigmoidal kinetics for both
substrates [9], while for T. gondii kinetic behavior is sig-
moidal for PEP but hyperbolic for ADP [7]. In terms of
kinetics, pfPyrK resembles E. histolytica pyruvate ki-
nase in that it exhibits hyperbolic kinetics with respect
to both substrates under saturating conditions [11].
Although F16BP is an activator for many pyruvate ki-
nases including those of E. histolytica, T. gondii pyru-
vate kinase is not sensitive to F16BP but instead is
activated by G6P. In the case of T. gondii pyruvate
kinase, the presence of G6P (1 mM) led to 16-fold
Fig. 2. Amino acid sequence alignment of P. falciparum PyrK with pyruvate kinases from other species. Accession Nos. are: pfPyrK, P. falciparum
(this study; MAL6P1.160); Pyoelii, P. yoelii (EAA16536); Tgondii, T. gondii (BAB47171); Etenella, E. tenella (AF043910); Tbrucei, T. brucei
(X17618); Lmexicana, L. mexicana (X74944); rabbit, rabbit muscle pyruvate kinase (15987970); humanM1, human muscle isozyme 1 (S64635); and
humanM2, human muscle isozyme 2 (O18919). The 3D-domains (N/A/B/C) are indicated by vertical lines. A box indicates pyruvate kinase signature
sequences. Open circles indicate ADP binding sites. The binding sites of the sugar, 1-phosphate, and 6-phosphate moieties of F16BP are indicated by
closed circles, open squares, and closed squares, respectively. Asterisks and triangles indicate the PEP and divalent-cation binding-sites, respectively.
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tions [7]. Interestingly, pfPyrK did not respond signiﬁ-
cantly to either F16BP (1 mM) or G6P (1 mM) over awide range of PEP and ADP concentrations, under both
saturating as well as non-saturating conditions (Figs. 5A
and C; Table 1). Pyridoxal-5 0-phosphate (PLP) is a
Fig. 3. Phylogenetic (neighbor-joining) tree constructed using pyruvate kinase amino acid sequences. The accession numbers, in addition to those
indicated in Fig. 2, are as follows: soybean (AAM94349), rice (CAE05765), tobacco (CAA82628), zebraﬁsh (NP_955365), Caenorhabditis elegans
(CAA93424), Anopheles gambiae (EAA10555), frog (AAH44007), rat (NP_445749), Clostridium tetani (NP_783015), and Thermoanaerobacter
tengcongensis (NP_623403).
Fig. 4. Determination of oligomerization state of pfPyrK by gel
ﬁltration. Enzyme activity of eluted fractions (j) corresponds to
elution of pfPyrK as a tetramer. Inset: calibration curve for
determining the oligomerization state of recombinant PyrK. The
column is calibrated using protein standards: (a) aldolase, (b) catalase,
(c) ferritin, and (d) thyroglobulin. Elution fractions indicated were
analyzed by SDS–PAGE electrophoresis and the results conﬁrm the
presence of pfPyrK in the enzymatically active fraction. M, molecular
weight marker.
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In an earlier study on rabbit muscle pyruvate kinase,
treatment by PLP inactivates the enzyme by 90%. In or-
der to assess the sensitivity of pfPyrK to inactivation by
PLP, enzyme inactivation study was carried out together
with rabbit muscle pyruvate kinase for comparison. For
these experiments, the test enzymes were incubated with
PLP at the indicated concentrations (Fig. 5F) for 15 min
before they were employed in the enzyme assays. It was
observed that pfPyrK was also sensitive to PLP. How-
ever, as compared to rabbit muscle pyruvate kinase,which could be inactivated up to 75% in this study,
pfPyrK was less disposed to inactivation, being inacti-
vated up to 22% maximally.
As there are almost no known inhibitors for pfPyrK,
the eﬀect of a wide array of metabolites was screened for
their eﬀect on pfPyrK activity (Fig. 6). Interestingly,
among the compounds tested, 2 mM citrate was found
to inhibit pfPyrK markedly (>97%) in a standard en-
zyme assay. The inhibition appears to be speciﬁc to cit-
rate, and does not apply to all carboxylic acids, because
the other carboxylic acids (a-ketoglutaric acid and iso-
citric acid) tested at identical concentrations did not
show inhibitory eﬀects. In addition, the enzyme was
64% inhibited by 2 mM ATP. Aspartate, the end-prod-
uct of the PEP carboxykinase–aspartate aminotransfer-
ase pathway (which competes with pfPyrK for PEP) did
not appear to regulate pfPyrK. Kinetic analysis in the
presence of inhibitors (ATP and citrate) was subse-
quently carried out to ascertain the nature of inhibition
with respect to each co-substrate under saturating con-
ditions (Fig. 5 and Table 1). When present at a concen-
tration of 1 mM, citrate appears to be a competitive
inhibitor of PEP. Interestingly, results revealed a transi-
tion from hyperbolic to sigmoidal kinetics for PEP in the
presence of 1.5 and 2 mM citrate, with Hill coeﬃcients
of 1.9 and 2.4, respectively (Fig. 5E). Signiﬁcant compet-
itive inhibitory behavior was observed for 2 and 2.5 mM
ATP with respect to PEP, under saturating ADP con-
centrations (Fig. 5B). In addition, at concentrations of
2.5–3.5 mM, citrate appears to demonstrate non-com-
petitive inhibition with respect to ADP under saturating
PEP concentrations (Fig. 5D). The use of a Dixon plot
at ADP concentrations of 0.2, 0.4, and 1.5 mM (not
shown) indicated a Ki of 0.8 mM for citrate with respect
to ADP.
Fig. 5. Kinetic properties of pfPyrK. (A) Hanes plot using varying concentrations of PEP in the absence of eﬀectors (closed lozenges ), or in the
presence of 1 mM glucose-6-phosphate (open squares h), or 1 mM fructose-1,6-bisphosphate (open circles s); (B) Hanes plot using varying
concentrations of PEP in the absence of eﬀectors (closed lozenges ), or 2.5 mM ATP (crosses ·), 2 mM ATP (open lozenges ), or 1 mM citrate
(open triangles n); (C) Hanes plot using varying concentrations of ADP in the absence of eﬀectors (closed lozenges ), or in the presence of 1 mM
glucose-6-phosphate (open squaresh), 1 mM fructose-1,6-bisphosphate (open circless); (D) Hanes plot using varying concentrations of ADP in the
absence of eﬀectors (closed lozenges ), or in the presence of 3 mM citrate (asterisks *), 2.5 mM citrate (open triangles n), or 3 mM ATP (open
squares h); (E) Hill plot of log (v/V  v) vs log [PEP] in the presence of citrate (1.5 or 2 mM); (F) eﬀect of enzyme inactivation by various
concentrations of pyridoxal 5 0 phosphate. Closed circles (d) indicate control experiments to conﬁrm that pyridoxal phosphate has no eﬀect on lactate
dehydrogenase employed in the coupled enzyme assay for pyruvate kinase. Experiments using pfPyrK and rabbit muscle pyruvate kinase are
indicated by open circles (s) and open triangles (n), respectively. Standard deviations from at least two independent experiments are shown.
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Because of the crucial role of pyruvate kinase in the
metabolism of parasitic organisms, it has been indicated
as a potential drug target against Trypanosomes and
Leishmania [8,9]. The recombinant T. brucei pyruvate
kinase is currently being crystallized as a step towards
its use in designing selective inhibitors for development
of anti-trypanosomal drugs [8]. Although the response
of parasitic pyruvate kinase to phosphorylated sugarsappears to be unusual in many parasitic organisms, rel-
atively little is known about the pyruvate kinase from
Plasmodium. Interestingly, it has been reported that in
a mouse model, pyruvate kinase deﬁciency of host cells
appears to protect against malaria, suggesting the
importance of this pathway for the parasites survival
[19], and that pyruvate kinase may be considered as a
potential target for the design of new drugs against ma-
laria. Observations indicating the potential importance
of pyruvate kinase in malaria [2,3,10,20] prompted us
Table 1
Enzyme kinetic parameters of pfPyrK
Substrate Km ± SD (mM) Vmax ± SD (U/mg) nH
Saturating conditions
PEP (0.1–2 mM)
No eﬀector 0.190 ± 0.028 (100%) 276 ± 28 (100%)
+F16P (1 mM) 0.214 ± 0.004 (112%) 291 ± 26 (105%)
+G6P (1 mM) 0.143 ± 0.030 (75%) 326 ± 15 (118%)
+citrate (1 mM) 0.507 ± 0.069 (266%) 275 ± 28 (99%)
+citrate (1.5 mM) 1.9
+citrate (2 mM) 2.4
+ATP (2 mM) 0.497 ± 0.074 (261%) 246 ± 17 (89%)
+ATP (2.5 mM) 1.205 ± 0.285 (634%) 283 ± 5 (102%)
+ATP (3 mM) 1.2
ADP (0.1–2 mM)
No eﬀector 0.126 ± 0.043 (100%) 258 ± 15 (100%)
+F16P (1 mM) 0.163 ± 0.027 (129%) 300 ± 3 (116%)
+G6P (1 mM) 0.204 ± 0.085 (161%) 375 ± 93 (145%)
+citrate (2.5 mM) 0.149 ± 0.060 (118%) 154 ± 18 (60%)
+citrate (3 mM) 0.154 ± 0.002 (122%) 136 ± 2 (52%)
+citrate (3.5 mM) 0.143 ± 0.057 (113%) 38 ± 8 (14%)
+ATP (3 mM) 0.151 ± 0.060 (119%) 207 ± 12 (80%)
Non-saturating conditions
PEP (0.1–2 mM)
No eﬀector 0.337 ± 0.031 (100%) 96.8 ± 9.4 (100%)
+F16BP (1 mM) 0.307 ± 0.070 (91%) 86.8 ± 4.7 (90%)
+G6P (1 mM) 0.392 ± 0.076 (116%) 121.6 ± 12.3 (126%)
ADP (0.1–2 mM)
No eﬀector 0.149 ± 0.022
Kinetic analysis of PEP and ADP (saturating conditions) was carried out using co-substrate concentrations of 3 mM ADP and 7 mM PEP,
respectively. Kinetic analysis of PEP and ADP (non-saturating conditions) was carried out in the presence of 1 mM ADP and PEP, respectively.
Fig. 6. Eﬀect of various eﬀector compounds on pfPyrK activity. All
compounds were tested at a ﬁnal concentration of 2 mM in the assay
system. Relative activities were expressed in percentage with respect to
the control reaction in which no eﬀector was included.
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duce active recombinant pfPyrK for detailed character-
ization and comparison with its counterparts in other
parasites, namely T. brucei, L. mexicana, and T. gondii.
RT-PCR using mRNA extracted from P. falciparum in-
fected cells indicated that pfPyrK is expressed during
the intraerythrocytic-stage. DNA sequencing of thecloned pfPyrK cDNA validated the positions of introns
predicted in PlasmoDB. With few exceptions, pyruvate
kinases have been reported to be homotetramers. Our
results also indicated that active recombinant pfPyrK
exists as a homotetramer. A BLAST search against
the complete P. falciparum genome sequence data
(PlasmoDB) using pfPyrK amino acid sequence did
not uncover any other ORF with signiﬁcant similarity
to pyruvate kinases. Hence, pyruvate kinase gene cloned
in this study appears to exist as a single copy in the
P. falciparum genome.
The aﬃnity of pfPyrK for ADP and PEP appears to
be higher than those of the corresponding enzymes from
mammalian enzymes (Km for ADP is 0.35 mM for cow
and pig pyruvate kinases; Km for PEP is 0.57 mM for
rat pyruvate kinases). The aﬃnity for PEP is also higher
than that of pyruvate kinase from T. gondii
(Km = 1 mM). Similar to pyruvate kinases from T. gon-
dii, rabbit muscle pyruvate kinase, and human M1 iso-
zyme, pfPyrK is not activated by F16BP, the common
activator of most pyruvate kinases [7]. In pyruvate ki-
nases, the lysine at position 418 is thought to be involved
in binding the 6-phosphate moiety of F16BP. However,
similar to non-allosteric enzymes, pfPyrK has a gluta-
mate at residue 418. In contrast, lysines are observed at
position 418 in pyruvate kinases activated by F16BP,
Fig. 7. Alignment of the binding site of the 6-phosphate moiety of
F16BP within the C-domain. Box indicates the essential amino acids
for binding within the binding site (indicated by arrows).
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observed properties of pfPyrK agree with amino acid se-
quence data. Unlike T. gondii pyruvate kinase, pfPyrK is
not signiﬁcantly activated by G6P. Hence, activation by
G6P may not be a universal property related to parasit-
ism as proposed earlier [7]. Interestingly, pfPyrK diﬀers
from T. gondii at three positions (K37, H40, and I473)
identiﬁed by Ernest et al. [8] to be important in eﬀector
binding. These diﬀerences may account for the distinc-
tion in response to G6P between pfPyrK and T. gondii
pyruvate kinase. The observation of sensitivity of
pfPyrK to citrate, PLP, and ATP is interesting because
no inhibitors have been described for pfPyrK so far.
ATP, citrate, a-ketoglutarate, and a number of organic
acids were known to inhibit E. histolytica pyruvate ki-
nase [11]. However, it is interesting to note that while
the E. histolyica enzyme is inhibited by 21 mM citrate
and 6 mM ATP [10], pfPyrK is strongly inhibited at 2–
2.5 mM citrate or ATP (Fig. 5), and is almost completely
inhibited at 4 mM of these inhibitors (not shown). Also,
inhibition of E. histolyica pyruvate kinase by citrate is
not accompanied by a transition from hyperbolic to sig-
moidal kinetics observed in pfPyrK. The binding sites
for citrate are as yet unknown but have been suggested
to be separate from those for phosphorylated sugars
[11]. Nevertheless, the observation of distinct mecha-
nisms of inhibition by citrate and ATP suggests indepen-
dent binding sites for these inhibitors. Also, the
physiological signiﬁcance of inactivation by PLP has
yet to be determined because the status of PLP in P. fal-
ciparum is unknown. Nevertheless, the diﬀerence in the
susceptibility to PLP between pfPyrK and rabbit muscle
pyruvate kinase may reﬂect structural diﬀerences in
accessibility of binding sites to PLP.
In summary, the results in this study showed that
P. falciparum genome encodes a biologically active pyru-
vate kinase that is expressed during the intraerythrocy-
tic-stage. The inhibition of pfPyrK by citrate, PLP,
and ATP, as well as its uniqueness in its insusceptibility
to F16BP and G6P, were characterized in detail. These
observations suggest that pfPyrK appears to be kineti-
cally unique among protozoan pyruvate kinases and
that pfPyrK is regulated by eﬀectors that may be corre-
lated with energy ﬂow or metabolite levels in the cell.
Molecular investigations to elucidate the binding sites
for the uncovered inhibitors may be relevant to designof molecules that would inhibit the parasites enzyme.
Currently, the availability of copious amounts of recom-
binant pfPyrK facilitates the employment of this en-
zyme in drug-screening.Acknowledgments
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Abstract The catalysis of malate dehydrogenase (MDH)
in Plasmodium falciparum (pfMDH) which involves
NAD/NADH coupling is crucial for the parasites
pathogenicity. Primers were designed based on the
P. falciparum genome resource, and these facilitated the
cloning of a gene coding for pfMDH from a local clin-
ical isolate. The DNA sequence of the cloned gene re-
vealed an open-reading frame that encodes a protein of
313 amino acids. After induction in Escherichia coli
BL21, enzyme assays of the expressed pfMDH puriﬁed
by aﬃnity chromatography exhibited signiﬁcant enzyme
activity of about 50 U/mg, where one unit (U) of en-
zyme activity is deﬁned as the amount of enzyme oxi-
dising 1 lol NADH/min. Based on its phylogenetic
status amongst MDHs and lactate dehydrogenases
(LDHs), the cloned gene was clearly deﬁned as belong-
ing to the NADH-dependent [LDH-like] MDHs. It is
noteworthy that pfMDH harbours unique structural
characteristics potentially useful for screening drugs
speciﬁc for disabling parasitic enzymes.
Introduction
Tropical malaria, a life-threatening disease caused by
Plasmodium falciparum, is still a global health threat that
is responsible for millions of deaths each year. Cloning
and a high level of expression of genes encoding P. fal-
ciparum enzyme activities would permit studies on the
structure and function of the parasites metabolic en-
zymes, eventually leading to identiﬁcation of drugs that
can selectively inhibit certain parasitic enzymes. The
focus has been on cloning glycolytic pathway genes in
P. falciparum because it is known that it relies on
anaerobic glycolysis for energy production during the
erythrocytic stages (Certa et al. 1988; Kaslow and Hill
1990; Hicks et al. 1991). However, its genome sequence
revealed that many other biochemical pathways could
also be reconstructed (Gardner et al. 2002), suggesting
the existence of yet uncharacterized pathways that may
be essential for the parasites pathogenicity.
Malate dehydrogenase
Malate dehydrogenase (MDH; 1.1.1.37) is a primary
anaplerotic enzyme that converts malate to oxaloacetate
(OAA). This reaction produces two important products:
NADH or NADPH as reducing equivalents, and OAA,
a metabolic substrate. In eukaryotic cells, there are two
MDH isozymes, the cytosolic and the mitochondrial
forms. The physiological roles for these forms have been
clearly established. The former is involved, together with
aspartate aminotransferase, in the transfer of reducing
equivalents from the cytosol to the mitochondrion,
whereas the latter is one of the tricarboxylic acid cycle
enzymes (Gietl 1992). MDHs are thought to play an
important role in metabolic channelling, thus contrib-
uting to cellular organization during growth. Both ma-
late and lactate dehydrogenases (LDHs) are members of
a large family of homologous dehydrogenases (Madern
2002). Two classes of MDH have been described, i.e.
MDHs coupled to NADH or NADPH, and LDH-like
MDHs which function like MDHs but are structurally
closer to LDHs.
Indeed MDHs have been puriﬁed, characterized, and
sequenced from a wide variety of organisms represen-
tative of the bacterial, archaeal, and eukaryal domains
of life (Goward and Nicholls 1994). As yet, there is no
study on genes encoding MDHs in Plasmodium. How-
ever, since malarial parasites are thought to be particu-
larly sensitive to oxidative stress during infection, it has
been suggested that pathways of the parasites redox
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reactions, such as those for NADH or NADPH regen-
eration, are crucial for the organisms survival and are
thereby prominent targets for the development of ra-
tional drugs. Hence, it is worthwhile investigating the
role of speciﬁc MDHs in P. falciparum. Interestingly, a
P. falciparum LDH (designated pfLDH) cloned earlier
(Bzik et al. 1993) was subsequently re-designated as
being a MDH, based on phylogenetic and sequence
Fig. 1 Multiple alignment of
malate dehydrogenase (MDH)
in Plasmodium falciparum






LDH, Escherichia coli MDH
and human cytosolic MDH
sequences. Conserved residues
are shaded. The active site is
marked by *. j Sites for
substrate binding, m; sites for
coenzyme binding. The
numbering is based on pfMDH
(this study)
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studies (Madern 2002). Intriguingly, inspection of its
genome sequence data revealed the existence of yet an-
other ORF encoding MDH [designated P. falciparum
MDH (pfMDH in this study)]. The cloning of this un-
characterized ORF, and demonstration of its biochem-
ical functionality, is herein reported.
Materials and methods
The full-length ORF encoding P. falciparum MDH (pfMDH) was
obtained by PCR ampliﬁcation using Pfu polymerase (Stratagene)
from the genomic DNA of a clinical P. falciparum isolate, followed
by cloning of the gene product into pCR-BluntII-TOPO (Invitro-
gen). The pair of PCR primers (5¢-TTTCATAT GGGATCC-
ACTAAAATTGCCTTAAT A-3¢ and 5¢-CTCGAG TTATTT
AATTAAGAC GAA-3¢) were designed based on the 5¢ and 3¢
sequences of the MDH ORF predicted from the P. falciparum
genome database (website: http://www.plasmoDB.org). Restriction
sites for BamH I and Xho I (underlined and italicized in the above
primer sequences, respectively) were incorporated that allowed the
ampliﬁed product to be cloned subsequently into pGEX-6P1
(Amersham) for bacterial expression in E. coli BL21(DE3). The
recombinant construct harbouring the pfMDH gene in the expres-
sion vector pGEX-6P1 was designated pG4B1. Subsequently,
pG4B1 was transformed into E. coli BL21 for isopropyl-b- D -thi-
ogalactopyranoside-inducible expression of pfMDH as a glutathi-
one-S-transferase (GST)-tagged recombinant protein.
Results and discussion
The full gene sequence obtained encoding pfMDH was
identical to that of the predicted pfMDH ORF depos-
ited in the P. falciparum genome sequence resource. The
pfMDH ORF encodes 313 amino acids (aa) with a
computed molecular mass of 34.0 kDa, consistent with
those of known MDHs (30–40 kDa). In terms of aa
sequence, pfMDH was most similar to an ORF encod-
ing a putative MDH in Plasmodium yoelii (62% iden-
tity). The closest mammalian and human homologues
were pig LDH (28%) and human LDH (27%), respec-
tively. Furthermore, pfMDH possesses conserved resi-
dues that distinguish it from LDHs, thereby categorizing
it as a [LDH-like] MDH (Fig. 1). Speciﬁcally, the Arg at
position 81 is replaced by a Gln in LDH. Also, pfMDH
possesses a Pro residue at 232 that is conserved in all
[LDH-like] MDHs (Madern 2002). LDHs have instead
an Ile at 232. The Asp at residue 32, observable in all the
NADH-dependent enzymes, was conserved in pfMDH.
The replacement of this residue is thought to lead to the
use of NADPH as cofactor (Madern 2002). Phylogenetic
analysis of diverse genes belonging to the MDH/LDH
superfamily led to the observation of three main groups
within the superfamily, comprising LDHs, MDHs, and
[LDH-like] MDHs (Fig. 2). The pfMDH cloned in this
study was clearly clustered with the [LDH-like] MDH
group, together with P. yoelii MDH. Madern (2002)
re-assigned pfLDH and that of Toxoplasma gondii as
[LDH-like] MDHs based on their phylogenetic positions
and identities of their conserved residues. As expected,
these LDHs clustered with [LDH-like] MDHs. Inter-
estingly, the pfMDH cloned in this study shares only
37% identity in aa sequence with pfLDH but they are
structurally quite similar, an observation similar to the
comparison of isopenicillin N synthase and deacetoxy-
cephalosporin N synthase (Sim et al., in press). As
expected, multiple-alignment showed that the active site
residue (His 174), as well as those for substrate (Arg 81,
Arg 87 and Arg 150) and coenzyme binding (Gly 8, Ile
12 and Ser 227) in the MDH family (Chapman et al.
Fig. 2 Phylogenetic tree of
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1999), are also conserved in pfMDH. Hence, phyloge-
netic and sequence analyses clearly deﬁned the pfMDH
cloned as belonging to the group of NADH-dependent
[LDH-like] MDH. Furthermore, it is clear that malarial
MDHs are not grouped distinctively with mammalian
homologues, reﬂecting signiﬁcant sequence dissimilari-
ties between the malarial and mammalian homologues.
The availability of crystal structures for pfLDH has
made it possible to generate the three-dimensional
structure of pfMDH by homology modelling (not
shown). Interestingly, the superimposition of the model
obtained for pfMDH over the porcine cytosolic MDH
revealed signiﬁcant conformational diﬀerences in the
active site loop and other solvent-exposed regions.
Therefore, together with primary structure comparisons,
these observations suggest a large scope for the use of
some of the domains of malarial MDHs as potential
drug targets. Finally, the use of bioinformatic software
did not identify any organellar targeting signal, sug-
gesting that this pfMDH is a cytosolic enzyme.
To conﬁrm the enzymatic function of the cloned
pfMDH gene, the ORF was heterologously expressed as
a GST fusion-protein. In addition, the GST fusion-pro-
tein was puriﬁed by aﬃnity chromatography followed by
glutathione elution (Fig. 3). As expected, the GST-
pfMDH fusion protein exhibited an apparent molecular
mass of ca. 60 kDa, larger than the computed molecular
weight of pfMDH due to the presence of the 26 kDa
GST-tag. Puriﬁed GST-tagged pfMDH exhibited high
levels of MDH activity (Fig. 3). No MDH activity was
detected in fractions puriﬁed from extracts expressing
pGEX-6P1 without the pfMDH gene insert, conﬁrming
that the puriﬁed pfMDH was enzymatically active.
E. coli extracts expressing recombinant pfMDH exhib-
ited signiﬁcantly higher (>ﬁvefold) MDH activity after
puriﬁcation, in contrast to those obtained from the cor-
responding expression vectors without the gene insert,
the latter representing basal or endogenous levels of
E. coli host enzymes. The RIG plasmid (a gift from
Professor WimG. J. Hol, University of Washington) was
co-transformed with recombinant constructs to provide
additional copies of rare E. coli tRNAs that recognize the
codons AGA/AGG (R), ATA (I), and GGA (G). Active
pfMDH could be competently expressed without the
support of the RIG plasmid, suggesting that co-trans-
formation with the RIG plasmid is not a prerequisite for
the heterologous expression for pfMDH.
In this study, the cloning and functional expression of
a gene encoding a NADH-dependent [LDH-like]
pfMDH is reported. The prediction of cytosolic locali-
zation of pfMDH is consistent with earlier biochemical
studies which suggested that P. falciparum possesses
cytosolic forms of MDHs only (Lang-Unnasch 1992).
Proteomic studies in P. falciparum suggested that MDH
enzyme activity is associated with the sporozoitic and
gametocytic stages (Florens et al. 2002). However,
P. falciparum LDH mRNA was only detectable at
erythrocytic stages. The cloning of pfMDH may allow
the biochemical and physiological diﬀerences between
the two MDH isoforms in P. falciparum to be investi-
gated.
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During infection, Plasmodium spp. require reducing equivalents such as NADPH to support the function of speciﬁc enzymes in
overcoming oxidative stress. The catalysis of isocitrate by the NADP-dependent isocitrate dehydrogenase of Plasmodium falciparum
(pfICDH) generates NADPH and is thus crucial for the parasites survival and pathogenecity. In this study, pfICDH was cloned
from a clinical isolate of P. falciparum. This was facilitated by designing primers based on the P. falciparum genome sequence
resource PlasmoDB. DNA sequence of the cloned gene revealed an ORF that encodes a protein of 468 aa. Furthermore, after
expression in Esherichia coli BL21, enzyme assays of cell-free extracts conﬁrmed the overexpression and function of pfICDH.
Further, pfICDH puriﬁed by aﬃnity chromatography retained its enzyme activity. Substitution of NADP for NAD, or the use of
EDTA, in enzyme assays abolished pfICDH activity. ATP and chloroquine, as well as cupric and argentic ions, inhibited pfICDH
activity. Phylogenetic analysis revealed high primary structure homology (45–97%) among genes coding for eukaryal NADP-de-
pendent ICDH, and the occurrence of three subfamilies of ICDH genes. Interestingly, there were signiﬁcant sequence dissimilarities
between pfICDH and its mammalian or bacterial homologs, particularly at the N- and C-termini. Conﬁrming the functionality of
the cloned pfICDH, and asserting its distance from the human homolog by molecular deﬁnitions, are important prerequisites for
promoting this gene as a drug target screen.
 2003 Elsevier Science (USA). All rights reserved.
Index Descriptors and Abbreviations: ICDH, isocitrate dehydrogenase; pfICDH, Plasmodium falciparum ICDH; NADPH, b-nicotinamide adenine
dinucleotide phosphate reduced; NADP, b-nicotinamide adenine dinucleotide; GST, gluthathione-S-transferase; ORF, open-reading frame
Keywords: Isocitrate dehydrogenase (1.1.1.42); Malaria; Protozoan; Plasmodium spp.1. Introduction
Malaria is a severe parasitic disease that continues to
plague mankind, resulting in considerable morbidity and
mortality, especially in the Third World countries.
During infection, the malaria parasite Plasmodium fal-
ciparum multiplies and diﬀerentiates within the erythro-
cytes. At this stage, the protozoan is particularly
sensitive to oxidative stress (Kanzok et al., 2000). Hence,
it has been suggested that pathways of the parasites
redox metabolism, especially those for NADH- or
NADPH-regeneration, are prominent targets for ra-* Corresponding author. Fax: +65-6776-6872.
E-mail address: micsimts@nus.edu.sg (T.S. Sim).
0014-4894/03/$ - see front matter  2003 Elsevier Science (USA). All rights
doi:10.1016/S0014-4894(03)00090-0tional drug development. The licensed antimalarial drug
primaquine, for example, appears to act partly via direct
oxidation of NADPH (Smith et al., 1987). The NADP-
dependent isocitrate dehydrogenase (EC 1.1.1.42)
(ICDH) is a redox enzyme which catalyses the oxidative
decarboxylation of isocitrate, leading to the formation of
2-oxoglutarate, CO2, and NADPH. 2-Oxoglutarate can
be further oxidized within the cycle or reductively ami-
nated to glutamate. ICDH thus supplies the cell with
reducing power in the form of NADPH, intermediates
for metabolism, as well as a precursor for biosynthesis.
Since the reaction catalyzed by ICDH represents an
important branch point between catabolic and anabolic
processes in the cell, ICDH can be considered as an an-
aplerotic enzyme.reserved.
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Eukarya, and Archaea, and has been extensively studied
with respect to structure, kinetics, and regulation
(Camacho et al., 1995; Chen and Gadal, 1990; Danson
and Wood, 1984; Galvez and Gadal, 1995). Genes en-
coding ICDH have been cloned and sequenced from a
variety of eukaryal and bacterial sources. Most bacteria
have only an NADP-dependent ICDH consisting of ei-
ther a homodimeric enzyme with molecular masses of
45 kDa or a monomeric enzyme of 90 kDa (Chen
and Gadal, 1990; Ishii et al., 1993). The three-dimen-
sional structure of the homodimeric Esherichia coli iso-
citrate dehydrogenase has been solved and residues
involved in the binding of isocitrate and NADP deter-
mined (Hurley et al., 1989). In Eukarya, two diﬀerent
isocitrate dehydrogenase activities co-exist in the cell
(Galvez and Gadal, 1995). NAD-dependent isocitrate
dehydrogenase appears to be heteromeric and is located
within mitochondria. The existence of at least two
homodimeric NADP-dependent enzymes, encoded by
independent genes, has been reported. One isoenzyme
is mitochondrial whereas the other is located in the
cytosol.
Although ICDH has been suggested to be useful for
diagnosis and clinical investigation of certain infectious
agents (Florio et al., 2002; Nguyen and Hirai, 1999),
there is no information on ICDH from P. falciparum. A
survey of automated predictions in the P. falciparum
genome sequence resource PlasmoDB (website:
www.plasmoDB.org) uncovered the presence of a pu-
tative ORF encoding an NADP-dependent ICDH. In
this study, the cloning, sequence analysis and heterolo-
gous expression of this ORF (designated P. falciparum
ICDH, pfICDH) are reported. Furthermore, pfICDH
was shown to be enzymatically active when expressed in
E. coli BL21. The coenzyme speciﬁcity of puriﬁed
pfICDH, and the eﬀects of certain chemicals on pfICDH
enzyme activity, were also investigated. Phylogenetic
analysis of known ICDH aa sequences suggests an ex-
istence of three subfamilies of ICDHs.2. Materials and methods
2.1. Strains, cultivation conditions, genomic DNA extrac-
tion and PCR ampliﬁcation
The source of P. falciparum Tan strain was National
University Hospital, Singapore. Tan strain was cultured
in vitro using treated human red blood cells and serum
according to the method of Trager and Jensen (1976).
Genomic DNA was extracted from cell cultures exhib-
iting about 8% parasitemia using the QIAamp DNA
Blood Mini Kit (Qiagen) according to the manufac-
turers instructions. A pair of PCR primers (50-TTT
GCTAGCATGGGATCCGGAAAGCATATACGAATT-30 and 50-AAGAATTCTTATGTTGAATGAATG
TTCTTG-30) was designed based on the 50 and 30 se-
quences of the ICDH ORF predicted from the P. fal-
ciparum genome database. In addition, restriction sites
for NheI, BamHI, and EcoRI (underlined) were incor-
porated that allowed the ampliﬁed product to be cloned
subsequently into pGEX-6P1 and pET24a for bacterial
expression in E. coli BL21(DE3). PCR were performed
according to the following conditions: 94 C for 1min;
94 C for 0.5min, 45 C for 2min, 68 C for 3min for 35
cycles; and 68 C for 10min. The reactions were held at
4 C after thermal cycling.
2.2. Cloning, DNA sequencing, and heterologous expres-
sion
The full-length gene product was subjected to agarose
gel electrophoresis using a 0.8% agarose gel and excised
for puriﬁcation using the GENEClean II kit (Bio101).
The puriﬁed target DNA was cloned into pCR-BluntII-
TOPO (Invitrogen) according to the manufacturers in-
structions. DNA inserts in positive recombinant clones
obtained were sequenced using the ABI PRISM BigDye
terminator cycle sequencing kit (Applied Biosystems)
and loaded onto an ABI PRISM 377 DNA sequencer
for sequence determination. Finally, the ICDH gene was
excised from the cloning vector by BamHI/EcoRI dou-
ble-digestion and subcloned into pGEX-6P1 for ex-
pression as a gluthathione-S-transferase- (GST-) tagged
fusion protein. The ICDH gene was also excised from
the cloning vector by NheI/EcoRI double-digestion and
subcloned into pET24a for expression as a non-tagged
protein. The recombinant constructs were transformed
into E. coli BL21 DE3 for expression by induction with
1mM IPTG. Where noted, the RIG plasmid (a gift from
Professor Wim G.J. Hol, University of Washington) was
co-transformed with recombinant constructs to provide
additional copies of rare E. coli tRNAs that recognize
the codons AGA/AGG (R), ATA (I), and GGA (G).
2.3. Protein puriﬁcation and ICDH enzyme assay
Recombinant GST fusion-protein was puriﬁed by
column glutathione elution method using the GST Pu-
riﬁcation Module (Amersham) according to manufac-
turers instructions. The assay of NADP-dependent
ICDH activity was based on established method of
monitoring of NADP reduction to NADPH (e340 ¼
6:22mM1 cm1). The standard assay solution (1ml)
contained 50mM Tris buﬀer (pH 7), 0.1mM NADP,
4mM DL-isocitrate, and 2mM MnSO4, unless noted
otherwise. One unit of enzyme activity is deﬁned as the
amount of enzyme reducing 1 nmol of NADP per min-
ute. The protein concentration of crude and puriﬁed
ICDH preparations were determined using Biorad
Protein Assay Reagent according to the manufacturers
Fig. 1. PCR ampliﬁcation and cloning of pfICDH gene. (a) PCR
ampliﬁcation of pfICDH gene from P. faliciparum (Tan strain) geno-
mic DNA. Lane 1, DNA marker; lane 2, ampliﬁed sample showing
1.4 kb band corresponding to pfICDH (arrowhead); lane 3, non-tem-
plate negative control. (b) Restriction analysis of recombinant plasmid
pG2A2 harbouring pfICDH DNA. Lane 1, DNA marker; lane
2, BamHI/EcoRI double-digest of pG2A2 showing gene insert
(arrowhead).
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inhibition study were of analytical grade.
2.4. Computational analyses and Accession numbers
Multiple sequence alignment and phylogenetic tree
construction were performed using the Clustal X pro-
gram (Thompson et al., 1994) and viewed with Box-
shade (Bioinformatics Group, ISREC). Trees were
visualized using the Treeview program (University of
Glasgow). Molecular mass calculation was performed
using the Compute pI/Mw Tool of the Expasy website
(www.expasy.org.ch). The Accession number for the
contig containing the pfICDH is AL844509. The Ac-
cession numbers of other sequences used in this study
are as follows: alfalfa, S28423; Anabaena sp., A55591;
Aeropyrum pernix, A72658; Bacillus subtilis, P39126;
bovine (NADP-dependent, subfamily II), Q04467; bo-
vine (NAD-dependent, subfamily III), P41563; E. coli,
P08200; human (NAD-dependent, subfamily III),
S55282; human (NADP-dependent, cytoplasmic, sub-
family II), O75874; human (NADP-dependent, mito-
chondrial, subfamily II), P48735; monkey (c-subunit),
P41564; monkey (a-subunit), X82632; rat (NAD-de-
pendent, subfamily III), P41565; mouse (NADP-de-
pendent, mitochondrial, subfamily II), P54071;
Plasmodium yoelii, EAA17070; rat (NADP-dependent,
subfamily II), P41562; Salmonella typhimurium,
AAL20167; Sphingomonas yanoikuyae, P50125; soy-
bean, Q06197; Streptococcus salivarius, L14780; Syn-
echocystis sp., P80046; Thermus thermophilus, P33197;
tobacco, P50218; Vibrio sp., B49341; Saccharomyces
cerevisiae (subunit 1, NAD-dependent, subfamily III),
P28834; Saccharomyces cerevisiae (subunit 2, NAD-de-
pendent, subfamily III), P28241; Saccharomyces cerevi-
siae (NADP-dependent, mitochondrial, subfamily II);
P21954; Saccharomyces cerevisiae (NADP-dependent,
cytoplasmic, subfamily II); and P41939.3. Results
3.1. Cloning and sequence analysis of P. falciparum
ICDH
The full-length ORF encoding P. falciparum ICDH
(pfICDH) was obtained by PCR ampliﬁcation from
P. falciparum Tan strain genomic DNA followed by
cloning of the gene product into pCR-BluntII-TOPO
(Fig. 1a). The full gene sequence encoding pfICDH was
obtained by sequencing positive clones harboring the
pfICDH gene insert. Further sub-cloning was carried
out to obtain recombinant constructs harboring the
pfICDH gene in expression vectors pGEX-6P1 and
pET24a, designated pG2A2 and p2B1, respectively. The
recombinant constructs were identiﬁed by double-di-gestion (Fig. 1b). DNA sequencing of recombinant
plasmids was employed to conﬁrm the identities of the
cloned inserts and in-frame insertion of the intact gene
into the expression vectors.
Comparison of the pfICDH DNA sequence obtained
with the predicted ICDH DNA sequence deposited in
PlasmoDB showed that the pfICDH gene cloned was
identical to the corresponding PlasmoDB entry. The
pfICDH ORF encodes 468 aa with a computed molec-
ular mass of 53.5 kDa, consistent with those of known
homodimeric NADP-dependent ICDHs (40–57 kDa)
(Chen and Gadal, 1990). In terms of aa sequence,
pfICDH was most similar to a predicted ORF for
NADP-dependent ICDH in P. yoelii (84% identity). The
closest mammalian counterpart was bovine NADP-de-
pendent ICDH (65%). In addition, pfICDH shares 64%
identity with human NADP-dependent ICDH. Multi-
ple-alignment of diverse genes coding for eukaryotic
NADP-dependent ICDH revealed high primary se-
quence homology (45–97%). In addition, 9 out of 12 of
the aa residues known to be involved in catalysis or
substrate binding in E. coli ICDH (Hurley et al., 1989)
are conserved among the ICDH sequences aligned (Fig.
2). Of the non-conserved residues, I320 (based on the E.
coli ICDH numbering as indicated in Fig. 2) present
conservative change. The similarity in the primary
structures of known ICDH sequences suggests that the
enzymes may have a similar reaction mechanism or
structure. The 3D-structures for the porcine as well as
four bacterial ICDHs are available. The aa sequence of
pfICDH shared suﬃcient similarity in the central do-
main with the porcine ICDH to enable homology-based
3D-modelling of pfICDH using the latter 3D-structure
as a template (Fig. 5). However, the unique C-terminal
Fig. 2. Multiple alignment of pfICDH aa sequences with bovine, human and E. coli ICDH sequences. Conserved residues are shaded. Boxed residues
and residues marked by an arrow are those that contact substrate and coenzyme, respectively, in the E. coli enzyme. Only 3 out of total of 29 se-
quences used for multiple alignment is shown. Their Accesion numbers are: bovine, Q04467; human, O75874; and E. coli, P08200.
Fig. 5. Homology model of pfICDH (yellow) superimposed on the
porcine ICDH crystal structure (blue) used as the template for thread-
ing. The PDB code for the porcine enzyme used in this study is 1LWD.
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porcine ICDH crystal structure. It is uncertain whether
diﬀerences at the N- and C-termini would inﬂuence its
eventual folding.
A phylogenetic tree (Fig. 3) generated by aligning the
ICDHs showed that ICDHs can be divided into three
distinct phylogenetic subfamilies: subfamily I (NAD- or
NADP-dependent ICDH from Archaea and Bacteria),
subfamily II (NADP-dependent ICDH from Eukarya
and Bacteria), and subfamily III (NAD-dependent
ICDH from Eukarya). Subfamilies I and II comprise of
homodimeric ICDHs while subfamily III comprises
NAD-dependent complex multimeric mitochondrial
isocitrate dehydrogenases and one bacterial homodi-
meric NADP–ICDH. Although all three subfamilies are
monophyletic, subfamily I is the only clearly deﬁned
Fig. 4. Enzymatic activity and puriﬁcation of pfICDH expressed in
E. coli BL21.(a) SDS–PAGE analysis of puriﬁed GST–pfICDH fusion
protein (arrowhead). (b) ICDH enzyme activities of recombinant
clones harbouring pfICDH gene and controls harbouring vectors
without inserts. Data from both cell-free extracts and puriﬁed fractions
are shown. Average values from two or more representative experi-
ments using separate enzyme preparations are shown.
Fig. 3. Phylogenetic tree of ICDHs from prokaryotic and eukaryotic
organisms. The Accession numbers are given in the text. M, mito-
chondrial; C, cytoplasmic; B, b-subunit; G, c-subunit; 1, subunit 1; and
2, subunit 2. Bootstrap values indicated at the nodes were generated
from 1000 replicates.
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deeply rooted member of subfamily II. It should be
noted that a bootstrap value of 862 indicates some de-
gree of uncertainty in the grouping of pfICDH in this
subfamily. The interfamilial homology between sub-
family II and the other two subfamilies do not exceed
17%. Phylogenetic analysis revealed that pfICDH is not
grouped distinctively with mammalian or bacterial IC-
DHs, suggesting signiﬁcant dissimilarities between
pfICDH and the mammalian or bacterial homologs. In
addition, there are clear sequence diﬀerences between
pfICDH and mammalian or bacterial ICDHs at the N-
and C-termini, particularly a C-terminal extension of 26
aa not present in the human, bovine or E. coli homologs
(Fig. 2).
3.2. Heterologous expression and enzymatic activity of
pfICDH
To conﬁrm the enzymatic function of the cloned
pfICDH gene, the ORF was heterologously expressed as
a GST fusion-protein and also as an untagged protein.
In addition, the GST fusion-protein was puriﬁed by
aﬃnity chromatography followed by gluthathione elu-
tion (Fig. 4a). E. coli cell-free extracts expressing bothtagged and untagged forms of pfICDH exhibited in-
creased ICDH enzyme activity as compared to extracts
obtained from the corresponding expression vectors
without pfICDH gene insert (Fig. 4b). In addition,
comparison between enzymatic activities in extracts ex-
pressing pfICDH with and without RIG plasmid indi-
cated that co-transformation with RIG plasmid did not
seem to elevate the yield of recombinant proteins
signiﬁcantly.
Puriﬁed GST-tagged pfICDH exhibited high levels of
ICDH activity, which represented signiﬁcant concen-
tration of the recombinant protein from the cell-free
extract. In contrast, no ICDH activity was detected in
fractions puriﬁed from extracts expressing pGEX-6P1
without pfICDH gene insert, conﬁrming that the puri-
ﬁed pfICDH was enzymatically active. The GST-
pfICDH fusion protein exhibited an apparent molecular
mass of ca. 78 kDa, larger than the computed molecular
weight of pfICDH due to the presence of the GST-tag
(26 kDa). Based on protein assay, the yield of pure
product that could be obtained from each induced cul-
ture of 50ml was about 127 lg/ml in a ﬁnal puriﬁed
fraction of 300 ll (mean of four separate experiments).
Hence, pfICDH could be solubly expressed in E. coli
BL21 DE3, with its enzymatic function intact, both as a
GST-fusion protein or as an untagged protein.
The properties of puriﬁed pfICDH are summarized in
Table 1. The enzyme exhibited a speciﬁc requirement for
NADP; substitution of NAD for NADP in the enzyme
assay led to total loss of enzyme activity. Inclusion of
5mM EDTA in the enzymatic assay eliminated
enzymatic activity, suggesting dependence on cations as
cofactors. Like many eukaryotic ICDHs, ATP signiﬁ-
cantly inhibited pfICDH activity. This observation
suggests that in vivo pfICDH activities may be sensitive
Table 1
Eﬀect of assay conditions on enzyme activity of pfICDH
Assay condition Percentage of ICDH
enzyme activitya
Standard condition 100
Substitution of NADP with NAD 0
5mM EDTA 0
5mM ATP 42
50 lg/ml chloroquineb 76
50 lg/ml tetracyclineb 100
50 lg/ml chloramphenicolb 100
0.1mM CuSO4Æ5H2O (Cu2þ ion)b 32
0.1mM AgNO3 (Ag
þ ion)b 80
a The % activity value is the mean of at least two separate obser-
vations using diﬀerent enzyme preparations.
b The enzyme was incubated with the drug or reagent for 15min at
37 C prior to assay.
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regulated in terms of ﬂux of primary metabolites in the
cell. Interestingly, pfICDH shares certain features with
its counterpart from the simian malaria parasite
P. knowlesi, in that it was markedly inhibited by chlo-
roquine, as well as by cupric and argentic ions (Sahni
et al., 1992).4. Discussion
Once in the red blood cell, primary metabolic path-
ways enable the parasite to derive the energy and re-
ducing equivalents required for proliferation. Some
primary metabolic enzymes of P. falciparum have been
cloned, but these were mainly conﬁned to those involved
in the glycolytic pathway. In this study, the cloning and
heterologous expression of functional pfICDH is re-
ported. The DNA sequence encoding pfICDH was
originally deposited as draft sequence from the P. fal-
ciparum genome project. The ORF encoding pfICDH
was identiﬁed by several automated prediction programs
(e.g., GlimmerM, Geneﬁnder, etc.) as well as by pre-
dictions from the sequencing centre. In addition, the
translated aa sequence contained the pfam domain
PF00180, which represents conserved motifs for ICDHs.
However, it should be noted that assignment of gene
function by a sequence similarity alone is not invariably
accurate. Loyevsky et al. (2001), for example, reported a
protein with signiﬁcant homology to aconitases but the
purported enzyme did not possess aconitase activity. In
this study, the function of the cloned pfICDH gene was
conﬁrmed by ICDH activity in expression studies. This
is an important prerequisite in endorsing the function-
ality of genes predicted from genome data bases. The
pfICDH ORF is found to be located in chromosome 13
(nt 1746298–1747704). However, inspection of the up-
and downstream regions of this location, up to about
2.3Mb from each end of the ICDH ORF, did notuncover any segment with homology to related primary
metabolic genes found in other organisms. It is possible
that genome sequence might fail to identify related
genes, given that 60% of predicted ORFs in the P. fal-
ciparum genome did not have suﬃcient similarity to
known proteins to justify functional assignments
(Gardner et al., 2002).
Redox enzymes have been suggested to be candidates
for drug targeting because it is thought that the malaria
parasite has a requirement for reduced environment
during infection in red blood cells (Kanzok et al., 2000).
Plasmodium spp. use glutathione and thioredoxin sys-
tems to cope with oxidative stress (Atamna and Gins-
burg, 1997; Kanzok et al., 2000). Both of these systems
are known to require reducing equivalents such as
NADPH to function. Interestingly, G6PD-deﬁcient in-
dividuals, who produce less NADPH than normal indi-
viduals, have been thought to be somewhat protected
against malaria (Brueckner et al., 2001). The distribution
of populations with high frequencies of G6PD deﬁciency
(G6PD)) alleles also coincides with the general distri-
bution of malaria, and studies have demonstrated that
the most common G6PD) alleles confer a degree of re-
sistance to malaria. It is therefore, assumed that G6PD)
alleles have risen in frequency due to natural selection by
malaria. Hence, it is possible that pfICDH may be useful
as a target for drug therapy, since it may function in
NADPH replenishment during infection. Further,
Dzierszinski et al. (1999) showed that some metabolic
enzymes of malarial parasites exhibit distinct primary
structural diﬀerences from their human homologs and
are possibly of plant origin. In this study, phylogenetic
studies revealed clear diﬀerences between pfICDH and
its mammalian homologs. These observations suggest a
large scope for the use of some of the domains of ma-
larial metabolic enzymes as potential drug targets. The
ICDH enzyme from the simian malaria parasite
P. knowlesi has been puriﬁed and characterized (Sahni
et al., 1992). The enzyme is manganese or magnesium ion
dependent, has a molecular mass of about 48.5 kDa, and
is cytosolic. Cupric and argentic ions have a marked
inhibitory eﬀect on its activity. Importantly, the enzyme
is signiﬁcantly inhibited by chloroquine and oxytetracy-
cline in vitro, but to a lesser degree by tetracycline.
However, the gene encoding ICDH from P. knowlesi has
yet to be identiﬁed and cloned to facilitate further in-
vestigation. The availability of active recombinant
pfICDH allows the characterization of this enzyme in
terms of its sensitivities to antimalarials such as chloro-
quine and primaquine. The inhibitory eﬀect of chloro-
quine on both pfICDH and P. knowlesi ICDH suggests
that chloroquine may be exercising its antimalarial eﬀect
by diminishing the NADPH pool available to the para-
site. It would be important to investigate the in vivo
expression of pfICDH and the possible role of pfICDH
in the pathogenecity of the parasite.
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